<?xml version="1.0"?>
<dataset>
    <table name="article_abstract_paras">
        <column>id</column>
        <column>article_id</column>
        <column>position</column>
        <column>heading</column>
        <column>nlm_category</column>
        <column>para</column>
        <row>
            <value>1</value>
            <value>1</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>2</value>
            <value>2</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Historically, the lack of melanocytes in the vaginal and cervical mucus membranes has deterred the
                findings of primary melanomas. Mainly due to its rarity, difficulty to diagnose, and poor prognosis,
                there has been no absolute agreement on comprehensive treatment so far. In this case report, we present
                a case of a 46-year-old woman with primary malignant melanoma of uterine cervix. She underwent
                neo-adjuvant chemotherapy initially followed by a radical hysterectomy. After adjuvant concurrent
                chemo-radiation, the patient has been followed up for 24 months. So far, she has not shown any symptoms
                or signs of recurrence. Further studies with more cases based on variable combinations of treatment
                regimen have been on the way.
            </value>
        </row>
        <row>
            <value>3</value>
            <value>3</value>
            <value>1</value>
            <value>Background and purpose</value>
            <value>Objective</value>
            <value>To evaluate volume changes and position shifts and their contribution to treatment margins of pelvic
                and para-aortic lymph nodes during Intensity Modulated Radiation Therapy (IMRT) for advanced cervical
                cancer.
            </value>
        </row>
        <row>
            <value>4</value>
            <value>3</value>
            <value>2</value>
            <value>Materials and methods</value>
            <value>Methods</value>
            <value>Seventeen patients with visible nodes on MR images underwent T2-weighted MR scans before and weekly
                during the course of IMRT. Thirty-nine pelvic and para-aortic nodes were delineated on all scans.
                Margins accommodating for volume and position changes were taken from the boundaries of the nodal
                volumes in the six main directions.
            </value>
        </row>
        <row>
            <value>5</value>
            <value>3</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Nodal volume regression from the pre-treatment situation to week 4 was 58% on average (range: 11.7%
                increase to 100% decrease). Nodal volumes partly increased between the pre-treatment scans and the scans
                in weeks 1-3, but in week 4 all nodes except one had regressed. Around the nodal volumes manually
                derived ITV margins accounting for volume changes and position shifts of 7.0, 4.0, 7.0, 8.0, 7.0 and
                9.0mm to the medial, lateral, anterior, posterior, superior and inferior directions were needed to cover
                95% of all nodes.
            </value>
        </row>
        <row>
            <value>6</value>
            <value>3</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>We used weekly MR scans to derive inhomogeneous margins that accommodate for nodal volume and
                position changes during treatment. These margins should be taken into consideration when planning
                external beam radiotherapy (EBRT) boosts, especially for highly conformal boosting techniques.
            </value>
        </row>
        <row>
            <value>7</value>
            <value>4</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>8</value>
            <value>5</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>There was performed a comparative analysis of quantitative load and physical status of human
                papillomavirus (HPV) type 16 in groups of patients with cervical intraepithelial neoplasia (CIN)--25
                people and cervical cancer (CC)--85 people. According to the analysis there were selected criteria
                appropriate to a combination of adverse factors that characterized HPV- infection and at the same time
                estimated both quantitative load and physical status of the virus: high viral load (&gt; 6,5 lg copies
                of HPV DNA per 100000 cells) in episomal form or low load (&lt; 6,5 lg copies of HPV DNA per 100000
                cells) in integrated form of the virus. According to calculations a relative chance of appearing of CC
                in CIN patients with unfavorable combination of factors was 7,5 times higher than in other patients.
            </value>
        </row>
        <row>
            <value>9</value>
            <value>6</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The article presents the results of a study of the dynamics of morbidity and mortality from cervical
                cancer among women in Karelia and detection rate of cancer in situ of the cervix during cytological
                screening in various areas of Karelia from 1998 to 2012. It is shown that cervical cancer incidence in
                Karelia for this period increased 3 times more. At the same time it is marked an increase of the level
                of cervical cancer early diagnosis by increasing the detection rate of the disease in Stages I-II from
                66.1% to 77.4% and also an increase in the detection rate of preinvasive cervical cancer from 24.3% in
                1998-2002 up to 62.8% in 2008-2012. On the example of Kondopoga region of Karelia it is showed that to
                ensure early diagnosis of cervical cancer in 95% it is necessary a coverage of the female population at
                least 70%. This coverage can be achieved by establishing a state program of organized cytological
                screening for cervical cancer.
            </value>
        </row>
        <row>
            <value>10</value>
            <value>7</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Cervical cancer is the leading gynecological tumor associated with pregnancy accounting for 1.2-4.5
                cases per 10,000 births. Precancerous diseases of the cervix, which include cervical intraepithelial
                neoplasia of high severity (H-SIL) combined with pregnancy, are even more relevant since the frequency
                of their occurrence can achieve 5.0%. Besides the peak of dysplastic cervical changes occurs in the mean
                age at delivery in the Russian Federation (28 years). The features of diagnosis and management of these
                patients during pregnancy, delivery and postpartum require a multidisciplinary approach from doctors of
                different specialties.
            </value>
        </row>
        <row>
            <value>11</value>
            <value>8</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Case Study Ms. S.G., a 56-year-old woman with a poorly differentiated squamous cell carcinoma of the
                anal canal, American Joint Committee on Cancer stage III (T2, N1, M0), was initially diagnosed in
                December, 2007 at an outside institution after she had noted blood in her stool for approximately 6
                months. Her medical history was unremarkable. She had no known history of HIV or other sexually
                transmitted diseases. At the time of presentation, Ms. S.G. had an Eastern Cooperative Oncology Group
                performance status of 1 related to cancer-related pain. Her appetite and weight were both stable. A
                complete colonoscopy demonstrated a large, immobile, ulcerated, firm, 4-cm lesion in the distal rectum,
                arising from the anal canal. Initial staging positron emission tomography/computed tomography (PET/CT)
                scan revealed a hypermetabolic inferior anorectal mass with left perirectal and presacral nodal
                metastases. There was no definite evidence of distant metastatic disease. Ms. S.G. received
                chemoradiation treatment following her diagnostic studies, with a total dose of 45 Gy over 26 fractions
                to the pelvis with concurrent infusional fluorouracil (5-FU; 2, 450 mg over 7 days) and mitomycin C (12
                mg/m(2) on day 1) at an outside institution. However, during her chemoradiation therapy, Ms. S.G.
                experienced a 3-week treatment break due to severe radiation dermatitis, as recommended by her outside
                treating oncologist. Upon treatment completion, Ms. S.G. underwent a biopsy of the anal canal, which
                revealed no evidence of residual malignancy. As recommended by her treating oncologist, she received
                four additional cycles of adjuvant infusional 5-FU in combination with leucovorin. Shortly thereafter,
                Ms. S.G. developed progressive pelvic pain. She underwent a second PET/CT scan, revealing mixed
                findings: interval resolution of abnormal standardized uptake value (SUV) activity at the primary tumor
                in the anal canal, but an increase in the size and SUV of nodal disease within the left perirectal and
                presacral regions. A CT-guided biopsy noted a perirectal abscess requiring drainage but was inconclusive
                for disease recurrence; Ms. S.G. was treated with IV antibiotics. Six weeks later, repeat radiographic
                imaging noted additional changes suspicious for regional recurrence, which was biopsy-confirmed. Ms.
                S.G. was subsequently referred to MD Anderson Cancer Center for consideration of salvage pelvic
                exenteration. On physical exam a mass was palpated in the left lower quadrant, but there was no evidence
                of inguinal adenopathy. On digital rectal exam there was notable external erythema with a fixed mass and
                moderate sphincter tone. A chest CT scan showed no definite evidence of metastatic disease, but an MRI
                of the abdomen/pelvis indicated the presence of a complex partially necrotic mass (7.6 ?? 4.9 ?? 7.3
                cm(3)) extending to the rectosigmoid junction, inseparable from the left lateral bowel wall, with
                partial encasement of the bowel. In addition, there was infiltration of the left piriformis muscle and
                cervix consistent with local recurrence. She was referred to medical oncology and radiation oncology for
                consideration of reirradiation with concurrent neoadjuvant chemotherapy for palliation and possible
                surgical resection. In early December 2008, Ms. S.G. received intensity-modulated radiation therapy
                (IMRT), with a total dose of 27 Gy over 18 fractions. She received concurrent infusional 5-FU at 300
                mg/m(2)/day, from Monday to Friday, on the days of radiation. She also received a weekly bolus dose of
                cisplatin at 20 mg/m(2). The intent was to treat to 30 Gy, but the patient deferred further treatment
                early due to anorectal irritation. She then underwent restaging with a PET/CT scan and a pelvic MRI in
                February 2009, revealing radiographic partial response of the known pelvic recurrence and reduced pelvic
                pain (Figures 1A and 1B). Figure 1 Figure 1. Contrast-enhanced axial MRI image of the lower pelvis. (A)
                Pretreatment, complex mass at the rectosigmoid junction measuring approximately 7.6 ?? 4.9 ?? 7.3 cm3.
                (B) Posttreatment, large necrotic mass measuring 3-4 cm in greatest dimension. Unfortunately, in the
                interim, she developed multiple bilateral liver lesions and punctate pulmonary nodules consistent with
                distant disease (Figures 2A, 2B, and 3A). Figure 2 Figure 2. Contrast-enhanced axial CT images of the
                lung. (A) Subcentimeter nodular opacity in the left upper lobe. (B) Subcentimeter opacity in the right
                upper lung lobe. Figure 3 Figure 3. Contrast-enhanced axial CT image of the liver. (A) Pretreatment,
                multiple bilateral liver lesions. (B) Posttreatment, near-complete resolution of liver lesions. Ms. S.G.
                proceeded to undergo systemic chemotherapy with carboplatin at an area under the concentration-time
                curve of 5 and paclitaxel at 175 mg/m(2) day 1, every 21 days. She tolerated the treatment well. After
                three cycles of chemotherapy, radiographic imaging indicated a mixed response to treatment: interval
                resolution of the pulmonary nodules, stability of disease in the pelvic mass, but progression of the
                hepatic metastases. Given Ms. S.G.'s continuing excellent performance status, further treatment was
                recommended. Based on recent published literature, a regimen of cisplatin at 80 mg/m(2) day 1,
                vinorelbine at 25 mg/m(2) day 1 (repeated every 28 days), and weekly cetuximab (VCC) at 250 mg/m(2) was
                initiated. Remarkably, following three cycles of treatment, despite receiving multiple prior lines of
                chemotherapy, her restaging CT scan demonstrated complete radiographic response of the intrathoracic
                disease, stable response of the anorectal mass, and near-complete resolution of the hepatic lesions
                (Figures 3A and 3B). Overall, Ms. S.G. had tolerated her treatment very well. Given her response and
                tolerability, she was evaluated again for curative surgical resection. However, she opted to receive the
                VCC regimen closer to home and was lost to follow-up. Unfortunately, we were unable to obtain medical
                records confirming if she indeed received additional treatment as recommended. Ms. S.G. was noted to
                have passed away due to progression of her disease approximately 6 months later.
            </value>
        </row>
        <row>
            <value>12</value>
            <value>9</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Objective???Cases of prolapsed myoma in which pregnancy was carried to full term or near term after
                vaginal myomectomy are very rare. Previously, only two such cases have been reported. In addition, both
                those patients had a pedunculated leiomyoma, which could be treated by twisting or clamping. Here, we
                report a case of a patient who was able to carry her pregnancy to term despite vaginal myomectomy for
                semipedunculated myoma at 13 weeks of pregnancy. Study Design???This study is a case presentation.
                Results???The myoma nucleus was removed by making an incision on the surface of the mass. Systemic and
                transvaginal antibiotics were prescribed after the surgery. Uterine contractions, short cervix, or
                cervical funneling was not observed in the remaining duration of pregnancy. Conclusion???While
                performing myomectomy during pregnancy, removal of the myoma nucleus is safer than twisting. In
                addition, postoperative administration of local or systemic antibiotic agents does not adversely affect
                pregnancy.
            </value>
        </row>
        <row>
            <value>13</value>
            <value>11</value>
            <value>1</value>
            <value>Purpose of investigation</value>
            <value>Objective</value>
            <value>To evaluate the distribution of GTPases RhoA, RhoB, and Cdc42 in cervical intraepithelial neoplasias
                (CIN) and invasive neoplasias of the uterine cervix.
            </value>
        </row>
        <row>
            <value>14</value>
            <value>11</value>
            <value>2</value>
            <value>Materials and methods</value>
            <value>Methods</value>
            <value>samples of neoplastic lesions of the uterine cervix of 44 patients were classified in: CIN I (n =
                10), CIN II (n = 10), CIN III (n = 09), and invasive carcinoma (n = 15). Antibodies anti-RhoA,
                anti-RhoB, and anti-Cdc42 were used and staining was classified as: negative, mild, moderate, and
                intense positive.
            </value>
        </row>
        <row>
            <value>15</value>
            <value>11</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>When compared with dysplastic cells, superficial cells showed: higher expression of RhoB in CIN I (p
                = 0.0018), and lower expression of Cdc42 in CIN I (p = 0.0225). The authors observed higher expression
                of RhoA (p = 0.0002) and RhoB (p = 0.0046) in CIN dysplastic cells when compared with invasive carcinoma
                cells.
            </value>
        </row>
        <row>
            <value>16</value>
            <value>11</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>GTPases Rho may be involved with the regulation of biological processes, important to the progression
                of cervical neoplasias. Probably, RhoA is important for maintenance of cell differentiation and RhoB
                protects cells from malignant cervical neoplasia.
            </value>
        </row>
        <row>
            <value>17</value>
            <value>12</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Uterine cervical cancer is one of the most frequently observed malignant gynaecologic tumors.
                Carcinoma in situ or invasive cervical carcinoma develops from a low-grade intraepithelial lesion of the
                cervix over time. Human papillomavirus (HPV) is known to be a major contributing factor. With
                improvements in molecular genetic technologies, the authors attempted to identify the genomic changes
                associated with cervical precancerous lesions. In this study, changes in gene copy numbers were
                evaluated in five cases of severe uterine cervical dysplasia (HPV negative, two cases; HPV 16 and 18
                positive only, three cases) by array comparative genomic hybridization (array CGH), and genes with copy
                number changes were compared between the two groups. Between the HPV positive and negative groups, only
                one gene was found to be upregulated more than 1.5 fold (3q23-q24), and no downregulated genes were
                identified. In conclusion, it is useful to evaluate genomic aberrations in cervical cancer using array
                CGH.
            </value>
        </row>
        <row>
            <value>18</value>
            <value>13</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>In this study, a well-defined glucose and guanidine based copolymer, galactosylated 2-hydroxypropyl
                methacrylamide-s-3-guanidinopropyl methacrylamide (HPMA-s-GPMA, abbreviated as GGH) was prepared and
                self-assembled with shRNA to inhibit human telomerase reverse transcriptase (hTERT) gene expression in
                vitro in order to develop small hairpin RNA (shRNA) carrier. First of all, 2-hydroxypropyl
                methacrylamide-s-3-aminopropyl methacrylamide (HPMA-s-APMA) copolymers were synthesized by aqueous
                reversible addition-fragmentation chain transfer polymerization (RAFT), followed by galactosylation and
                guanidinylation. Then, three target shRNAs containing green fluorescent proteins (GFP) report gene were
                combined with GGH to form shRNA/GGH polyplexes. The results indicated that GGH copolymers could condense
                shRNA to form shRNA/GGH polyplex particles with diameter ranged from 122.8 to 331.6???nm in PBS, and
                zeta potential values from +3.7 to +16.5???mV at various charge ratios (N/P). MTT assay of shRNA/GGH and
                shRNA/poly(ethylenimine) (PEI) polyplexes revealed that the cytotoxicity of GGH copolymers was
                significantly lower than that of PEI in human hepatocellular liver carcinoma cells (HepG2) and human
                cervix epithelial carcinoma cells (HeLa) cell lines. The results showed that the transfection efficiency
                of shRNA/GGH polyplexes was higher than that of PEI at charge ratio of 12 in HepG2 cell line. The
                galactose competition assay as showed that galactose might inhibit the ASGP-R mediate cell uptake of
                GGH3/NC polyplex. Furthermore, shRNA/GGH polyplexes could effectively silence hTERT mRNA expression in
                the serum-free medium (P???&lt;???0.01). In addition, it was indicated that shRNA/GGH polyplexes can
                decrease the aggregation of protein in the media with the presence of 10 % serum. The hTERT mRNA
                expressions in HepG2 cells also have significant difference between siRNA/GGH polyplexes and blank
                samples (P???&lt;???0.05). This article is protected by copyright. All rights reserved.
            </value>
        </row>
        <row>
            <value>19</value>
            <value>14</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>20</value>
            <value>15</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>21</value>
            <value>16</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>The "see and treat" approach, proceeding without a biopsy directly to uterine cervix conization in
                women diagnosed with high grade squamous intraepithelial lesion (HGSIL) on Pap smear, shortens the
                treatment duration, lessens patient anxiety, and reduces health care costs.
            </value>
        </row>
        <row>
            <value>22</value>
            <value>16</value>
            <value>2</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value>To evaluate the level of diagnostic accuracy and the over-treatment rate in the "see and treat"
                versus conventional management of women diagnosed with HGSIL.
            </value>
        </row>
        <row>
            <value>23</value>
            <value>16</value>
            <value>3</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We retrospectively reviewed all women with HGSIL who had undergone the "see and treat" approach
                during 2001-2011 at Soroka University Medical Center. Similar cohorts, who were managed conventionally
                with a cervical biopsy prior to the conization, served as a comparison group.
            </value>
        </row>
        <row>
            <value>24</value>
            <value>16</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value>The study population consisted of 403 women: 72 (18%) had undergone the "see and treat" approach and
                331 (82%) conventional management. The false positive rate was 11% for the "see and treat" group,
                compared to 6% for the conventional management group (P = 0.162). Similarly, no statistically
                significant difference was observed when comparing the positive predictive value (PPV) of high grade
                dysplasia diagnosed on Pap smear (PPV 88.9%) versus cervical biopsy (PPV 93.8%) (P = 0.204). Moreover,
                both the false positive rate and PPV remained similar in subgroups of patients, according to age,
                menopausal status, number of births, and colposcopy findings.
            </value>
        </row>
        <row>
            <value>25</value>
            <value>16</value>
            <value>5</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>The accuracy level of HGSIL diagnosis on Pap smear is similar to that of high grade dysplasia on a
                cervical biopsy. We therefore recommend referring patients with HGSIL directly to conization. Skipping
                the biopsy step was not associated with significant over-treatment or other adverse effects.
            </value>
        </row>
        <row>
            <value>26</value>
            <value>17</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value></value>
        </row>
        <row>
            <value>27</value>
            <value>17</value>
            <value>2</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value></value>
        </row>
        <row>
            <value>28</value>
            <value>17</value>
            <value>3</value>
            <value>Material and methods</value>
            <value>Methods</value>
            <value>The data from the Lower Silesian Cancer Registry concerning the years 1984-2009 formed the material
                of the present study.
            </value>
        </row>
        <row>
            <value>29</value>
            <value>17</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>30</value>
            <value>17</value>
            <value>5</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value></value>
        </row>
        <row>
            <value>31</value>
            <value>18</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value>Many cases of unexpected radioiodine uptake have been reported, including physiological uptake in
                healthy tissue and in both benign and malignant nonthyroidal lesions. However, iodine uptake in the
                uterus has not been well assessed. In this article, we systemically analyzed iodine uptake in the uterus
                and identified the site in which uptake occurred.
            </value>
        </row>
        <row>
            <value>32</value>
            <value>18</value>
            <value>2</value>
            <value>Materials and methods</value>
            <value>Methods</value>
            <value>Seventy-six female patients who underwent SPECT/CT from neck to pelvis were included in this study; 5
                patients with uterine uptake received pelvic MRI. Iodine uptake in the uterus was diagnosed with
                SPECT/CT and compared with the findings of the MRI. Serum TSH level, administered dose of iodine-131 and
                number of radioiodine therapies were compared between the 2 groups with and without iodine uptake in the
                uterus.
            </value>
        </row>
        <row>
            <value>33</value>
            <value>18</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Twenty (26.3%) of 76 patients showed iodine uptake in the uterine cervix on SPECT/CT. It was
                difficult to distinguish the uptake in the uterus from that in the urinary bladder or rectum using only
                planar images. The patients with the uterine uptake were younger than those without (median age, 46.5
                vs. 62, P = 0.011). There were no significant differences in serum TSH level, administered dose of
                iodine-131, or number of radioiodine therapies between the 2 groups. In all instances of the 5 patients
                who underwent pelvic MRI, iodine uptake in the uteri was located in nabothian cysts.
            </value>
        </row>
        <row>
            <value>34</value>
            <value>18</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Iodine uptake in the uterus is frequently found if pelvic SPECT/CT is performed. Nabothian cysts are
                a predominant cause of iodine uptake in the uterine cervix.
            </value>
        </row>
        <row>
            <value>35</value>
            <value>19</value>
            <value>1</value>
            <value>Summary</value>
            <value>Conclusions</value>
            <value>The aims of this study were to: investigate fascin expression in normal cervix, cervical
                intraepithelial neoplasia (CIN), and stage IA1 squamous cell carcinoma (SCC).Fascin immunostaining was
                performed in cervical biopsies showing normal squamous epithelium (n???=???10), CIN 1 (n???=???10), CIN
                2-3 without invasion (n???=???11), and CIN 2-3 adjacent to SCC (n???=???40); SCC was also present in 27
                of the latter cases.Fascin expression in normal squamous epithelium was restricted to basal and
                parabasal cells, whereas there was increased staining in immature squamous metaplasia and in most CIN
                lesions. Full thickness staining was more frequent in high grade CIN adjacent to invasion than in CIN
                2-3 alone. Eighteen SCCs (67%) were fascin positive and seven cases showed accentuated staining at the
                tumour-stromal interface (invasive front). There was no consistent relationship between fascin
                expression in CIN lesions and in corresponding carcinomas. Fascin staining in reactive stromal cells
                sometimes made identification of the invasive neoplastic cells difficult.Fascin is overexpressed in most
                CIN lesions and this may be a marker of increased invasive potential in high grade CIN. However, fascin
                staining does not distinguish low and high grade CIN or in situ and invasive squamous neoplasia.
                Therefore fascin has limited diagnostic utility in demonstrating superficial stromal invasion.
            </value>
        </row>
        <row>
            <value>36</value>
            <value>20</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>Studies on the development of the embryological and fetal development of the cervix and the vagina
                are rare and mostly go back to the first decades of the last century. The aims of this review were to
                present the latest knowledge concerning the developmental origin of cervical and vaginal epithelium and
                to point out new results in the context of different clinical findings.
            </value>
        </row>
        <row>
            <value>37</value>
            <value>20</value>
            <value>2</value>
            <value>Materials and methods</value>
            <value>Methods</value>
            <value>Relevant studies published between 1910 and 2013 were identified via PubMed, MEDLINE, OVID, Web of
                Science, and EMBASE. The reference lists of retrieved articles were reviewed to locate additional
                articles. Each abstract was reviewed, and the appropriate publications were obtained and reviewed as
                well. A total of 33 articles and 8 book chapters were selected for citation in this review.
            </value>
        </row>
        <row>
            <value>38</value>
            <value>20</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>39</value>
            <value>20</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>These results are of high clinical relevance and may provide new insight into the histogenesis of
                ectopy, vaginal adenosis, and the congenital transformation zone. They should be added to the
                explanations in gynecological, colposcopical, and gynecopathological textbooks.
            </value>
        </row>
        <row>
            <value>40</value>
            <value>21</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Ferritin, a major iron storage protein in most living organisms, plays a crucial role in iron
                metabolism. In this study, the ferritin subunit MnFer was identified in the oriental river prawn
                (Macrobrachium nipponense) and functionally characterized. The full-length cDNA of MnFer is 999 bp in
                size with a 122-bp 5'-untranslated region (UTR), a 364-bp 3'-UTR and a 513-bp open reading frame that
                encodes a protein possessing 171 amino acids and a deduced molecular weight of 19.40 kDa. Prawn ferritin
                transcripts are expressed in muscle, heart, hepatopancreas, gill, hemocytes, ovary and testis.
                Quantitative real-time PCR revealed that the abundance of ferritin transcript was highest in the
                hepatopancreas followed by muscle. Ferritin transcript expression in muscle increased six-fold 3 h after
                the injection of iron. In the gill, a four-fold increase in ferritin transcript expression was detected
                3 h post-injection; the expression remained elevated for 48 h. Heart ferritin mRNA expression increased
                up to seven-fold at 24 h post-injection. No significant difference was found in the hepatopancreas. The
                iron binding capacity of recombinant ferritin protein was also demonstrated in this study. In hemocyte
                experiments, the transcriptional expression of MnFer showed the strongest response to Aeromonas
                hydrophila. As a whole, our study suggested that the ferritin from M. nipponense may play critical roles
                in cellular and organismic iron homeostasis along with in innate immune defense.
            </value>
        </row>
        <row>
            <value>41</value>
            <value>22</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The HLH transcriptional regulator Id4 exerts important roles in different organs, including the
                neural compartment, where Id4 loss usually results in early lethality. To explore the role of this
                basally restricted transcription factor in the mammary gland, we generated a cre-inducible mouse model.
                MMTV- or K14-cre-mediated deletion of Id4 led to a delay in ductal morphogenesis, consistent with
                previous findings using a germ-line knockout mouse model. A striking increase in the expression of ER?
                (Esr1), PR and FoxA1 was observed in both the basal and luminal cellular subsets of Id4-deficient
                mammary glands. Together with chromatin immunoprecipitation of Id4 on the Esr1 and Foxa1 promoter
                regions, these data imply that Id4 is a negative regulator of the ER? signaling axis. Unexpectedly,
                examination of the ovaries of targeted mice revealed significantly increased numbers of secondary and
                antral follicles, and reduced Id4 expression in the granulosa cells. Moreover, expression of the cascade
                of enzymes that are crucial for estrogen biosynthesis in the ovary was decreased in Id4-deficient
                females and uterine weights were considerably lower, indicating impaired estrogen production. Thus,
                compromised ovarian function and decreased circulating estrogen likely contribute to the mammary ductal
                defects evident in Id4-deficient mice. Collectively, these data identify Id4 as a novel regulator of
                estrogen signaling, where Id4 restrains ER? expression in the basal and luminal cellular compartments of
                the mammary gland and regulates estrogen biosynthesis in the ovary.
            </value>
        </row>
        <row>
            <value>42</value>
            <value>23</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The sloth's giant tick Amblyomma varium Koch, which is a neotropical species that inhabits tropical
                rainforests, is the largest tick reported to date. The adult stage of this tick parasitizes mammals from
                the families Bradypodidae and Magalonychidae (Xenarthra) nearly exclusively. This study aimed to
                describe morphological and histological features of the reproductive system and the oocyte maturation
                process of this tick species. The ovary of A. varium is a long single tubular organ that is
                horseshoe-shaped, winding and arranged in the posterior part of the body. Two oviducts are connected to
                the ovary on each side; these thicken at certain region forming the uterus (common oviduct), followed by
                a muscular connecting tube, vagina and genital aperture. A large number of oocytes at different stages
                of development are attached to the ovary wall by the pedicel, as they reach maturity they are released
                into the ovary lumen and from there to the genital aperture. These oocytes develop simultaneously and
                asynchronically along the ovary. Amblyomma varium oocytes were classified into five development stages
                (i.e., I-V), and specific characteristics were observed; the processes of yolk and chorion deposition
                begin early in oocytes stage II, and oocytes V exhibit a very thick chorion and eggs of a large size.
                These characteristics are likely adaptations that enhance the survival and the reproductive success of
                this extremely host-specific tick, which is limited to a particular environment.
            </value>
        </row>
        <row>
            <value>43</value>
            <value>24</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>For many decades, elevated androgens in women have been associated with poor reproductive health.
                However, recent studies show that androgens, contrary to popular belief, play a crucial role in women's
                fertility. The following review provides an overall perspective about how androgens and androgen
                receptor-mediated actions regulate normal follicular development as well as discuss emerging concepts,
                latest perceptions and controversies regarding androgen actions and signaling in the ovary.
            </value>
        </row>
        <row>
            <value>44</value>
            <value>26</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value></value>
        </row>
        <row>
            <value>45</value>
            <value>26</value>
            <value>2</value>
            <value>Study design</value>
            <value>Methods</value>
            <value>Fifty-eight adolescent girls (29 normal weight and 29 overweight-obese) diagnosed with PCOS and 28
                apparently healthy girls (controls) were enrolled in the study. BMI was calculated in all cases. Serum
                AMH, hormonal and metabolic parameters were compared between patients with PCOS (normal weight and
                overweight-obese) and controls.
            </value>
        </row>
        <row>
            <value>46</value>
            <value>26</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Serum AMH did not differ between patients with PCOS and controls (p=0.283), and no correlation was
                found between BMI and AMH. A significant positive correlation was found between 2-h plasma glucose on
                75-g oral glucose tolerance test and AMH (R=0.364, p=0.005). HOMA-IR index and insulin were
                significantly higher in overweight-obese patients with PCOS than in controls, but no significant
                difference was found between controls and normal-weight patients with PCOS.
            </value>
        </row>
        <row>
            <value>47</value>
            <value>26</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>AMH was not found to be a reliable predictor for the presence of PCOS, and serum AMH did not differ
                between obese and non-obese adolescent patients with PCOS.
            </value>
        </row>
        <row>
            <value>48</value>
            <value>27</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Interest in hydroxy - carboxylic acid 2 (HCA2) receptor has been raised since it is the target of
                antidyslipidemic drug nicotinic acid. The present study aimed to evaluate the presence of mRNA of this
                receptor in different organs of laboratory rat. Twenty two different organs of rats including mesenteric
                fat, epididymis (head, body and tail), testis, ovary, xiphoid process, liver, adrenal gland, femoral
                head, proximal epiphyseal and metaphyseal bone marrow of femur, esophagus, glandular stomach,
                forestomach, intestines, colons, heart, spleen, kidney, trachea, lung, skeletal muscle (quadriceps),
                cerebrum and cerebellum were removed and examined for HCA2 mRNA by RT- PCR method. The mRNA for HCA2
                receptor was detected in all analyzed tissues. In conclusion, the different organs of rat express HCA2
                receptor mRNA which makes a proper animal model for future studies on the physiological and
                pharmacological roles of this receptor in vivo.
            </value>
        </row>
        <row>
            <value>49</value>
            <value>28</value>
            <value>1</value>
            <value>Study question</value>
            <value>Objective</value>
            <value>Are arterial stiffness, carotid intima-media thickness and diastolic dysfunction increased in young
                women with polycystic ovary syndrome (PCOS) independently of the effects of obesity?
            </value>
        </row>
        <row>
            <value>50</value>
            <value>28</value>
            <value>2</value>
            <value>Summary answer</value>
            <value>Unassigned</value>
            <value>Insulin resistance and central obesity are associated with subclinical cardiovascular dysfunction in
                young women, but a diagnosis of PCOS does not appear to confer additional risk at this age.
            </value>
        </row>
        <row>
            <value>51</value>
            <value>28</value>
            <value>3</value>
            <value>What is known already</value>
            <value>Unassigned</value>
            <value>Some studies have shown that young women with PCOS may have increased measures of cardiovascular
                risk, including arterial stiffness, carotid intima-media thickness and myocardial dysfunction. However,
                it is difficult to establish how much of this risk is due to PCOS per se and how much is due to obesity
                and insulin resistance, which are common in PCOS and themselves associated with greater vascular risk.
            </value>
        </row>
        <row>
            <value>52</value>
            <value>28</value>
            <value>4</value>
            <value>Study design, size, duration</value>
            <value>Unassigned</value>
            <value>This cross-sectional study comprised 84 women with PCOS and 95 healthy volunteers, aged 16-45
                years.
            </value>
        </row>
        <row>
            <value>53</value>
            <value>28</value>
            <value>5</value>
            <value>Participants/materials, setting, methods</value>
            <value>Unassigned</value>
            <value>The study was conducted in a university hospital. Subjects underwent a comprehensive assessment of
                body composition (including computed tomography (CT) assessment of visceral fat; VF), measurements of
                arterial stiffness (aortic pulse wave velocity; aPWV), common carotid intima-media thickness (ccIMT),
                diastolic function (longitudinal tissue velocity; e':a') and endocrinological measures. A sample size of
                80 in each group gave 80% power for detecting a difference of 0.45 m/s in aPWV or a difference of 0.25
                in e':a'.
            </value>
        </row>
        <row>
            <value>54</value>
            <value>28</value>
            <value>6</value>
            <value>Main results and the role of chance</value>
            <value>Unassigned</value>
            <value></value>
        </row>
        <row>
            <value>55</value>
            <value>28</value>
            <value>7</value>
            <value>Limitations, reasons for caution</value>
            <value>Unassigned</value>
            <value>The study recruited young women meeting the Rotterdam criteria for PCOS diagnosis; hence our findings
                may not be generalizable to older patients or those meeting other definitions of the syndrome.
                Biochemical hyperandrogenism was based solely on measurement of total testosterone. Cases and controls
                were not matched in advance for age and BMI, although the influence of these variables on the
                cardiovascular outcome measures was adjusted for.
            </value>
        </row>
        <row>
            <value>56</value>
            <value>28</value>
            <value>8</value>
            <value>Wider implications of the findings</value>
            <value>Unassigned</value>
            <value>This study shows that central arterial stiffness and diastolic dysfunction are not increased in young
                women with PCOS, whereas they are associated with both insulin resistance and central obesity. Obesity
                thus represents the greatest modifiable risk factor for cardiovascular disease in young women with PCOS
                and lifestyle measures which target weight reduction are critical.
            </value>
        </row>
        <row>
            <value>57</value>
            <value>28</value>
            <value>9</value>
            <value>Study funding/competing interests</value>
            <value>Unassigned</value>
            <value>This study received no specific grant support from any funding body. The authors have no conflicts of
                interest to declare.
            </value>
        </row>
        <row>
            <value>58</value>
            <value>29</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Twenty-one-day-old female Wistar rats were treated daily with orally administered soy isoflavones
                (SIFs) at concentrations of 50, 100, or 200mg/kg body weight from weaning until sexual maturity (3mo.),
                and ovarian follicle development was evaluated. At the end of the treatment period, the ultrastructure
                of the ovarian granulosa cells was examined by transmission electron microscopy. The apoptotic cell
                death of ovarian granulosa cells was detected using TUNEL staining. The mRNA expression levels of
                caspase-3, caspase-8, caspase-9, Bcl2, Bax, and Fas were determined by real-time quantitative PCR. The
                protein expression levels of caspase-3, Bcl2, Bax, and Fas were determined by western blotting. Our data
                showed that exposure to SIFs resulted in morphological changes consistent with ovarian granulosa cell
                apoptosis. The percentage of TUNEL-positive granulosa cells was increased. The mRNA expression levels of
                the apoptosis-related genes caspase-3, caspase-8, caspase-9, Bax, and Fas increased significantly. The
                protein levels of Bax, Fas, and cleaved caspase-3 were also increased. These results indicate that the
                exposure of rats to modest doses of SIFs from weaning until sexual maturity can affect ovarian follicle
                development by inducing apoptosis. The mechanism of SIF-induced alterations in ovarian follicle
                development may involve the activation of Fas-mediated and Bcl2/Bax-mediated apoptotic signaling
                pathways.
            </value>
        </row>
        <row>
            <value>59</value>
            <value>30</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>60</value>
            <value>31</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Lung transplant recipients (LTRs) are at life-long risk for infections and disseminated diseases
                owing to their immunocompromised state. Besides organ failure and sepsis, infection can trigger acute
                and chronic graft rejection which increases mortality. Medical prophylaxis and treatment are based on
                comprehensive diagnostic work-up including previous history of infection and airway colonisation to
                reduce long-term complications and mortality. Common bacterial pathogens include Pseudomonas and
                Staphylococcus, whilst Aspergillus and Cytomegalovirus (CMV) are respectively the commonest fungal and
                viral pathogens. Clinical symptoms can be various in lung transplant recipients presenting an
                asymptomatic to severe progress. Regular control of infection parameters, daily lung function testing
                and lifelong follow-up in a specialist transplant centre are mandatory for early detection of bacterial,
                viral and fungal infections. After transplantation each patient receives intensive training with rules
                of conduct concerning preventive behaviour and to recognize early signs of post transplant
                complications. Early detection of infection and complications are important goals to reduce major
                complications after lung transplantation.
            </value>
        </row>
        <row>
            <value>61</value>
            <value>32</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Undifferentiated embryonal sarcoma of the liver (UESL) is a rare malignant tumor that occurs
                predominantly in children and has a poor prognosis. Here, we report a novel case in which the UESL
                presented in the left lobe of the liver and metastasized into both lungs after surgical resection. The
                patient recovered after our administration of an immunotherapeutic combination of DCs (Dendritic Cells)
                and multi-immune cells, such as cytokine-induced killer cells (CIKs) and natural killer cells (NKs).
                After the third cycle of immunotherapy, a CT scan showed a remarkable regression of the lung metastases.
                This finding supports the conclusion that the DC-based treatment is a promising potential strategy for
                treating patients with relapsed UESL.
            </value>
        </row>
        <row>
            <value>62</value>
            <value>33</value>
            <value>1</value>
            <value>Objective:</value>
            <value>Unassigned</value>
            <value>Identify predictors of non-compliance with first round screening exams in the Prostate, Lung,
                Colorectal and Ovarian (PLCO) Cancer Screening Trial.
            </value>
        </row>
        <row>
            <value>63</value>
            <value>33</value>
            <value>2</value>
            <value>Method:</value>
            <value>Unassigned</value>
            <value>PLCO was conducted from 1993-2011 at 10 US institutions. A total of 154,897 healthy men and women
                ages 55-74 years were randomized. Intervention arm participants were invited to receive
                gender-appropriate screening exams for prostate, lung, colorectal and ovarian cancer. Using
                intervention-arm data (73,036 participants), non-compliance percentages for 13 covariates were
                calculated, as were unadjusted and adjusted odds ratios (ORs), and 95% confidence intervals. Covariates
                included demographic factors as well as factors specific to PLCO (e.g., method of consent, distance from
                screening center).
            </value>
        </row>
        <row>
            <value>64</value>
            <value>33</value>
            <value>3</value>
            <value>Results:</value>
            <value>Unassigned</value>
            <value>The rate of non-compliance was 11% overall but varied by screening center. Significant associations
                were observed for most covariates but indicated modest increases or decreases in odds. An exception was
                use of a two-step consent process (consented intervention arm participants for exams after
                randomization) relative to a one-step process (consented all participants prior to randomization) (OR:
                2.2, 95% CI: 2.0-2.5). Non-compliance percentages increased with further distance from screening
                centers, but ORs were not significantly different from 1.
            </value>
        </row>
        <row>
            <value>65</value>
            <value>33</value>
            <value>4</value>
            <value>Conclusions:</value>
            <value>Unassigned</value>
            <value>Many factors modestly influenced compliance. Consent process was the strongest predictor of
                compliance.
            </value>
        </row>
        <row>
            <value>66</value>
            <value>34</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Chemoradiotherapy is a well-established treatment paradigm in oncology. There has been strong
                interest in identifying strategies to further improve its therapeutic index. An innovative strategy is
                to utilize nanoparticle (NP)chemotherapeutics in chemoradiation. Since the most commonly utilized
                chemotherapeutic with radiotherapy is cisplatin, the development of a NP cisplatin for chemoradiotherapy
                has the highest potential impact on this treatment. Here, we report the development of a NP comprised of
                polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin prodrug (Cisplatin-PSQ) and its utilization
                in chemoradiotherapy using non-small cell lung cancer as a disease model. Cisplatin-PSQ NP has an
                exceptionally high loading of cisplatin. Cisplatin-PSQ NPs were evaluated in chemoradiotherapy in vitro
                and in vivo. They demonstrated significantly higher therapeutic efficacy when compared to cisplatin.
                These results suggest that the Cisplatin-PSQ NP holds potential for clinical translation in
                chemoradiotherapy.
            </value>
        </row>
        <row>
            <value>67</value>
            <value>35</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Laboratory mice are important tools for biomedical research. Aiming to investigate the phylogeny and
                evolution of laboratory mice, we investigated the mtDNA sequences of classical inbred strains, classical
                outbred stocks and wild-derived inbred strains. Our results showed that the most classical outbred
                stocks and classical inbred strains are descended from a single mtDNA ancestor. The phylogenic analysis
                supports the topology of M. m. castaneus / M. m. domesticus as sister subspecies, and the divergence
                time between the two sister subspecies and M. m. musculus was 493,000 (435,000-557,000) years ago.
                Furthermore, the mtDNA polymorphisms accumulated in the last 100years in the laboratory mice are under a
                relaxed purifying selection.
            </value>
        </row>
        <row>
            <value>68</value>
            <value>36</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Coccidioides immitis and Coccidioides posadasii contribute to the development of Valley Fever. The
                ability of these fungal pathogens to evade the host immune system creates difficulty in recognition and
                treatment of this debilitating infection. In this review, we describe the current knowledge of Valley
                Fever and approaches to improve prevention, detection, and treatment.
            </value>
        </row>
        <row>
            <value>69</value>
            <value>41</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>BACKGROUND. Patients with mutations that inactivate kisspeptin signaling are infertile.
                Kisspeptin-54, the major circulating isoform of kisspeptin in humans, potently stimulates reproductive
                hormone secretion in humans. Animal studies suggest that kisspeptin is involved in generation of the
                luteinizing hormone surge, which is required for ovulation; therefore, we hypothesized that
                kisspeptin-54 could be used to trigger egg maturation in women undergoing in vitro fertilization
                therapy. METHODS. Following superovulation with recombinant follicle-stimulating hormone and
                administration of gonadotropin-releasing hormone antagonist to prevent premature ovulation, 53 women
                were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n =
                3; 6.4 nmol/kg, n = 24; 12.8 nmol/kg, n = 24) to induce a luteinizing hormone surge and egg maturation.
                Eggs were retrieved transvaginally 36 hours after kisspeptin injection, assessed for maturation (primary
                outcome), and fertilized by intracytoplasmic sperm injection with subsequent transfer of one or two
                embryos. RESULTS. Egg maturation was observed in response to each tested dose of kisspeptin-54, and the
                mean number of mature eggs per patient generally increased in a dose-dependent manner. Fertilization of
                eggs and transfer of embryos to the uterus occurred in 92% (49/53) of kisspeptin-54-treated patients.
                Biochemical and clinical pregnancy rates were 40% (21/53) and 23% (12/53), respectively. CONCLUSION.
                This study demonstrates that a single injection of kisspeptin-54 can induce egg maturation in women with
                subfertility undergoing in vitro fertilization therapy. Subsequent fertilization of eggs matured
                following kisspeptin-54 administration and transfer of resulting embryos can lead to successful human
                pregnancy. TRIAL REGISTRATION. ClinicalTrials.gov NCT01667406 FUNDING. Medical Research Council,
                Wellcome Trust, and National Institute for Health Research.
            </value>
        </row>
        <row>
            <value>70</value>
            <value>42</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The occurrence of Kalicephalus sp. of hookworms in a Russell's viper snake maintained in Chennai
                snake park trust, Chennai is reported. These worms were found in the stomach and intestine. They were
                cylindrical, thread like and had an elongate body. Anterior end was obliquely truncated with bivalvular
                buccal capsule. Short, thick and muscularised oesophagus ending in a rounded bulb was observed. In
                males, a well developed trilobed bursa was observed and the spicules were short and equal. Typical
                strongyle type eggs were found in the uterus of female worms as well as in the intestinal contents.
            </value>
        </row>
        <row>
            <value>71</value>
            <value>43</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To evaluate whether contrast-enhanced magnetic resonance imaging (MRI) could be used as a routine
                method for diagnosing cesarean scar pregnancy (CSP).
            </value>
        </row>
        <row>
            <value>72</value>
            <value>43</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>A retrospective study was performed, with review and analysis of medical records, ultrasonography
                results, MRI results, and clinical outcomes of 44 women with CSP admitted to Beijing Chaoyang Hospital,
                Beijing, China, between May 2010 and November 2013. The women initially underwent ultrasonography
                followed approximately 5days later by contrast-enhanced MRI.
            </value>
        </row>
        <row>
            <value>73</value>
            <value>43</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>CSP was accurately diagnosed in 42 cases (95.5%) using contrast-enhanced MRI compared with 39 cases
                (88.6%) using ultrasonography (P&lt;0.05). Two cases with a heterogeneous signal intensity pattern using
                MRI were initially misdiagnosed as a uterine leiomyoma and a trophoblastic tumor. No contrast
                agent-related complications occurred. The typical findings of a gestational sac embedded in the anterior
                lower part of the uterus in the sagittal T2-weighted views were identified in all the patients. All
                patients recovered well without experiencing major morbidity after treatment.
            </value>
        </row>
        <row>
            <value>74</value>
            <value>43</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Contrast-enhanced MRI could be used as a reliable adjunct and initial imaging modality for diagnosing
                CSP in select cases. The imaging features of contrast-enhanced MRI may result in a more accurate
                diagnosis before specific treatment for CSP.
            </value>
        </row>
        <row>
            <value>75</value>
            <value>44</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>76</value>
            <value>45</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Uterine intravenous leiomyomatosis (IVL) is a distinct smooth muscle neoplasm with a potential of
                clinical aggressiveness due to its ability to extend into intrauterine and extrauterine vasculature. In
                this study, chromosomal alterations analyzed by oligonucleotide array comparative genomic hybridization
                were performed in 9 cases of IVL. The analysis was informative in all cases with multiple copy number
                losses and/or gains observed in each tumor. The most frequent recurrent loss of 22q12.3-q13.1 was
                observed in 6 tumors (66.7%), followed by losses of 22q11.23-q13.31, 1p36.13-p33, 2p25.3-p23.3, and
                2q24.2-q32.2 and gains of 6p22.2, 2q37.3 and 10q22.2-q22.3, in decreasing order of frequency. Copy
                number variants were identified at 14q11.2, 15q11.1-q11.2, and 15q26.2. Genes mapping to the regions of
                loss include CHEK2, EWS, NF2, PDGFB, and MAP3K7IP1 on chromosome 22q, HEI10 on chromosome 14q, and
                succinate dehydrogenase subunit B, E2F2, ARID1A KPNA6, EIF3S2 , PTCH2, and PIK3R3 on chromosome 1p.
                Regional losses on chromosomes 22q and 1p and gains on chromosomes 12q showed overlaps with those
                previously observed in uterine leiomyosarcomas. In addition, presence of multiple chromosomal
                aberrations implies a higher level of genetic instability. Follow-up polymerase chain reaction (PCR)
                sequencing analysis of MED12 gene revealed absence of G&gt; A transition at nucleotides c.130 or c.131
                in all 9 cases, a frequent mutation found in uterine leiomyoma and its variants. In conclusion, this is
                the first report of high-resolution, genome-wide investigation of IVL by oligonucleotide array
                comparative genomic hybridization. The presence of high frequencies of recurrent regional loss involving
                several chromosomes is an important finding and likely related to the pathogenesis of the disease.
            </value>
        </row>
        <row>
            <value>77</value>
            <value>46</value>
            <value>1</value>
            <value>Aims</value>
            <value>Objective</value>
            <value>In contrast to clear cell carcinomas developing in other organs (e.g. ovary and uterus), gastric
                adenocarcinomas with clear cell features are not well characterized.
            </value>
        </row>
        <row>
            <value>78</value>
            <value>46</value>
            <value>2</value>
            <value>Methods and results</value>
            <value>Results</value>
            <value>We evaluated a series of 762 gastric adenocarcinomas for the presence of clear cell changes; and
                investigated the nature of the changes using several histochemical and immunohistochemical markers,
                their association with various clinicopathological features, and their prognostic significance. Clear
                cell changes were observed in 8.5% (n = 65) of gastric cancers. Cases with clear cell changes (GCC) were
                associated significantly with older age, intestinal type histology, body/fundic location, greater depth
                of invasion, lymph node metastases and lymphovascular invasion. An increasing proportion of clear cell
                changes indicated a worsening prognosis, and was identified as an independent marker of poor prognosis
                using the Cox proportional hazard model (hazard ratio, 0.462; P = 0.003). Of 62 GCCs subjected to
                special staining, 35 cases (55.6%) displayed cytoplasmic accumulation of glycogen, while 21 (33.3%)
                contained mucin. GCCs showing glycogen accumulation expressed AFP, glypican-3 and CD10 more commonly
                than those with mucin, which commonly expressed Muc5AC and Muc6.
            </value>
        </row>
        <row>
            <value>79</value>
            <value>46</value>
            <value>3</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Clear cell gastric adenocarcinoma is a unique subgroup of gastric cancer which, although
                heterogeneous, has a poor prognosis.
            </value>
        </row>
        <row>
            <value>80</value>
            <value>47</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>It was thought to be impossible to prolong the pregnancy in a case of uterine rupture in the second
                trimester. We encountered a case of rupture of the pregnant uterus in early mid-trimester, which we
                repaired with suture and overlapping of collagen fleece coated with fibrin glue, resulting in pregnancy
                prolongation until the 34th week. Our case and five previously reported cases were reviewed. Pregnant
                uterine rupture in mid-trimester could be repaired with suture and overlapping of collagen fleece in the
                absence of placenta percreta.
            </value>
        </row>
        <row>
            <value>81</value>
            <value>48</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Neurotensin (NT) has multiple functions, ranging from acting as a neurotransmitter to regulating
                intestinal movement. However, its function in reproductive physiology is unknown. Here, we investigated
                the functions of NT receptors (NTR1/2) and effect of NT on sperm function using mouse epididymal
                spermatozoa. Sperm protein tyrosine phosphorylation, one of the indices of sperm capacitation, was
                facilitated dose-dependently by NT administration. In addition, the acrosome reaction was promoted in
                capacitated spermatozoa and addition of a selective antagonist of NTR1 and NTR2 blocked the induction.
                Furthermore, intracellular calcium mobilization was observed following NT treatment. Thus, NT is an
                accelerator of sperm function via its functional receptors. The presence of NT was confirmed by
                immunohistochemistry and its localization was observed in epithelia of the uterus, oviduct isthmus and
                ampulla, which correspond to the fertilization route of spermatozoa. The NT mRNA level in ovulated
                cumulus cells was remarkably increased by treatment with human chorionic gonadotropin (hCG). Using an in
                vitro maturation model, we analyzed the effects of FSH, epidermal growth factor (EGF), estradiol and
                progesterone in NT production in cumulus cells. We found that FSH and EGF upregulated NT release and
                mRNA expression. Both FSH- and EGF-induced upregulation levels were inhibited by U0126, a MAPK kinase
                inhibitor, indicating that FSH and EGF regulate NT expression via a MAPK-dependent pathway. This
                evidence suggests that NT can act as a promoter of sperm capacitation and the acrosome reaction in the
                female reproductive tract.
            </value>
        </row>
        <row>
            <value>82</value>
            <value>49</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Hematopoietic stem cell gene therapy for HIV/AIDS is a promising alternative to lifelong
                anti-retroviral therapy. One of the limitations of this approach is the number and quality of stem cells
                available for transplant following &lt;i&gt;in vitro&lt;/i&gt; manipulations associated with stem cell
                isolation and genetic modification. The development of methods to increase the number of autologous,
                gene modified stem cells available for transplantation would overcome this barrier. Hematopoietic stem
                and progenitor cells (HSPC) from adult growth factor mobilized peripheral blood were cultured in the
                presence of an aryl hydrocarbon receptor antagonist (AhRA) previously shown to expand HSPC from
                umbilical cord blood. Qualitative and quantitative assessment of the hematopoietic potential of
                minimally cultured (MC-HSPC) or expanded HSPC (Exp-HSPC) was performed using an immunodeficient mouse
                model of transplantation. Our results demonstrate robust, multilineage engraftment of both MC-HSPC and
                Exp-HSPC although estimates of expansion based on stem cell phenotype were not supported by a
                corresponding increase in &lt;i&gt;in vivo&lt;/i&gt; engrafting units. Bone marrow of animals
                transplanted with either MC-HSPC or Exp-HSPC contained secondary engrafting cells verifying the presence
                of primitive stem cells in both populations. However, the frequency of &lt;i&gt;in vivo&lt;/i&gt;
                engrafting units among the more primitive CD34+/CD90+ HSPC population was significantly lower in
                Exp-HSPC compared to MC-HSPC. Exp-HSPC also produced fewer lymphoid progeny and more myeloid progeny
                than MC-HSPC. These results reveal that &lt;i&gt;in vitro&lt;/i&gt; culture of adult HSPC in AhRA
                maintains but does not increase the number of &lt;i&gt;in vivo&lt;/i&gt; engrafting cells and that HSPC
                expanded &lt;i&gt;in vitro&lt;/i&gt; contain defects in lymphopoiesis as assessed in this model system.
                Further investigation is required prior to implementation of this approach in the clinical setting.
            </value>
        </row>
        <row>
            <value>83</value>
            <value>50</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>-Pulmonary arterial hypertension (PH), whether idiopathic or related to underlying diseases such as
                HIV infection, results from complex vessel remodeling involving both pulmonary-artery smooth muscle cell
                (PA-SMC) proliferation and inflammation. CCR5, a co-receptor for cellular HIV-1 entry expressed on
                macrophages and vascular cells, may be involved in the pathogenesis of PH. Maraviroc is a new CCR5
                antagonist designed to block HIV entry.
            </value>
        </row>
        <row>
            <value>84</value>
            <value>50</value>
            <value>2</value>
            <value>Methods and results</value>
            <value>Results</value>
            <value>-Marked CCR5 expression was found in lungs from patients with idiopathic PH, in mice with
                hypoxia-induced PH and in SIV-infected macaques, in which it was chiefly localized in the PA-SMCs. To
                assess the role for CCR5 in experimental PH, we used both gene disruption and pharmacological CCR5
                inactivation in mice. Because maraviroc does not bind to murine CCR5, we used human-CCR5ki mice for
                pharmacological and immunohistochemical studies. Compared to wild-type mice, CCR5(-/-) mice or
                human-CCR5ki mice treated with maraviroc exhibited decreased PA-SMC proliferation and recruitment of
                perivascular and alveolar macrophages during hypoxia exposure. CCR5(-/-) mice reconstituted with
                wild-type bone-marrow cells and wild-type mice reconstituted with CCR5(-/-) bone-marrow cells were
                protected against PH, suggesting CCR5-mediated effects on PA-SMCs and macrophage involvement. The CCR5
                ligands CCL5 and the HIV-1 gp120 protein increased intracellular calcium and induced growth of human and
                h-CCR5ki mouse PA-SMCs; maraviroc inhibited both effects. Maraviroc also reduced the growth-promoting
                effects of conditioned media from CCL5-activated macrophages derived from human-CCR5ki mice on PA-SMCs
                from wild-type mice.
            </value>
        </row>
        <row>
            <value>85</value>
            <value>50</value>
            <value>3</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>-The CCL5-CCR5 pathway represents a new therapeutic target in PH associated with HIV or with other
                conditions.
            </value>
        </row>
        <row>
            <value>86</value>
            <value>51</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Despite a high frequency of anaemia, a positive direct antiglobulin test (DAT) and bone marrow
                hyperplasia HIV-infected patients, lack of reticulocytosis may cause underdiagnosis autoimmune
                haemolytic anaemia (AIHA) in them. This study was carried out to determine the prevalence of autoimmune
                haemolytic anaemia in HIV-infected patients and to compare the haematological/immunological
                characteristics of subjects with anaemia and those without.
            </value>
        </row>
        <row>
            <value>87</value>
            <value>51</value>
            <value>2</value>
            <value>Materials and methods</value>
            <value>Methods</value>
            <value>A total of 350 HIV-infected subjects attending the Lagos University Teaching Hospital who consented
                were recruited for the study. This included 250 subjects with anaemia (haemoglobin concentration &lt;10
                g/dl) as cases and 100 subjects without anaemia as controls. Five milliliters of venous blood drawn from
                each subject was used for the full blood count, reticulocyte count and DAT.
            </value>
        </row>
        <row>
            <value>88</value>
            <value>51</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Subjects with anaemia had lower mean CD4 cell count (284.3 cells/?l) and higher mean reticulocyte per
                cent (1.5%) than the non-anaemic subjects. The frequency of reticulocytosis was higher in female
                subjects than in males. Only 0.8% (2 of 250) of the study group screened positive to DAT, p = 0.0339.
                None of the subjects in control group screened positive to DAT.
            </value>
        </row>
        <row>
            <value>89</value>
            <value>51</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Autoimmune haemolytic anaemia is a rare complication of HIV infection in our geographical location.
            </value>
        </row>
        <row>
            <value>90</value>
            <value>52</value>
            <value>1</value>
            <value>Introduction</value>
            <value>Background</value>
            <value>Persons with HIV infection frequently present with anaemia from different causes, including use of
                antiretroviral therapy (typically zidovudine), iron deficiency, vitamin B12 deficiency, opportunistic
                infections (such as mycobacterial and fungal infections), chronic disease, AIDS-associated malignancies,
                autoimmune haemolysis, and direct effects of HIV infection itself. Persistent infection with Parvovirus
                B19 (B19) is an important treatable cause of anaemia in HIV-infected patients.
            </value>
        </row>
        <row>
            <value>91</value>
            <value>52</value>
            <value>2</value>
            <value>Case presentation</value>
            <value>Methods</value>
            <value>We present a case of anaemia in HIV positive patient who did not respond to change of drug therapy
                and nutritional supplements. Bone marrow biopsy suggested parvo virus infection.
            </value>
        </row>
        <row>
            <value>92</value>
            <value>52</value>
            <value>3</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Chronic anaemia due to Parvo virus B19 infection is a treatable cause. Human Parvo virus B19
                infection is a diagnosis of exclusion in patients who are started on antiretroviral therapy develop
                anaemia and later not responding to empirical management. Chronic anaemia requiring recurrent
                transfusions in HIV positive patient Parvo virus infection should be suspected and evaluated.
            </value>
        </row>
        <row>
            <value>93</value>
            <value>53</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The ability to elicit potent and long-lasting broadly neutralizing HIV envelope (Env)-specific
                antibodies has become a key goal for HIV vaccine development. Consequently, the ability to rapidly and
                efficiently monitor development of memory B cells in pre-clinical and clinical vaccine trails is
                critical for continued progress in vaccine design. We have developed an improved flow cytometry-based
                method for the rapid and efficient identification of gp120-specific memory B cells in peripheral blood,
                bone marrow, and mucosal tissues which allows their direct staining without the need for prior cell
                sorting or enrichment. We demonstrate staining of both HIV and SIV Env-specific memory B cells in PBMC,
                bone marrow, and rectal tissue of vaccinated and infected rhesus macaques. Validation of the method is
                illustrated by statistically significant correlations with memory B cell levels quantified by ELISPOT
                assay and with serum binding antibody titers determined by ELISA. In addition to quantification, this
                method will bring the power of flow cytometry to the study of homing and trafficking of Env-specific
                memory B cells.
            </value>
        </row>
        <row>
            <value>94</value>
            <value>54</value>
            <value>1</value>
            <value>Background and aims</value>
            <value>Objective</value>
            <value>There is little information regarding the extent difficult to cure patients with advanced liver
                fibrosis due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple
                therapy with telaprevir (TVR), pegylated interferon alfa (P) and ribavirin(R). In the TVR early access
                program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained
                virological response (SVR24).
            </value>
        </row>
        <row>
            <value>95</value>
            <value>54</value>
            <value>2</value>
            <value>Patients and methods</value>
            <value>Methods</value>
            <value>1078 patients with bridging fibrosis (n=552) or cirrhosis (n=526) diagnosed by either liver biopsy or
                noninvasive markers, with compensated bone marrow (Neutrophils &gt;1,500/mm(3), Hb &gt;12/13g/dL) and
                liver function (Albumin &gt;3.3g/dL, Platelets &gt;90,000/mL) received TVR PR for 12 weeks, followed by
                a PR tail according to label.
            </value>
        </row>
        <row>
            <value>96</value>
            <value>54</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>97</value>
            <value>54</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value></value>
        </row>
        <row>
            <value>98</value>
            <value>55</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>99</value>
            <value>56</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Systemic delivery of a lentiviral vector carrying a therapeutic gene represents a new treatment for
                monogenic disease. Previously, we have shown that transfer of the ADA cDNA in vivo rescues the lethal
                phenotype and reconstitutes immune function in ADA-deficient mice. In order to translate this approach
                to ADA-deficient SCID patients, neonatal ADA-deficient mice and newborn monkeys were treated with
                species-matched and mismatched vectors and pseudotypes. We compared gene delivery by the HIV-1-based
                vector to murine ?-retroviral vectors pseudotyped with VSV-G or murine retroviral envelopes in
                ADA-deficient mice. The VSV-G pseudotyped lentiviral vectors had the highest titer and resulted in the
                highest vector copy number in multiple tissues, particularly liver and lung. In monkeys, HIV-1 or SIV
                vectors resulted in similar biodistribution in most tissues including bone marrow, spleen, liver, and
                lung. SIV pseudotyped with the GALV envelope produced 10-30-fold lower titers than the VSV-G pseudotype,
                but had a similar tissue biodistribution and similar copy number in blood cells. The relative copy
                numbers achieved in mice and monkeys were similar when adjusted to the administered dose/kg. These
                results suggest that this approach can be scaled-up to clinical levels for treatment of ADA-deficient
                SCID subjects with sub-optimal hematopoietic stem cell transplantation options.Molecular Therapy (2014);
                doi:10.1038/mt.2014.88.
            </value>
        </row>
        <row>
            <value>100</value>
            <value>57</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Understanding the cytokine/chemokine networks in CD4+ and CD8+ T-cells during acute infection is
                crucial to design therapies for the control of early human immunodeficiency virus (HIV)/simian
                immunodeficiency virus (SIV) replication. Here, we measured early changes in CD4+ and CD8+ T-cells in
                peripheral blood (PB), bone marrow (BM) and axillary lymph node (ALN) of rhesus macaques infected with
                SIVMAC251. At 21 days after infection, all tissues showed a statistically significant loss of CD4+
                T-cells alongwith immune activation of CD8+ T-cells in PB and ALN tissues. Twenty-eight different
                cytokines/chemokines were quantified in either anti-CD3/28 antibody or Staphylococcus enterotoxin B
                stimulated single-positive CD4+ and CD8+ T-cells. PB CD4+ T-cells predominantly produced interleukin
                (IL)-2 whereas CD4+ and CD8+ T-cell subsets in tissues produced ?-chemokines both before and 21 days
                after SIV infection. Tissues generally exhibited massive upregulation of many cytokines/chemokines
                following infection, possibly in an attempt to mitigate the loss of CD4+ T-cells. There was no evidence
                of a TH1 to TH2 shift for CD4+ T-cells or TC1 to TC2 cytokine shift for CD8+ T-cells in PB, BM and ALN
                T-cell subsets during acute SIV infection. Despite upregulation of several important effector
                cytokines/chemokines (IL-2, IL-12, IL-17, IFN-?, GM-CSF) by CD4+ and CD8+ T-cells, upregulation of
                ?-chemokines (CCL2 and 22), FGF-basic, HGF and MIF, chemokines may provide a poor prognosis either by
                inducing increased virus replication or by other unknown mechanisms. Therefore drugs targeting
                ?-chemokines (CCL2 and 22), FGF-basic, HGF or MIF might be important for developing effective vaccines
                and therapeutics against HIV.
            </value>
        </row>
        <row>
            <value>101</value>
            <value>57</value>
            <value>2</value>
            <value>Importance</value>
            <value>Objective</value>
            <value>Human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection results in early
                depletion of CD4+ T-cells and dysregulation of protective immune responses. Therefore understanding the
                cytokine/chemokine networks in CD4+ and CD8+ T-cells in different tissues during acute infection is
                crucial to design therapies for the control of early viral replication. Here, we measured early changes
                in CD4+ and CD8+ T-cells in peripheral blood (PB), bone marrow (BM) and axillary lymph node (ALN) of
                rhesus macaques infected with SIVMAC251. There was no evidence of a T-helper 1 (TH1) to TH2 shift for
                CD4+ T-cells or T-cytotoxic 1 (TC1) to TC2 cytokine shift for CD8+ T-cells in PB, BM and ALN T-cell
                subsets during acute SIV infection. Despite upregulation of several important effector
                cytokines/chemokines by CD4+ and CD8+ T-cells, upregulation of ?-chemokines, fibroblast growth
                factor-basic, hepatocyte growth factor and migration inhibition factor, chemokines may provide a poor
                prognosis.
            </value>
        </row>
        <row>
            <value>102</value>
            <value>58</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Combinatorial HIV/SIV vaccine approaches targeting multiple arms of the immune system might improve
                protective efficacy. We compared SIV-specific humoral immunity induced in rhesus macaques by five
                vaccine regimens. Systemic regimens included ALVAC-SIVenv priming and Env boosting (ALVAC/Env); DNA
                immunization; and DNA plus Env co-immunization (DNA&amp;Env). RepAd/Env combined mucosal
                replication-competent Ad-env priming with systemic Env boosting. A Peptide/Env regimen, given solely
                intrarectally, included HIV/SIV peptides followed by MVA-env and Env boosts. Serum antibodies mediating
                neutralizing, phagocytic and ADCC activities were induced by ALVAC/Env, RepAd/Env and DNA&amp;Env
                vaccines. Memory B cells and plasma cells were maintained in the bone marrow. RepAd/Env vaccination
                induced early SIV-specific IgA in rectal secretions before Env boosting, although mucosal IgA and IgG
                responses were readily detected at necropsy in ALVAC/Env, RepAd/Env, DNA&amp;Env and DNA vaccinated
                animals. Our results suggest that combined RepAd priming with ALVAC/Env or DNA&amp;Env regimen boosting
                might induce potent, functional, long-lasting systemic and mucosal SIV-specific antibodies.
            </value>
        </row>
        <row>
            <value>103</value>
            <value>59</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Estrogens affect brain development of vertebrates, by impacting activity and morphology of existing
                circuits, but also by modulating embryonic and adult neurogenesis. The issue is complex as estrogens can
                not only originate from peripheral tissues, but be locally produced within the brain itself due to local
                aromatization of androgens. In this respect, teleost fishes are quite unique because aromatase is
                expressed exclusively in radial glial cells, which represent pluripotent cells in the brain of all
                vertebrates. Expression of aromatase in the brain of fish is also strongly stimulated by estrogens and
                some androgens. This creates a very intriguing positive auto-regulatory loop leading to dramatic
                aromatase expression in sexually mature fish with elevated levels of circulating steroids. Looking at
                the effects of estrogens or anti-estrogens in the brain of adult zebrafish showed that estrogens inhibit
                rather than stimulate cell proliferation and newborn cell migration. The functional meaning of these
                observations is still unclear, but these data suggest that the brain of fish is experiencing constant
                remodelling under the influence of circulating steroids and brain-derived neurosteroids, possibly
                permitting a diversification of sexual strategies, notably hermaphroditism. Recent data in frogs
                indicate that aromatase expression is limited to neurons and do not concern radial glial cells. Thus,
                until now, there is no other example of vertebrates in which radial progenitors express aromatase. This
                raises the question of when and why these new features were gained and what are their adaptive benefits.
                This article is part of a Special Issue entitled: Nuclear receptors in animal development.
            </value>
        </row>
        <row>
            <value>104</value>
            <value>60</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Using 11.7 T ultra high-field T2-weighted MRI, the present study aimed to investigate pathological
                changes of primary and secondary trigeminal pathways following neonatal transection of infraorbital
                nerve in rats. The trigeminal pathways consist of spinal trigeminal tract, trigeminal sensory nuclear
                complex, medial lemniscus, ventromedial portion of external medullary lamina and ventral posterior
                nucleus of thalamus. By selecting optimum parameters of MRI such as repetition time, echo time, and
                slice orientation, this study visualized the trigeminal pathways in rats without any contrast agents.
                Pathological changes due to the nerve transection were found at 8 weeks of age as a marked reduction of
                the areas of the trigeminal pathways connecting from the injured nerve. In addition, T2-weighted MR
                images of the trigeminal nerve trunk and the spinal trigeminal tract suggest a communication of CSF
                through the trigeminal nerve between the inside and outside of the brain stem. These results support the
                utility of ultra high-field MRI system for noninvasive assessment of effects of trigeminal nerve injury
                upon the trigeminal pathways.
            </value>
        </row>
        <row>
            <value>105</value>
            <value>61</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Neurodegeneration of cholinergic and dopaminergic neurons is a major hallmark in Alzheimer's or
                Parkinson's disease, respectively. A dysregulation in calcium homeostasis may be part of this process
                and counteracting calcium influx may have neuroprotective properties in both diseases. Therefore, we
                investigated the putative neuroprotective or neurotoxic activity of L-type calcium channel (LTCC)
                inhibitors on cholinergic and dopaminergic neurons in a rat organotypic vibrosection model. Sagittal or
                coronal vibrosections (200?m thick) of postnatal day 10 rats were cultured on 0.4?m semipermeable
                membranes for 2 weeks with 10ng/ml nerve growth factor (NGF) and/or glial-cell line derived neurotrophic
                factor (GDNF) to maintain survival of cholinergic or dopaminergic neurons, respectively. Thereafter,
                sections were incubated with 0.1, 1 or 10?M isradipine, nicardipine or verapamil for 2 weeks to explore
                cytotoxicity. Alternatively, in order to explore neuroprotective activity, vibrosections were incubated
                without growth factors but with isradipine or verapamil or with nicardipine, nimodipine or nifedipine
                from the beginning for 4 weeks. Our data show that all LTCC inhibitors exhibited no neurotoxic effect on
                cholinergic and dopaminergic neurons. Further, LTCC inhibitors did not have any neuroprotective activity
                on cholinergic neurons. However, nimodipine and nifedipine significantly enhanced the survival of
                dopaminergic substantia nigra (SN) but not ventral tegmental area (VTA) neurons, while nicardipine,
                isradipine and verapamil had no effect. Nifedipine (and more potently GDNF) reduced inflammatory
                cytokines (macrophage inflammatory protein-2, tumor necrosis factor-?), but did not influence oxidative
                stress or caspase-3 activity and did not interfere with iron-mediated overload. Our data show that
                nifedipine and nimodipine are very potent to enhance the survival of axotomized SN neurons, possibly
                influencing inflammatory processes.
            </value>
        </row>
        <row>
            <value>106</value>
            <value>62</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Nerve decompression is an important therapeutic strategy to relieve neuropathic pain and promote the
                peripheral nerve regeneration. To address these issues, we investigated the effects of nerve
                decompression on relief of neuropathic pain behaviors, redistribution of voltage-gated sodium channels
                (VGSCs), and skin reinnervation with chronic constriction injury (CCI). At post-operative week (POW) 4,
                animals were divided into a decompression group, in which the ligatures were removed, and a CCI group,
                in which the ligatures remained. Thermal hyperalgesia and mechanical allodynia at POW 8 had distinct
                reductions in decompression group compared to CCI group. At that time in CCI group, morphological
                evidence of pan VGSCs (Pan Nav) and isoforms of VGSCs (Nav1.6, Nav1.9, except for Nav1.8) were shown the
                widely distribution along the injured sciatic nerve. All of the VGSCs in decompression group became
                clustering around the node of Ranvier, similar to the pattern of control sciatic nerve at POW 8. Skin
                reinnervation was demonstrated by epidermal nerve density (END) for protein gene product 9.5 (PGP
                9.5)-immunoreactive (IR) nerve fibers and a significant difference between groups only at POW 24
                (p=0.01). Growth-associated protein 43 (GAP-43) is participated in the nerve fiber growth and sprouting,
                a difference in END for GAP-43-IR nerve fibers at POW 24 between groups were also significant (p=0.02).
                These observations demonstrated that nerve decompression was accompanied with the disappearance of
                neuropathic pain behaviors after CCI. Morphological studies provided the evidence that redistribution of
                VGSCs along the injured sciatic nerve but still with an incomplete skin reinnervation. These significant
                findings demonstrated a role of VGSCs in the pathogenesis of neuropathic pain, and gave an approaching
                in pharmacological basis of therapeutics.
            </value>
        </row>
        <row>
            <value>107</value>
            <value>63</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Limited uncoupling of oxidative phosphorylation is known to be beneficial in various laboratory
                models of diseases. The search for cationic uncouplers is promising as their protonophorous effect is
                self-limiting because these uncouplers lower membrane potential which is the driving force for their
                accumulation in mitochondria. In this work, the penetrating cation Rhodamine 19 butyl ester (C4R1) was
                found to decrease membrane potential and to stimulate respiration of mitochondria, appearing to be a
                stronger uncoupler than its more hydrophobic analog Rhodamine 19 dodecyl ester (C12R1). Surprisingly,
                C12R1 increased H(+) conductance of artificial bilayer lipid membranes or induced mitochondria swelling
                in potassium acetate with valinomycin at concentrations lower than C4R1. This paradox might be explained
                by involvement of mitochondrial proteins in the uncoupling action of C4R1. In experiments with HeLa
                cells, C4R1 rapidly and selectively accumulated in mitochondria and stimulated oligomycin-sensitive
                respiration as a mild uncoupler. C4R1 was effective in preventing oxidative stress induced by brain
                ischemia and reperfusion in rats: it suppressed stroke-induced brain swelling and prevented the decline
                in neurological status more effectively than C12R1. Thus, C4R1 seems to be a promising example of a mild
                uncoupler efficient in treatment of brain pathologies related to oxidative stress.
            </value>
        </row>
        <row>
            <value>108</value>
            <value>65</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Children are exposed to advertisements and products that incorporate familiar characters, such as
                Dora the Explorer and Bob the Builder, virtually from birth. How does the presence of these characters
                influence children's judgments about information and products? Three experiments (N=125) explored how
                4-year-olds evaluate messages from familiar characters and how their trust in a familiar character's
                testimony relates to their product preferences. Children endorsed objective and subjective claims made
                by a familiar character more often than those made by a perceptually similar but unfamiliar character
                even in situations where they had evidence that the familiar character was unreliable. Children also
                preferred low-quality products bearing a familiar character's image over high-quality products without a
                character image up to 74% of the time (whereas control groups preferred the low-quality products less
                than 6% of the time when they did not include a character image). These findings suggest that young
                children are powerfully influenced by familiar characters encountered in the media, leaving them
                vulnerable to advertising messages and clouding their judgments about products.
            </value>
        </row>
        <row>
            <value>109</value>
            <value>66</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Anxiety caused by the novelty of food or of the environment where the food is presented leads to
                suppression of consumption (hyponeophagia) reflected by an increased latency to begin feeding and
                decreased food intake. Studies suggest that some anxiolytics, mainly benzodiazepines and SSRIs, resolve
                hyponeophagia. Though the neurohormone oxytocin (OT) affects both anxiety responsiveness and
                feeding-related homeostasis, the link between OT and hyponeophagia has not been established. The current
                experiments examined the effect of OT receptor stimulation on hyponeophagia in mice and associated
                changes in brain activity. We found that the OT receptor agonist, WAY-267,464, at 10 and 30mg/kg b. wt.
                IP, reduced the latency to approach food and increased the amount of food eaten in hyponeophagia tests
                differing in animals' motivation to eat (hunger, reward) and the anxiogenic context of environmental
                novelty (illumination and type of the cage). This effect was abolished by the pretreatment with the OT
                receptor antagonist, L-368,899, at 10mg/kg b. wt. The antagonist also suppressed social transmission of
                preference for novel food. Mice subjected to novelty conditions causing hypophagia showed significant
                changes in c-Fos immunoreactivity in the hippocampus, lateral septum, cingulate and piriform cortex and
                in the bed nucleus of the stria terminalis, lateral division, posterolateral part (STLP). The
                pretreatment with WAY-267,464 restored c-Fos levels in the STLP to values detected in control animals
                subjected to non-anxiogenic conditions. We conclude that OT plays a role in shaping the magnitude of the
                novelty stress-provoked hypophagia and the activity of the relevant neural networks.
            </value>
        </row>
        <row>
            <value>110</value>
            <value>67</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>We introduce a novel method to estimate bivariate synchronization, i.e. interacting brain sources at
                a specific frequency or band, from MEG or EEG data robust to artifacts of volume conduction. The data
                driven calculation is solely based on the imaginary part of the cross-spectrum as opposed to the
                imaginary part of coherency. In principle, the method quantifies how strong a synchronization between a
                distinct pair of brain sources is present in the data. As an input of the method all pairs of
                pre-defined locations inside the brain can be used which is computationally exhaustive. In contrast to
                that, reference sources can be used that have been identified by any source reconstruction technique in
                a prior analysis step. We introduce different variants of the method and evaluate the performance in
                simulations. As a particular advantage of the proposed methodology, we demonstrate that the novel
                approach is capable of investigating differences in brain source interactions between experimental
                conditions or with respect to a certain baseline. For measured data, we first show the application on
                resting state MEG data where we find locally synchronized sources in the motor-cortex based on the
                sensorymotor idle rhythms. Finally, we show an example on EEG motor imagery data where we contrast hand
                and foot movement. Here, we also find local interactions in the expected brain areas.
            </value>
        </row>
        <row>
            <value>111</value>
            <value>68</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Intelligent action entails exploiting predictions about associations between elements of ones
                environment. The hippocampus and mediotemporal cortex are endowed with the network topology, physiology,
                and neurochemistry to automatically and sparsely code sensori-cognitive associations that can be
                reconstructed from single or partial inputs. Whilst acquiring fMRI data, and performing an attentional
                task, participants were incidentally presented with a sequence of cartoon images. By assigning subjects
                a post-scan free-association task on the same images we assayed the density of associations triggered by
                these stimuli. Using Multivariate Bayesian Decoding, we show that human hippocampal and temporal
                neocortical structures host sparse associative representations that are automatically triggered by
                visual input. Furthermore, as predicted theoretically, there was a significant increase in sparsity in
                the Cornu Ammonis subfields, relative to the entorhinal cortex. Remarkably, the sparsity or granularity
                of CA encoding correlated significantly with associative memory performance over subjects; elsewhere
                within the temporal lobe, entorhinal, parahippocampal, perirhinal and fusiform cortices showed the
                highest model evidence for the sparse encoding of associative density. In the absence of reportability
                or attentional confounds, this charts a distribution of visual associative representations within
                hippocampal populations and their temporal lobe afferent fields, and demonstrates the viability of
                retrospective associative sampling techniques for assessing the form of reflexive associative encoding.
            </value>
        </row>
        <row>
            <value>112</value>
            <value>69</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Cancer incidence in male farmers has been studied extensively; however, less is known about risk
                among women residing on farms or in agricultural areas, who may be exposed to pesticides by their
                proximity to crop fields. We extended a previous follow-up of the Iowa Women?s Health Study cohort to
                examine farm residence and the incidence of lymphohematopoietic cancers. Further, we investigated crop
                acreage within 750m of residences, which has been associated with higher herbicide levels in Iowa homes.
            </value>
        </row>
        <row>
            <value>113</value>
            <value>69</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We analyzed data for a cohort of 37,099 Iowa women aged 55-69 years who reported their residence
                location (farm, rural (not a farm), town size based on population) at enrollment in 1986. We identified
                incident lymphohematopoietic cancers (1986-2009) by linkage with the Iowa Cancer Registry. Using a
                geographic information system, we geocoded addresses and calculated acreage of pasture and row crops
                within 750m of homes using the 1992 National Land Cover Database. Cox regression was used to estimate
                hazard ratios (HR) and 95% confidence intervals (CI) in multivariate analyses of cancer risk in relation
                to both residence location and crop acreage.
            </value>
        </row>
        <row>
            <value>114</value>
            <value>69</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>As found in an earlier analysis of residence location, risk of acute myeloid leukemia (AML) was
                higher among women living on farms (HR=2.23, 95%CI: 1.25-3.99) or rural areas (but not on a farm)
                (HR=1.95, 95%CI: 0.89-4.29) compared with women living in towns of &gt;10,000 population. We observed no
                association between farm or rural residence and non-Hodgkin lymphoma (NHL; overall or for major
                subtypes) or multiple myeloma. In analyses of crop acreage, we observed no association between pasture
                or row crop acreage within 750m of homes and risk of leukemia overall or for the AML subtype. Chronic
                lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) risk was nonsignificantly elevated among
                women with pasture acreage within 750m of their home (HRs for increasing tertiles=1.8, 1.8 and 1.5) and
                with row crop acreage within 750m (HRs for increasing tertiles of acreage=1.4, 1.5 and 1.6) compared to
                women with no pasture or row crop acreage, respectively.
            </value>
        </row>
        <row>
            <value>115</value>
            <value>69</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Iowa women living on a farm or in a rural area were at increased risk of developing AML, which was
                not related to crop acreage near the home. Living near pasture or row crops may confer an increased risk
                of CLL/SLL regardless of residence location. Further investigation of specific farm-related exposures
                and these cancers among women living on farms and in agricultural areas is warranted.
            </value>
        </row>
        <row>
            <value>116</value>
            <value>70</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Current chemotherapy regimens for adults with acute lymphoblastic leukemia (ALL) result in high rates
                of complete remission (CR), but relapses are still frequent.
            </value>
        </row>
        <row>
            <value>117</value>
            <value>70</value>
            <value>2</value>
            <value>Patients and methods</value>
            <value>Methods</value>
            <value>In this retrospective single-center study, we evaluated the results of the Hyper-CVAD (fractionated
                cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen in 49 ALL patients treated
                between 2001 and 2013. No exclusion criteria were applied. The primary outcome measure was the CR rate.
            </value>
        </row>
        <row>
            <value>118</value>
            <value>70</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>119</value>
            <value>70</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Hyper-CVAD as an induction regimen for adults and adolescents with ALL was feasible and yielded a
                high rate of CR. Relapse rates and OS were comparable to other series but still unsatisfactory.
            </value>
        </row>
        <row>
            <value>120</value>
            <value>72</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value>Sorafenib is a multikinase inhibitor that targets the MAPK pathway and is currently used for the
                treatment of hepatocellular and renal carcinoma. Recently, it has been shown that sorafenib is also
                cytotoxic to multiple myeloma (MM) cells. Here, we have further analyzed the mechanism of
                sorafenib-induced death in MM cells.
            </value>
        </row>
        <row>
            <value>121</value>
            <value>72</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Cell death induced by sorafenib in MM cell lines and in plasma cells from MM patients was evaluated
                by analysis of gene expression by RT-MLPA and quantitative PCR, protein levels and functionality by
                Western blot and flow cytometry and gene silencing with siRNA.
            </value>
        </row>
        <row>
            <value>122</value>
            <value>72</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>123</value>
            <value>72</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Our results demonstrate a key role for Puma in the triggering of sorafenib-induced apoptosis and that
                this drug can also induce death by necroptosis in multiple myeloma cells.
            </value>
        </row>
        <row>
            <value>124</value>
            <value>74</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Melphalan (L-PAM) has been an integral part of multiple myeloma (MM) treatment as a conditioning
                regimen before stem cell transplant (SCT). After initial response, most treated patients experience
                relapse with an aggressive phenotype. Increased glutathione (GSH) in MM may mediate resistance to L-PAM.
                We demonstrated that the GSH synthesis inhibitor buthionine sulfoximine (BSO) synergistically enhanced
                L-PAM activity (inducing 2-4 logs of cell kill) against nine MM cell lines (also in the presence of
                marrow stroma or cytokines) and in seven primary MM samples (combination indices &lt;1.0). In MM cell
                lines, BSO significantly (P&lt;0.05) depleted GSH, increased L-PAM-induced single-strand DNA breaks,
                mitochondrial depolarization, caspase cleavage and apoptosis. L-PAM depleted GSH, but GSH rapidly
                recovered in a L-PAM-resistant MM cell line unless also treated with BSO. Treatment with
                N-acetylcysteine antagonized BSO+L-PAM cytotoxicity without increasing GSH. In human MM xenografted into
                beige-nude-xid mice, BSO significantly depleted MM intracellular GSH and significantly increased
                apoptosis compared with L-PAM alone. BSO+L-PAM achieved complete responses (CRs) in three MM xenograft
                models including maintained CRs &gt;100 days, and significantly increased the median event-free survival
                relative to L-PAM alone. Combining BSO with L-PAM warrants clinical testing in advanced MM.
            </value>
        </row>
        <row>
            <value>125</value>
            <value>75</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Introduction: The integration of diagnostic testing for the presence of a molecular target is of
                interest to predict successful targeted radionuclide therapy (TRNT). This so-called 'theranostic'
                approach aims to improve personalized treatment based on the molecular characteristics of cancer cells.
                Moreover, it offers new insights in predicting adverse effects and provides appropriate tools to monitor
                therapy responses. Recent findings using nanobodies emphasize their potential as theranostic tools in
                cancer treatment. Nanobodies are recombinant, small antigen-binding fragments that are derived from
                camelid heavy-chain-only antibodies. Areas covered: We review the current status of theranostic
                approaches in TRNT, with a focus on antibodies, peptides, scaffold proteins and emerging nanobodies. In
                recent years, nanobodies have been evaluated intensively for molecular imaging. In addition, novel data
                on TRNT using radiolabeled nanobodies for carcinomas and multiple myeloma highlight their promising
                opportunities in cancer treatment. Expert opinion: We trust that radiolabeled nanobodies will have a
                future potential as theranostic tools in cancer therapy, both for diagnosis as well as for TRNT.
            </value>
        </row>
        <row>
            <value>126</value>
            <value>76</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Medical imaging is of crucial importance for diagnosis and initial staging as well as for
                differentiation of multiple myeloma (MM) from other monoclonal plasma cell diseases. Conventional
                radiography represents the reference standard for diagnosis of MM due to its wide availability and low
                costs despite its known limitations such as low sensitivity, limited specificity and its inability to
                detect extraosseous lesions. Besides conventional radiography, newer cross-sectional imaging modalities
                such as whole-body low-dose computed tomography (CT), whole-body magnetic resonance imaging (MRI) and
                (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT are available for the diagnosis of
                osseous and extraosseous manifestations of MM. Whole-body low-dose CT is used increasingly, replacing
                conventional radiography at selected centers, due to its higher sensitivity for the detection of osseous
                lesions and its ability to diagnose extraosseous lesions. The highest sensitivity for both detection of
                bone marrow disease and extraosseous lesions can be achieved with whole-body MRI and (18)F-FDG PET/CT.
                According to current evidence, MRI is the most sensitive method for initial staging while (18)F-FDG
                PET/CT allows monitoring of treatment of MM. There is an evolving role for assessment of treatment
                response using newer MR imaging techniques. Future studies are needed to further define the exact role
                of the different imaging modalities for individual risk stratification and therapy monitoring.
            </value>
        </row>
        <row>
            <value>127</value>
            <value>77</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>We tried to understand whether or not there is a higher risk of left renal atrophy in human being.
            </value>
        </row>
        <row>
            <value>128</value>
            <value>77</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>All patients applying to the Hematology Service with any underlying complaint were studied.</value>
        </row>
        <row>
            <value>129</value>
            <value>77</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>130</value>
            <value>77</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Left renal atrophy may be significantly higher than the right side in human being. Aortic pressure
                induced flow disorders in the left renal vein, structural anomalies of the left renal vein, and possibly
                the higher arterial pressure of the left kidney due to the shorter distance to the heart as an
                underlying cause of atherosclerosis may be some of the possible causes. Due to the stronger arterial
                wall protecting itself from compression and high prevalences of SM and left varicocele in population, SM
                induced flow disorders of the left renal vein may be the most common cause.
            </value>
        </row>
        <row>
            <value>131</value>
            <value>78</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Objective: The prominent functions of the local renin-angiotensin system (RAS) in primitive
                hematopoiesis further support the hypothesis that local autocrine bone marrow RAS could also be active
                in neoplastic hematopoiesis. The aim of this study is to examine critical RAS elements in normal CD34+
                hematopoietic stem cells and multiple myeloma (MM)-related progenitor cells. Materials and Methods: The
                study group comprised the total bone marrow cells (CBM) of 10 hematologically normal people, the CD34+
                stem cell samples (CD34+CBM) of 9 healthy donors for allogeneic peripheral stem cell transplantation,
                and the CD34+ stem cell samples (CD34+MM) of 9 MM patients undergoing autologous peripheral stem cell
                transplantation. We searched for the gene expression of the major RAS components in healthy
                hematopoietic cells and myeloma cells by quantitative real-time polymerase chain reaction analysis.
                Results: RENIN, angiotensinogen (ANGTS), and angiotensin converting enzyme-I (ACE I) mRNA expression
                levels of CBM were significantly higher than those in myeloma patients (p=0.03, p=0.002, and p=0.0008,
                respectively). Moreover, RENIN and ANGTS mRNA expression levels were significantly higher in CD34+ stem
                cell samples of healthy allogeneic donors compared to those in myeloma patients (p=0.001 and p=0.01).
                However, ACE I expression levels were similar in CD34+CBM and CD34+MM hematopoietic cells (p=0.89).
                Conclusion: Although found to be lower than in the CBM and CD34+CBM hematopoietic cells, the local RAS
                components were also expressed in CD34+MM hematopoietic cells. This point should be kept in mind while
                focusing on the immunobiology of MM and the processing of autologous cells during the formation of
                transplantation treatment protocols.
            </value>
        </row>
        <row>
            <value>132</value>
            <value>79</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>In this article, we embarked on production of mouse monoclonal antibodies against aflatoxin B1 which
                is the most commonly occurring fungal toxin in food and feed products. After immunization and fusion
                with myloma cells, two stable clones (A218 and B319) were selected. Isotyping showed that these
                monoclonal antibodies (mAbs) were IgG2b with kappa light chains. The affinity of A218 and B319 clons
                were 5??10(11) M(-1) and 6??10(9) M(-1), respectively. Competitive indirect ELISA results indicated
                these mAbs had complete (100%) cross-reaction with four major types of aflatoxins: B1, B2, G1, and G2.
                These mAbs could be used for immunoassay measurement of aflatoxins with high affinity and low detection
                limits.
            </value>
        </row>
        <row>
            <value>133</value>
            <value>80</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>134</value>
            <value>81</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Multiple myeloma (MM) is a clonal B-cell malignancy charactered by the aberrant proliferation of
                malignant plasma cells in the bone marrow. MM is still an incurable malignancy. In this regard, novel
                treatments are urgently required. MUC1 (mucin 1), a type ?? transmembrane protein, is overexpressed and
                aberrantly glycosylated in many carcinomas particularly in MM resulting in an antigenically distinct
                molecule and may be a potential target for specific immunotherapy. In this study, we first designed a
                unique DNA vaccine, termed MUC1-2-VNTR (various number tandem repeats) to investigate whether the
                vaccine could specifically suppress tumor growth in a murine multiple myloma model. Our results showed
                that the constructed DNA vaccine pcDNA3.1-VNTR elicited both humoral and cellular tumor-specific immune
                responses in the MM mouse model leading to delay in tumor growth and prolonged survival of the mice.
                Consequently, our study indicates that this DNA vaccine shows promise to be used as a novel strategy for
                the treatment of MM.
            </value>
        </row>
        <row>
            <value>135</value>
            <value>82</value>
            <value>1</value>
            <value>Aim</value>
            <value>Objective</value>
            <value>To prepare and identify a monoclonal antibody (mAb) against human platelet glycoprotein Ib and make
                its application.
            </value>
        </row>
        <row>
            <value>136</value>
            <value>82</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>BALB/c mice were immunized with human platelets washed, and the spleen cells of them were fused with
                myloma cells. A hybridoma cell was screened by indirect ELISA and cloned, and the mAb were purified from
                the ascites of mice. Ig subclass was analysed by double immunodiffusion. The antigen recognized by
                monoclonal antibody was identified by flow cytometry and radioimmunoassy, respectively. The inhibition
                of mAb on plasma von Willebrand factor ristocetin cofactor activity (vWF:Rcof) was investigated by
                enzyme linked immunosorbent assay (ELISA).
            </value>
        </row>
        <row>
            <value>137</value>
            <value>82</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>A murine mAb against human platelet membrane glycoprotein (GP) Ib was developed and denominated as
                SZ-151. SZ-151 belonged to IgG1 subclass and its titer in ascites was 1:20 000. Flow cytometry and
                radioimmunoassy showed that the antigen recognized by monoclonal antibody SZ-151 was platelet membrane
                GPIb. ELISA showed that SZ-151 did not inhibit plasma von Willebrand factor ristocetin cofactor
                activity.
            </value>
        </row>
        <row>
            <value>138</value>
            <value>82</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>A mAb, SZ-151 against platelet glycoprotein Ib was developed, which could be useful in assays of
                plasma von Willebrand factor ristocetin cofactor activity(vWF:Rcof) and can be used for diagnose
                patients with vWD.
            </value>
        </row>
        <row>
            <value>139</value>
            <value>83</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>In order to construct an eukaryotic expression vector for gene of multiple myeloma mucin1
                (muc1-2vntr) gene and to express it in COS-7 cells in vitro, so to provide the basic material for
                further research of multiple myeloma DNA vaccine. muc1-2vntr coding gene was used as a research gene and
                a KOZAK sequence was inserted before the gene Hind III and XbaI restriction sites were inserted before
                and after the coding gene. Then the whole sequence was synthesized and inserted into pcDNA3.1/myc-his B
                vector, and the resulted recombinant vector was transformed into E.coil competent cells to get an
                engineering strain, the recombinant plasmid pcDNA3.1-2vntr/myc-his B identified by restriction analysis
                and DNA sequencing were transfected into COS-7 cells by liposome-mediated gene transfer method. Finally,
                fluorescent microscopy was used to assess GFP expression and Western blot analysis using muc1 monoclonal
                antibody was used to recognize vntr, confirming the expression of vntr. The results showed that the full
                length of synthesized muc1-2vntr gene, as expected, was 140 bp. Both restriction analysis and DNA
                sequencing demonstrated that pcDNA3.1-2vntr/myc-his B included the whole translation frame region and
                muc1-2vntr gene. Furthermore, the fluorescence microscopy proved that the recombinant plasmid had been
                successfully transfected into COS-7 cells. The expression of mucin-1 protein was observed both in the
                transfected cell and the cell supernatant by Western blot. It is concluded that the
                pcDNA3.1-2vntr/myc-his B has been successfully constructed and expressed in COS-7 cells in vitro, which
                provides the basic material for further researches of mucin-1 function and possible multiple myloma DNA
                vaccine.
            </value>
        </row>
        <row>
            <value>140</value>
            <value>84</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To obtain the monoclonal antibody against hexon protein of human adenovirus.</value>
        </row>
        <row>
            <value>141</value>
            <value>84</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>BALB/c mice were immunized with purified recombinant hexon protein, and the spleen cells of the mice
                were isolated and fused with myloma cells. Four hybridoma cell strains were screened by indirect ELISA
                and cultured, and the sensitivity, specificity and virus neutralizing activity were analyzed with ELISA,
                Western blotting and neutralizing test.
            </value>
        </row>
        <row>
            <value>142</value>
            <value>84</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>The mouse ascites produced by these hybridoma cells contained specific monoclonal antibodies against
                hexon protein of human adenovirus as identified by ELISA and Western blot, and the antibody generated by
                4C6 strain showed human adenovirus type 3-neutralizing activity.
            </value>
        </row>
        <row>
            <value>143</value>
            <value>84</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>The monoclonal antibodies against hexon protein with high specificity have been successfully
                obtained, and these antibodies can be useful in developing assays for early diagnosis of HAdV3 infection
                and also in study of therapeutic drugs of the infection.
            </value>
        </row>
        <row>
            <value>144</value>
            <value>85</value>
            <value>1</value>
            <value>Aim</value>
            <value>Objective</value>
            <value>To prepare novel anti-OX40L functional monoclonal antibodies and characterize their distinct
                biological functions.
            </value>
        </row>
        <row>
            <value>145</value>
            <value>85</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Routine immunization of BALB/c mice by a tansfected cell line L929/OX40L expressing high level of
                OX40L as antigens. Then fuse the immunized spleen with Sp2/0, a kind of myloma, and screen the positive
                clones by FCS with L929/OX40L as a positive control.After acquisition of the hybidomas secreting
                anti-OX40L mAb, investigation of their biological activities by Western blot, rapid isotyping analysis,
                karyotype analysis, competitive inhibition test, indirect immunofluorescence and MTT incorporation assay
                were followed.
            </value>
        </row>
        <row>
            <value>146</value>
            <value>85</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Obtain two stable hybridomas, 4D6 and 5C2, which could continuously secret specific anti-OX40L
                monoclonal antibodies. The following biological activity studies showed that these monoclonal antibodies
                could both recognize the natural OX40L expressed on the mature DC, especially the OX40L on the several
                leukemia cell lines, such as Jurkat, SHI-1, U937 etc. Furthermore, they could also suppress the
                proliferation of SHI-1 in vitro.
            </value>
        </row>
        <row>
            <value>147</value>
            <value>85</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Two hybridomas secreting anti-OX40L monoclonal antibodies continuously and steadily have been
                established. These monoclonal antibodies could specifically recognize human OX40L and effect the
                proliferation of leukemia cell line SHI-1 through OX40/OX40L costimulatory signals.
            </value>
        </row>
        <row>
            <value>148</value>
            <value>86</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>This study was aimed to investigate the effect of T cells activated by DCs loaded with whole antigens
                of U266 cells on the U266 cells survival in vitro. Peripheral blood mononuclear cells were isolated from
                healthy donor, and adherented on culture plate. Adherent cells were cultured in AIM-V serum-free medium
                or in RPMI 1640 medium contained 20% fetal bovine serum (FBS), supplemented with granulocyte-macrophage
                colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). Methyl thiazolyl tetrazolium (MTT) assay
                was used to evaluate killing rate of U266 cells by T cells activated by DCs loaded with whole antigen of
                U266 cells. The results showed that DCs derived from peripheral blood mononuclear cells cultured by
                AIM-V serum-free medium or RPMI 1640 medium containing FBS had similar immunophenotype. T cells
                activated by DCs loaded with whole antigen of U266 cells or mature DCs might kill U266 cells in a
                dose-dependent manner. It is concluded, DCs derived from peripheral blood mononuclear cells of healthy
                donor and loaded with whole antigen of U266 cells can induce anti-myeloma response of T cells in vitro.
            </value>
        </row>
        <row>
            <value>149</value>
            <value>87</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM) are
                plasma cell disorders with a risk of progression of approximately 1% and 10% per year, respectively. We
                have previously shown that the proportion of bone marrow (BM) aberrant plasma cells (aPCs) within the
                BMPC compartment (aPC/BMPC) as assessed by flow cytometry (FC) contributes to differential diagnosis
                between MGUS and multiple myloma (MM). The goal of the present study was to investigate this parameter
                as a marker for risk of progression in MGUS (n = 407) and SMM (n = 93). Patients with a marked
                predominance of aPCs/BMPC (&gt; or = 95%) at diagnosis displayed a significantly higher risk of
                progression both in MGUS and SMM (P&lt; .001). Multivariate analysis for progression-free survival (PFS)
                selected the percentage aPC/BMPC (&gt; or = 95%) as the most important independent variable, together
                with DNA aneuploidy and immunoparesis, for MGUS and SMM, respectively. Using these independent
                variables, we have identified 3 risk categories in MGUS (PFS at 5 years of 2%, 10%, and 46%,
                respectively; P&lt; .001) and SMM patients (PFS at 5 years of 4%, 46%, and 72%, respectively; P &lt;
                .001). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that
                could help to individualize the follow-up strategy for MGUS and SMM patients.
            </value>
        </row>
        <row>
            <value>150</value>
            <value>88</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and are now the
                treatment of choice for the management of hypercalcaemia of malignancy. The incidences of hypercalcaemia
                and other skeletal complications (bone pain, pathological fracture) remain high despite apparent
                responses to systemic therapy, with particularly high event rates in women with advanced skeletal
                metastases of breast cancer. This review focuses on studies addressing the long-term efficacy of
                bisphosphonates to reduce skeletal complications in breast cancer (5 studies) and multiple myeloma (4
                studies), with particular reference to controlled studies of sufficient magnitude and duration to allow
                confidence in the estimation of efficacy. Bearing in mind the limitations of differences in trial design
                and the lack of direct studies comparing drugs, adequate exposure to a bisphosphonate reduces the
                incidence of skeletal complication by 30 to 40% in both breast cancer and multiple myeloma. Oral
                clondronate and intravenous pamidronate have similar efficacy in both diseases, but the duration of
                efficacy may differ between drugs. Both agents have shown intriguing survival benefits in subgroups of
                patients. The numbers needed to treat (NNT) to prevent a skeletal complication during one year are
                lowest in metastatic skeletal disease in breast cancer (NNT &lt; 8) but also compare very favourably
                with other disease for patients with recurrent nonskeletal breast cancer or multiple myeloma (NNTs 7 to
                31 depending on the complication to be prevented). Treatment costs of both breast cancer and multiple
                myloma are driven by inpatient and outpatient hospital visits so that bisphosphonate regimens should be
                developed that reduce both. Further research is required to determine if subgroups of patients can be
                better identified that will derive particular benefit, or perhaps no benefit at all, from bisphosphonate
                therapy. It is not known whether more potent bisphosphonates will deliver greater clinical efficacy in
                the future.
            </value>
        </row>
        <row>
            <value>151</value>
            <value>90</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>APOBEC3 proteins are a family of cytidine deaminases that exhibit broad antiretroviral activity.
                Among APOBEC3 proteins, APOBEC3G (hA3G) and APOBEC3F (hA3F) exhibit the most potent anti-HIV-1
                activities. Although the incorporation of hA3F into virions is a prerequisite for exerting its antiviral
                function, the detail mechanism underlying remains incompletely understood. In this work, we present data
                showing that the nucleocapsid (NC) domain of HIV-1 Gag and a linker sequence between the two cytidine
                deaminase domains within hA3F, i.e., 104-156 amino acids, are required for viral packaging of hA3F. A
                detailed mapping study reveals that the cluster of basic residues surrounding the N-terminal zinc finger
                (ZF) and the linker region between the ZFs of HIV-1 NC play an important role in A3F incorporation, in
                addition, at least one of two ZFs is required. A hA3F fragment is able to compete with both hA3G and
                hA3F for viral incorporation, suggesting a common mechanism underlying virion encapsidation of hA3G and
                hA3F. Taken together, these results shed a light on the detail mechanism underlying viral incorporation
                of hA3F.
            </value>
        </row>
        <row>
            <value>152</value>
            <value>94</value>
            <value>1</value>
            <value>Importance</value>
            <value>Unassigned</value>
            <value>New data and antiretroviral regimens expand treatment choices in resource-rich settings and warrant
                an update of recommendations to treat adults infected with human immunodeficiency virus (HIV).
            </value>
        </row>
        <row>
            <value>153</value>
            <value>94</value>
            <value>2</value>
            <value>Objective</value>
            <value>Unassigned</value>
            <value>To provide updated treatment recommendations for adults with HIV, emphasizing when to start
                treatment; what treatment to start; the use of laboratory monitoring tools; and managing treatment
                failure, switches, and simplification.
            </value>
        </row>
        <row>
            <value>154</value>
            <value>94</value>
            <value>3</value>
            <value>Data sources, study selection, and data synthesis</value>
            <value>Unassigned</value>
            <value>An International Antiviral Society-USA panel of experts in HIV research and patient care considered
                previous data and reviewed new data since the 2012 update with literature searches in PubMed and EMBASE
                through June 2014. Recommendations and ratings were based on the quality of evidence and consensus.
            </value>
        </row>
        <row>
            <value>155</value>
            <value>94</value>
            <value>4</value>
            <value>Results</value>
            <value>Unassigned</value>
            <value>Antiretroviral therapy is recommended for all adults with HIV infection. Evidence for benefits of
                treatment and quality of available data increase at lower CD4 cell counts. Recommended initial regimens
                include 2 nucleoside reverse transcriptase inhibitors (NRTIs; abacavir/lamivudine or tenofovir
                disoproxil fumarate/emtricitabine) and a third single or boosted drug, which should be an integrase
                strand transfer inhibitor (dolutegravir, elvitegravir, or raltegravir), a nonnucleoside reverse
                transcriptase inhibitor (efavirenz or rilpivirine) or a boosted protease inhibitor (darunavir or
                atazanavir). Alternative regimens are available. Boosted protease inhibitor monotherapy is generally not
                recommended, but NRTI-sparing approaches may be considered. New guidance for optimal timing of
                monitoring of laboratory parameters is provided. Suspected treatment failure warrants rapid
                confirmation, performance of resistance testing while the patient is receiving the failing regimen, and
                evaluation of reasons for failure before consideration of switching therapy. Regimen switches for
                adverse effects, convenience, or to reduce costs should not jeopardize antiretroviral potency.
            </value>
        </row>
        <row>
            <value>156</value>
            <value>94</value>
            <value>5</value>
            <value>Conclusions and relevance</value>
            <value>Unassigned</value>
            <value>After confirmed diagnosis of HIV infection, antiretroviral therapy should be initiated in all
                individuals who are willing and ready to start treatment. Regimens should be selected or changed based
                on resistance test results with consideration of dosing frequency, pill burden, adverse toxic effect
                profiles, comorbidities, and drug interactions.
            </value>
        </row>
        <row>
            <value>157</value>
            <value>95</value>
            <value>1</value>
            <value>Importance</value>
            <value>Unassigned</value>
            <value>Emerging data warrant the integration of biomedical and behavioral recommendations for human
                immunodeficiency virus (HIV) prevention in clinical care settings.
            </value>
        </row>
        <row>
            <value>158</value>
            <value>95</value>
            <value>2</value>
            <value>Objective</value>
            <value>Unassigned</value>
            <value>To provide current recommendations for the prevention of HIV infection in adults and adolescents for
                integration in clinical care settings.
            </value>
        </row>
        <row>
            <value>159</value>
            <value>95</value>
            <value>3</value>
            <value>Data sources, study selection, and data synthesis</value>
            <value>Unassigned</value>
            <value>Data published or presented as abstracts at scientific conferences (past 17 years) were
                systematically searched and reviewed by the International Antiviral (formerly AIDS) Society-USA HIV
                Prevention Recommendations Panel. Panel members supplied additional relevant publications, reviewed
                available data, and formed recommendations by full-panel consensus.
            </value>
        </row>
        <row>
            <value>160</value>
            <value>95</value>
            <value>4</value>
            <value>Results</value>
            <value>Unassigned</value>
            <value>Testing for HIV is recommended at least once for all adults and adolescents, with repeated testing
                for those at increased risk of acquiring HIV. Clinicians should be alert to the possibility of acute HIV
                infection and promptly pursue diagnostic testing if suspected. At diagnosis of HIV, all individuals
                should be linked to care for timely initiation of antiretroviral therapy (ART). Support for adherence
                and retention in care, individualized risk assessment and counseling, assistance with partner
                notification, and periodic screening for common sexually transmitted infections (STIs) is recommended
                for HIV-infected individuals as part of care. In HIV-uninfected patients, those persons at high risk of
                HIV infection should be prioritized for delivery of interventions such as preexposure prophylaxis and
                individualized counseling on risk reduction. Daily emtricitabine/tenofovir disoproxil fumarate is
                recommended as preexposure prophylaxis for persons at high risk for HIV based on background incidence or
                recent diagnosis of incident STIs, use of injection drugs or shared needles, or recent use of
                nonoccupational postexposure prophylaxis; ongoing use of preexposure prophylaxis should be guided by
                regular risk assessment. For persons who inject drugs, harm reduction services should be provided
                (needle and syringe exchange programs, supervised injection, and available medically assisted therapies,
                including opioid agonists and antagonists); low-threshold detoxification and drug cessation programs
                should be made available. Postexposure prophylaxis is recommended for all persons who have sustained a
                mucosal or parenteral exposure to HIV from a known infected source and should be initiated as soon as
                possible.
            </value>
        </row>
        <row>
            <value>161</value>
            <value>95</value>
            <value>5</value>
            <value>Conclusions and relevance</value>
            <value>Unassigned</value>
            <value>Data support the integration of biomedical and behavioral approaches for prevention of HIV infection
                in clinical care settings. A concerted effort to implement combination strategies for HIV prevention is
                needed to realize the goal of an AIDS-free generation.
            </value>
        </row>
        <row>
            <value>162</value>
            <value>96</value>
            <value>1</value>
            <value>Importance</value>
            <value>Unassigned</value>
            <value>Among patients infected with human immunodeficiency virus (HIV), visceral adiposity is associated
                with metabolic dysregulation and ectopic fat accumulation. Tesamorelin, a growth hormone-releasing
                hormone analog, specifically targets visceral fat reduction but its effects on liver fat are unknown.
            </value>
        </row>
        <row>
            <value>163</value>
            <value>96</value>
            <value>2</value>
            <value>Objective</value>
            <value>Unassigned</value>
            <value>To investigate the effect of tesamorelin on visceral and liver fat.</value>
        </row>
        <row>
            <value>164</value>
            <value>96</value>
            <value>3</value>
            <value>Design, setting, and patients</value>
            <value>Unassigned</value>
            <value>Double-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-treated
                HIV-infected men and women with abdominal fat accumulation at Massachusetts General Hospital in Boston.
                The first patient was enrolled on January 10, 2011; for the final patient, the 6-month study visit was
                completed on September 6, 2013.
            </value>
        </row>
        <row>
            <value>165</value>
            <value>96</value>
            <value>4</value>
            <value>Interventions</value>
            <value>Unassigned</value>
            <value>Participants were randomized to receive tesamorelin, 2 mg (n=28), or placebo (n=22), subcutaneously
                daily for 6 months.
            </value>
        </row>
        <row>
            <value>166</value>
            <value>96</value>
            <value>5</value>
            <value>Main outcomes and measures</value>
            <value>Unassigned</value>
            <value>Primary end points were changes in visceral adipose tissue and liver fat. Secondary end points
                included glucose levels and other metabolic end points.
            </value>
        </row>
        <row>
            <value>167</value>
            <value>96</value>
            <value>6</value>
            <value>Results</value>
            <value>Unassigned</value>
            <value>Forty-eight patients received treatment with study drug. Tesamorelin significantly reduced visceral
                adipose tissue (mean change, -34 cm2 [95% CI, -53 to -15 cm2] with tesamorelin vs 8 cm2 [95% CI, -14 to
                30 cm2] with placebo; treatment effect, -42 cm2 [95% CI, -71 to -14 cm2]; P???=???.005) and liver fat
                (median change in lipid to water percentage, -2.0% [interquartile range {IQR}, -6.4% to 0.1%] with
                tesamorelin vs 0.9% [IQR, -0.6% to 3.7%] with placebo; P???=???.003) over 6 months, for a net treatment
                effect of -2.9% in lipid to water percentage. Fasting glucose increased in the tesamorelin group at 2
                weeks (mean change, 9 mg/dL [95% CI, 5-13 mg/dL] vs 2 mg/dL [95% CI, -3 to 8 mg/dL] in the placebo
                group; treatment effect, 7 mg/dL [95% CI, 1-14 mg/dL]; P???=???.03), but changes at 6 months in fasting
                glucose (mean change, 4 mg/dL [95% CI, -2 to 10 mg/dL] with tesamorelin vs 2 mg/dL [95% CI, -4 to 7
                mg/dL] with placebo; treatment effect, 2 mg/dL [95% CI, -6 to 10 mg/dL]; P???=???.72 overall across time
                points) and 2-hour glucose (mean change, -1 mg/dL [95% CI, -18 to 15 mg/dL] vs -8 mg/dL [95% CI, -24 to
                8 mg/dL], respectively; treatment effect, 7 mg/dL [95% CI, -16 to 29 mg/dL]; P???=???.53 overall across
                time points) were not significant.
            </value>
        </row>
        <row>
            <value>168</value>
            <value>96</value>
            <value>7</value>
            <value>Conclusions and relevance</value>
            <value>Unassigned</value>
            <value>In this preliminary study of HIV-infected patients with abdominal fat accumulation, tesamorelin
                administered for 6 months was associated with reductions in visceral fat and additionally with modest
                reductions in liver fat. Further studies are needed to determine the clinical importance and long-term
                consequences of these findings.
            </value>
        </row>
        <row>
            <value>169</value>
            <value>96</value>
            <value>8</value>
            <value>Trial registration</value>
            <value>Unassigned</value>
            <value>clinicaltrials.gov Identifier: NCT01263717.</value>
        </row>
        <row>
            <value>170</value>
            <value>97</value>
            <value>1</value>
            <value>Importance</value>
            <value>Unassigned</value>
            <value>Self-testing for HIV infection may contribute to early diagnosis of HIV, but without necessarily
                increasing antiretroviral therapy (ART) initiation.
            </value>
        </row>
        <row>
            <value>171</value>
            <value>97</value>
            <value>2</value>
            <value>Objective</value>
            <value>Unassigned</value>
            <value>To investigate whether offering optional home initiation of HIV care after HIV self-testing might
                increase demand for ART initiation, compared with HIV self-testing accompanied by facility-based
                services only.
            </value>
        </row>
        <row>
            <value>172</value>
            <value>97</value>
            <value>3</value>
            <value>Design, setting, and participants</value>
            <value>Unassigned</value>
            <value>Cluster randomized trial conducted in Blantyre, Malawi, between January 30 and November 5, 2012,
                using restricted 1:1 randomization of 14 community health worker catchment areas. Participants were all
                adult (???16 years) residents (n???=???16???660) who received access to home HIV self-testing through
                resident volunteers. This was a second-stage randomization of clusters allocated to the HIV self-testing
                group of a parent trial.
            </value>
        </row>
        <row>
            <value>173</value>
            <value>97</value>
            <value>4</value>
            <value>Interventions</value>
            <value>Unassigned</value>
            <value>Clusters were randomly allocated to facility-based care or optional home initiation of HIV care
                (including 2 weeks of ART if eligible) for participants reporting positive HIV self-test results.
            </value>
        </row>
        <row>
            <value>174</value>
            <value>97</value>
            <value>5</value>
            <value>Main outcomes and measures</value>
            <value>Unassigned</value>
            <value>The preplanned primary outcome compared between groups the proportion of all adult residents who
                initiated ART within the first 6 months of HIV self-testing availability. Secondary outcomes were uptake
                of HIV self-testing, reporting of positive HIV self-test results, and rates of loss from ART at 6
                months.
            </value>
        </row>
        <row>
            <value>175</value>
            <value>97</value>
            <value>6</value>
            <value>Results</value>
            <value>Unassigned</value>
            <value>A significantly greater proportion of adults in the home group initiated ART (181/8194, 2.2%)
                compared with the facility group (63/8466, 0.7%; risk ratio [RR], 2.94, 95% CI, 2.10-4.12; P???&lt;???.001).
                Uptake of HIV self-testing was high in both the home (5287/8194, 64.9%) and facility groups (4433/8466,
                52.7%; RR, 1.23; 95% CI, 0.96-1.58; P???=???.10). Significantly more adults reported positive HIV
                self-test results in the home group (490/8194 [6.0%] vs the facility group, 278/8466 [3.3%]; RR, 1.86;
                95% CI, 1.16-2.97; P???=???.006). After 6 months, 52 of 181 ART initiators (28.7%) and 15 of 63 ART
                initiators (23.8%) in the home and facility groups, respectively, were lost from ART (adjusted incidence
                rate ratio, 1.18; 95% CI, 0.62-2.25, P???=???.57).
            </value>
        </row>
        <row>
            <value>176</value>
            <value>97</value>
            <value>7</value>
            <value>Conclusions and relevance</value>
            <value>Unassigned</value>
            <value>Among Malawian adults offered HIV self-testing, optional home initiation of care compared with
                standard HIV care resulted in a significant increase in the proportion of adults initiating ART.
            </value>
        </row>
        <row>
            <value>177</value>
            <value>97</value>
            <value>8</value>
            <value>Trial registration</value>
            <value>Unassigned</value>
            <value>clinicaltrials.gov Identifier: NCT01414413.</value>
        </row>
        <row>
            <value>178</value>
            <value>98</value>
            <value>1</value>
            <value>Importance</value>
            <value>Unassigned</value>
            <value>Antiretroviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and
                combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of
                human immunodeficiency virus (HIV) acquisition. PrEP could reduce periconception HIV risk, but the
                effect on pregnancy outcomes is not well defined.
            </value>
        </row>
        <row>
            <value>179</value>
            <value>98</value>
            <value>2</value>
            <value>Objective</value>
            <value>Unassigned</value>
            <value>To assess pregnancy incidence and outcomes among women using PrEP during the periconception period.
            </value>
        </row>
        <row>
            <value>180</value>
            <value>98</value>
            <value>3</value>
            <value>Design, setting, and participants</value>
            <value>Unassigned</value>
            <value>Randomized trial among 1785 HIV-serodiscordant heterosexual couples (the Partners PrEP Study) in
                which the female partner was HIV uninfected that demonstrated that PrEP was efficacious for HIV
                prevention, conducted between July 2008 and June 2013 at 9 sites in Kenya and Uganda.
            </value>
        </row>
        <row>
            <value>181</value>
            <value>98</value>
            <value>4</value>
            <value>Interventions</value>
            <value>Unassigned</value>
            <value>Daily oral TDF (n???=???598), combination FTC+TDF (n???=???566), or placebo (n???=???621) through
                July 2011, when PrEP demonstrated efficacy for HIV prevention. Thereafter, participants continued
                receiving active PrEP without placebo. Pregnancy testing occurred monthly and study medication was
                discontinued when pregnancy was detected.
            </value>
        </row>
        <row>
            <value>182</value>
            <value>98</value>
            <value>5</value>
            <value>Main outcomes and measures</value>
            <value>Unassigned</value>
            <value>Pregnancy incidence, birth outcomes (live births, pregnancy loss, preterm birth, congenital
                anomalies), and infant growth.
            </value>
        </row>
        <row>
            <value>183</value>
            <value>98</value>
            <value>6</value>
            <value>Results</value>
            <value>Unassigned</value>
            <value>A total of 431 pregnancies occurred. Pregnancy incidence was 10.0 per 100 person-years among women
                assigned placebo, 11.9 among those assigned TDF (incidence difference, 1.9; 95% CI, -1.1 to 4.9
                [P???=???.22 vs placebo]), and 8.8 among those assigned FTC+TDF (incidence difference, -1.3; 95% CI,
                -4.1 to 1.5 [P???=???.39 vs placebo]). Before discontinuation of the placebo treatment group in July
                2011, the occurrence of pregnancy loss (96 of 288 pregnancies) was 42.5% for women receiving FTC+TDF
                compared with 32.3% for those receiving placebo (difference for FTC+TDF vs placebo, 10.2%; 95% CI, -5.3%
                to 25.7%; P???=???.16) and was 27.7% for those receiving TDF alone (difference vs placebo, -4.6%; 95%
                CI, -18.1% to 8.9%; P???=???.46). After July 2011, the frequency of pregnancy loss (52 of 143
                pregnancies) was 37.5% for FTC+TDF and 36.7% for TDF alone (difference, 0.8%; 95% CI, -16.8% to 18.5%;
                P???=???.92). Occurrence of preterm birth, congenital anomalies, and growth throughout the first year of
                life did not differ significantly for infants born to women who received PrEP vs placebo.
            </value>
        </row>
        <row>
            <value>184</value>
            <value>98</value>
            <value>7</value>
            <value>Conclusions and relevance</value>
            <value>Unassigned</value>
            <value>Among HIV-serodiscordant heterosexual African couples, differences in pregnancy incidence, birth
                outcomes, and infant growth were not statistically different for women receiving PrEP with TDF alone or
                combination FTC+TDF compared with placebo at conception. Given that PrEP was discontinued when pregnancy
                was detected and that CIs for the birth outcomes were wide, definitive statements about the safety of
                PrEP in the periconception period cannot be made. These results should be discussed with HIV-uninfected
                women receiving PrEP who are considering becoming pregnant.
            </value>
        </row>
        <row>
            <value>185</value>
            <value>98</value>
            <value>8</value>
            <value>Trial registration</value>
            <value>Unassigned</value>
            <value>clinicaltrials.gov Identifier: NCT00557245.</value>
        </row>
        <row>
            <value>186</value>
            <value>99</value>
            <value>1</value>
            <value>Importance</value>
            <value>Unassigned</value>
            <value>Treatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency
                virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need
                to use interferon.
            </value>
        </row>
        <row>
            <value>187</value>
            <value>99</value>
            <value>2</value>
            <value>Objective</value>
            <value>Unassigned</value>
            <value>To determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in
                patients with HCV-HIV coinfection receiving sofosbuvir and ribavirin treatment.
            </value>
        </row>
        <row>
            <value>188</value>
            <value>99</value>
            <value>3</value>
            <value>Design, setting, and participants</value>
            <value>Unassigned</value>
            <value>Open-label, nonrandomized, uncontrolled phase 3 trial conducted at 34 treatment centers in the United
                States and Puerto Rico (August 2012-November 2013) evaluating treatment with sofosbuvir and ribavirin
                among patients with HCV genotypes 1, 2, or 3 and concurrent HIV. Patients were required to be receiving
                ART with HIV RNA values of 50 copies/mL or less and a CD4 T-cell count of more than 200 cells/?L or to
                have untreated HIV infection with a CD4 T-cell count of more than 500 cells/?L. Of the treatment-naive
                patients, 114 had HCV genotype 1 and 68 had HCV genotype 2 or 3, and 41 treatment experienced
                participants who had been treated with peginterferon-ribavirin had HCV genotype 2 or 3, for a total of
                223 participants.
            </value>
        </row>
        <row>
            <value>189</value>
            <value>99</value>
            <value>4</value>
            <value>Interventions</value>
            <value>Unassigned</value>
            <value>Treatment-naive patients with HCV genotype 2 or 3 received 400 mg of sofosbuvir and weight-based
                ribavirin for 12 weeks and treatment-naive patients with HCV genotype 1 and treatment-experienced
                patients with HCV genotype 2 or 3 received the same treatment for 24 weeks.
            </value>
        </row>
        <row>
            <value>190</value>
            <value>99</value>
            <value>5</value>
            <value>Main outcomes and measures</value>
            <value>Unassigned</value>
            <value>The primary study outcome was the proportion of patients with SVR (serum HCV &lt;25 copies/mL) 12
                weeks (SVR12) after cessation of HCV therapy.
            </value>
        </row>
        <row>
            <value>191</value>
            <value>99</value>
            <value>6</value>
            <value>Results</value>
            <value>Unassigned</value>
            <value>Among treatment-naive participants, 87 patients (76%) of 114 (95% CI, 67%-84%) with genotype 1, 23
                patients (88%) of 26 with genotype 2 (95% CI, 70%-985), and 28 patients (67%) of 42 with genotype 3 (95%
                CI, 51%-80%) achieved SVR12. Among treatment-experienced participants, 22 patients (92%) of 24 with
                genotype 2 (95% CI, 73%-99%) and 16 patients (94%) of 17 (95% CI, 71%-100%) achieved SVR12. The most
                common adverse events were fatigue, insomnia, headache, and nausea. Seven patients (3%) discontinued HCV
                treatment due to adverse events. No adverse effect on HIV disease or its treatment was observed.
            </value>
        </row>
        <row>
            <value>192</value>
            <value>99</value>
            <value>7</value>
            <value>Conclusions and relevance</value>
            <value>Unassigned</value>
            <value>In this open-label, nonrandomized, uncontrolled study, patients with HIV who were coinfected with HCV
                genotype 1, 2, or 3 who received the oral, interferon-free combination of sofosbuvir and ribavirin for
                12 or 24 weeks had high rates of SVR12. Further studies of this oral regimen in diverse populations of
                coinfected patients are warranted.
            </value>
        </row>
        <row>
            <value>193</value>
            <value>99</value>
            <value>8</value>
            <value>Trial registration</value>
            <value>Unassigned</value>
            <value>clinicaltrials.gov Identifier: NCT01667731.</value>
        </row>
        <row>
            <value>194</value>
            <value>100</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The identification and characterization of human mast cell (MC) functions is hindered by the shortage
                of MC populations suitable for investigation. Here, we present a novel technique for generating large
                numbers of well differentiated and functional human MCs from peripheral stem cells (=peripheral stem
                cell-derived MCs, PSCMCs). Innovative and key features of this technique include 1) the use of stem cell
                concentrates, which are routinely discarded by blood banks, as the source of CD34+ stem cells, 2) cell
                culture in serum free medium and 3) the addition of LDL as well as selected cytokines. In contrast to
                established and published protocols that use CD34+ or CD133+ progenitor cells from full blood, we used a
                pre-enriched cell population obtained from stem cell concentrates, which yielded up to 10(8)
                differentiated human MCs per batch after only three weeks of culture starting with 10(6) total CD34+
                cells. The total purity on MCs (CD117+, Fc?R1+) generated by this method varied between 55-90%, of which
                4-20% were mature MCs that contain tryptase and chymase and show expression of Fc?RI and CD117 in
                immunohistochemistry. PSCMCs showed robust histamine release in response to stimulation with anti-Fc?R1
                or IgE/anti-IgE, and increased proliferation and differentiation in response to IL-1?? or IFN-?. Taken
                together, this new protocol the generation of large numbers of human MCs provides for an innovative and
                suitable option to investigate the biology of human MCs.
            </value>
        </row>
        <row>
            <value>195</value>
            <value>101</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Objective: The purpose of this study was to determine the rate and causes of wastage of blood and
                blood products (packed red cells, plasma, platelets, and cryoprecipitate) in Qazvin hospitals. Materials
                and Methods: The study was conducted in all hospitals in Qazvin, including 5 teaching hospitals, 2
                social welfare hospitals, 3 private hospitals, 1 charity hospital, and 1 military hospital. This
                descriptive study was based on available data from hospital blood banks in the province of Qazvin. The
                research instrument was a 2-part questionnaire. The first part was related to demographic
                characteristics of hospitals and the second part elicited information about blood and blood component
                wastage. The collected data were then analyzed using descriptive statistic methods and SPSS 11.5.
                Results: Blood wastage may occur for a number of reasons, including time expiry, wasted imports, blood
                medically or surgically ordered but not used, stock time expired, hemolysis, or miscellaneous reasons.
                Data indicated that approximately 77.9% of wasted pack cell units were wasted for the reason of time
                expiry. Pack cell wastage in hospitals is reported to range from 1.93% to 30.7%. Wastage at all
                hospitals averaged 9.8% among 30.913 issued blood products. Overall blood and blood product (packed red
                cells, plasma, platelets, and cryoprecipitate) wastage was 3048 units and average total wastage per
                participant hospital for all blood groups was 254 units per year. Conclusion: Blood transfusion is an
                essential part of patient care. The blood transfusion system has made significant advancements in areas
                such as donor management, storage of blood, cross-matching, rational use of blood, and distribution. In
                order to improve the standards of blood banks and the blood transfusion services in Iran, comprehensive
                standards have been formulated to ensure better quality control in collection, storage, testing, and
                distribution of blood and its components for the identified major factors affecting blood product
                wastage.
            </value>
        </row>
        <row>
            <value>196</value>
            <value>102</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Background: Crimean-Congo hemorrhagic fever (CCHF) is a viral disease with fatality rate up to 30%.
                Up to date, only one CCHF case has been reported in Greece, while a distinct virus strain (AP92) had
                been isolated in 1975 from ticks in Imathia prefecture, northern Greece. The aim of the present study
                was to estimate the CCHF virus (CCHFV) seroprevalence among humans residing in the prefecture of
                Imathia, and the neighboring prefecture of Pella, and to investigate the risk factors associated with
                the seropositivity. Material and Methods: A total of 277 persons randomly selected from the general
                population were tested for the presence of CCHFV IgG antibodies. Additional 51 persons belonging in
                groups with risk for acquisition of CCHFV infection (19 slaughterhouse workers and 32 hunters) were also
                tested. All participants filled in a questionnaire related to demographics and probable risk factors
                (e.g. occupation, former tick bite, animal contact). Results: Six of the 277 (2.2%) persons were found
                to carry CCHFV IgG antibodies: 3 in Imathia and 3 in Pella prefecture, resulting in seroprevalence of
                1.7% and 2.9%, respectively. History of tick bite, residence in a hilly territory and increased age were
                significantly associated with CCHFV seropositivity. None of the slaughterers was found IgG-positive,
                while CCHFV IgG antibodies were detected in a 67-year old hunter who reported agricultural activities
                and a former tick bite. Conclusions: A relatively low seroprevalence is observed in the area where the
                AP92 strain has been isolated, with tick bite being significantly associated with CCHFV seropositivity.
                Further studies in ticks in the area will show whether are they infected by the AP92 strain or other
                more pathogenic CCHFV strains and at which rate.
            </value>
        </row>
        <row>
            <value>197</value>
            <value>103</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To investigate the influence of seasons, blood types and semen parameters on the cryosurvival rate of
                frozen-thawed spermatozoa from sperm donors.
            </value>
        </row>
        <row>
            <value>198</value>
            <value>103</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We retrospectively analyzed the influence of seasons, blood types, abstinence period, semen volume,
                sperm morphology, and pre-freeze sperm motility and concentration on the cryosurvival rate of
                frozen-thawed sperm in 4 088 semen samples from Shaanxi Human Sperm Bank.
            </value>
        </row>
        <row>
            <value>199</value>
            <value>103</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>The cryosurvival rate of the post-thaw sperm was correlated negatively with the progressive motility
                of the pre-freeze sperm (r = -0.262, P &lt; 0.01), but positively with pre-freeze sperm concentration (r
                = 0.247, P &lt; 0.01), and it was significantly higher in the 6-day abstinence group ([70.2 +/- 5.4]%)
                than in the other abstinence groups (P &lt; 0.01), so was it in the normal sperm morphology rate &gt;
                20% group ([71.4 +/- 5.1]%) than in the others (P &lt; 0.01). The survival rate of the post-thaw sperm
                was not correlated with seasons, blood types, and semen volume (P &gt; 0.05).
            </value>
        </row>
        <row>
            <value>200</value>
            <value>103</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Sperm motility, concentration and morphology and the abstinence period of sperm donors may be
                valuable predictors of the cryosurvival rate of post-thaw sperm, but no correlation was found between
                the survival rate and seasons, blood types and semen volume.
            </value>
        </row>
        <row>
            <value>201</value>
            <value>104</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>analyze and propose a theoretical model that describes blood donor decisions to help staff working in
                blood banks (nurses and others) in their efforts to capture and retain donors.
            </value>
        </row>
        <row>
            <value>202</value>
            <value>104</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>analysis of several studies on the motivations to give blood in Spain over the last six years, as
                well as past literature on the topic, the authors' experiences in the last 25 years in over 15 Non
                Governmental Organizations with different levels of responsibilities, their experiences as blood donors
                and the informal interviews developed during those 25 years.
            </value>
        </row>
        <row>
            <value>203</value>
            <value>104</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>a model is proposed with different internal and external factors that influence blood donation, as
                well as the different stages of the decision-making process.
            </value>
        </row>
        <row>
            <value>204</value>
            <value>104</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>the knowledge of the donation process permits the development of marketing strategies that help to
                increase donors and donations.
            </value>
        </row>
        <row>
            <value>205</value>
            <value>105</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>A variety of compounds distribute into brain when placed at the cribriform plate by intranasal
                administration (i.n.). Here, we investigated the ability of albumin, a protein that can act as a drug
                carrier but is excluded from brain by the blood-brain barrier, to distribute into brain after i.n.
                administration. We labeled bovine serum albumin with 125I (I-Alb) and studied its uptake into 11 brain
                regions and entry into blood from 5 min to 6 h after i.n. administration. I-Alb was present throughout
                the brain at 5 min. Several regions showed distinct peaks in uptake that ranged from 5 min (parietal
                cortex) to sixty min (midbrain). About 2-4% of the i.n. I-Alb entered the blood stream. The highest
                levels occurred in olfactory bulb and striatum. Distribution was dose-dependent with less being taken up
                by whole brain, cortex, and blood at the higher dose of albumin. Uptake was selectively increased into
                the olfactory bulb and cortex by the fluid phase stimulator phorbol 12-myristate 13-acetate, but
                inhibitors to receptor-mediated transcytosis, caveolae, and phosphoinositide 3-kinase were without
                effect. Albumin altered distribution of radioactive leptin given by i.n. administration, decreasing
                uptake into blood and by cerebellum and increasing uptake by the hypothalamus. We conclude that I-Alb
                administered i.n. reaches all parts of the brain through a dose-dependent mechanism that may involve
                fluid phase transcytosis and, as illustrated by leptin, can affect the delivery of other substances to
                the brain after their i.n. administration.
            </value>
        </row>
        <row>
            <value>206</value>
            <value>106</value>
            <value>1</value>
            <value>Introduction</value>
            <value>Background</value>
            <value>Barrett's oesophagus (BE) remains the strongest risk factor for oesophageal adenocarcinoma (OAC).
                Several studies describe an association between BE and obesity through mechanical and metabolic
                consequences. Visceral fat is a recognised endocrine organ. Adipokines and insulin resistance impact
                upon obesity-related diseases and cancer pathways. Our aims were to evaluate the relationship between
                BE, abdominal adiposity/BMI and pathways in the progression to cancer.
            </value>
        </row>
        <row>
            <value>207</value>
            <value>106</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Height, weight, waist-hip ratio, blood pressure assessment and fasting blood samples were obtained
                from sequential patients (pts), undergoing gastroscopy. BMI, fasting glucose and insulin, lipids, leptin
                and adiponectin were measured. Pts were then classified as normal-weight, overweight or obese and the
                presence of abdominal obesity (AO) and/or metabolic syndrome (MS, defined by WHO criteria) documented.,
                to evaluate the relationship between BMI and abdominal adiposity with metabolic indices and adipokines
                in BE compared to controls. Biopsies were obtained from BE and histological progression to cancer was
                correlated with metabolic indexes. Chi square, Fisher, t-Student test and logistic analysis were used
                for comparison.
            </value>
        </row>
        <row>
            <value>208</value>
            <value>106</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>209</value>
            <value>106</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>BE association with insulin resistance and MS suggests activation of specific metabolic pathways in
                pts with abdominal obesity or BMI. Progression to cancer appears driven by metabolic dysfunction in MS
                and a carcinogenic insulin pathway.
            </value>
        </row>
        <row>
            <value>210</value>
            <value>106</value>
            <value>5</value>
            <value>Disclosure of interest</value>
            <value>Unassigned</value>
            <value>None Declared.</value>
        </row>
        <row>
            <value>211</value>
            <value>107</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>212</value>
            <value>108</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Mucolipidosis type II (MLII), or I-Cell Disease, is a rare, but severe disorder affecting
                localization of enzymes to the lysosome, generally resulting in death before the 10(th) birthday.
                Although hematopoietic stem cell transplant (HSCT) has been used to successfully treat some lysosomal
                storage diseases, there have been only two case reports in the use of HSCT to treat MLII. For the first
                time, we describe the combined international experience in the use of HSCT for MLII in 22 patients.
                Although 95% of the patients engrafted, the overall survival was low with only 6 patients (27%) alive at
                last follow-up. The most common cause of death post-transplant was cardiovascular complications, most
                likely due to disease progression. Survivors were globally delayed in development, and often required
                complex medical support such as gastrostomy tubes for nutrition, and tracheostomy with mechanical
                ventilation. Although HSCT has demonstrated efficacy in treating some lysosomal storage disorders, the
                neurologic outcome and survival for patents with MLII were poor. Therefore new medical and cellular
                therapies should be sought for these patients.
            </value>
        </row>
        <row>
            <value>213</value>
            <value>109</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>214</value>
            <value>110</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>The main purpose of this study was to establish the prevalence of antibodies against five
                transfusion-transmissible infections (TTIs) in blood donors from one of the most important blood banks
                in Colombia.
            </value>
        </row>
        <row>
            <value>215</value>
            <value>110</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>A cross-sectional, descriptive and case control study was performed from a database of
                Higuera-Escalante blood bank, for a period of a year. Serum was used for donor screening. Surface
                antigens for hepatitis B (HbsAg), anti-hepatitis C antibodies, Chagas disease, syphilis, and HIV were
                identified. Chemiluminescent Microparticle Immunoassay (CMIA, Abbott Diagnostics) was performed.
            </value>
        </row>
        <row>
            <value>216</value>
            <value>110</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>From 41,575 total donors analyzed, 1,226 were reactive for any of the infectious markers (total
                prevalence of 2.95%). The prevalence of specific infections was: Chagas disease 0.49%, HbsAg 0.21%, HCV
                0.45%, HIV 0.12%, and syphilis 1.68%. Reactivity was more frequent in men (n = 785, 64%) with a mean age
                of 36.35 years. HIV was present in the youngest donors with a mean age of 26.5 years (IC 95%: 23.6 -
                27.6); on the other hand, Chagas disease was found in the oldest donor population, with a mean age of 40
                years (IC 95%: 39.1 - 41.3).
            </value>
        </row>
        <row>
            <value>217</value>
            <value>110</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Identifying the prevalence of circulating antibodies against transfusion transmissible infections
                allows us to establish an epidemiological profile of donors inhabiting the geographic catchment area of
                our blood bank. Total prevalence in this study was 2.95% for any of the five markers. Syphilis
                prevalence demonstrates its high distribution within the blood donor population of our country, although
                this result could be influenced by the high rate of false-reactive test. Chagas disease is endemic in
                Santander, Colombia, which correlates with the results obtained in this study.
            </value>
        </row>
        <row>
            <value>218</value>
            <value>111</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Although anti-Jkb is a well-defined cause of severe acute or delayed hemolytic transfusion reactions,
                it is rarely associated with severe Hemolytic Disease of the Newborn (HDN), even with high antibody
                titer. To date, only 13 cases have been reported, so the possible reasons for that still remain unclear.
                Most of HDN due to anti-Jkb are mild-to-moderate, and usually have a good prognosis. A 41-years-old
                woman, who had a positive antibody screening test in her 13th week of pregnancy, was sent to the blood
                bank for study before an amniocentesis. Antibody identification and red blood cell (RBC) phenotyping of
                the patient and his husband were performed, plus arrays study in the amniotic fluid. An anti-Jkb was
                identified in the patient's serum with a titer of 1:1, and her RBC phenotype was O Rh(D) positive, C(+),
                c(+), E(-), e(+), K(-), Jka(+), Jkb(-). The RBC genotype of the fetus was B Rh(D) positive, Jka(+),
                Jkb(+). Antibody titer remained stable and the pregnancy was uneventful. At birth, there was no need of
                phototherapy or exchange transfusion for the newborn and her Jk(b+) typing result was confirmed in a
                cord blood sample. Although most of HDN cases due to anti-Jkb have a good outcome, monitoring antibody
                titer should be done to prevent fatal complications. Furthermore, antenatal antibody screening should be
                performed in every pregnant woman irrespective of her Rh(D) antigen status in order to detect red cell
                alloimmunization to other clinically significant blood group antigens.
            </value>
        </row>
        <row>
            <value>219</value>
            <value>112</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>220</value>
            <value>113</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The mobilization and homing of endothelial progenitor cells (EPCs) are critical to the development of
                an antithrombotic cardiovascular prosthesis. Polyurethane (PU) with superior elasticity may provide a
                mechanical environment resembling that of the natural vascular tissues. The topographical cues of PU
                were maximized by making nanocomposites with a small amount of gold nanoparticles (AuNPs). The
                nanocomposites of PU-AuNPs ("PU-Au") with a favorable response of endothelial cells were previously
                established. In the current study, the effect of PU and PU-Au nanocomposites on the behavior of human
                peripheral blood EPCs was investigated in vitro and in vivo. It was found that PU-Au promoted EPCs to
                become differentiated endothelial cells in vitro, confirmed by the increased expressions of CD31 and
                VEGF-R2 surface markers. The increased maturation of EPCs was significantly more remarkable on PU-Au,
                probably through the stromal derived factor 1? (SDF-1?)/CXCR4 signaling pathway. In vivo experiments
                showed that EPCs seeded on PU-Au coated catheters effectively reduced thrombosis by differentiation into
                endothelial cells. Surface endothelialization with CD31 and CD34 expression as well as intimal formation
                with ?-SMA expression was significantly accelerated in the group receiving EPC-seeded PU-Au catheters.
                Moreover, the analysis of collagen deposition revealed a reduction of fibrosis in the group receiving
                EPC-seeded PU-Au catheters as compared to the other groups. These results suggest that EPCs engineered
                with a proper elastic substrate may provide unique endothelialization and antithrombogenic properties
                that benefit vascular tissue regeneration.
            </value>
        </row>
        <row>
            <value>221</value>
            <value>114</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>During the past several years, trauma resuscitation in human patients has evolved from decreased use
                of crystalloids to increased use of blood products. Of high interest is the role of platelets in trauma
                resuscitation. Because conducting prehos- pital resuscitation in human trauma patients is very
                difficult, swine are often the animal model of choice for such studies because their coagulation and
                hemodynamic systems are similar to those in humans. However, consistent production of sufficient swine
                platelets for such studies has not previously been achieved. We developed a method for producing swine
                platelets by using standard human techniques and equipment. We assessed pH, pO2, pCO2, lactate,
                thromboelastography, and platelet aggregation over 5 d of storage to determine whether the swine
                platelet product met the American Association of Blood Banks (AABB) standards for transfusion. Swine
                platelets met AABB standards at 24 h but not at later time points. In addition, we fluorescently labeled
                nonautologous platelets and then measured their percentage recovery over 5 h (the time used in
                subsequent experimental studies) when transfused into a recipient pig. We showed that 80% of the
                platelets stored for 24 h remained in the circulation and increased the recipient pigs'
                thromboelastographic responses, indicating that the platelets were viable and active. Therefore, swine
                platelets stored for 24 h by using standard human products met the AABB criteria and were functional.
            </value>
        </row>
        <row>
            <value>222</value>
            <value>115</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Since the first use of umbilical cord blood (UCB) as a medical therapy, the number of UCB banks
                worldwide has grown. Public UCB banks offer the option of altruistic donation, whereas private banks
                allow a product to be stored for the exclusive use of the paying client. With many more UCB products
                banked privately than publicly in countries such as the USA, hybrid models blending aspects of public
                and private banking have been proposed. One such bank is in operation in the UK. In this paper we review
                the hybrid UCB model and conclude that it offers limited benefit to the general public. Furthermore,
                compared with private banking, this model provides few advantages and potential disadvantages to private
                clients.
            </value>
        </row>
        <row>
            <value>223</value>
            <value>117</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Umbilical cord blood banks use two methods to store frozen umbilical cord blood (UCB): red cell
                reduction (RCR) or plasma depletion (PD). The RCR method centrifuges cord blood in hetastarch or albumin
                to isolate 21 ml of cord blood containing mostly white blood cells, adds 4 ml of 50% dimethyl sulfoxide
                (DMSO), and then freezes the resulting 25 ml of cell suspension. The PD method removes plasma, saves all
                the cells, and freezes the cells in 10% DMSO. PD UCB units are cheaper to process but more expensive to
                store and somewhat more troublesome to thaw. However, when properly thawed and washed, PD UCB units have
                as many or more total nucleated cells (TNCs), CD34(+) cells, and colony-forming units (CFU) than RCR
                units. Two studies suggest that PD units have 20-25% more TNCs, MNCs, and CD34(+) cells, as well as two
                to three times more CFU than RCR units. Higher TNC, CD34(+), and CFU counts predict engraftment rate
                with faster neutrophil and platelet recovery. PD units have high engraftment rates with low mortality
                and high disease-free survival, comparable with clinical results of treatments with RCR units. One
                recent series of studies suggests that PD units are more effective for treating thalassemia with 2-year
                survival rates of 88%, disease-free survival rates of 74%, and 100% cure rate for children under age 7,
                compared to only 61% overall survival and 23% disease-free survival rate in thalassemic children treated
                with RCR units. These findings suggest that PD units not only have more TNCs, CD34(+) cells, and CFU
                than RCR units but also have high engraftment rates and may be more effective for treating certain
                conditions such as ?-thalassemia.
            </value>
        </row>
        <row>
            <value>224</value>
            <value>118</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Thalassemia Intermedia (TI) has a wide clinical profile with many patients requiring only occasional
                transfusions. To prevent alloimmunization, we adopted a policy of issuing phenotype matched red blood
                cells in 2009. We examined transfusion indications and alloimmunization rate in TI patients.
            </value>
        </row>
        <row>
            <value>225</value>
            <value>118</value>
            <value>2</value>
            <value>Study design and methods</value>
            <value>Methods</value>
            <value>Clinical and blood bank records of 37 TI patients were reviewed.</value>
        </row>
        <row>
            <value>226</value>
            <value>118</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>23 Patients required transfusion for pregnancy (26), splenectomy (8) and anemia (11). Since 2009,
                total of 335 units were transfused with only one antibody developing after transfusing a non-phenotype
                matched unit.
            </value>
        </row>
        <row>
            <value>227</value>
            <value>118</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>The commonest indication for blood transfusion was pregnancy. Providing phenotype matched blood has
                successfully reduced the rate of alloimmunization.
            </value>
        </row>
        <row>
            <value>228</value>
            <value>119</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>229</value>
            <value>120</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Viral pneumonia is a major cause of acute respiratory distress syndrome (ARDS). Anti-inflammatory
                therapies for viral-induced lung injury show promise in preclinical models. Mesenchymal stem/stromal
                cells (MSCs) are multipotent, self-renewing cells that secrete anti-inflammatory cytokines and
                epithelial and endothelial growth factors. We inoculated mice intranasally with influenza A
                (murine-adapted PR8) or PBS, and sacrificed at multiple time points after infection for measures of lung
                injury and viral load. We report that influenza induces marked, long-lasting dysfunction of the
                alveolar-capillary barrier peaking at one week but lasting longer than 3 weeks post-infection. Weight
                loss, commonly employed as a criterion for euthanasia (and hence "survival") was found to be poorly
                predictive of the severity of lung injury at its peak; rather, persistent weight loss 11 days
                post-infection identified mice with impaired injury resolution. Murine and human bone-marrow derived
                MSCs (obtained from the NIH repository) were then administered intravenously during the rapid phase of
                injury progression. Murine MSCs (mMSCs) given twice 24 hours apart failed to improve weight loss, lung
                water, BAL inflammation, or histology. However, mMSCs prevented influenza-induced thrombocytosis and
                caused a modest reduction in lung viral load at day 7. Human MSCs administered intravenously showed a
                similar lack of efficacy. The results demonstrate that the influenza murine model bears important
                similarities to the slow resolution of ARDS in patients. Despite their potent therapeutic effects in
                many models of acute inflammation and lung injury, MSCs do not improve influenza-mediated lung injury in
                mice.
            </value>
        </row>
        <row>
            <value>230</value>
            <value>121</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Cultured human bone marrow mesenchymal cells (MSCs) have immunomodulatory and tissue regenerative
                properties. This report summarizes the result of post-transplant treatment with MSCs of a 26-year-old
                patient with aplastic anemia complicated by invasive sino-orbital aspergillosis. The patient was treated
                with MSCs to benefit from the dual effects of MSCs in immune reconstitution: suppression against
                alloreactive T cells and facilitation of the re-engraftment process. The patient did not develop acute
                or chronic graft-versus-host disease. The aspergillus infection healed completely. The engraftment
                failure was also ended without any complications. During his last visit in his fourth year after
                transplantation, the patient was in hematological remission. Human bone marrow-derived MSCs seem to have
                an important role in preventing or overcoming immunological complications in patients who undergo stem
                cell transplantation.
            </value>
        </row>
        <row>
            <value>231</value>
            <value>122</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>232</value>
            <value>123</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Patients with primary immunodeficiencies are usually susceptible to enterovirus infections and have
                higher risks to develop severe clinical forms. We report a unique description of a boy with MHC-ClassII
                deficiency infected by 9 different enterovirus serotypes during a 2-years-period, with very mild
                clinical symptoms; probably due to the immunoglobulin therapy he was receiving.
            </value>
        </row>
        <row>
            <value>233</value>
            <value>125</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Programmed death-1 (PD-1) belongs to the CD28 family of co-stimulatory and co-inhibitory molecules
                and regulates adaptive immunity. This molecule induces the development of regulatory T cells, T cell
                tolerance, or apoptosis. We examined the role of PD-1 pathway in Theiler's murine encephalomyelitis
                virus (TMEV)-induced demyelinating disease (TMEV-IDD) mice. Up-regulation of PD-1 and PD-1 ligand-1
                (PD-L1) mRNA expression in bone marrow-derived dendritic cells were induced by TMEV infection in vitro.
                Furthermore, PD-1 and PD-L1 mRNA expression was increased in the spinal cords of the TMEV-infected mice
                in vivo. Treatment with a blocking monoclonal antibody (mAb) against PD-1, especially during the
                effector phase, resulted in significant deterioration of the TMEV-IDD both clinically and
                histologically. Flow cytometric analysis revealed a dramatically increase of CD4(+) T cells producing
                Th1 cytokines such as IFN-? and TNF-? in the spinal cord of anti-PD-1 mAb-treated mice. These results
                indicate that the PD-1 pathway plays a pivotal regulatory role in the development of TMEV-IDD.
            </value>
        </row>
        <row>
            <value>234</value>
            <value>126</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>X-linked severe combined immunodeficiency (XSCID) is caused by a genetic mutation within the common
                gamma chain (?c), an essential component of the cytokine receptors for interleukin (IL)-2, IL-4, IL-7,
                IL-9, IL-15, and IL-21. XSCID patients are most commonly treated with bone marrow transplants (BMT) to
                restore systemic immune function. However, BMT-XSCID humans and dogs remain at an increased risk for
                development of cutaneous papillomavirus (PV) infections and their associated neoplasms, most typically
                cutaneous papillomas. Since basal keratinocytes are the target cell for the initial PV infection, we
                wanted to determine if canine XSCID keratinocytes have a diminished antiviral cytokine response to
                poly(dA:dT) and canine papillomavirus-2 (CPV-2) upon initial infection. We performed quantitative RT-PCR
                for antiviral cytokines and downstream interferon stimulated genes (ISG) on poly(dA:dT) stimulated and
                CPV-2 infected monolayer keratinocyte cultures derived from XSCID and normal control dogs. We found that
                XSCID keratinocytes responded similarly to poly(dA:dT) as normal keratinocytes by upregulating antiviral
                cytokines and ISGs. CPV-2 infection of both XSCID and normal keratinocytes did not result in
                upregulation of antiviral cytokines or ISGs at 2, 4, or 6 days post infection. These data suggest that
                the antiviral response to initial PV infection of basal keratinocytes is similar between XSCID and
                normal patients, and is not the likely source for the remaining immunodeficiency in XSCID patients.
            </value>
        </row>
        <row>
            <value>235</value>
            <value>127</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>236</value>
            <value>128</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Diagnosis of invasive fungal infection remains challenging. Here we report a case of early diagnosis
                of invasive aspergillosis in a neutropenic patient affected by acute myeloid leukaemia, achieved through
                the detection of Aspergillus fumigatus species-specific ribonucleic acid sequences by a sensitive
                multiplex real-time polymerase chain reaction-based molecular assay. Thanks to the early diagnosis,
                targeted therapy was promptly established and the severe fungal infection controlled, allowing the
                patient to subsequently receive allogeneic hematopoietic stem cell transplantation from a haploidentical
                donor, her only curative option. Also in this instance, targeted secondary antifungal prophylaxis with
                voriconazole avoided any other fungal infection afterwards. This report suggests how the implementation
                of molecular assays in combination with routine diagnostic procedures, can improve microbiological
                diagnosis in sepsis, particularly in case of fungal infection, difficult to detect with standard
                microbiological culture methods.
            </value>
        </row>
        <row>
            <value>237</value>
            <value>129</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Toxoplasma gondii is an obligate intracellular parasite that can cause severe neurological disease in
                infected humans. CD40 is a receptor on macrophages that plays a critical role in controlling T. gondii
                infection. We examined the regulation of CD40 on the surface of T. gondii-infected bone marrow-derived
                macrophages (BMdM). T. gondii induced CD40 expression at both the transcript level and on the cell
                surface, and interestingly, the effect was parasite strain-specific: CD40 levels were dramatically
                increased in type II T. gondii-infected BMdM compared to type I- or type III-infected cells. Type II
                induction of CD40 was specific to cells harboring intracellular parasites and detectable as early as 6
                hours post-infection (hpi) at the transcript level. CD40 protein expression peaked at 18 hpi. Using
                forward genetics with progeny from a type II x type III cross, we found that CD40 induction mapped to a
                region of chromosome X that included the gene encoding the dense granule protein 15 (GRA15). Using type
                I parasites stably expressing the type II allele of GRA15 (GRA15II), we found that GRA15II induced the
                expression of CD40 on infected cells in an NF-?B-dependent manner. In addition, stable expression of
                HA-tagged GRA15II in THP-1 cells resulted in CD40 up-regulation in the absence of infection. Since CD40
                signaling contributes to IL-12 production, we examined IL-12 from infected macrophages and found that
                CD40L engagement of CD40 amplified the IL-12 response in type II-infected cells. These data indicate
                that GRA15II induction of CD40 promotes parasite immunity through the production of IL-12.
            </value>
        </row>
        <row>
            <value>238</value>
            <value>130</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>239</value>
            <value>131</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma. It usually
                presents with nonspecific symptoms, such as fever, rather than with overt lymphadenopathy. Reports of
                hypercalcemia, as the initial presentation of IVLBCL, are limited in the literature, despite it being a
                well-known complication of various solid cancers. We present a 68-year-old male with severe
                hypercalcemia and increased levels of serum parathyroid hormone-related protein. He was diagnosed with
                IVLBCL, involving the bone marrow and spleen, and was successfully treated with rituximab-containing
                chemotherapy. A few previous case reports have shown hypercalcemia in patients with IVLBCL. Much like
                our case, previous cases with hypercalcemia had advanced diseases, including bone marrow invasion.
                Although it was an extremely rare manifestation of IVLBCL, we suggest that IVLBCL should be a part of
                the differential diagnosis in patients with unexplained hypercalcemia. Therefore, an active work-up
                might be recommended, including positron emission tomography/ computed tomography scan and bone marrow
                examination, which may be useful for early diagnosis.
            </value>
        </row>
        <row>
            <value>240</value>
            <value>132</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Iron deficiency is common in non-dialysis chronic kidney disease (ND-CKD) patients and, on occasion,
                requires parenteral iron therapy. We investigated the effect of intravenous iron repletion on platelet
                counts in ND-CKD patients with and without concomitant darbepoetin administration.
            </value>
        </row>
        <row>
            <value>241</value>
            <value>132</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We conducted a retrospective analysis of ND-CKD patients with iron deficiency anemia treated with low
                molecular weight iron dextran (LMWID) between 2005 and 2009 at our CKD clinic. The primary end-point was
                change in platelet count 60 days post infusion of LMWID in those with and without concomitant
                darbepoetin administration. Secondary end-points were the correlations between changes in platelet count
                and iron indices.
            </value>
        </row>
        <row>
            <value>242</value>
            <value>132</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>A total of 108 patients met inclusion and exclusion criteria. The decrease in platelet counts in
                response to iron repletion was statistically significant (305.72 +/- 108.86 vs 255.58 +/- 78.97, P =
                &lt; .0001). The decrease in platelet count was independent of concomitant darbepoetin use. Bivariate
                regression analysis between baseline platelet count and transferrin saturation by iron (TSAT) showed a
                negative association (betaTSAT = -5.82, P = .0007) and moderate correlation (R = 0.32). Following iron
                treatment, the within individual changes in platelet count in 60 days were not related to changes in
                TSAT (betaDeltaTSAT = -0.41, P = .399) and demonstrated a poor correlation (R = 0.10).
            </value>
        </row>
        <row>
            <value>243</value>
            <value>132</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Parenteral iron treatment by LMWID is associated with reduction in platelet counts in iron deficient
                anemic ND-CKD patients. However, ESA use in the majority of patients prior to intravenous iron
                administration could have altered platelet production through bone marrow competition.
            </value>
        </row>
        <row>
            <value>244</value>
            <value>133</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value></value>
        </row>
        <row>
            <value>245</value>
            <value>133</value>
            <value>2</value>
            <value>Patients and methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>246</value>
            <value>133</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>247</value>
            <value>133</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Biweekly S-1 plus paclitaxel showed promising activity with acceptable toxicities as second-line
                chemotherapy in pretreated patients with AGC. This regimen deserves further investigation in a phase III
                trial.
            </value>
        </row>
        <row>
            <value>248</value>
            <value>134</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Therapeutic options for progressive multifocal leukoencephalopathy (PML) caused by reactivation of
                John Cunningham virus (JCV) are limited and inefficient in preventing neurological progression and
                death. The current study investigated the course of JCV reactivation resulting in PML in patients
                undergoing allogeneic stem cell transplantation (allo-SCT) and assessed the feasibility and potential
                significance of preemptive JCV detection in peripheral blood, enabling early cessation of
                immunosuppressive therapy and immune restoration. Two allografted patients were diagnosed with PML at
                188 and 808 days post-allo-SCT. Stored DNA samples of both patients, originally obtained for
                quantitative cytomegalovirus PCR analysis since transplantation, were evaluated for JCV. JCV
                reactivation in peripheral blood was found to precede the appearance of neurological symptoms by 126 and
                105 days. JCV blood levels were found to be highly correlated with the steroid dosage administered for
                treating graft-versus-host disease (GVHD). In one patient, the cessation of immunosuppression, including
                steroids, led to the disappearance of JCV in peripheral blood, with a remarkable improvement in
                neurological symptoms. In conclusion, the current study suggests the feasibility of early detection of
                JCV reactivation in blood. Immune restoration at that point may prevent PML development; however
                prospective studies are warranted to elucidate these issues.
            </value>
        </row>
        <row>
            <value>249</value>
            <value>135</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Ageing is associated with an overall decline in the functional capacity of tissues and stem cells,
                including haematopoietic stem and progenitor cells (HSPCs), as well as telomere dysfunction. Dietary
                restriction (DR) is a recognised anti-ageing intervention that extends lifespan and improves health in
                several organisms. To investigate the role of telomeres and telomerase in haematopoietic ageing, we
                compared the HSPC profile and clonogenic capacity of bone marrow cells from wild type with
                telomerase-deficient mice and the effect of DR on these parameters. Compared with young mice, aged wild
                type mice demonstrated a significant accumulation of HSPCs (1.3% vs 0.2%, P=0.002) and elevated numbers
                of granulocyte/macrophage colony forming units (CFU-GM, 26.4 vs 17.3, P=0.0037) consistent with myeloid
                "skewing" of haematopoiesis. DR was able to restrict the increase in HSPC number as well as the myeloid
                "skewing" in aged wild type mice. In order to analyse the influence of short telomeres on the ageing
                phenotype we examined mice lacking the RNA template for telomerase, TERC(-/-). Telomere shortening
                resulted in a similar bone marrow phenotype to that seen in aged mice, with significantly increased HSPC
                numbers and an increased formation of all myeloid colony types but at a younger age than wild type mice.
                However, an additional increase in erythroid colonies (BFU-E) was also evident. Mice lacking telomerase
                reverse transcriptase without shortened telomeres, TERT(-/-), also presented with augmented
                haematopoietic ageing which was ameliorated by DR, demonstrating that effect of DR was not dependent on
                the presence of telomerase in HSPCs. We conclude that whilst shortened telomeres mimic some aspects of
                haematopoietic ageing, both shortened telomeres and the lack of telomerase produce specific phenotypes,
                some of which can be prevented by dietary restriction.
            </value>
        </row>
        <row>
            <value>250</value>
            <value>136</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Wnt signaling plays a major role in bone homeostasis and mechanotransduction, but its role and
                regulatory mechanism in osteoclast development are not fully understood. Through genome-wide in silico
                analysis, we examined Wnt3a-driven regulation of osteoclast development. Mouse bone marrow-derived cells
                were incubated with RANKL in the presence and absence of Wnt3a. Using microarray mRNA expression data,
                we conducted a principal component analysis and predicted transcription factor binding sites (TFBS) that
                were potentially involved in the responses to RANKL and Wnt3a. The principal component analysis
                predicted potential Wnt3a responsive regulators that would reverse osteoclast development, and a TFBS
                prediction algorithm indicated that the AP1 binding site would be linked to Wnt3a-driven suppression.
                Since c-Fos was upregulated by RANKL and downregulated by Wnt3a in a dose-dependent manner, we examined
                its role using RNA interference. The partial silencing of c-Fos suppressed RANKL-driven
                osteoclastogenesis by downregulating NFATc1, a master transcription factor of osteoclast development.
                Although the involvement of c-Myc was predicted and partial silencing c-Myc slightly reduced the level
                of TRAP, c-Myc silencing did not alter the expression of NFATc1. Collectively, the presented
                systems-biology approach demonstrates that Wnt3a attenuates RANKL-driven osteoclastogenesis by blocking
                c-Fos expression and suggests that mechanotransduction of bone alters the development of not only
                osteoblasts but also osteoclasts through Wnt signaling.
            </value>
        </row>
        <row>
            <value>251</value>
            <value>137</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>252</value>
            <value>138</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>253</value>
            <value>139</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Effective skin regeneration therapies require a successful interface between progenitor cells and
                biocompatible delivery systems. We previously demonstrated the efficiency of a biomimetic
                pullulan-collagen hydrogel scaffold for improving bone marrow-derived mesenchymal stem cell survival
                within ischemic skin wounds by creating a "stem cell niche" that enhances regenerative cytokine
                secretion. Adipose-derived mesenchymal stem cells (ASCs) represent an even more appealing source of stem
                cells because of their abundance and accessibility, and in this study we explored the utility of ASCs
                for hydrogel-based therapies. To optimize hydrogel cell seeding, a rapid, capillary force-based approach
                was developed and compared with previously established cell seeding methods. ASC viability and
                functionality following capillary hydrogel seeding were then analyzed in vitro and in vivo. In these
                experiments, ASCs were seeded more efficiently by capillary force than by traditional methods and
                remained viable and functional in this niche for up to 14 days. Additionally, hydrogel seeding of ASCs
                resulted in the enhanced expression of multiple stemness and angiogenesis-related genes, including Oct4,
                Vegf, Mcp-1, and Sdf-1. Moving in vivo, hydrogel delivery improved ASC survival, and application of both
                murine and human ASC-seeded hydrogels to splinted murine wounds resulted in accelerated wound closure
                and increased vascularity when compared with control wounds treated with unseeded hydrogels. In
                conclusion, capillary seeding of ASCs within a pullulan-collagen hydrogel bioscaffold provides a
                convenient and simple way to deliver therapeutic cells to wound environments. Moreover, ASC-seeded
                constructs display a significant potential to accelerate wound healing that can be easily translated to
                a clinical setting.
            </value>
        </row>
        <row>
            <value>254</value>
            <value>140</value>
            <value>1</value>
            <value>Purpose:</value>
            <value>Unassigned</value>
            <value>To describe characteristics and outcomes of combined pars plana vitrectomy and Baerveldt tube
                insertion procedure from 2005 to 2010 in eyes with neovascular glaucoma.
            </value>
        </row>
        <row>
            <value>255</value>
            <value>140</value>
            <value>2</value>
            <value>Methods:</value>
            <value>Unassigned</value>
            <value>Seventy-nine patients (89 eyes) with ???2 months of follow-up were included. Outcome measures were
                visual acuity, intraocular pressure (IOP), number of glaucoma medications, and complications. Changes in
                mean logMAR visual acuity, IOP, and glaucoma medications were compared by a two-tailed t-test.
            </value>
        </row>
        <row>
            <value>256</value>
            <value>140</value>
            <value>3</value>
            <value>Results:</value>
            <value>Unassigned</value>
            <value></value>
        </row>
        <row>
            <value>257</value>
            <value>140</value>
            <value>4</value>
            <value>Conclusion:</value>
            <value>Unassigned</value>
            <value>Combined pars plana vitrectomy and Baerveldt glaucoma shunt may be a useful procedure in reducing IOP
                and number of glaucoma medications in eyes with neovascular glaucoma along with stabilizing visual
                acuity in a majority of these eyes. Further studies are warranted to verify and expand on these
                findings.
            </value>
        </row>
        <row>
            <value>258</value>
            <value>141</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>259</value>
            <value>142</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>260</value>
            <value>143</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value>To evaluate the efficacy and safety of diode laser transscleral cyclophotocoagulation (DLTSC) as an
                adjuvant therapy to treat refractory glaucoma diagnosed before or after Moscow Eye Microsurgery Complex
                (MICOF) keratoprosthesis surgery.
            </value>
        </row>
        <row>
            <value>261</value>
            <value>143</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Fifteen patients underwent unilateral DLTSC to treat refractory glaucoma diagnosed before or after
                undergoing MICOF keratoprosthesis surgery. The cause for keratoprosthesis was alkali burn in 8 patients
                (53.33%); thermal burn, sulfuric acid burn, and Steven-Johnson syndrome in 2 patients (13.33%) each; and
                ocular cicatricial pemphigoid in 1 patient (6.67%). Best-corrected visual acuity (BCVA), intraocular
                pressure (IOP), any medications, and adverse events were recorded before DLTSC and on postoperative day
                7; months 1, 3, and 6; and every 6 months afterwards.
            </value>
        </row>
        <row>
            <value>262</value>
            <value>143</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>263</value>
            <value>143</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Diode laser transscleral cyclophotocoagulation is an effective treatment option for refractory
                glaucoma and can be used as a therapy adjuvant to keratoprosthesis. Long-term effects require further
                clinical observation.
            </value>
        </row>
        <row>
            <value>264</value>
            <value>144</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value>To report vascular comorbidities, arterial hypertension (HT), ischemic heart disease (IHD), and
                diabetes mellitus (DM) in patients with low-tension glaucoma (LTG) with maximum intraocular pressure
                (IOP) of 18 mm Hg or less. Uniform criteria for glaucoma and the comorbidities were applied.
            </value>
        </row>
        <row>
            <value>265</value>
            <value>144</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We reviewed records of 519 consecutive patients to whom the Finnish National Social Insurance
                Institution (FSII) had granted cost-free medication for the treatment of glaucoma. The FSII operates
                national health insurance, which is compulsory for all Finnish citizens. There were 344 patients with
                primary open-angle glaucoma (POAG) and 155 with exfoliative glaucoma (EG). Twenty cases were discarded
                for having other types of glaucoma. In the POAG group, there were 38 patients, with a median IOP of 16
                mm Hg (range 12-18). We were masked to the systemic comorbidities when the registry provided us data on
                those to whom FSII had also granted cost-free medication for HT, IHD, or DM according to the uniform
                national criteria.
            </value>
        </row>
        <row>
            <value>266</value>
            <value>144</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>None of the patients with LTG had exfoliation syndrome. There was a female predominance, 81%,
                compared to 68% in high-tension POAG. Hypertension had been diagnosed in 34%, which is the same as in
                high-tension POAG. A total of 24% had IHD, which is the same as in the Finnish population registry.
                Diabetes mellitus was present in only 5%. In all groups, patients with LTG with systemic comorbidity
                were markedly older than those without.
            </value>
        </row>
        <row>
            <value>267</value>
            <value>144</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>In patients with LTG with median IOP 16 mm Hg (range 12-18), glaucomatous optic disc cupping and
                glaucomatous visual field defects probably developed independently of the systemic vascular comorbidity.
                However, the diagnostic criteria for HT, IHD, and DM used in the current study were based on the
                severity of stages set in the FSII system.
            </value>
        </row>
        <row>
            <value>268</value>
            <value>145</value>
            <value>1</value>
            <value>Purpose:</value>
            <value>Unassigned</value>
            <value>To evaluate the efficacy and safety of latanoprost compared with other glaucoma medications in the
                treatment of chronic angle-closure glaucoma (CACG) and to provide the basis for clinical medication.
            </value>
        </row>
        <row>
            <value>269</value>
            <value>145</value>
            <value>2</value>
            <value>Methods:</value>
            <value>Unassigned</value>
            <value>Major literature databases were searched for randomized controlled trials (RCT) involving latanoprost
                among patients with CACG. Primary outcome measures were absolute changes in intraocular pressure (IOP)
                and incidence of ocular adverse events. Statistical analyses included the calculation of standardized
                mean difference (SMD) and relative risk (RR). The statistical analysis was performed using STATA version
                12.0 software.
            </value>
        </row>
        <row>
            <value>270</value>
            <value>145</value>
            <value>3</value>
            <value>Results:</value>
            <value>Unassigned</value>
            <value>Ten RCT involving 1096 patients were included in this meta-analysis. Analysis showed that latanoprost
                was not significantly different from other glaucoma medications in reducing IOP (SMD = 0.29, 95%
                confidence interval [CI] -0.02 to 0.59, p=0.069). Further subgroup analysis revealed that latanoprost
                was superior compared with timolol (SMD = 0.64, 95% CI 0.46 to 0.82, p&amp;lt;0.001) and marginally
                inferior to travoprost and bimatoprost (SMD = -0.19, 95% CI -0.35 to -0.02, p = 0.026). As for
                conjunctival hyperemia, latanoprost caused a higher proportion than timolol (RR = 2.36, 95% CI 1.27 to
                4.37, p = 0.007). However, latanoprost was associated with lower incidence of conjunctival hyperemia (RR
                = 0.42, 95% CI 0.30 to 0.59, p&amp;lt;0.001), and with fewer occurrence of other ocular side effects
                (excluding conjunctival hyperemia) than travoprost and bimatoprost (RR = 0.61, 95% CI 0.48 to 0.78, p&amp;lt;0.001).
            </value>
        </row>
        <row>
            <value>271</value>
            <value>145</value>
            <value>4</value>
            <value>Conclusions:</value>
            <value>Unassigned</value>
            <value>Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better
                tolerated in patients with CACG.
            </value>
        </row>
        <row>
            <value>272</value>
            <value>146</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value>To report the effect of oral propranolol on intraocular pressure (IOP) in infants newly diagnosed
                with unilateral Sturge-Weber syndrome (SWS) glaucoma receiving no other treatment.
            </value>
        </row>
        <row>
            <value>273</value>
            <value>146</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>This was a prospective, nonrandomized interventional case series. Four infants presenting with
                unilateral SWS glaucoma with no prior treatment were treated with oral propranolol at a dose of 2 mg/kg
                and followed thereafter.
            </value>
        </row>
        <row>
            <value>274</value>
            <value>146</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Propranolol had a temporary IOP-lowering effect in 3 of 4 children after 1 week of treatment. This
                effect diminished thereafter and 3 of 4 children required additional medical or surgical treatment.
            </value>
        </row>
        <row>
            <value>275</value>
            <value>146</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Oral propranolol has a temporary effect on IOP in SWS glaucoma and is not effective as a single
                treatment in this syndrome, yet can serve to delay surgical treatment for a short period of time. In one
                case, the glaucoma was well-controlled on this medication.
            </value>
        </row>
        <row>
            <value>276</value>
            <value>147</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>277</value>
            <value>148</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>278</value>
            <value>149</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Glaucoma is one of the leading causes of blindness worldwide. Historically, it has been considered an
                ocular disease primary caused by pathological intraocular pressure (IOP). Recently, researchers have
                emphasized intracranial pressure (ICP), as translaminar counter pressure against IOP may play a role in
                glaucoma development and progression. It remains controversial what is the best way to measure ICP in
                glaucoma. Currently, the 'gold standard' for ICP measurement is invasive measurement of the pressure in
                the cerebrospinal fluid via lumbar puncture or via implantation of the pressure sensor into the brains
                ventricle. However, the direct measurements of ICP are not without risk due to its invasiveness and
                potential risk of intracranial haemorrhage and infection. Therefore, invasive ICP measurements are
                prohibitive due to safety needs, especially in glaucoma patients. Several approaches have been proposed
                to estimate ICP non-invasively, including transcranial Doppler ultrasonography, tympanic membrane
                displacement, ophthalmodynamometry, measurement of optic nerve sheath diameter and two-depth
                transcranial Doppler technology. Special emphasis is put on the two-depth transcranial Doppler
                technology, which uses an ophthalmic artery as a natural ICP sensor. It is the only method which
                accurately and precisely measures absolute ICP values and may provide valuable information in glaucoma.
            </value>
        </row>
        <row>
            <value>279</value>
            <value>150</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To evaluate intraoperative subtenon triamcinolone acetonide (TA) as an adjunct to Ahmed glaucoma
                valve (AGV) implantation.
            </value>
        </row>
        <row>
            <value>280</value>
            <value>150</value>
            <value>2</value>
            <value>Design</value>
            <value>Methods</value>
            <value>Retrospective comparative case series.</value>
        </row>
        <row>
            <value>281</value>
            <value>150</value>
            <value>3</value>
            <value>Participants</value>
            <value>Methods</value>
            <value>Forty-two consecutive cases of uncontrolled glaucoma undergoing AGV implantation: 19 eyes receiving
                intraoperative subtenon TA and 23 eyes that did not receive TA.
            </value>
        </row>
        <row>
            <value>282</value>
            <value>150</value>
            <value>4</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>A retrospective chart review was performed on consecutive pseudophakic adult patients with
                uncontrolled glaucoma undergoing AGV with and without intraoperative subtenon TA injection by a single
                surgeon. Clinical data were collected from 42 eyes and analyzed for the first 6 months after surgery.
            </value>
        </row>
        <row>
            <value>283</value>
            <value>150</value>
            <value>5</value>
            <value>Main outcome measures</value>
            <value>Methods</value>
            <value>Primary outcomes included intraocular pressure (IOP) and number of glaucoma medications prior to and
                after AGV implantation. The hypertensive phase (HP) was defined as an IOP measurement of greater than 21
                mmHg (with or without medications) during the 6-month postoperative period that was not a result of tube
                obstruction, retraction, or malfunction. Postoperative complications and visual acuity were analyzed as
                secondary outcome measures.
            </value>
        </row>
        <row>
            <value>284</value>
            <value>150</value>
            <value>6</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>285</value>
            <value>150</value>
            <value>7</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Subtenon TA injection during AGV implantation may decrease the occurrence of the HP but does not
                alter the ultimate IOP outcome and may pose increased risk of serious complications within the first 6
                months of surgery.
            </value>
        </row>
        <row>
            <value>286</value>
            <value>151</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value></value>
        </row>
        <row>
            <value>287</value>
            <value>151</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>288</value>
            <value>151</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Both groups showed a significant decrease in intraocular pressure starting at one month after surgery
                when compared with values before surgery. At 3, 6, 9, and 15 months after surgery, the intraocular
                pressure was significantly lower and the survival rate was significantly higher in the 360P-LOT + DS
                group compared with the 120P-LOT + DS group. The number of antiglaucoma medications, best-corrected
                visual acuity value, and complications did not differ significantly between the groups.
            </value>
        </row>
        <row>
            <value>289</value>
            <value>151</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Although the complications are similar to those seen in 120P-LOT + DS, treatment of primary open
                angle glaucoma and coexisting cataracts using 360P-LOT + DS may yield better outcomes.
            </value>
        </row>
        <row>
            <value>290</value>
            <value>154</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To report and compare the success rate of a conjunctival pedicle flap (CPF) alone vs. a CPF with an
                underlying acellular submucosa implant for the repair of deep or perforating corneal wounds in dogs.
            </value>
        </row>
        <row>
            <value>291</value>
            <value>154</value>
            <value>2</value>
            <value>Procedures</value>
            <value>Methods</value>
            <value>Records of 69 dogs (73 eyes) receiving a CPF with or without an acellular submucosa implant between
                2004 and 2012 were reviewed. Successful outcome was defined as a comfortable eye with vision at the last
                post-operative evaluation. Age, breed, underlying corneal disease, surgical time, lesion
                characteristics, topical therapies, and postoperative complications were investigated.
            </value>
        </row>
        <row>
            <value>292</value>
            <value>154</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>293</value>
            <value>154</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>A comparable success rate is achieved for deep or perforating corneal wounds stabilized with a CPF
                alone vs. a CPF plus acellular submucosa. Glaucoma, persistent uveitis, and cataract formation were not
                reported as post-operative complications in this study population.
            </value>
        </row>
        <row>
            <value>294</value>
            <value>155</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To investigate the relation of residual worst lead ST segment elevation (WL-STE) after ST segment
                myocardial infarction (STEMI) with infarct size and microvascular injury assessed by cardiovascular
                magnetic resonance (CMR) imaging.
            </value>
        </row>
        <row>
            <value>295</value>
            <value>155</value>
            <value>2</value>
            <value>Background</value>
            <value>Background</value>
            <value>WL-STE in patients with acute reperfused STEMI has been shown to identify high risk patients for
                major adverse cardiovascular events (MACE). However, the relation of WL-STE with myocardial damage is
                unknown.
            </value>
        </row>
        <row>
            <value>296</value>
            <value>155</value>
            <value>3</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>In this multicentre study we analysed ECG data 90???min after primary percutaneous coronary
                intervention (PCI) in 763 STEMI patients. WL-STE was defined as the absolute magnitude of STE in the
                most affected lead on the post-PCI ECG. Patients were categorised into three groups (&lt;1???mm,
                1-2???mm, and ???2???mm). CMR was performed within 1???week after infarction for comprehensive
                assessment of myocardial damage using a standardised protocol. The primary clinical endpoint was MACE
                defined as death, reinfarction, and new congestive heart failure within 12???months after infarction.
            </value>
        </row>
        <row>
            <value>297</value>
            <value>155</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value>WL-STE &lt;1???mm, 1-2???mm, and ???2???mm was present in 155 (20%), 328 (43%), and 280 (37%)
                patients, respectively. Myocardial damage determined by CMR demonstrated a graded relationship of
                infarct size (median (IQR) 13.3 (6.2-20.3)%LV vs 13.7 (7.6-21.3)%LV vs 22.5 (15.6-31.2)%LV, p&lt;0.001),
                the myocardial salvage index (60.8 (37.0-84.5) vs 55.0 (36.6-73.9) vs 42.7 (26.2-58.2), p&lt;0.001), and
                microvascular obstruction (0.0 (0.0-0.9)%LV vs 0.0 (0-1.0)%LV vs 1.2 (0.0-3.6)%LV, p&lt;0.001) across
                the three groups. WL-STE ???2???mm was strongly associated with MACE 12???month after infarction (HR
                1.93, 95% CI 1.11 to 3.37; p=0.02).
            </value>
        </row>
        <row>
            <value>298</value>
            <value>155</value>
            <value>5</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>This largest CMR study to date correlating post-PCI WL-STE with markers of myocardial damage
                demonstrates that WL-STE is significantly associated with infarct size, myocardial salvage,
                microvascular obstruction, and MACE in a high risk STEMI population.
            </value>
        </row>
        <row>
            <value>299</value>
            <value>155</value>
            <value>6</value>
            <value>Trial registration number</value>
            <value>Background</value>
            <value>NCT00712101.</value>
        </row>
        <row>
            <value>300</value>
            <value>156</value>
            <value>1</value>
            <value>Background/aims</value>
            <value>Objective</value>
            <value>The aim of the present study was to evaluate the relationship between thyroid hormone levels and
                infarct severity in patients with ST-elevation myocardial infarction (STEMI).
            </value>
        </row>
        <row>
            <value>301</value>
            <value>156</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We retrospectively reviewed thyroid hormone levels, infarct severity, and the extent of transmurality
                in 40 STEMI patients evaluated via contrast-enhanced cardiac magnetic resonance imaging.
            </value>
        </row>
        <row>
            <value>302</value>
            <value>156</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>The high triiodothyronine (T3) group (??? 68.3 ng/dL) exhibited a significantly higher extent of
                transmural involvement (late transmural enhancement &gt; 75% after administration of gadolinium contrast
                agent) than did the low T3 group (60% vs. 15%; p = 0.003). However, no significant difference was
                evident between the high- and low-thyroid-stimulating hormone/free thyroxine (FT4) groups. When the T3
                cutoff level was set to 68.3 ng/dL using a receiver operating characteristic curve, the sensitivity was
                80% and the specificity 68% in terms of differentiating between those with and without transmural
                involvement. Upon logistic regression analysis, high T3 level was an independent predictor of transmural
                involvement after adjustment for the presence of diabetes mellitus (DM) and the use of glycoprotein
                IIb/IIIa inhibitors (odds ratio, 40.62; 95% confidence interval, 3.29 to 502; p = 0.004).
            </value>
        </row>
        <row>
            <value>303</value>
            <value>156</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>The T3 level predicted transmural involvement that was independent of glycoprotein IIb/IIIa inhibitor
                use and DM positivity.
            </value>
        </row>
        <row>
            <value>304</value>
            <value>157</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To explore the relationship between fragmented QRS complexes (fQRS) and imperfect ST-segment
                resolution in ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous
                coronary intervention (p-PCI).
            </value>
        </row>
        <row>
            <value>305</value>
            <value>157</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>This study included 227 consecutive patients with STEMI who underwent p-PCI. They were divided into
                two groups: ECG with fQRS (n = 142) and without fQRS (n = 85). Baseline clinical characteristics,Gensini
                score, coronary angiography features and the rate of ST-segment resolution were compared between the two
                groups.
            </value>
        </row>
        <row>
            <value>306</value>
            <value>157</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>(1) Patients with fQRS of ECG had higher cTnI, CK, CK-MB levels and Gensini score, prolonged QRS
                interval, lower rate of ST-segment resolution and left ventricular ejection fraction (LVEF) than in
                patients without fQRS (all P &lt; 0.01 or P &lt; 0.05). (2) Pearson correlation analysis showed that the
                rate of ST-segment resolution (r = -0.207, P = 0.002),Gensini score (r = 0.191, P = 0.004), LVEF(r =
                -0.188, P = 0.006), cTnI(r = 0.172, P = 0.010), and the TIMI grade post p-PCI (r = -0.148, P = 0.028)
                were significantly related with the presence of fQRS. (3) Multivariate logistic regression analysis
                demonstrated that presence of fQRS at pre-PCI (OR = 2.908, 95%CI:1.095-7.723, P = 0.032) , the number of
                leads with fQRS before PCI (OR = 1.582, 95%CI:1.250-2.002, P &lt; 0.001), and increased QRS interval (OR
                = 0.955, 95%CI: 0.924-0.988, P = 0.008) were independent predictors of imperfect ST-segment resolution.
            </value>
        </row>
        <row>
            <value>307</value>
            <value>157</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>fQRS is related to imperfect ST-segment resolution in STEMI patients undergoing p-PCI.fQRS may be a
                useful parameter to identify the patients with severe coronary lesion, larger areas of ischemic injury
                and myocardial infarction as well as severe left ventricular contracted dysfunction.
            </value>
        </row>
        <row>
            <value>308</value>
            <value>158</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Aims: The aim of this study was to identify predictors of adverse events among patients with
                ST-elevation myocardial infarction (STEMI) undergoing contemporary primary percutaneous coronary
                intervention (PCI). Methods and results: Individual data of 2,655 patients from two primary PCI trials
                (EXAMINATION, N=1,504; COMFORTABLE AMI, N=1,161) with identical endpoint definitions and event
                adjudication were pooled. Predictors of all-cause death or any reinfarction and definite stent
                thrombosis (ST) and target lesion revascularisation (TLR) outcomes at one year were identified by
                multivariable Cox regression analysis. Killip class III or IV was the strongest predictor of all-cause
                death or any reinfarction (OR 5.11, 95% CI: 2.48-10.52), definite ST (OR 7.74, 95% CI: 2.87-20.93), and
                TLR (OR 2.88, 95% CI: 1.17-7.06). Impaired left ventricular ejection fraction (OR 4.77, 95% CI:
                2.10-10.82), final TIMI flow 0-2 (OR 1.93, 95% CI: 1.05-3.54), arterial hypertension (OR 1.69, 95% CI:
                1.11-2.59), age (OR 1.68, 95% CI: 1.41-2.01), and peak CK (OR 1.25, 95% CI: 1.02-1.54) were independent
                predictors of all-cause death or any reinfarction. Allocation to treatment with DES was an independent
                predictor of a lower risk of definite ST (OR 0.35, 95% CI: 0.16-0.74) and any TLR (OR 0.34, 95% CI:
                0.21-0.54). Conclusions: Killip class remains the strongest predictor of all-cause death or any
                reinfarction among STEMI patients undergoing primary PCI. DES use independently predicts a lower risk of
                TLR and definite ST compared with BMS. The COMFORTABLE AMI trial is registered at:
                http://www.clinicaltrials.gov/ct2/show/NCT00962416. The EXAMINATION trial is registered at:
                http://www.clinicaltrials.gov/ct2/show/NCT00828087.
            </value>
        </row>
        <row>
            <value>309</value>
            <value>160</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>The relationship between endogenous estrogens and cardiovascular disease in menopausal women remains
                poorly understood. Studies examining the relationship have yielded conflicting results. Therefore, we
                performed this study to prospectively assess the effects of endogenous estrogen on the risk of
                myocardial no-reflow in postmenopausal women with ST-elevation myocardial infarction (STEMI).
                Consecutive 100 postmenopausal women diagnosed with STEMI and who had undergone emergence percutaneous
                coronary intervention (PCI) were included in this study. Blood samples were obtained before PCI and
                assayed for endogenous sex hormones. Logistic regression models were developed with adjustment for
                confounders. Compared with normal-reflow group, the circulating levels of estrone, estradiol, sex
                hormone binding globulin (SHBG), and hypersensitive C-reaction protein (Hs-CRP) were significantly
                higher in the no-reflow group (P???&lt;???0.05). In univariable logistic regression models, lesion
                length, reference luminal diameter, thrombus score?????????4, and the levels of estrone, estradiol, and
                SHBG were all found to be positively associated with the risk of no-reflow (P???&lt;???0.05). After
                adjusting for these factors, thrombus score?????????4 (OR???=???4.994, CI 1.987-10.518; P???=???0.035),
                SHBG (OR???=???0.800, CI 0.341-0.983; P???=???0.047), and estradiol levels (OR 4.091, CI 1.105-8.582;
                P???=???0.046) continued to demonstrate strong positive associations with the risk of no-reflow. Our
                data showed that high circulating levels of endogenous estrogens have a positive and statistically
                significant relationship with no-reflow in postmenopausal women with STEMI. It has been suggested that
                estrogens may have a potential detrimental effect on myocardial no-reflow. However, our results need to
                be confirmed in a larger population.
            </value>
        </row>
        <row>
            <value>310</value>
            <value>161</value>
            <value>1</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value>Fragmented QRS (fQRS) has been found to be associated with high mortality and arrhythmic events in
                acute coronary syndromes. Regional systolic function using wall motion score index (WMSI) is an
                alternative to left ventricular ejection fraction (LVEF) for the assessment of left ventricular systolic
                function. The aim of this study was to investigate the relation between the presence of fQRS on
                admission electrocardiogram (ECG) and WMSI in ST elevation myocardial infarction (STEMI) underwent
                primary coronary intervention (PCI). The in-hospital and long-term prognostic significance of persistent
                fQRS was also evaluated.
            </value>
        </row>
        <row>
            <value>311</value>
            <value>161</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>In this retrospective study, 542 patients with a diagnose of STEMI underwent primary PCI were
                included. Study patients were divided into two groups according to the presence (n = 153) or absence (n
                = 389) of a fQRS on admission ECG.
            </value>
        </row>
        <row>
            <value>312</value>
            <value>161</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>313</value>
            <value>161</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>WMSI was significantly related with the presence of the fQRS, which reflects the linking between
                impairment of regional left ventricular systolic function and the presence of severe myocardial injury
                in STEMI.
            </value>
        </row>
        <row>
            <value>314</value>
            <value>162</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Adjunctive therapy with intracoronary nitroprusside (NTP) in primary percutaneous coronary
                intervention (PPCI) had controversial benefits in patients with ST segment elevation myocardial
                infarction (STEMI).
            </value>
        </row>
        <row>
            <value>315</value>
            <value>162</value>
            <value>2</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value>To evaluate the effect of intracoronary NTP on no reflow phenomenon (NR) and clinical outcomes in
                STEMI patients undergoing PPCI.
            </value>
        </row>
        <row>
            <value>316</value>
            <value>162</value>
            <value>3</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We searched the following databases without language or time limitation in January 2014: PubMed,
                EMBASE, CENTRAL, ISI Web of Science, and CNKI. Trials compared the effect of intracoronary NTP with
                control group (placebo or no NTP treatment) on NR in STEMI patients undergoing PPCI enrolled for
                analyzing.
            </value>
        </row>
        <row>
            <value>317</value>
            <value>162</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value>A total of 7 trials involving 781 patients were included into this meta-analysis. Intracoronary NTP
                significantly reduced the incidence of thrombolysis in myocardial infarction (TIMI) flow grade
                (TFG)??????2 (RR: 0.47, 95% CI: 0.30-0.73, P???=???0.001); the corrected TIMI frame count (CTFC) (WMD:
                -5.28, 95% CI: -6.79 to 3.78, P???=???0.000) increased the events of myocardial blush grade (MBG)??????2
                (RR: 1.12, 95% CI: 1.01-1.24, P???=???0.038), and reduced the incidence of major adverse cardiac events
                (MACE) (RR: 0.43, 95% CI: 0.27-0.70, P???=???0.001). Although the events of the complete ST segment
                resolution (STR) did not reach statistical significance, there was a trend indicating improvement in the
                intracoronary NTP group (RR: 1.143, 95% CI: 0.97-1.34, P???=???0.101).
            </value>
        </row>
        <row>
            <value>318</value>
            <value>162</value>
            <value>5</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Intracoronary NTP can significantly reduce the incidence of angiographic NR during PPCI, as well as
                the incidence of MACE. It seems to be a promising adjunctive therapy for NR during PPCI.
            </value>
        </row>
        <row>
            <value>319</value>
            <value>163</value>
            <value>1</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value>The aim of this study was to evaluate the prognostic value of fragmented QRS (fQRS) on
                electrocardiography (ECG) patients with acute ST-segment elevation in myocardial infarction (STEMI), who
                are undergoing primary percutaneous coronary intervention (PCI).
            </value>
        </row>
        <row>
            <value>320</value>
            <value>163</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>321</value>
            <value>163</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>322</value>
            <value>163</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>These results suggest that the presence of fQRS on ECG was associated with an increased in-hospital
                cardiovascular mortality, and one-year all-cause mortality in patients with STEMI who are under primary
                PCI.
            </value>
        </row>
        <row>
            <value>323</value>
            <value>164</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>It is important to know the elapsed symptom-to-door (StD) time between the emergence of ST-elevation
                myocardial infarction (STEMI) symptoms and admission to the hospital in terms of the selection of
                appropriate treatment and prognosis. In this study, we aimed to assess the relationship between serum
                C-reactive protein (CRP) and StD time after STEMI.
            </value>
        </row>
        <row>
            <value>324</value>
            <value>164</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>325</value>
            <value>164</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>As the time progressed, an increase in CRP levels was observed. The difference among the means of the
                G1-G3 (p=0.002), G1-G4 (p&lt;0.001), G2-G4 (p&lt;0.001) and G3-G4 (p&lt;0.001) groups was found to be
                statistically significant. There was a good correlation between the StD time and CRP levels (r=0.676).
                (ROC) analysis of the predictive value of CRP for the third hour was determined as 0.78 mg/dL,
                respectively (AUC was 0.824; 95% C.I. was 0.785-0.859; 73.9% sensitivity, 78.1% specificity).
            </value>
        </row>
        <row>
            <value>326</value>
            <value>164</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>According to serum CRP levels after STEMI at hospital admission, StD time can be estimated.</value>
        </row>
        <row>
            <value>327</value>
            <value>165</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Eosinophilic folliculitis (EF) comprises classic eosinophilic pustular folliculitis (EPF), human
                immunodeficiency virus (HIV)-related EF, and infantile EPF subtypes. A fourth proposed subtype describes
                EF associated with hematologic malignancy. Recently, EF has occurred after bone marrow or stem cell
                transplantation (SCT).
            </value>
        </row>
        <row>
            <value>328</value>
            <value>165</value>
            <value>2</value>
            <value>Objectives</value>
            <value>Objective</value>
            <value>We report a unique case of EF after haploidentical allogeneic SCT for acute lymphoblastic leukemia
                (ALL) and review the literature for similar cases.
            </value>
        </row>
        <row>
            <value>329</value>
            <value>165</value>
            <value>3</value>
            <value>Methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>330</value>
            <value>165</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>331</value>
            <value>165</value>
            <value>5</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value></value>
        </row>
        <row>
            <value>332</value>
            <value>166</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Severe aplastic anemia (SAA), which is considered to be an immune-mediated destruction of bone marrow
                stem cells with pancytopenia and hypoplasia, can be successfully treated with immunosuppressive therapy
                or hematopoietic stem cell transplantation (HSCT). Between January 2009 and December 2012, thirteen
                patients diagnosed with SAA were treated with tacrolimus plus rabbit antithymocyte globulin (ATG)-based
                immunosuppressive therapy (IST). The outcomes were then compared with our previous data for twenty-four
                patients administered with cyclosporine (CsA) plus rabbit ATG-based IST. All 37 cases accepted
                methylpredenisolone and recombinant human granulocyte colony-stimulating factor (rhG-CSF) from the first
                day that rabbit ATG was initiated. A total of 7 (54%) of the 13 patients in the tacrolimus group and 10
                (42%) of the 24 cases in the ATG+CsA group achieved the criteria for complete response (CR); the partial
                response (PR) rate was 31% in the tacrolimus group and 33% in the ATG+CsA group. The median follow-up
                duration of the tacrolimus group and ATG+CsA group patients was 28months and 27months, respectively. Two
                patients in the tacrolimus group who were red blood cell- and platelet transfusion-dependent died, one
                of sepsis and the other of cerebral hemorrhage, whereas one patient died from serious infection on the
                5th day after ATG was initiated in the ATG+CsA group. No clonal transformation to paroxysmal nocturnal
                hemoglobinuria (PNH) was observed in either group. Our data provide a possibility of using tacrolimus as
                part of an IST regimen for SAA in adults who have no opportunity of HSCT from human leukocyte antigen
                (HLA)-matched sibling donors.
            </value>
        </row>
        <row>
            <value>333</value>
            <value>167</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>A 40-year-old man was diagnosed with Langerhans cell histiocytosis (LCH) in October 2010. His LCH was
                refractory to conventional chemotherapy, and thus worsened to Langerhans cell sarcoma (LCS) in May 2011.
                Although we repeated combination chemotherapies, new infiltration of the liver and bone marrow, as well
                as primary lesions of the bone, lymph nodes, and skin, appeared. These intensive chemotherapies caused
                candida liver abscesses, invasive aspergillosis, disseminated varicella zoster virus infection and
                bacterial sepsis. We administered bendamustine for chemotherapy, which resulted in a partial response
                (PR) with no severe adverse events. Because of pancytopenia caused by secondary myelodysplastic
                syndrome, we stopped the bendamustine chemotherapy after two courses. PR was maintained for 4 months. We
                plan to perform allogeneic hematopoietic stem cell transplantation from a sibling donor after a
                conditioning regimen. Optimal therapy for adult LCH, which is a rare and treatment-resistant disease,
                has yet to be established. Bendamustine is a potential chemotherapeutic agent for standard treatment of
                LCS.
            </value>
        </row>
        <row>
            <value>334</value>
            <value>168</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, autosomal recessive disorder induced by
                mutations of the gene coding for thrombopoietin (TPO) receptor (c-MPL) despite high levels of serum TPO.
                Patients initially present with isolated thrombocytopenia that subsequently progresses into
                pancytopenia. Although the mechanisms leading to aplasia are unknown, the age of onset has been reported
                to depend on the severity of the c-MPL functional defect. The primary treatment for CAMT is bone marrow
                transplantation. This report describes a newborn girl who presented to us with symptoms of sepsis but
                septic profile came negative except thrombocytopenia. Bone marrow biopsy was done for thrombocytopenia
                which revealed amegakaryocytic thrombocytopenia. She was given prednisolone.
            </value>
        </row>
        <row>
            <value>335</value>
            <value>169</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>A 71-year-old patient receiving combination chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil
                (5-FU)) for metastatic pancreas cancer was admitted after her first cycle of chemotherapy with a severe
                and unexpectedly prolonged episode of neutropenic sepsis associated with pancytopenia and marked
                mucositis. Owing to the unusual picture, the patient was tested for mutations in the gene encoding the
                enzyme dihydropyrimidine dehydrogenase (DPD)--an enzyme involved in the metabolism of the chemotherapy
                drug 5-FU. The patient was found to be heterozygous for a mutation, DPD IVS14+1G&gt;A, leading to the
                severe toxicity exhibited following this regimen caused by delayed metabolism of 5-FU. She was treated
                aggressively with supportive care and recovered from this episode. Importantly she was subsequently
                switched to an alternative chemotherapy regimen to treat her disease. She continues to maintain an
                excellent quality of life some 9 months after her initial diagnosis on third-line chemotherapy.
            </value>
        </row>
        <row>
            <value>336</value>
            <value>171</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The objective of this study was to identify the different causes of death in calves affected with
                bovine neonatal pancytopenia (BNP). A total of 51 precolostral calves were fed with colostrum from cows
                which had lost at least one calf after parturition due to BNP in previous lactations. Clinical BNP could
                be induced in 71% (36/51) and subclinical BNP in 20% (10/51) of the calves. 9% (5/51) of the calves
                stayed BNP-unaffected despite challenging with the same mixed colostrum and approved passive transfer of
                colostral antibodies. The case fatality rate in BNP-affected cases was 83% (38/46). In the 38 lethal
                BNP-cases gross-pathological and histopathological examinations were performed. BNP-induced haemorrhagic
                anaemia was the cause of death in 18 calves (47%). 19 of these lethal cases (50%) died due to infectious
                diseases, especially due to pneumonia, enteritis and septicaemia. One calf died due to severe enteritis
                and exsiccosis without any signs of BNP (3%). In conclusion, anaemia as the consequence of haemorrhages
                was the most prevalent cause of death in BNP-affected calves, however, BNP has been approved to increase
                the lethality of common infectious neonatal diseases.
            </value>
        </row>
        <row>
            <value>337</value>
            <value>172</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>338</value>
            <value>173</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Fever of unknown origin in patients with common variable immune deficiency (CVID) can be caused by
                variety of infectious, autoimmune, or malignancy-related etiologies. We present a 52-year-old man with
                history of CVID, who presented with 3 weeks of persistent high-grade fevers. During admission, he
                developed severe pancytopenia with shock and multiorgan failure. An extensive workup was performed for
                typical and atypical infections, autoimmune pathologies, and malignancy. His peripheral blood smear
                showed marked anisocytosis and poikilocytosis with elevated atypical lymphocytes. Flow cytometry showed
                markedly elevated CD8 counts, with abnormal CD4/CD8 ratio. Monospot test was negative but real-time
                polymerase chain reaction showed high Epstein-Barr virus load. Initial clinical suspicion was high for
                bacterial infections including pneumonia and acute sinusitis complicated by bacteremia and sepsis.
                Hematologic malignancy was also high on the differentials because of presence of rapidly progressive
                pancytopenia. The final diagnosis in this case illustrates a rare but potentially fatal disease that can
                present in CVID patients with persistent fevers and pancytopenia and can be refractory to standard
                treatment regimen. Because allergy and immunology physicians commonly treat CVID patients, they should
                be aware of this disease condition including pathophysiology, clinical presentation, laboratory workup,
                and treatment options.
            </value>
        </row>
        <row>
            <value>339</value>
            <value>174</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Graft-versus-host disease (GVHD) after pancreas transplantation is a rare but serious complication:
                All previously reported cases were fatal. We herein report three cases of GVHD after pancreas
                transplantation with favorable outcomes. Patients with a history of kidney (and pancreas)
                transplantation subsequently received a pancreas (and kidney) transplantation (i.e., pancreas
                retransplantation or pancreas after kidney transplantation) and developed acute GVHD. All of them
                responded to increased immunosuppression (e.g., steroid bolus, antithymocyte globulin) and retained
                normal graft function. Because the clinical manifestations are non-specific, vigilance is necessary to
                make an accurate diagnosis. We underscored the importance of a biopsy of involved organs and the
                clinicopathologic correlation in the early diagnosis of GVHD. Augmented immunosuppression to prevent
                progression from a self-limited disease to life-threatening pancytopenia or sepsis may be most critical
                to improve outcome.
            </value>
        </row>
        <row>
            <value>340</value>
            <value>175</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Severe childhood infections can occasionally be accompanied by bone marrow suppression. It is unusual
                for infection induced marrow aplasia to evolve into acute leukemia. We share our experience in managing
                four children with severe sepsis and pancytopenia which in due course evolved into acute leukemia. This
                report emphasizes that sepsis related pancytopenia can be a harbinger of evolving hematopoietic
                disorders.
            </value>
        </row>
        <row>
            <value>341</value>
            <value>176</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Myelosuppression is the life-threatening adverse effect of methotrexate. Impaired kidney function is
                a major aggravating factor of methotrexate-induced myelosuppression. In end-stage renal disease
                patients, methotrexate therapy must be with cautious because the efficacy of removal of methotrexate by
                means of dialysis is in doubt. In clinical practice, low-dose methotrexate is still used by clinicians
                in treatment of dialysis patients with immunological disorders. We reported a 61-year-old woman on
                continued ambulatory peritoneal dialysis who developed pancytopenia with a nadir leukocyte count of 0.03
                x 109/L, leading to severe sepsis after 3 doses of methotrexate, 7.5 mg weekly. We highlighted that
                methotrexate therapy in dialysis patients, even with low doses could impose the risk of
                myelosuppression, causing a fatal outcome. Alternative medications to methotrexate might be recommended
                in dialysis patients.
            </value>
        </row>
        <row>
            <value>342</value>
            <value>177</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Trichosporon asahii (T. asahii) is an uncommon fungal pathogen rarely seen in patients with
                hematologic malignancies. Although appropriate therapy is started, infection with T. asahii usually
                leads to mortality. Here, we describe two patients developed severe T. asahii infection and secondary
                HLH. Despite rapid identification of T. asahii and negative blood cultures achieved by prompt initiation
                of treatment with voriconazole, fever and pancytopenia, persisted and both developed hepatosplenomegaly,
                and their clinical state worsened. Bone marrow aspiraton revealed hemophagocytosis. Elevated ferritin,
                triglyceride levels were seen. The first patient did not receive HLH directed therapy and died with
                multiple organ dysfunctions. Prompt diagnosis and treatment of secondary HLH led to rapid improvement in
                clinical and laboratory abnormalities in the second patient and kept her alive. We suggest that HLH may
                present as a secondary condition, accompanying a severe infection with T. asahii may, at least in part,
                contribute to high mortality rates in these cases.
            </value>
        </row>
        <row>
            <value>343</value>
            <value>178</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized aggressive disease commonly
                associated with Epstein-Barr virus (EBV) infection after hematopoietic stem cell transplantation (HSCT).
                Although rituximab (RTX) is incorporated into the first-line therapy for EBV-PTLD patients, the outcome
                of the clinically overt disease is still not optimal mainly due to the regrowth of tumor cells. The
                proliferation of CD20-/CD19+ tumor cells is increasingly reported in RTX-treated EBV-PTLD patients,
                whereas the emergence of CD20-/CD19- tumor cells is barely recognized. Here, we report a fatal case of
                an 18-year-old patient who developed EBV-PTLD after allogeneic HSCT for anaplastic large-cell lymphoma.
                On day 60 after HSCT, the patient developed abdominal pain, watery diarrhea, and low-grade fever. Colon
                biopsy revealed the proliferation of CD20+/CD19+/EBV-encoded RNA (EBER)+ tumor cells, and an increase of
                EBV DNA was detected in peripheral blood (PB). He was treated with RTX for EBV-PTLD and was cleared of
                EBV DNA in PB. However, he manifested high-grade fever, pancytopenia, and elevated soluble interleukin-2
                receptor with a prominent hemophagocytosis in bone marrow aspirates and was treated with etoposide for
                hemophagocytic lymphohistiocytosis (HLH) complication. He then developed EBV DNA positivity in PB and
                finally died of Bacteroides fragilis sepsis subsequent to bloody stool and ileus on day 163. Autopsy
                revealed erosion and bleeding in the whole colon with the proliferation of CD20-/CD19-/EBER+ tumor
                cells. Immunohistochemical analysis uncovered the CD3-/CD56-/CD79a+/CD79b+ B-cell origin of tumor cells.
                This case clinically demonstrates the removal of both CD20 and CD19 antigens from EBER+ B cells in an
                RTX-treated EBV-PTLD patient with HLH complication.
            </value>
        </row>
        <row>
            <value>344</value>
            <value>179</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Although coagulase-negative staphylococci (CONS) constitute normal flora of the human body, some
                species can produce human infections, particularly when the host defense is breached. There is little
                evidence of the pathogenicity of CONS in HIV-infected individuals. We present the case of a 14-year-old
                HIV-infected boy who presented with a right lower zone pneumonia and a cutaneous abscess, following
                which he developed pancytopaenia due to underlying CONS infection that responded to antibiotic
                treatment.
            </value>
        </row>
        <row>
            <value>345</value>
            <value>180</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>Hemophagocytic lymphohistiocytosis (HLH) is a severe immunological disorder that leads to a massive
                inflammatory reaction that may prove rapidly fatal. We show that HLH may present by masquerading as
                surgical disease or as a postoperative complication leading to delays in diagnosis and treatment.
            </value>
        </row>
        <row>
            <value>346</value>
            <value>180</value>
            <value>2</value>
            <value>Study design</value>
            <value>Methods</value>
            <value>A case series of four children with acute surgical presentation and prolonged unexplained
                postoperative sepsis, who were diagnosed with HLH.
            </value>
        </row>
        <row>
            <value>347</value>
            <value>180</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Four children with different clinical presentations (1. neonatal abdominal distension, 2. ileostomy
                closure and Hirschsprung's disease, 3. iatrogenic sigmoid perforation and Crohn's disease, and 4.
                streptococcal toxic shock syndrome with primary peritonitis) were diagnosed with HLH at our regional
                pediatric surgical centre in the last two years. All developed signs of prolonged postoperative sepsis
                with hepatosplenomegaly and pancytopenia, requiring intensive care support. In the absence of
                explanation for their symptoms and deteriorating clinical condition, a total of six 'negative'
                exploratory laparotomies were performed. Eventually, HLH was diagnosed with bone marrow aspiration after
                an average of 23 days (range 17-40), following the finding of significantly elevated ferritin (up to
                293150 ng/ml) and triglyceride levels. All children improved with initiation of high-dose steroid
                treatment followed by etoposide and cyclosporin.
            </value>
        </row>
        <row>
            <value>348</value>
            <value>180</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>HLH may rarely present with symptoms and signs of surgical disease or complicate post-operative
                recovery. This diagnosis should be considered in children with unexplained prolonged fever,
                hepatosplenomegaly and pancytopenia, especially if associated with high ferritin levels. HLH can prove
                rapidly fatal without appropriate treatment.
            </value>
        </row>
        <row>
            <value>349</value>
            <value>181</value>
            <value>1</value>
            <value>Introduction</value>
            <value>Background</value>
            <value>One of the bacterial agents that has been found to be associated with colorectal cancer is
                Streptococcus bovis, with 13% of infective endocarditis cases caused by this pathogenic species.
            </value>
        </row>
        <row>
            <value>350</value>
            <value>181</value>
            <value>2</value>
            <value>Case presentation</value>
            <value>Methods</value>
            <value>We describe the case of a 57-year-old Caucasian man with infiltrating and ulcerating metastatic
                adenocarcinoma of the sigmoid colon. The patient was receiving second-line chemotherapy treatment and,
                on the eighth day of the second cycle, he developed a grade IV pancytopenia. We diagnosed a severe
                sepsis with positive blood cultures for Streptococcus bovis/gallolyticus with a secondary endocarditis.
            </value>
        </row>
        <row>
            <value>351</value>
            <value>181</value>
            <value>3</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>A recent study suggests that the majority of patients affected by colonic cancer have a Streptococcus
                bovis/gallolyticus colonization that becomes apparent as an overt infection only when immunosystem
                disorders or cardiac valve lesions occur. This correlation is important for involving more specialists
                in a correct and early diagnosis of this rare, but potentially fatal, complication.
            </value>
        </row>
        <row>
            <value>352</value>
            <value>182</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Pancytopenia is defined by reduction of all the three formed elements of blood below the normal
                reference. It may be a manifestation of a wide variety of disorders, which primarily or secondarily
                affect the bone marrow. Haematological investigation forms the bedrock in the management of patients
                with pancytopenia and therefore needs detailed study. The total number of cases studied were 100 over a
                period of two years in the department of pathology, JSS Hospital, Mysore. Megaloblastic anaemia (33%)
                was the commonest cause of pancytopenia. Other causes were nutritional anaemia (16%), aplastic anaemia
                (14%), hypersplenism (10%), sepsis (9%) and leukaemia (5%). Less common causes were alcoholic liver
                disease, haemolytic anaemia, HIV, dengue, systemic lupus erythematosus, viral hepatitis, disseminated TB
                and multiple myeloma. Most of the patients were in the age group of 11-30 years with a male:female ratio
                of 1.6:1.Generalised weakness and fatigue (88%) were the commonest presenting complaints. Haemoglobin
                level varied from 1-10 g/dl with majorIty (70%) of them in the range of 5.1-10 g/dI. TLC was in the
                range of 500-4000 cells/cmm. Most (34%) of them had 3100-4000 cells/cmm. Platelet count was in the range
                of 4000-1,40,000 cells/cmm. Reticulocyte count varied from 0.1%-15% with majority (82%) of them ranging
                from 0.1%-2%. The bone marrow cellularity was hypocellular in 14%, hypercellular in 75%, and
                normocellular in 11% of the patients. Pancytopenia is a relatively common entity with inadequate
                attention in Indian subcontinent. A comprehensive clinical and haematological study of patients with
                pancytopenia will usually help in the identification of the underlying cause. However in view of wide
                array of aetiologies, pancytopenia continues to be a diagnostic challenge for haematologists.
            </value>
        </row>
        <row>
            <value>353</value>
            <value>183</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Peripheral T-cell lymphoma (PTCL) of the colon is classified as a subtype of intestinal T-cell
                lymphoma, which usually has multiple ulcerations. Herein, we report a case of multiple ulcers in the
                large intestine of a 55-year-old male, who presented to us with symptoms of abdominal pain and watery
                diarrhea for a month. In addition, results of his endoscopic biopsy revealed crypt abscess with dense
                inflammatory cells infiltrated in the lamina propria of the colon. One week later, he presented with
                pancytopenia and jaundice, and results of a biopsy of the bone marrow showed the appearance of
                hemophagocytosis. Unfortunately, colon perforation occurred during the 10th day of hospitalization, and
                a histopathological analysis of the colonic resection revealed PTCL. Finally, the patient died of sepsis
                on the 29th day of hospitalization. The endoscopic character of ulcerative colon T-cell lymphoma is
                easily confused with Crohn's disease, tuberculosis colitis, and viral colitis. In addition, it is also
                difficult to distinguish between lymphoma cells and dense inflammatory cells while performing endoscopic
                biopsy of the mucosa in colon lymphoma. Once a typical geographic and punched out ulcers of the colon
                are found accompanying the presentation of hemophagocytic lymphohistiocytosis, the diagnosis of PTCL
                involving the colon should be highly suspected, even if the initial endoscopic biopsy has failed to
                confirm it.
            </value>
        </row>
        <row>
            <value>354</value>
            <value>184</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>A 13-year-old boy presented with spontaneous skin and mucosal bleeds 3 weeks after acute hepatitis of
                unknown aetiology. Laboratory analyses revealed pancytopenia and bone marrow biopsy that confirmed the
                diagnosis of aplastic anaemia. Other causes of congenital and acquired aplastic anaemia were excluded.
                He was diagnosed with hepatitis-associated aplastic anaemia. He developed a critical clinical condition,
                becoming totally dependent on erythrocyte and platelet transfusions, and severe neutropenia, which led
                to invasive bacterial infection. He died due to sepsis with multiple organ failure 3 months after
                admission.
            </value>
        </row>
        <row>
            <value>355</value>
            <value>186</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>We report a case of a 15-year-old girl with severe aplastic anemia who underwent orthotopic liver
                transplantation 5 years ago for fulminant hepatic failure during the course of immunodeficiency of
                unknown etiology. She previously exhibited similar immunodeficiency and experienced recurrent viral
                infections. She developed jaundice at 9 years of age and was diagnosed with fulminant hepatitis. One
                month later, she underwent living donor liver transplantation, with the donor being her father. Five
                years after the liver transplant, pancytopenia was noted; she did not respond to treatment with
                increasing doses of tacrolimus/prednisone and administration of granulocyte-colony stimulating factor.
                Bone marrow biopsy was performed, and severe aplastic anemia was diagnosed. Six years after the liver
                transplant, she underwent bone marrow transplantation (BMT), with the donor being her HLA-matched
                sibling. However, she developed liver dysfunction with recovery of white blood cells. She developed
                sepsis, which eventually led to her death on day 30 after BMT.
            </value>
        </row>
        <row>
            <value>356</value>
            <value>187</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Podostroma cornu-damae is a rare fungus that houses a fatal toxin in its fruit body. In this case
                report, two patients collected and boiled the wild fungus in water, which they drank for one month. One
                patient died, presenting with desquamation of the palms and soles, pancytopenia, severe sepsis and
                multiple organ failure. The other patient recovered after one month of conservative care after
                admission. We found a piece of Podostroma cornu-damae in the remaining clusters of mushrooms. Mushroom
                poisoning by Podostroma cornu-damae has never been previously reported in Korea.
            </value>
        </row>
        <row>
            <value>357</value>
            <value>188</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>This is the first study demonstrating that nonimmune hydrops fetalis (NIHF) in identical twin
                neonates is associated with biallelic gene defect causing familial hemophagocytic lymphohistiocytosis.
            </value>
        </row>
        <row>
            <value>358</value>
            <value>188</value>
            <value>2</value>
            <value>Observations</value>
            <value>Methods</value>
            <value>Preterm male twins (31(4/7) wk) with NIHF and hepatosplenomegaly gradually developed pancytopenia,
                hyperferritinemia, hyponatremia, hypoalbuminemia, and elevated alanine aminotransferase, aspartate
                aminotransferase, bilirubin, and lactate dehydrogenase levels. Suspected sepsis led to antibiotic
                therapy. Upon detection of hemophagocytosis in bone marrow, multiorgan failure and pulmonary bleeding
                led to death. Homozygous His222Arg (c665A&gt;G) mutation was identified in Perforin.
            </value>
        </row>
        <row>
            <value>359</value>
            <value>188</value>
            <value>3</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Familial hemophagocytic lymphohistiocytosis should be considered in first days of NIHF cases to have
                chance for HLH-2004 therapy. Missense mutations of Perforin codon His222 may lead to intrauterine
                presentation.
            </value>
        </row>
        <row>
            <value>360</value>
            <value>189</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Ovine babesiosis, caused by Babesia ovis, is of major economic importance in Turkey. The changes in
                the blood profile of infected animals are informative about the course of infection. The aim of the
                present study was to evaluate the hematological and biochemical changes in the pre- and post-treatment
                periods of the natural B. ovis infections. The presence of the parasites was confirmed by microscopy and
                polymerase chain reaction (PCR) analysis. On the basis of the clinical and laboratory findings, the
                infections were categorized into different groups according to the degree of anemia and the level of
                parasitemia. All infected sheep were treated with imidocarb dipropionate (IMDP). The blood pictures in
                the pre- and post-treatment periods were compared. Pancytopenia occurred in animals with severe anemia
                and very high parasitemia, and bicytopenia in the other groups. The platelet count (PLT), plateletcrit
                (PCT) and mean platelet volume (MPV) returned to the normal ranges after treatment, except those in the
                group with severe anemia. In the biochemical profile, B. ovis infection caused an increase in blood urea
                nitrogen and total bilirubin, and these parameters returned to normal levels after treatment. The
                indirect fluorescein antibody test (IFAT) results showed that 38.1% of the cases raised specific
                antibodies during the period of infection, with titers ranging from 1/160 to 1/640. All of 45 animals
                re-examined after treatment were seropositive, with high titers that rose up to 1/5120.
            </value>
        </row>
        <row>
            <value>361</value>
            <value>190</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>This paper presents a case report of a 15-year-old boy admitted to the hospital for persistent right
                knee pain and limping. The clinical appearance of his condition was the basis on which diagnosis of
                chronic recurrent multifocal osteomyelitis was made. Continuous deterioration in the clinical status
                also led to a suspicion of the presence of other pathological processes. A bone biopsy was performed and
                the results of histopathology showed diffused large cell B lymphoma. Chemotherapy was initiated;
                nevertheless, the patient's general state worsened gradually and subsequent pancytopenia resulted in
                septicemia and multiorgan failure that led to the patient's death. This paper reports the exceptional
                diagnostic challenges that emerged from the obscure course of the disease.
            </value>
        </row>
        <row>
            <value>362</value>
            <value>191</value>
            <value>1</value>
            <value>Purpose</value>
            <value>Objective</value>
            <value>Neutrophil and platelet activation and their interactions with endothelial cells are considered
                central features of sepsis-induced microcirculatory alterations. However, no study has evaluated the
                microvascular pattern of septic shock patients with chemotherapy-induced severe cytopenia.
            </value>
        </row>
        <row>
            <value>363</value>
            <value>191</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Demographic and hemodynamic variables together with sublingual microcirculation recording [orthogonal
                polarization spectral imaging enhanced by sidestream dark-field technology (OPS-SDF) videomicroscopy]
                were collected in four groups of subjects: septic shock (SS, N = 9), septic shock in cytopenic patients
                (NSS, N = 8), cytopenia without infection (NEUTR, N = 7), and healthy controls (CTRL, N = 13). Except
                for controls, all measurements were repeated after complete resolution of septic shock and/or
                neutropenia. Video files were processed using appropriate software tool and semiquantitatively evaluated
                [total vascular density (TVD, mm/mm(2)), perfused vessel density (PVD, mm/mm(2)), proportion of perfused
                vessels (PPV, %), mean flow index (MFI), and flow heterogeneity index (FHI)].
            </value>
        </row>
        <row>
            <value>364</value>
            <value>191</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Compared with controls, there were statistically significant microcirculatory alterations within all
                tested groups of patients (TVD: SS = 8.8, NSS = 8.8, NEUTR = 9.1 versus CTRL = 12.6, p &lt; 0.001; PVD:
                SS = 6.3, NSS = 6.1, NEUTR = 6.9 versus CTRL = 12.5, p &lt; 0.001; PPV: SS = 71.6, NSS = 68.9, NEUTR =
                73.3 versus CTRL = 98.7, p &lt; 0.001; MFI: SS = 2.1, NSS = 1.9, NEUTR = 2.1 versus CTRL = 3.0, p &lt;
                0.05; FHI: SS = 1.0, NSS = 0.9, NEUTR = 0.6 versus CTRL = 0.0, p &lt; 0.001). No significant differences
                were detected between SS, NSS, and NEUTR groups at baseline. Incomplete restoration of microcirculatory
                perfusion was observed after septic shock and/or neutropenia resolution with a trend towards better
                recovery in MFI and FHI variables in NSS as compared with SS patients.
            </value>
        </row>
        <row>
            <value>365</value>
            <value>191</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Microvascular derangements in septic shock did not differ between noncytopenic and cytopenic
                patients. Our data might suggest that profound neutropenia and thrombocytopenia do not render
                microcirculation more resistant to sepsis-induced microvascular alterations. The role and mechanisms of
                microvascular alterations associated with chemotherapy-induced cytopenia warrant further investigation.
            </value>
        </row>
        <row>
            <value>366</value>
            <value>192</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>We present a case of a 27-year-old man who received an unrelated donor umbilical cord blood
                transplant for chronic lymphocytic leukemia. His postsurgery course was complicated by acute kidney
                injury, hemorrhagic cystitis, and pancytopenia. Transjugular kidney biopsy showed interstitial
                nephritis. Viral inclusions were present in tubular epithelial cells, and in situ hybridization studies
                confirmed the presence of adenovirus. Kidney function improved after a short course of cidofovir.
                Adenovirus-induced interstitial nephritis should be considered in the differential diagnosis in all
                cases of interstitial nephritis occurring in immunocompromised patients.
            </value>
        </row>
        <row>
            <value>367</value>
            <value>193</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Bone marrow is a very unusual site of metastasis for germ cell tumors.</value>
        </row>
        <row>
            <value>368</value>
            <value>193</value>
            <value>2</value>
            <value>Case report</value>
            <value>Methods</value>
            <value>We report the case of a 21-year-old male patient who was treated with chemotherapy and secondary
                surgery for a primary mediastinal non-seminomatous germ cell tumor (NSGCT). The patient achieved
                complete remission. However, 4 months after completion of therapy, he complained of rapidly worsening
                bone pain. No evidence for disease relapse was found in the computed tomography scan of thorax and
                abdomen, magnetic resonance imaging of the spine, or bone scan. A blood test revealed pancytopenia and
                elevated serum tumor markers. A bone marrow aspirate showed infiltration by tumor cells positive for
                AE1/AE3 and AFP confirming the diagnosis of isolated bone marrow metastatic relapse. Salvage
                chemotherapy was started and resulted in a rapid decrease of serum tumor markers. However, pancytopenia
                did not improve and the patient died of severe sepsis 3 weeks later.
            </value>
        </row>
        <row>
            <value>369</value>
            <value>193</value>
            <value>3</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>We report here the first case of isolated bone marrow metastatic relapse of an NSGCT. 2 other cases
                of bone marrow metastasis in patients with NSGCT have been reported. In these 2 cases, as in our
                patient, the primary site was not testicular but mediastinal suggesting a non-fortuitous association.
            </value>
        </row>
        <row>
            <value>370</value>
            <value>194</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>A 43-year-old man with a cardiac device for dilated cardiomyopathy presented with fever, night
                sweats, and weight loss. Investigations revealed pancytopenia, acute renal failure, abnormal lung
                function, and raised inflammatory markers. A renal biopsy demonstrated pauci-immune necrotizing
                crescentic glomerulonephritis. He was diagnosed with pulmonary-renal antineutrophil cytoplasmic
                antibody-negative systemic small vessel vasculitis. He commenced immunosuppression with prednisolone and
                cyclophosphamide with recovery from pancytopenia and improvement in renal function 3 months later.
                Subsequently, a bone marrow culture grew Mycobacterium fortuitum. Isolation on repeat peripheral
                mycobacterial blood cultures prompted treatment with ciprofloxacin and clarithromycin. Four months
                later, he presented with neutropenic sepsis, influenza A/H1N1, and Aspergillus flavus pneumonia. Despite
                treatment he deteriorated. A transthoracic echocardiogram revealed a vegetation on the right ventricular
                pacing wire. The device was removed. The vegetation revealed acid and alcohol fast bacilli on
                Ziehl-Neelsen staining and grew M. fortuitum on culture, sensitive to ciprofloxacin and clarithromycin.
                Despite device removal and antimicrobial therapy, the patient succumbed to treatment-related
                complications. The association between glomerulonephritis and endocarditis is well known; however, this
                is the first case to our knowledge describing pauci-immune necrotizing crescentic glomerulonephritis in
                the context of M. fortuitum endocarditis. Clinicians should maintain a high index of suspicion for
                endocarditis in patients with a cardiac device who present with fever and pauci-immune necrotizing
                crescentic glomerulonephritis. Patients should be investigated with mycobacterial blood cultures, at
                least three sets of standard blood cultures and transthoracic and transesophageal echocardiography.
                Clinicians should beware the perils of immunosuppression in the face of an occult sepsis.
            </value>
        </row>
        <row>
            <value>371</value>
            <value>195</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Haemophagocytic lymphohistiocytosis (HLH) is a heterogeneous group of clinical syndromes
                characterised by activation and subsequent uncontrolled non-malignant proliferation of T lymphocytes and
                macrophages, leading to a cytokine storm that accounts for most of its clinical features such as acute
                febrile illness, hepatosplenomegaly, multi-organ dysfunction and fulminant pancytopenia-resembling
                severe sepsis. Here, we present a series of 23 cases of infection-associated HLH diagnosed in our
                hospital within a time period of last three and half years. Though the presentation and progression of
                disease was variable, the patients shared some common features like prolonged fever unresponsive to
                broad spectrum antibiotics, organomegaly and cytopenias. In most of the cases, however, the triggering
                infectious agent could not be identified. They were treated using a steroid only protocol along with
                supportive measures and showed an excellent response.
            </value>
        </row>
        <row>
            <value>372</value>
            <value>196</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value></value>
        </row>
        <row>
            <value>373</value>
            <value>197</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Hemophagocytic lymphohistiocytosis (HLH) is a rare and often fatal hyperinflammatory syndrome
                characterized by fever, cytopenia, dramatically increased ferritin and hepatosplenomegaly. Here, we
                describe a previously healthy 39 year old pregnant woman in 30th week of her pregnancy with diarrhoea,
                intermittent gastrointestinal bleeding and fever of unknown focus. After cesarean section of twins in
                the 31st week she deteriorated with fulminant upper and lower gastrointestinal bleeding and disseminated
                intravascular coagulation. Gastro-, ileocolonoscopy and capsule endoscopy identified multiple bleeding
                punched ulcerations in the stomach, the entire small bowel and in parts of the colon. Emergency surgery
                with intraoperative endoscopy for uncontrolled hemorrhagic shock resulted in the resection of actively
                bleeding ulcers in the jejunum which temporally stabilized the critically ill patient. Jejunal histology
                and in situ hybridisation showed extensive ulcerations, focal lymphohistiocytic infiltration and
                EBV-positive immunoblasts. The diagnosis fulminant EBV-related HLH was confirmed based on the HLH-2004
                diagnostic criteria and through detection of a reactivated EBV infection (up to 3????????10(7) DNA
                copies/mL serum). Despite immunosuppressive therapy with steroids, cyclosporine A and etoposide in
                combination with Rituximab, the patient died from this sepsis-like, hyper-inflammatory syndrome in
                multiorgan failure with uncontrolled bleeding.
            </value>
        </row>
        <row>
            <value>374</value>
            <value>198</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Several severe complications may be associated with the use of central venous catheters (CVC). We
                retrospectively evaluated on a large cohort of patients the incidence of CVC-related early and late
                complications. From 7/99 to 12/2005, 1102 CVC have been implanted at our Institution in 881 patients
                with hematological malignancies (142,202 total day number of implanted CVC). Early mechanic
                complications were 79 (7.2% - 0.55/1,000 days/CVC). Thirty-nine episodes of early infective
                complications (&lt;1 week from CVC implant) occurred (3.5% - 0.3/1000 days/CVC): furthermore, 187
                episodes of CVC-related sepsis (17% - 1.3/1000 days/CVC) were recorded. There were 29 episodes (2.6%) of
                symptomatic CVC-related thrombotic complications, with a median interval from CVC implant of 60 days
                (range 7 - 395). The rate of CVC withdrawal due to CVC-related complications was 26%. The incidence of
                CVC-related complications in our series is in the range reported in the literature notwithstanding
                cytopenia often coexisting in hematological patients.
            </value>
        </row>
        <row>
            <value>375</value>
            <value>199</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>To investigate the clinical features of adult patients with hemophagocytic lymphohistiocytosis (HLH)
                and to explore possible risk factors for death, we retrospectively reviewed the medical records of 103
                adult HLH patients hospitalized from 1997 to 2012. We analyzed the underlying diseases, clinical
                characteristics, laboratory findings, outcomes, and prognostic factors. The most common cause of HLH was
                hematologic malignancies (n = 49), followed by infectious diseases (n = 24) and autoimmune disorders (n
                = 14); 24 cases were of unknown etiology. Eight patients had a combination of underlying diseases. HLH
                was clinically characterized by high fever (96.1%), splenomegaly (79.6%), hepatomegaly (65.0%),
                lymphadenopathy (53.4%), proteinuria (31.1%), skin rash (25.2%), gastrointestinal hemorrhage (14.6%),
                disseminated intravascular coagulation (13.6%), increased creatinine (7.8%), and central nervous system
                involvement (12.6%) including altered mental status (9.7%) and cranial hemorrhage (2.9%). Laboratory
                abnormalities included cytopenia (99.0%), serum ferritin &gt;500 ug/L (98.4%), liver dysfunction
                (98.1%), hypertriglyceridemia (88.5%), hemophagocytosis in bone marrow smear (87.4%), and
                hypofibrinogenemia (60.9%).In addition to the treatment they received for the underlying causes,
                patients received therapy for HLH consisting of corticosteroids, immunosuppressive drugs, and
                intravenous immunoglobulin. Twenty-six patients (25.2%) recovered after treatment, and 19 of them
                achieved long-term remission during follow-up. Seventy-seven patients (74.8%) died because of tumor,
                sepsis, multiple organ failure, or HLH-related organ hemorrhage and coagulopathy. The deceased patients
                were more likely to be older at disease onset, male, and to present with splenomegaly and
                thrombocytopenia, compared to the survivors. Treatment for the underlying diseases combined with
                corticosteroids, immunosuppressive agents, and immunoglobulin therapy may improve the prognosis of HLH.
                More attention should be paid to high-risk patients to prevent the development of serious complications
                associated with HLH.
            </value>
        </row>
        <row>
            <value>376</value>
            <value>200</value>
            <value>1</value>
            <value>Introduction</value>
            <value>Background</value>
            <value>Large granular lymphocyte leukemia is rare, mainly chronic disease. The most common complication is
                neutropenia, but other immune-mediated cytopenia may also occur. There are no unified treatment
                recommendations and initiation of treatment mainly depends on the severity of the symptoms.
            </value>
        </row>
        <row>
            <value>377</value>
            <value>200</value>
            <value>2</value>
            <value>Aim</value>
            <value>Objective</value>
            <value>The aim of the authors was to analyze the main steps of the diagnosis and the necessity and outcome
                of treatment in their patients diagnosed with large granular lymphocyte leukaemia.
            </value>
        </row>
        <row>
            <value>378</value>
            <value>200</value>
            <value>3</value>
            <value>Method</value>
            <value>Methods</value>
            <value>The authors retrospectively analyzed the data of 17 large granular lymphocyte leukemia patients.
            </value>
        </row>
        <row>
            <value>379</value>
            <value>200</value>
            <value>4</value>
            <value>Results</value>
            <value>Results</value>
            <value>Of the 17 patients, 7 patients required treatment because of transfusion dependent anemia (4
                patients) or neutropenia (3 patients). In 4 patients corticosteroid was given (supplemented with
                cyclosporine in one patients), while the other patients received anti-CD52 (one patient), low dose
                methotrexate (one patient) and combined chemotherapy (one patient). Five patients achieved partial
                response, and two patients died in sepsis.
            </value>
        </row>
        <row>
            <value>380</value>
            <value>200</value>
            <value>5</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>In this cohort only a smaller proportion of patients required therapy. Immunosuppression can be
                successful, but the effect in most cases was temporary. The most serious complication was sepsis, which
                is associated with a significant risk of mortality in cases with neutropenia.
            </value>
        </row>
        <row>
            <value>381</value>
            <value>201</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>For over two decades, we have embraced the cytokine storm theory to explain sepsis, severe sepsis and
                septic shock. The failure of numerous large-scale clinical trials, which aimed to treat sepsis by
                neutralizing inflammatory cytokines and LPS, indicates that alternative pathophysiological mechanisms
                are likely to account for sepsis and the associated immune suppression in patients with severe
                infection. Recent insights that extricate pyroptotic death from inflammatory cytokine production in vivo
                have highlighted a need to investigate the consequences of apoptotic and non-apoptotic death in
                contributing to cytopenia and immune suppression. In this review, we will focus on the biochemical and
                cellular mechanisms controlling pyroptosis, a Caspase-1/11 dependent form of cell death during
                infection.
            </value>
        </row>
        <row>
            <value>382</value>
            <value>202</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>Primary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition that clinically
                characterized by fever, hepatosplenomegaly, and cytopenia. Hematopoietic stem cell transplantation
                (HSCT) is the only curative treatment option for patients diagnosed with primary HLH.
            </value>
        </row>
        <row>
            <value>383</value>
            <value>202</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>384</value>
            <value>202</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>385</value>
            <value>202</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Because of pretransplant infections caused by underlying immunodeficiency in patients with primary
                HLH, the use of less toxic regimen with RIC seems to be highly effective in this regard. Recipients of
                RIC transplant, with either full or mixed chimerism, had a long-term survival rate with no manifestation
                of primary HLH symptoms.
            </value>
        </row>
        <row>
            <value>386</value>
            <value>203</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Macrophage activation syndrome (MAS) is an infrequent but potentially life-threatening complication
                of various autoimmune diseases. It is characterized by excessive activation of macrophages induced by a
                dysfunction of the immune system, although the underlying abnormalities remain to be delineated.
                Sepsis-like symptoms accompanied by cytopenia, hepatosplenomegaly, coagulopathy and multiple organ
                dysfunctions are typical disease manifestations. Due to the lack of validated classification criteria
                and distinct laboratory markers, the diagnosis of MAS is often difficult to establish. However, early
                diagnosis and therapy is of utmost importance to ensure best possible outcome. Treatment regimens
                include high doses of glucocorticoids, classical immunosuppressive agents as well as novel biologics.
            </value>
        </row>
        <row>
            <value>387</value>
            <value>204</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Endocan is a soluble proteoglycan expressed only by vascular endothelium and is also found
                circulating in the bloodstream. Inflammatory cytokines as well as proangiogenic growth factors increase
                its expression, and increased serum levels are found in immunocompetent patients with sepsis. We
                investigated serum endocan levels in patients with untreated acute myeloid leukemia (AML) and AML
                patients during chemotherapy-induced bone marrow failure. We observed increased levels in 40 AML
                patients compared with healthy controls, which was also confirmed in a second cohort. The serum levels
                decreased after intensive chemotherapy and subsequent severe chemotherapy-induced cytopenia, and
                increased levels were thereafter observed during bone marrow regeneration. However, even for these
                severely immunocompromized patients, serum endocan levels increased during complicating bacterial
                infections before a decrease was seen during antibiotic therapy. To conclude, serum endocan is a disease
                marker in AML, but serum levels are also affected by complicating infections and bone marrow
                regeneration.
            </value>
        </row>
        <row>
            <value>388</value>
            <value>205</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>The purpose of this retrospective study was to characterize the presentation, treatment, and outcomes
                of patients with multiple myeloma requiring surgical evaluation for abdominal pain.
            </value>
        </row>
        <row>
            <value>389</value>
            <value>205</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Medical records of patients with myeloma and abdominal pain evaluated by surgery over a period of 18
                months were examined.
            </value>
        </row>
        <row>
            <value>390</value>
            <value>205</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Twenty-one patients underwent surgical evaluation, with 23 diagnoses. Neutropenic enterocolitis (n =
                5 [22%]) and ileus (n = 4 [17%]) were common diagnoses. Eleven patients (52%) were neutropenic.
                Peritonitis was noted in only 1 patient. Eastern Cooperative Oncology Group performance status was
                either 3 or 4 in most patients (67%). Surgery was performed in 5 patients. The 90-day mortality rate for
                all patients was 43%, with all deaths secondary to sepsis in patients managed without surgery.
            </value>
        </row>
        <row>
            <value>391</value>
            <value>205</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Patients with myeloma requiring surgical evaluation for abdominal pain have a unique differential
                diagnosis, with notable findings at presentation including the presence of cytopenia, lack of peritoneal
                signs, and low performance status.
            </value>
        </row>
        <row>
            <value>392</value>
            <value>206</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Hemophagocytic syndrome (HS) is a severe hyper inflammatory condition whose cardinal symptoms are
                prolonged fever, cytopenia, hepatosplenomegaly, and hemophagocytosis by activated, morphologically
                benign macrophages. The clinical course resembles sepsis, sharing similar physiopathological features.
                We report four patients with the syndrome. A 61-year-old female presenting with fever and pleuritic
                pain. During the course of the disease, a pancytopenia was detected and a bone marrow aspiration was
                suggestive of HS. The patient was treated with cyclosporine and steroids with a good response. A
                61-year-old male with fever and pancytopenia and a bone marrow aspirate suggestive of HS. The patient
                did not respond to treatment and died. A 23-year-old male with fever, pancytopenia and positive Hanta
                virus antibodies. A bone marrow aspirate was suggestive of HS. The patient recovered without any
                treatment. A 72-year-old male admitted with the diagnosis of pneumonia, that developed a progressive
                pancytopenia and bone marrow aspirate was suggestive of HS. A bronchoalveolar lavage showed the presence
                of Acinetobacter baumanii. Despite treatment with methylprednisolone and gammaglobulin, the patient
                died. Awareness of the clinical symptoms and of the diagnostic criteria of HS is important to start
                life-saving therapy in time.
            </value>
        </row>
        <row>
            <value>393</value>
            <value>207</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Hemophagocytic lymphohistiocytosis (HLH) was originally described as a genetic disorder of immune
                regulation, presenting in neonates with protracted fever, hepatosplenomegaly, and cytopenia. A secondary
                form of HLH, triggered by serious infections, was subsequently described in adults.
            </value>
        </row>
        <row>
            <value>394</value>
            <value>207</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We report three adult patients who presented with systemic inflammatory response syndrome and
                features consistent with severe sepsis and septic shock, who subsequently received a diagnosis of
                secondary HLH. We reviewed the relationship between infection-triggered HLH and septic shock from the
                perspective of the adult intensivist.
            </value>
        </row>
        <row>
            <value>395</value>
            <value>207</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>The hyperinflammatory pathophysiologic characteristics of HLH and septic shock are closely
                intertwined. Clinical and laboratory features of HLH and septic shock overlap in some patients, making
                the syndromes difficult to distinguish. In our experience and review, progressive pancytopenia was the
                feature most likely to suggest secondary HLH in the adult patient with presumed (or definite) septic
                shock. Use of other HLH-2004 diagnostic criteria is hindered by the poor operating characteristics of
                these tests in critically ill adults. Bone marrow aspiration is the most useful diagnostic test, but may
                yield an initial false-negative result.
            </value>
        </row>
        <row>
            <value>396</value>
            <value>207</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>The HLH-2004 treatment protocol is not of proven benefit in critically ill adults, but observational
                data suggest that aggressive immunosuppressive therapy should not be delayed. Further study of HLH in
                the critical care setting might provide important insights into the pathogenesis and clinical treatment
                of sepsis.
            </value>
        </row>
        <row>
            <value>397</value>
            <value>208</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Hemophagocytic syndrome, also known as hemophagocytic lymphohistiocytosis (HLH), is a rare and
                frequently fatal disorder caused by an uncontrollable and ineffective systemic immune response. Patients
                initially present with fever, cytopenia, and hepatosplenomegaly, and subsequently develop multiorgan
                failure (MOF). Hemophagocytosis can be found on biopsy specimen but is not required. Acquired forms of
                HLH can occur in apparently healthy adults, while children present more often with an inherited form of
                the disease. Since HLH often presents with sepsis-like symptoms and organ dysfunction, patients are
                usually treated for presumed sepsis, which inevitably leads to delayed diagnosis and treatment.
                Intensivists need to have a low threshold for suspecting this disorder when previously healthy
                individuals present with a fulminant sepsis-like syndrome, which are unresponsive to conventional
                treatment. We present 3 patients with HLH who were admitted to our adult medical intensive care unit
                (MICU) over a 2-year period with fatal outcomes and emphasize the diagnostic importance of markedly
                elevated serum ferritin levels and the need for tissue biopsy in making an accurate diagnosis in a
                timely manner.
            </value>
        </row>
        <row>
            <value>398</value>
            <value>209</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is universal and tends to be more
                aggressive. Data on post-transplant HCV genotype 4 treatment is scarce. The aim of this study is to
                assess the safety and efficacy of pegylated interferon alpha-2a (PEG-IFN) in combination with ribavirin
                in the treatment of recurrent HCV genotype 4 after LT.
            </value>
        </row>
        <row>
            <value>399</value>
            <value>209</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>Twenty-five patients infected with HCV genotype 4 were treated with PEG-IFN alpha-2a at a dose of 180
                ?g/week in addition to 800 mg/day of ribavirin (the dose was adjusted within the tolerated range of
                400-1,200 mg). Pretreatment liver biopsies were obtained from all patients. Biochemical and virological
                markers were assessed before, during, and after treatment.
            </value>
        </row>
        <row>
            <value>400</value>
            <value>209</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Twenty-two patients (88%) achieved an early virological response (EVR) (12 patients tested negative
                for HCV-RNA). Fifteen (60%) and 14 patients (56%) achieved an end of treatment virological response
                (ETVR) and a sustained virological response (SVR), respectively. Five patients had advanced pretreatment
                liver fibrosis. Pretreatment ALT was elevated in 24 patients (96%). The most common adverse effects were
                flu-like symptoms and cytopenia. Eighteen patients (72%) required erythropoietin alpha and/or
                granulocyte-colony stimulating factor as a supportive measure. One patient developed severe rejection
                complicated by sepsis, renal failure, and death. Other adverse effects included depression, mild
                rejection, impotence, itching, and vitiligo.
            </value>
        </row>
        <row>
            <value>401</value>
            <value>209</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Post-transplant treatment with pegylated interferon alpha-2a and ribavirin achieved SVR in 56% of
                liver transplant recipients with chronic HCV genotype 4 infection. The combination was relatively safe
                and exhibited a low rate of treatment withdrawal.
            </value>
        </row>
        <row>
            <value>402</value>
            <value>210</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>A 6-year-old boy presented with pancytopenia. Bone marrow morphology showed dyspoiesis and
                cytoplasmic vacuolation in myeloid precursor cells. Cytoplasmic vacuoles are described in erythroid
                cells in myelodysplastic syndrome (MDS) but are extremely rare in myeloid precursor cells. We ruled out
                viral and autoimmune etiology, hypocupremia, Pearson syndrome, and chromosomal abnormalities. Finally, a
                diagnosis of MDS of refractory cytopenia of childhood subtype was made. The patient then underwent an
                allogenic stem cell transplant that resulted in normalization of the complete blood counts and bone
                marrow morphology. However, he later developed late graft failure; this was followed by a second
                transplant after which he died of sepsis and multiorgan failure. The case is presented here for the rare
                morphologic features, hitherto not earlier described in pediatric MDS.
            </value>
        </row>
        <row>
            <value>403</value>
            <value>211</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>This study assessed the feasibility and safety of out of hospital management of acute myeloid
                leukemia (AML) patients during consolidation therapy.
            </value>
        </row>
        <row>
            <value>404</value>
            <value>211</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>103 consolidation cycles were analyzed retrospectively. All patients received treatment as
                inpatients; they were discharged provided they were in a good clinical condition and then either
                electively readmitted or managed as outpatients during the aplastic phase.
            </value>
        </row>
        <row>
            <value>405</value>
            <value>211</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>In 95/103 cycles (92%), discharge was feasible after a median of 7 (6-16) days. In 45 cycles,
                patients were electively readmitted at the onset of chemotherapy induced cytopenia after a median time
                of 12 (9-16) days. In 50 cycles, patients were managed as outpatients. In 23/50 outpatient cycles (46%),
                patients required rehospitalization, the main cause being neutropenic fever. There was 1 treatment
                related death due to sepsis in a patient in the outpatient group, accounting for an overall mortality of
                2%. Transfusion requirements, occurrence of grade 3-4 toxicity, and disease free and overall survival
                after a median followup of 20 months did not differ between the treatment strategies. Comparison of
                diagnosis related group (DRG) proceeds revealed a 40% reduction with the outpatient strategy.
            </value>
        </row>
        <row>
            <value>406</value>
            <value>211</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Outpatient management of consolidation therapy in selected AML patients appears to be feasible and
                safe and may reduce hospital treatment costs.
            </value>
        </row>
        <row>
            <value>407</value>
            <value>212</value>
            <value>1</value>
            <value>Background and objectives</value>
            <value>Objective</value>
            <value>Late onset sepsis (LOS)( onset of sepsis &gt;72 hours of age or nosocomial sepsis) is an important
                cause of morbidity and mortality in the neonatal intensive care unit (NICU). Thrombocytopenia is an
                important complication of sepsis. We investigated the incidence of thrombocytopenia in LOS patients and
                studied the influence of various parameters on platelet response.
            </value>
        </row>
        <row>
            <value>408</value>
            <value>212</value>
            <value>2</value>
            <value>Patients and methods</value>
            <value>Methods</value>
            <value>Infants born in the level 3 neonatal intensive care unit between January 2002 and December 2006 with
                documented LOS were included in this prospective study. Multiple hemograms with platelet counts,
                bacterial blood culture and fungal blood culture were obtained in all patients. Demographic and clinical
                data were compared between patients without thrombocytopenia and with mild, moderate and severe
                thrombocytopenia. Duration of thrombocytopenia in relation to type of organism and mortality with
                respect to degree of thrombocytopenia were also studied.
            </value>
        </row>
        <row>
            <value>409</value>
            <value>212</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Of 200 patients with culture-proven nosocomial sepsis, 119 (59.5%) patients developed
                thrombocytopenia (platelet count &lt;150 X 109/L). In our series Klebsiella pneumoniae was the most
                frequently isolated organism (125/200, 62.5%) and the incidence of thrombocytopenia was 60.0% (75/125).
                However, the incidence of thrombo- cytopenia was highest among patients who had concurrent bacterial and
                fungal sepsis (28/31, 90.3%). Coagulase- negative staphylococcal (CoNS) sepsis was present in 21 (10.5%)
                patients and the incidence of thrombocytopenia was 33.3%. Isolated fungal sepsis was present only in 6
                (3%) patients and the incidence of thrombocytopenia was 66.0%. The incidence of thrombocytopenia was
                highest among preterm babies and low-birth weight (LBW) babies. Twenty-seven percent (54/200) of babies
                presented with mild thrombocytopenia, 20% (40/200) presented with moderate thrombocytopenia, and
                12.5%(25/200) developed severe thrombocytopenia. Severity of thrombocytopenia was also directly related
                to the presence of necrotizing enterocolitis (NEC) and disseminated intravascular coagulation (DIC). The
                mortality rate was significantly associated with the degree of thrombocytopenia.
            </value>
        </row>
        <row>
            <value>410</value>
            <value>212</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>LOS sepsis is an important risk factor for thrombocytopenia in the NICU. Fungal and gram- negative
                sepsis are frequently associated with a decreased platelet count. Sepsis-induced thrombocytopenia is
                more common among LBW babies and preterm babies. The mortality rate is significantly related to degree
                of thrombocytopenia.
            </value>
        </row>
        <row>
            <value>411</value>
            <value>213</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Gaucher's disease (GD) may go undiagnosed for many years, leading to severe complications that are
                preventable or reversible by enzyme replacement therapy with imiglucerase. GD is associated with
                cytopenia, bone complications, hepatosplenomegaly, hypermetabolism, and hyperactivity of the immune
                system manifested by polyclonal hyper gamma-globulinemia and an increased incidence of monoclonal
                gammopathies. High ferritin and presence of autoimmune antibodies may present and because of these
                abnormalities, clinical similarities with primary liver diseases may occur. We report on two patients
                who suffered diagnostic delay that could potentially lead to life-threatening manifestations of GD.
                Potential complications include: avascular necrosis, severe bleeding, chronic bone pain,
                life-threatening sepsis, pathologic fractures, growth failure, and liver pathology. Physician awareness
                will increase the likelihood of prompt detection of GD and improve its management.
            </value>
        </row>
        <row>
            <value>412</value>
            <value>214</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Hemophagocytic lymphohistiocytosis (HL) is a rare syndrome, although more common in children, that
                may be underdiagnosed. The clinical presentation can be aggressive, and patients may rapidly develop
                lethal multiple organ failure....HL simulates the presentation of infectious sepsis, although the
                response to treatment and evolution are worse. HL should be suspected in young children with persistent
                fever of unknown origin, general malaise, hepatosplenomegaly, cytopenia, elevated triglycerides and
                ferritin, and decreased fibrinogen. Brain MRI shows diffuse leptomeningeal and perivascular enhancement,
                patchy areas of hyperintensity in the white matter of both cerebral hemispheres on T2-weighted
                sequences, and cerebral atrophy. Diffusion-weighted sequences are useful for staging the lesions. We
                present a fatal case of familial HL and review the literature about the clinical, histological, and
                radiological characteristics of this disease.
            </value>
        </row>
        <row>
            <value>413</value>
            <value>215</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To report our experience in children with primary or secondary hemophagocytic lymphohistiocytosis
                (HLH) presented with multiple organ dysfunction syndrome (MODS) in pediatric intensive care unit (PICU).
            </value>
        </row>
        <row>
            <value>414</value>
            <value>215</value>
            <value>2</value>
            <value>Design</value>
            <value>Methods</value>
            <value>The records of patients with a diagnosis of HLH and MODS between January 2005 and January 2008 were
                reviewed. The patients' characteristics, treatment modalities, and outcomes were assessed.
            </value>
        </row>
        <row>
            <value>415</value>
            <value>215</value>
            <value>3</value>
            <value>Setting</value>
            <value>Methods</value>
            <value>PICU of Ege University Hospital.</value>
        </row>
        <row>
            <value>416</value>
            <value>215</value>
            <value>4</value>
            <value>Patients/subjects</value>
            <value>Methods</value>
            <value>Twelve children who were hospitalized in the PICU met the diagnostic criteria for HLH, and presented
                with MODS were entered into the study.
            </value>
        </row>
        <row>
            <value>417</value>
            <value>215</value>
            <value>5</value>
            <value>Results</value>
            <value>Results</value>
            <value>The median age of the patients was 3 years (range, 2 months-15.5 years). Six patients had a history
                of parental consanguinity and two had an affected sibling. Five of the patients were classified as
                primary HLH. All of the patients had hepatosplenomegaly, elevated ferritin levels, hypofibrinogenemia,
                anemia, thrombocytopenia, and hemophagocytosis in bone marrow examination at presentation. The median
                Pediatric Logistic Organ Dysfunction score of the patients at onset was 51 (range, 12-62). Four patients
                had six, four had five, two had four, and the remaining two had three organ dysfunctions. Organ
                dysfunction, other than hematologic dysfunction which was present in all patients, was most commonly
                seen in hepatic (n = 11, 91.7%), respiratory (n = 11, 91.7%), and cardiovascular systems (n = 10,
                83.3%). Although nine patients showed neurologic dysfunction including convulsion and coma, renal
                failure was detected in five patients. Eleven patients were supported with mechanical ventilation and
                four patients required hemodialysis. Eight patients were treated according to the HLH 2004 treatment
                protocol, consisting of cyclosporine A, etoposide, and dexamethasone. The remaining four patients
                received only intravenous immunoglobulin and supportive treatment. Seven of the patients died.
            </value>
        </row>
        <row>
            <value>418</value>
            <value>215</value>
            <value>6</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>HLH is a frequently lethal disease and with a clinical presentation similar to severe sepsis, MODS,
                disseminated intravascular coagulation, or septic shock, which are frequent diagnoses in the PICU. In
                the PICU, HLH should be considered in the case of prolonged fever, splenomegaly, cytopenia, and MODS. It
                is important for pediatricians and particularly pediatric intensivists to know the diagnostic criteria
                and possible clinical presentations of HLH so treatment is initiated promptly.
            </value>
        </row>
        <row>
            <value>419</value>
            <value>216</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Severe cytopenias in patients with autoimmune conditions treated with azathioprine are
                well-recognized. Thiopurine methyltransferase (TPMT) enzymatic activity is subject to individual and
                ethnic variability. Patients with low TPMT activity (poor metabolizers) are at high risk of developing
                severe and potentially fatal haematopoietic toxicity. Studies have shown that essentially all
                TPMT-deficient patients will develop haematopoietic toxicity on administration of conventional
                thiopurine dosages (6-mercaptopurine, azathioprine). Therefore, screening for TPMT polymorphisms in
                patients before prescribing thiopurine drugs has been proposed. However, despite normal in vitro
                enzymatic activity, cytopenia may still occur in vivo. This is the case report of an Asian patient with
                Crohn disease harbouring a rare TPMT mutation on DNA sequencing, who developed neutropenic sepsis and
                anaemia after a flare of Crohn disease. The report illustrates the importance of monitoring for
                cytopenia in the setting of active inflammatory disease despite prior normal phenotyping, the role of
                predictive pharmacogenetics and the limitations of TPMT phenotype assays that may result in
                misclassification of at-risk patients.
            </value>
        </row>
        <row>
            <value>420</value>
            <value>217</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>In an effort to attain earlier diagnoses in children with hemophagocytic lymphohistiocytosis (HLH),
                the International Histiocyte Society has now broadened their diagnostic criteria to no longer
                differentiate primary (HLH) and secondary hemophagocytic lymphohistiocytosis (SHLH). Five of the
                following eight diagnostic criteria needed to be met: 1) fever, 2) cytopenia of two lines, 3)
                hypertriglyceridemia and/or hypofibrinogenemia, 4) hyperferritinemia (&gt;500 microg/L), 5)
                hemophagocytosis, 6) elevated soluble interleukin-2 receptor (CD25), 7) decreased natural killer-cell
                activity, and 8) splenomegaly can also commonly be found in patients with sepsis, systemic inflammatory
                response syndrome (SIRS), multiorgan dysfunction syndrome (MODS), and macrophage activation syndrome
                (MAS). Nevertheless, the therapeutic options for these are radically different. Chemotherapy and bone
                marrow transplant have been used for treatment of HLH/SHLH, whereas antibiotics and supportive treatment
                are used in severe sepsis/SIRS and MODS. MAS is treated with limited immune suppression. Outcomes are
                also different, SHLH has a mortality rate around 50%, whereas pediatric septic shock and MODS have a
                mortality of 10.3% and 18%, respectively, and severe sepsis in previously healthy children has a
                mortality rate of 2%. MAS has a mortality rate between 8% and 22%. Because SHLH and severe
                sepsis/SIRS/MODS/MAS share clinical and laboratory inflammatory phenotypes, we recommend extreme caution
                when considering applying HLH therapies to children with sepsis/SIRS/MODS/MAS. HLH therapies are clearly
                warranted for children with HLH; however, a quantitative functional estimate of cytotoxic lymphocyte
                function may be a more precise approach to define the overlap of these conditions, better identify these
                processes, and develop novel therapeutic protocols that may lead to improved treatments and outcomes.
            </value>
        </row>
        <row>
            <value>421</value>
            <value>218</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Gaucher disease (GD) is a progressive macrophage lipidosis capable of causing disabling and
                life-threatening complications. Anecdotal experiences suggest that GD may go undiagnosed for many years,
                leading to severe complications that are preventable or reversible by enzyme replacement therapy (ERT)
                with imiglucerase. We conducted surveys of patients and Hematology-Oncology specialists to assess the
                frequency of diagnostic delays. Additionally, we report a series of patients who suffered diagnostic
                delays and as a result developed disabilities including potentially life-threatening manifestations of
                GD. Of 136 patients surveyed, the average time from first appearance of GD symptoms to final diagnosis
                was 48.7 +/- 123.6 months. More than two-thirds were evaluated and managed by a hematologist-oncologist
                (Hem-Onc). A global survey of 406 Hem-Oncs found that only 20% considered GD in the differential
                diagnosis for all of its classic symptoms (cytopenia, hepatosplenomegaly, bone pain); the diagnosis
                considered most likely included leukemia, lymphoma, and multiple myeloma. To illustrate actual
                consequences of diagnostic delays, we describe 14 patients with GD who suffered from symptoms for up to
                10 years before correct diagnosis. Diagnostic delays led to complications that are preventable or
                reversible with ERT (i.e., avascular necrosis, severe bleeding, chronic bone pain, life-threatening
                sepsis, pathologic fractures, growth failure, liver pathology). Patients homozygous for N370S mutation
                in this series were vulnerable to diagnostic delays. In conclusion, prolonged diagnostic delays occur in
                GD and may result in severe disease manifestations. Our findings suggest that physician education will
                increase the likelihood of prompt detection of GD and improve its management with ERT with imiglucerase
                when indicated.
            </value>
        </row>
        <row>
            <value>422</value>
            <value>219</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The dermatology staff was called to evaluate abnormal hair on a 22-month-old Hispanic girl whose
                parents were first cousins. Her medical history was significant for leptomeningitis with subsequent
                neurologic devastation, gastroesophageal reflux disease, and recurrent respiratory infections. Her
                hospital course was complicated by sepsis, liver dysfunction, pan-cytopenia, and disseminated
                intravascular coagulation. She had developed normally for the first year of life. At 13 months she
                became progressively lethargic and developed floppy muscle tone; a delay in mental and motor milestones
                was recognized. Results of a metabolic workup were negative. On examination she was noted to have
                generalized excessively fair skin when compared with her parents. She had silver-gray hair (Figure 1)
                and white eyebrows and body hair. Her maternal grandfather and granduncles had silver hair since
                childhood, but were without health problems. A maternal family member was said to have light skin. The
                presumed diagnosis before pathologic examination was Chediak-Higashi syndrome. Hematoxylin and eosin
                stain tests revealed prominent melanocytes in the basal layer of the epidermis. The melanocytes were
                large and distended with a large volume of melanin (Figure 2). The adjacent keratinocytes were
                completely devoid of melanin. Application of Masson-Fontana ammoniac silver stain highlighted prominent
                melanocytic melanin and a relative paucity of melanin in the adjacent keratinocytes (Figure 3).
                Microscopic examination of her hair revealed clumps of melanin of various sizes and shapes irregularly
                distributed throughout the hair shaft. Ultrastructural examination of the epidermis showed the
                melanocytes were distended by an accumulation of large stage IV mature melanosomes. Peripheral blood
                smear failed to show abnormal granules, even after repeated examination. Based on the clinical features
                and the pathologic findings, a diagnosis of Griscelli syndrome type 2 was made.
            </value>
        </row>
        <row>
            <value>423</value>
            <value>220</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Reactive hemophagocytic syndrome or hemophagocytic lymphohistiocytosis comprises a variety of
                disorders, many of them associated with infection. It is characterized by hemophagocytosis, with
                cytopenia involving at least two cellular lines, increase in cytokines and serum ferritin. The clinical
                course resembles sepsis, sharing similar physiopathological features. We propose that hemophagocytic
                syndrome is an underdiagnosed entity in the critical care setting; simple tests aid to identify which
                patients should undergo diagnostic procedures. We discuss current therapeutic approaches.
            </value>
        </row>
        <row>
            <value>424</value>
            <value>221</value>
            <value>1</value>
            <value>Aim</value>
            <value>Objective</value>
            <value>To analyze the perioperative period in children who required surgery anticipated in the protocol and
                suffered from prolonged bone marrow suppression.
            </value>
        </row>
        <row>
            <value>425</value>
            <value>221</value>
            <value>2</value>
            <value>Material and methods</value>
            <value>Methods</value>
            <value>The surgical treatment of 15 children with prolonged bone marrow suppression, resistant to GM-CSF for
                5-15 weeks (M=10), was retrospectively analyzed. Criteria to submit a patient to the group were:
                neutropenia &lt;1000/ml or/and thrombocytopenia &lt;70,000/ml. Four had thrombocytopenia, 8 neutropenia
                and 3 cytopenia of both cell lines. Neutropenic patients were divided into two groups: severe
                neutropenia--&lt;500/ml (2), and moderate--500-1000/ml (7). Children with thrombocytopenia were divided
                into two groups: with thrombocytes &lt;30,000/ml (2) and between 30,000-70,000/ml (5).
            </value>
        </row>
        <row>
            <value>426</value>
            <value>221</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Complications (pneumonia and sepsis) were noted in 2 out of 4 children with severe neutropenia,
                remaining patients had uncomplicated perioperative period. Patients with moderate neutropenia did not
                show any alarming signs after surgery. As a major haemorrhage we assumed loosing &gt; 30 percent of
                circulating blood. This was observed only in 1 patient (with thrombocytes &lt;30,000/ml). 13 patients
                were discharged from our Department between 3-10 days after surgery in good general condition. Two had
                to be treated for a longer time because of advanced cancers (18 and 21 days).
            </value>
        </row>
        <row>
            <value>427</value>
            <value>221</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Neutropenia does not seem to be an absolute contraindication for surgical procedures needed in
                complex cure of malignancies. In our opinion thrombocyte level &gt; 30,000/ml appears to be safe enough
                to conduct surgery.
            </value>
        </row>
        <row>
            <value>428</value>
            <value>222</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology.
                Despite advances in understanding the pathophysiology underlying this disorder, no effective medical
                therapy has been identified for halting disease progression. The aim of this investigation was to
                determine the safety and estimated efficacy of mycophenolate mofetil (MMF) for the treatment of PSC.
                Thirty patients with PSC received MMF 1 g daily to a maximum of 3 g daily for 1 yr. Liver tests were
                determined at 3-month intervals with the Mayo risk score calculated at baseline and at the end of
                therapy. Twenty-three (77%) patients completed 1 yr of therapy. Significant but clinically marginal
                improvement in serum alkaline phosphatase level after 1 yr of therapy was observed (1135 +/- 581 U/L vs
                912 +/- 463 U/L, p= 0.02). No other significant changes in liver biochemistries or Mayo risk score was
                observed. Seven patients (23%) discontinued MMF due to adverse events possibly related to therapy.
                Adverse reactions resolved spontaneously or with dose reduction in 10 (33%) patients. One patient
                developed pancreatitis, bacterial cholangitis, and sepsis during the eighth month of MMF therapy. No
                patient developed cytopenia on therapy. In conclusion, MMF does not appear to have clinically important
                benefits for PSC despite being tolerated by most patients. The results of this pilot study do not
                support further study of MMF as a single agent in the treatment of PSC.
            </value>
        </row>
        <row>
            <value>429</value>
            <value>223</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four
                patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in
                accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by
                all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%)
                attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%),
                toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate
                oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and
                23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3
                months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved
                CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from
                progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate
                that imatinib is safe also in elderly with clinical results as good as in younger patients.
            </value>
        </row>
        <row>
            <value>430</value>
            <value>224</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Lung resection for invasive pulmonary aspergillosis (IPA) is controversial. Neutropenia, thrombopenia
                and poor general condition may increase perioperative morbidity and mortality, and the redeeming benefit
                is questionable. Therefore we analyzed short- and long-term outcome after lung resection for IPA.
            </value>
        </row>
        <row>
            <value>431</value>
            <value>224</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>41 patients with hematological disease underwent lung resection for suspected IPA: lobectomy (23
                patients), wedge-resection (16) and enucleation (2).
            </value>
        </row>
        <row>
            <value>432</value>
            <value>224</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>4 (10%) patients developed major complications: pleural aspergillosis, bronchial stump insufficiency,
                severe bleeding, ARDS. 11 (27%) patients showed minor complications: pleural effusion (6), pneumothorax
                (2), seroma (2) and hematothorax (1). 30-day mortality was 10 % (4 of 41 patients): two died of
                bacterial septicemia, two of disseminated aspergillosis. One (2%) death was possibly surgery-related.
                IPA was cleared in 87% of patients, fungal relapse occurred in 4 (10%) patients. Overall survival was
                65%, 58% and 40% at 6 months, 12 months and 5 years.
            </value>
        </row>
        <row>
            <value>433</value>
            <value>224</value>
            <value>4</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Lung resection for IPA even in profound cytopenia is feasible with acceptable morbidity and
                mortality. Fungal infection can be cured in more than 80 % of patients. Long-term outcome can be
                achieved if the hematological disease is under control.
            </value>
        </row>
        <row>
            <value>434</value>
            <value>225</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>We report the occurrence of human herpesvirus (HHV)-8 primary infection in an adult male kidney
                recipient. Four months after transplantation, the patient developed visceral Kaposi sarcoma, and 1 month
                later he presented with progressive and severe peripheral cytopenia, in the presence of a normocellular
                or hypercellular bone marrow (BM) with hemophagocytosis. HHV-8 was the sole pathogen detected by
                polymerase chain reaction either in the serum or in the BM. HHV-8 latent nuclear antigen was detected in
                immature progenitor cells from the BM. Immunosuppressive therapy was reduced, and the patient was
                treated with foscarnet for 2 weeks, leading to a dramatic normalization of blood cell counts,
                concomitantly with the disappearance of HHV-8 viremia. At the end of antiviral therapy, the patient
                received chemotherapy, and Kaposi sarcoma regressed in 2 months. Severe peripheral cytopenia may be a
                posttransplant complication after HHV-8 infection, for which treatment with foscarnet seems appropriate.
            </value>
        </row>
        <row>
            <value>435</value>
            <value>226</value>
            <value>1</value>
            <value>Background and objectives</value>
            <value>Objective</value>
            <value>To evaluate the outcomes of splenectomy in myelofibrosis and myeloid metaplasia (MMM).</value>
        </row>
        <row>
            <value>436</value>
            <value>226</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We retrospectively reviewed our records of 26 patients with MMM who underwent an open splenectomy at
                Boston University Medical Center between 1979 and 1995. Fourteen patients had agnogenic myeloid
                metaplasia (AMM) and 12 had myelofibrosis with antecedent myeloproliferative disorders (MF). The main
                indications for splenectomy were progressive transfusion-dependent anemia, painful splenomegaly, and
                hypercatabolic symptoms associated with cytopenia.
            </value>
        </row>
        <row>
            <value>437</value>
            <value>226</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Median time to splenectomy after the diagnosis of MMM was 29 months ranging from 1 to 96 months.
                Three patients (11%) died within 1 month after the surgery because of sepsis. The most common peri- and
                postoperative complications were pneumonia and other bacterial infections (42%), cardiac events (19%),
                acute bleeding (15%), ileus (15%), and venous thrombosis (12%). Of the eight surviving patients who
                underwent splenectomy for transfusion dependent anemia, six (75%) had improvement in their hematocrit
                levels with abolishment of blood transfusions. A durable symptomatic palliation was achieved in all
                patients. Liver enlargement was noted in seven patients at 1-year evaluation. None of these patients
                developed hepatic failure. Leukemic transformation occurred in 8 of 18 patients (44%) postsplenectomy.
                The median overall survival for the entire group was 58.5 and 28 months from the diagnosis of MMM and
                the time of splenectomy, respectively. There was no difference in survival rates between patients with
                AMM and MF.
            </value>
        </row>
        <row>
            <value>438</value>
            <value>226</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Splenectomy is an effective palliative procedure with an acceptable morbidity in selected patients
                with MMM. Progressive transfusion-dependent anemia should also be considered an indication for
                splenectomy in the absence of leukemic evolution.
            </value>
        </row>
        <row>
            <value>439</value>
            <value>227</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The period during which pigs are protected after vaccination is important for the successful usage of
                a marker vaccine against classical swine fever virus (CSFV) in an eradication programme. In four animal
                experiments with different vaccination-challenge intervals we determined the duration of protection of
                an E2 subunit marker vaccine in pigs after a single vaccination. Unvaccinated pigs were included in each
                group to detect transmission of the challenge virus. Three groups of six pigs were vaccinated once and
                subsequently inoculated with the virulent CSFV strain Brescia after a vaccination-challenge interval of
                3, 51/2, 6 or 13 months. All vaccinated pigs, 16 out of 18, with neutralising antibodies against CSFV at
                the moment of challenge, 3, 51/2, 6 or 13 months later, survived, whereas unvaccinated control pigs died
                from acute CSF or were killed being moribund. A proportion of the vaccinated pigs did however develop
                fever or cytopenia after challenge and two vaccinated pigs were viremic after challenge. Virus
                transmission of vaccinated and challenged pigs to unvaccinated sentinel pigs did not occur in groups of
                pigs which were challenged 3 or 6 months after a single vaccination. Two out of eight vaccinated pigs
                that were found negative for CSFV neutralising antibody at 13 months after vaccination died after
                subsequent challenge. The findings in this study demonstrate that pigs can be protected against a lethal
                challenge of CSFV for up to 13 months after a single vaccination with an E2 subunit marker vaccine.
            </value>
        </row>
        <row>
            <value>440</value>
            <value>228</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Human herpesvirus 8 (HHV-8) infection has been linked to the development of Kaposi's sarcoma and to
                rare lymphoproliferative disorders.
            </value>
        </row>
        <row>
            <value>441</value>
            <value>228</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>We used molecular methods, serologic methods, in situ hybridization, and immunohistochemical analyses
                to study HHV-8 infection in association with nonmalignant illnesses in three patients after
                transplantation.
            </value>
        </row>
        <row>
            <value>442</value>
            <value>228</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Primary HHV-8 infections developed in two patients four months after each received a kidney from the
                same HHV-8-seropositive cadaveric donor. Seroconversion and viremia occurred coincidentally with
                disseminated Kaposi's sarcoma in one patient and with an acute syndrome of fever, splenomegaly,
                cytopenia, and marrow failure with plasmacytosis in the other patient. HHV-8 latent nuclear antigen was
                present in immature progenitor cells from the aplastic marrow of the latter patient. Identification of
                the highly variable K1 gene sequence of the HHV-8 genome in both the donor's peripheral-blood cells and
                the recipients' serum confirmed that transmission had occurred. HHV-8 viremia also occurred after
                autologous peripheral-blood stem-cell transplantation in an HHV-8-seropositive patient with
                non-Hodgkin's lymphoma. Reactivation of the infection was associated with the development of fever and
                marrow aplasia with plasmacytosis; there was no evidence of other infections. HHV-8 transcripts and
                latent nuclear antigen were expressed in the aplastic marrow but not in two normal marrow samples
                obtained before transplantation.
            </value>
        </row>
        <row>
            <value>443</value>
            <value>228</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Primary HHV-8 infection and reactivation of infection may be associated with nonneoplastic
                complications in immunosuppressed patients.
            </value>
        </row>
        <row>
            <value>444</value>
            <value>229</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Sepsis is often associated with a downward spiral through a spectrum of systemic inflammatory
                response syndrome (SIRS) culminating in organ failure and death. Here we present a 3-year-old girl with
                Hemophilus influenzae septic meningitis who developed SIRS and acute renal failure. In the initial
                stage, the patient showed uremia, cytopenia, disseminated intravascular coagulation, elevation of tissue
                enzyme and ferritin values, hemophagocytosis and overproduction of nitric oxide. The serum cytokine
                profile revealed increased levels of soluble interleukin (IL)-2 receptor, IL-6, IL-10 and tumor necrosis
                factor alpha. The patient responded positively to early and intensive interventions including
                antibiotics, repeated exchange transfusions, dexamethasone and high-dose gamma-globulin. The above
                laboratory abnormalities almost normalized with clinical improvement. We consider that SIRS was probably
                responsible for the sequence of events resulting in renal failure in this case, and suggest that renal
                failure should be included among the serious complications of SIRS associated with Hemophilus influenzae
                septic meningitis.
            </value>
        </row>
        <row>
            <value>445</value>
            <value>230</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Twenty-three patients who had myelofibrosis with myeloid metaplasia (MMM) were treated at our
                institution with 50 courses of splenic irradiation (SI) for symptomatic splenomegaly. The median dose of
                radiation per course was 277.5 cGy, administered in a median of 7.5 fractions. 8/23 patients received
                multiple courses of SI. Of 49 evaluable courses of SI, 46 (93.9%) resulted in an objective decrease in
                spleen size. The median duration of response was 6 months (range 1-41). Reduction in spleen size was
                associated with symptomatic relief in all patients. Overall median survival after SI was 22 months.
                Significant cytopenia occurred in 10 (43.5%) patients, or 16 (32%) of the 50 courses of SI. Prolonged,
                life-threatening pancytopenia after a single course of SI occurred in six patients (26%), resulting in
                fatal sepsis or haemorrhage in three (13%). Nine patients underwent subsequent splenectomy: the
                perioperative mortality rate was 11%. One third of patients experienced postoperative intra-abdominal
                haemorrhage necessitating surgical re-exploration. SI can provide symptomatic relief and a reduction in
                spleen size in most MMM patients. The increased risk of postoperative bleeding in patients requiring
                subsequent splenectomy dictates against considering SI as an alternative to splenectomy for patients who
                are otherwise good surgical candidates.
            </value>
        </row>
        <row>
            <value>446</value>
            <value>231</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Irradiation is known to cause temporary to permanent marrow aplasia in cancer patients when
                administered as a sole therapy or in combination with chemotherapy. Until now, no studies have been
                carried out evaluating the haematological toxicities of involved field radiation administered post
                autologous stem cell transplantation (ASCT). We assessed bone marrow (BM) toxicity in 93 patients who
                received involved field radiation post ASCT (non-Hodgkin's lymphoma 21, Hodgkin's disease 7, breast
                cancer 15, and other solid tumours 50. Severe BM toxicity, with grade IV neutropenia, and/or
                thrombocytopenia, and/or anaemia necessitating interruption of radiotherapy for more than a week, was
                observed in 11 patients (malignant lymphoma-8 of which 7 were NHL, and 1 HD, breast cancer-1, Wilm's
                tumour-1, Ewing's sarcoma-1). Patients with malignant lymphoma were at higher risk of developing post
                ASCT radiation-induced cytopenias than patients with breast cancer or solid tumours, 28% vs 4.5%,
                respectively (P &lt; 0.05). Of the 11 patients, 7 developed bacterial sepsis and 10 were hospitalised.
                The radiation-induced cytopenia patients necessitated platelets and red blood cell transfusions,
                interrupting the course of irradiation. Of the patients suffering from non-Hodgkin's lymphoma, 8/14
                (57%) of those who received conventional courses of radiotherapy relapsed compared to 6/7 (86%) of those
                who received interrupted radiotherapy (P &lt; 0.05). The most appropriate timing for radiation in
                malignant lymphoma patients who are scheduled for ASCT, as well as the protective role of haematopoietic
                growth factors like erythropoietin and Granulocyte (G) or Granulocyte-Monocyte (GM), colony stimulating
                factors (CSF) and others, are discussed.
            </value>
        </row>
        <row>
            <value>447</value>
            <value>232</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>224 patients with a recent diagnosis of chronic lymphocytic leukemia, confirmed by immune phenotype,
                were studied with a mean follow-up of 16 months. The median age was 72 years and the ratio of men to
                women was 1.51. An incidental diagnosis because of leukocytosis was made in 75% of the patients; in only
                22% was the diagnosis related to symptoms. 80% were in stage A, 7.5% in stage B, and 12.5% in stage C. A
                relation was found between advanced stage and the number of lymphocytes in the blood, the percentage of
                lymphocytes in the bone marrow, WHO performance status, bacterial infection and disease-related
                mortality. Thus, six patients in stage C (21%) died because of infection (septicaemia or pneumonia), as
                opposed to only one out of 196 patients in stages A and B. The incidence of bacterial infection was 64%
                in stage C, as compared to 8.3% in stage A. Treatment with chlorambucil, started in 59 patients, was in
                accordance with the guidelines of the national programme for 52 of them. In contrast, a strict
                indication for prednisone (autoimmune cytopenia) was found in only 42% of 42 patients given this
                treatment.
            </value>
        </row>
        <row>
            <value>448</value>
            <value>233</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Hepatitis C virus (HCV) has been recognized as the cause of thrombocytopenia occurring in patients
                with chronic hepatitis C, possibly through autoimmune mechanisms. A patient is described with B cell
                chronic lymphocytic leukaemia, presenting with a marked leuko-thrombocytopenia and an associated mild
                haemolysis secondary to HCV infection, in the absence of clinical and biochemical signs of hepatitis.
                Anti-HCV antibodies were detected in the serum both by ELISA and RIBA but not 2 months before the onset
                of cytopenia. The presence of HCV RNA was documented both in the peripheral blood mononuclear cells and
                in the bone marrow by reverse transcriptase polymerase chain reaction of the 5' untranslated region of
                the viral genome. Of interest, HCV RNA was also found in the serum, showing that viraemia was associated
                with the presence of circulating anti-HCV antibodies. HCV genotyping, performed by PCR amplification of
                the core region, revealed the presence of an unclassifiable genotype. The hypothetical mechanisms
                leading to HCV-induced cytopenia in this patient are briefly discussed. Treatment with corticosteroids
                was effective in controlling blood cell counts, without increasing viraemia and deterioration of liver
                disease. HCV infection should be considered in the differential diagnosis of possible causes of
                cytopenia, mainly in immunosuppressed patients, even in absence of clinical and biochemical signs of
                hepatitis.
            </value>
        </row>
        <row>
            <value>449</value>
            <value>234</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>We report the cases of six patients with AIDS in whom reactive hemophagocytic syndrome (RHPS)
                secondary to disseminated histoplasmosis was diagnosed. RHPS was diagnosed by established criteria,
                including fever (duration of &gt; or = 7 days, with peak temperatures of &gt; 38.5 degrees C),
                unexplained thrombocytopenia with anemia and/or neutropenia, and bone marrow biopsy findings of
                hemophagocytic histiocytosis. Disseminated Histoplasma capsulatum infection was diagnosed on the basis
                of the results of cultures of the bone marrow sample. The serum lactate dehydrogenase (LDH) level was
                elevated (&gt; 1,000 IU/L) in all patients, and five of six patients had hyperferritinemia (range of
                ferritin level, 15,848-425,984 ng/mL). Five patients had features resembling severe sepsis with
                multiorgan dysfunction. Three patients recovered, and the findings of RHPS resolved following therapy
                with amphotericin B. In patients with AIDS, the combination of fever, cytopenia, elevated serum LDH
                level (&gt; 1,000 IU/L), and/or hyperferritinemia (ferritin level of &gt; 10,000 ng/mL) is a clue to the
                diagnosis of RHPS and disseminated histoplasmosis; bone marrow biopsy is valuable in establishing the
                diagnosis.
            </value>
        </row>
        <row>
            <value>450</value>
            <value>235</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Aplastic anaemia (AA) of the chronic type with severe cytopenia is very frequently a difficult
                therapeutic problem. Patients with granulocyte values below 0.5 G/l are threatened by infections, incl.
                sepsis possibly with a fatal outcome. If the pool of stem cells for granulocytes is not completely
                exhausted and can respond to growth factors, these patients can be treated either chronically and/or in
                risk situations (e.g. injury, surgery) with preparations of the type of a recombinant, granulocyte
                colony stimulating factor (rhG-CSF), or granulocyte and monocyte colony stimulating factor (rhGM-CSF).
                The authors present a review of diagnostic and therapeutic algorithms in patients with the AA syndrome
                and summarize their own experience with the preparation Neupogen Roche (rhG-CSF).
            </value>
        </row>
        <row>
            <value>451</value>
            <value>236</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Splenectomy is a major surgical intervention that has many implications for patients with malignant
                non-Hodgkin's lymphoma. As debated during the last few decades, the therapeutic benefit must outweigh
                the surgical risk and the loss of cellular immunity. A more liberal attitude toward splenectomy
                developed during the years 1980-1990 at the Norwegian Radium Hospital, as illustrated by the higher
                number of operations performed in the last 5 years (21 patients) compared to the first 5 years (14
                patients).
            </value>
        </row>
        <row>
            <value>452</value>
            <value>236</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>A 10-year retrospective review of the effects and side effects of splenectomy in 35 patients with
                malignant non-Hodgkin's lymphoma was performed, based on information obtained from the patient files at
                the authors' institution.
            </value>
        </row>
        <row>
            <value>453</value>
            <value>236</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Clinical Stage IV disease was found in 29 patients (83%), and B symptoms in 15 patients (43%). At
                diagnosis, 26 patients (74%) had splenomegaly, and 8 patients (23%) had primary splenic lymphoma. The
                surgical mortality was 2.9%, and the morbidity was 37%. Infection was the most common complication,
                occurring in seven patients (20%). Pneumococcal vaccination had been performed in 13 patients, and the
                frequency of septicemia and pneumonia tended to be higher during follow-up in unvaccinated patients (not
                significant). Blood counts returned to normal during the first postoperative month in 18 of 25 patients
                (72%) who had cytopenia. After splenectomy, a durable remission was achieved in five patients (14%) who
                did not receive subsequent treatment.
            </value>
        </row>
        <row>
            <value>454</value>
            <value>236</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Splenectomy has the potential to relieve local symptoms, correct cytopenias, and modify the disease
                course in patients with malignant non-Hodgkin's lymphomas, even in advanced stages, at the cost of an
                acceptable operative risk.
            </value>
        </row>
        <row>
            <value>455</value>
            <value>237</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Forty cases of paroxysmal nocturnal hemoglobinuria (PNH) were studied from 1978 to 1988. Thirty
                patients were male and 10 were female. Their ages ranged from 15 to 58 years with a median of 32 years.
                Symptoms related to anemia (85%) and dark colored urine (45%) were the most frequent clinical
                manifestations. Seven patients (17.5%) had a previous history of aplastic anemia. The interval between
                the diagnosis of aplastic anemia and PNH ranged from 11 months to 26 years. All the patients had anemia
                with varying combinations of cytopenia. In 36 patients, bone marrow examinations were performed, and 32
                were hypercellular, one normocellular and 3 hypocellular. Documented thrombosis was noted in 3 patients,
                involving the intra-abdominal, cerebral and renal veins, respectively. The patient with intra-abdominal
                venous thrombosis subsequently died of E. coli septicemia. The remaining two patients achieved complete
                recovery. All 40 patients were treated with corticosteroids and/or anabolic agents, 32 (80%) patients
                improved and 4 (10%) achieved normal hemoglobin levels. Our studies demonstrate that there is a male
                predominance in Chinese PNH patients and the incidence of thrombotic complications is much lower than
                that reported by Western countries.
            </value>
        </row>
        <row>
            <value>456</value>
            <value>238</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Early institution of empiric therapy with a broad-spectrum antibiotic has markedly reduced the
                morbidity and mortality from infections complicating severe or prolonged cytopenia in patients receiving
                either an allogeneic or autologous bone marrow transplant. Ceftazidime in combination with an
                aminoglycoside, i.e. netilmicin, has been established as a combination schedule offering low or even
                avoiding therapy-related toxicity. We evaluated teicoplanin for suspected Gram-positive infections after
                inadequate response to initial beta-lactam and aminoglycoside combination therapy. All 11 patients so
                far included in this study received either an allogeneic (five patients) or an autologous (six patients)
                bone marrow transplant for acute myeloid leukaemia (AML), non-Hodgkin lymphoma (NHL, high grade) or
                other malignant diseases. All patients developing a primary septicaemia of unknown origin (10 patients)
                or a catheter related septicaemia (one patient) were treated with 400 mg teicoplanin, administered i.v.
                once daily in combination with a cephalosporin and an aminoglycoside (ceftazidime 2 g, i.v., t.i.d.,
                netilmicin 400 mg once daily). All 11 patients responded to therapy, 10 patients were clinically cured,
                one patient improved under therapy. The therapeutic regimen was well tolerated and adverse drug
                reactions did not occur. We have not observed any delayed take of prolonged neutropenia or
                thrombocytopenia with this therapeutic regimen when compared to other bone marrow transplant patients
                who did not receive this antimicrobial therapy. Our preliminary results suggest that teicoplanin is a
                potentially effective and well-tolerated antimicrobial agent in bone marrow transplant patients with
                infections not responding primarily to beta-lactams and aminoglycosides.
            </value>
        </row>
        <row>
            <value>457</value>
            <value>239</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Our series of 195 patients, plus 134 reported on in the literature and 949 reviewed by various
                physicians provide 1,278 patients for review of bacillus Calmette-Guerin therapy complications. Cystitis
                occurred in 91 per cent of the patients. Complications identified included fever more than 103F in 50
                patients (3.9 per cent), granulomatous prostatitis in 17 (1.3 per cent), bacillus Calmette-Guerin
                pneumonitis or hepatitis in 12 (0.9 per cent), arthritis or arthralgia in 6 (0.5 per cent), hematuria
                requiring catheterization or transfusion in 6 (0.5 per cent), skin rash in 5 (0.4 per cent), skin
                abscess in 5 (0.4 per cent), ureteral obstruction in 4 (0.3 per cent), epididymo-orchitis in 2 (0.2 per
                cent), bladder contracture in 2 (0.2 per cent), hypotension in 1 (0.1 per cent) and cytopenia in 1 (0.1
                per cent). Most of the severe irritative side effects and subsequent systemic complications can be
                prevented with prophylactic isoniazid given for 3 days, beginning the morning of treatment. Patients
                with life-threatening systemic bacillus Calmette-Guerin infection or anaphylaxis should receive 500 mg.
                cycloserine twice daily for 3 days in addition to combination antituberculous therapy because the rapid
                action of this drug may be life-saving. Direct intralesional bacillus Calmette-Guerin immunotherapy can
                produce sepsis and death, and should be avoided but intravesical bacillus Calmette-Guerin generally is
                well tolerated and has produced no complication in more than 95 per cent of the patients treated.
            </value>
        </row>
        <row>
            <value>458</value>
            <value>240</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Between January 1978 and December 1982 successful sequential chromosome analyses were carried out on
                bone marrow cells of five patients previously treated for Hodgkin's lymphoma (HL) presenting unexplained
                cytopenia or pancytopenia during follow-up. All patients had concurrent morphological examination of
                bone marrow specimens showing signs of dysplasia and/or hypoplasia, without leukaemic infiltrate. Six
                other patients treated for HL who had normal haematological parameters served as controls. All the
                patients with unexplained cytopenias had clonal chromosome abnormalities; monosomy for chromosome No. 5
                was the most frequent. No abnormalities were detected in the control group. Two patients have evolved to
                resistant leukaemia, one died of sepsis before leukaemic conversion while severely neutropenic, and two
                are in full marrow and cytogenetic recovery after aggressive anti-leukaemic treatment in the
                pre-leukaemic phase. Our data suggest that cytogenetic studies may be of crucial value in detecting
                therapy-induced preleukaemia (t-PL) at an early stage of its evolution and in planning appropriate
                therapy before the establishment of overt leukaemia.
            </value>
        </row>
        <row>
            <value>459</value>
            <value>241</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Fifty patients undergoing splenectomy for complications of hematologic malignancy were reviewed to
                define indications and results. Primary diseases included lymphoma (n = 14), chronic lymphatic leukemia
                (n = 13), hairy-cell leukemia (n = 12), myeloid metaplasia (n = 6), and other similar disorders (n = 5).
                Indications for splenectomy in these patients included cytopenia (n = 37), diagnostic laparotomy (n =
                8), "small stomach" syndrome (n = 3), and abdominal pain (n = 2). Splenectomy was performed by the
                midline approach in 32 patients. In 40 patients, the splenic artery was ligated prior to mobilization of
                the spleen. The spleens averaged 1650 g; in eight patients accessory spleens were removed. Additional
                surgical procedures included liver biopsy (n = 30), lymph node biopsy (n = 15), and cholecystectomy (n =
                3). Intraoperative blood loss averaged 750 ml. In 14 patients, drainage of the left subphrenic space was
                used. Splenectomy was effective in 36 of 50 patients. In seven patients, splenectomy was ineffective in
                correction of cytopenia. Seven mortalities were from bleeding (n = 2), pulmonary embolus (n = 2),
                postoperative sepsis (n = 2), and progression of primary disease (n = 1). Additional complications
                included reoperation for bleeding (n = 3), septic complications including pneumonia (n = 14), wound
                infection (n = 4), and intra-abdominal abscess (n = 2). Splenectomy for the patients with hematologic
                malignancy is generally effective. Meticulous hemostasis, timely administration of intraoperative
                platelets, surgical asepsis, and aggressive pulmonary care are essential to reduce morbidity and
                mortality.
            </value>
        </row>
        <row>
            <value>460</value>
            <value>242</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Sequential chemotherapeutic regimens, primarily used in the treatment of hematopoietic malignancies,
                and employing ara-C as a basic antineoplastic agent induce mucosal alterations in the entire
                gastrointestinal tract. These are characterized by surface and glandular epithelial atypia, immaturity,
                and necrosis. Glandular regeneration is characteristically delayed leading to a state of intestinal
                aproliferative cytopenia. Other toxic intestinal changes include telangiectasia of blood vessels and the
                formation of intramural hematomas. Intestinal infections develop frequently and are complicated by
                peritonitis, liver abscesses, pneumatosis cystoides in testinalis and sepsis. These intestinal lesions
                are accompanied by a predictable clinical syndrome which begins concomitantly with ara-C infusions and
                is characterized by diarrhea, ileus, abdominal pain, hematemesis and melena, severe hypokalemia,
                hypocalcemia and a protein-losing enteropathy. Additional toxic manifestations induced by ara-C include
                transient weight gains, fever elevations and severe bone marrow depression. The genesis of the
                intestinal lesions is linked to the three day dose schedule of ara-C infusions which insures both arrest
                of the cycling intestinal cells in the S-phase and a high cytotoxic index. The severity of these lesions
                is markedly augmented by prior treatment with ara-C and cyclophosphamide which causes synchronization
                and probable recruitment of intestinal stem cells, respectively.
            </value>
        </row>
        <row>
            <value>461</value>
            <value>243</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Pancytopenia is a common occurrence in pediatric patients. Though acute leukemias and bone marrow
                failure syndromes are usual causes of pancytopenia, etiologies such as infections and megaloblastic
                anemia also contribute. The aim of this study was to evaluate the clinico-hematological profile of
                varying degrees of childhood cytopenias with special reference to the non-malignant presentations. This
                is a retrospective study carried out in a tertiary care children's hospital. We retrospectively analyzed
                109 pediatric patients who presented with pancytopenia for different etiologies. Acute leukemia
                (including ALL, AML and myelodysplastic syndrome) and aplastic anemia accounted for 21 per cent and 20
                per cent cases respectively. Megaloblastic anemia was found in 31 (28.4 per cent) patients and was
                single most common etiological factor. Severe thrombocytopenia (platelet &lt; or = 20 x 10(9)/l)
                occurred in 25.2 per cent of these patients. Various skin and mucosal bleeding occurred in 45.1 per cent
                of patients with megaloblastic anemia. Infections accounted for 23 (21 per cent) patients who presented
                with pancytopenia. Amongst infections, enteric fever occurred in 30 per cent patients. Malaria,
                kala-azar and bacterial infections were other causes of pancytopenia at presentation. The study focuses
                on identifying easily treatable causes such as megaloblastic anemia and infections presenting with
                pancytopenia. These conditions though look ominous but respond rapidly to effective therapy.
            </value>
        </row>
        <row>
            <value>462</value>
            <value>244</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Objective: To determine the various spectrum of pancytopenia with its frequency on the basis of bone
                marrow examination in children from 6 months to 14 years. Methods: A retrospective descriptive study was
                carried out at Department of Pediatric Rehman Medical Institute Peshawar from January 2006 to December
                2012. A total of 205 patient's age between 6 months and 14 years, fulfilling the inclusion and exclusion
                criteria were included in the study. Complete blood count, peripheral smear, bone marrow examination and
                Serum vitamin B12 level was done in all the cases. Results: Out of 14642 patients admitted to the
                Pediatric department during the study period, 205 (1.4%) patients were pancytopenic on their peripheral
                blood smear. Male outnumbered female with a ratio of 1.8:1. 42.5% of the patients were in the age group
                of 1 month to 5 years. Common etiological pattern identified were Aplastic anemia 58(28.3%),
                Hematological malignancies 49 (23.9%), megaloblastic anemia 40 (19.5%), idiopathic thrombocytopenic
                purpura 16 (7.8%), iron deficiency anemia 9 (4.4%), hemolytic anemia 7 (3.41%), Visceral leishmaniasis 6
                (2.93%), hypersplenism 5 (2.44%), malaria 5 (2.44%), anemia of chronic disorder 4 (1.95%),
                Myelodisplastic syndrome 3 (1.46%), Niemen pick disease 2 (0.97%) and Gaucher disease in 1(0.49%).
                Common clinical presentations were fever, pallor, body aches, petechial hemorrhages and epistaxis.
                Conclusion: Pancytopenia is one of the importance occurrences in pediatric patients. Acute leukemia and
                bone marrow failure are the most common causes yet megaloblastic anemia and infections are the treatable
                and reversible causes of pancytopenia.
            </value>
        </row>
        <row>
            <value>463</value>
            <value>245</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To study the clinical features and etiological spectrum of pancytopenia in children.</value>
        </row>
        <row>
            <value>464</value>
            <value>245</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>The clinical data of 174 children with pancytopenia between September 2003 and January 2010 were
                retrospectively reviewed.
            </value>
        </row>
        <row>
            <value>465</value>
            <value>245</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>Pale face was the most common clinical manifestation (147 cases, 84.5%), followed by bleeding (87
                cases, 50.0%) and fever (41 cases, 23.6%). Mild to moderate anemia, severe thrombocytopenia and mild
                leucopenia were common in complete blood count. Of the 174 children, pancytopenia was attributed to
                hematopoietic system diseases in 155 cases (89.1%) and non-hematopoietic system diseases (virus
                infections, systemic lupus erythematosus, hypersplenism and neuroblastoma) in 6 cases (3.4%). Aplastic
                anemia (91 cases, 52.3%) was the most common cause of pancytopenia, followed by myelodysplastic syndrome
                (37 cases, 21.3%), acute leukemia and other hematological tumours (11 cases, 6.3%) and hemophagocytic
                syndrome (6 cases, 3.4%). The cause of pancytopenia was not identified in 13 cases (7.5%).
            </value>
        </row>
        <row>
            <value>466</value>
            <value>245</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Anemia, bleeding and fever are the main clinical manifestations of pancytopenia in children.
                Pancytopenia is mostly caused by aplastic anemia in children. Myelodysplastic syndrome, hematological
                tumours and hemophagocytic syndrome are also the common causes.
            </value>
        </row>
        <row>
            <value>467</value>
            <value>246</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To determine the spectrum of pancytopenia with its frequency, common clinical presentation and
                etiology on the basis of bone marrow examination in children from 2 months to 15 years.
            </value>
        </row>
        <row>
            <value>468</value>
            <value>246</value>
            <value>2</value>
            <value>Design</value>
            <value>Methods</value>
            <value>Observational study.</value>
        </row>
        <row>
            <value>469</value>
            <value>246</value>
            <value>3</value>
            <value>Place and duration of study</value>
            <value>Methods</value>
            <value>Department of Paediatrics, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, from
                October 2005 to March 2007.
            </value>
        </row>
        <row>
            <value>470</value>
            <value>246</value>
            <value>4</value>
            <value>Patients and methods</value>
            <value>Methods</value>
            <value>All patients aged 2 months to 15 years having pancytopenia were included. Patients beyond this age
                limits, already diagnosed cases of aplastic anemia and leukemia, clinical suspicion of genetic or
                constitutional pancytopenia, history of blood transfusion in recent past, and those not willing for
                either admission or bone marrow examination were excluded. History, physical and systemic examination
                and hematological parameters at presentation were recorded. Hematological profile included hemoglobin,
                total and differential leucocyte count, platelet count, reticulocyte count, peripheral smear and bone
                marrow aspiration/biopsy.
            </value>
        </row>
        <row>
            <value>471</value>
            <value>246</value>
            <value>5</value>
            <value>Results</value>
            <value>Results</value>
            <value>During the study period, out of the 7000 admissions in paediatric ward, 250 patients had pancytopenia
                on their peripheral blood smear (3.57%). Out of those, 230 patients were finally studied. Cause of
                pancytopenia was identified in 220 cases on the basis of bone marrow and other supportive
                investigations, while 10 cases remained undiagnosed. Most common was aplastic anemia (23.9%),
                megaloblastic anemia (13.04%), leukemia (13.05%), enteric fever (10.8%), malaria (8.69%) and sepsis
                (8.69%). Common clinical presentations were pallor, fever, petechial hemorrhages, visceromegaly and
                bleeding from nose and gastrointestinal tract.
            </value>
        </row>
        <row>
            <value>472</value>
            <value>246</value>
            <value>6</value>
            <value>Conclusion</value>
            <value>Conclusions</value>
            <value>Pancytopenia is a common occurrence in paediatric patients. Though acute leukemia and bone marrow
                failure were the usual causes of pancytopenia, infections and megaloblastic anemia are easily treatable
                and reversible.
            </value>
        </row>
        <row>
            <value>473</value>
            <value>247</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>We report a series of seven patients with reactive hemophagocytic syndrome, which was quite
                characteristic of its etiological spectrum. Infections were the leading cause, among them a case
                associated with HIV and another one with Salmonella enteritidis (a hitherto unreported association). The
                clinical findings consisted of fever, hepatomegaly, splenomegaly, lymphadenopathy, rash and
                pancytopenia. The diagnosis was carried out by bone marrow aspiration-biopsy except in two patients who
                were diagnosed at autopsy. The difficulty of the differentiation from malignant histiocytosis is
                discussed: one case of hemophagocytic syndrome due to diphenylhydantoin toxicity (the second reported
                one in the literature) was histologically undistinguishable from it. We think that, in any etiology,
                hemophagocytic syndrome is a reactive syndrome with variable intensity. The need for extensive
                microbiological investigation even in cases of histiocytosis of neoplastic appearance is emphasized.
            </value>
        </row>
        <row>
            <value>474</value>
            <value>249</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Objective: Presentation of a comprehensive body of knowledge on the role of insulin sensitizer
                myo-inositol in the treatment of polycystic ovary syndrome (PCOS).Design: Review article.Setting:
                Institute for the Care of Mother and Child, Prague.Method: An overview of publishing data.Results and
                conclusion: Polycystic ovary syndrome is the most common cause of ovarian dysfunction and anovulatory
                infertility in women. The insulin resistance occurs very frequently as a part of PCOS. This paper
                reviews the literature documenting the effectiveness of insulin sensitizer myo-inositol in the treatment
                of ovarian dysfunction, symptoms of hyperandrogenism and wide complex of symptoms of metabolic syndrome.
                Six randomized controlled trials provides evidence of a positive effect of myo-inositol to normalize
                ovarian function, improve laboratory and clinical manifestations of hyperandrogenism and insulin
                resistance. The myo-inositol treatment has been demonstrated as a safe method of PCOS
                management.Keywords: polycystic ovary syndrome, insulin resistance syndrome, insulin sensitizers,
                myoinositol, metformin.
            </value>
        </row>
        <row>
            <value>475</value>
            <value>250</value>
            <value>1</value>
            <value>Background</value>
            <value>Background</value>
            <value>Polycystic ovary syndrome (PCOS) represents a moving spectrum of hormonal to metabolic abnormalities,
                as women with the syndrome are aging. Hormonal abnormalities, anovulation, and hyperandrogenic signs
                were predominant during the early years of PCOS and fade away with the years. Metabolic abnormalities
                and insulin resistance (IR) remain throughout the PCOS life cycle; however, it is unclear as to how they
                change, as women with the syndrome are aging.
            </value>
        </row>
        <row>
            <value>476</value>
            <value>250</value>
            <value>2</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To evaluate the changes in IR and its associations with clinical, biochemical, hormonal, and
                ultrasound findings in a large cohort of women with PCOS and controls, as they are aging.
            </value>
        </row>
        <row>
            <value>477</value>
            <value>250</value>
            <value>3</value>
            <value>Design</value>
            <value>Methods</value>
            <value>A cross-sectional study was carried out to evaluate the diverse impacts of aging on IR.</value>
        </row>
        <row>
            <value>478</value>
            <value>250</value>
            <value>4</value>
            <value>Setting</value>
            <value>Methods</value>
            <value>An outpatient clinic was chosen for the study.</value>
        </row>
        <row>
            <value>479</value>
            <value>250</value>
            <value>5</value>
            <value>Participants</value>
            <value>Methods</value>
            <value>A total of 1345 women with PCOS (Rotterdam criteria) and 302 controls of Caucasian origin and Greek
                ethnicity comprised the study group.
            </value>
        </row>
        <row>
            <value>480</value>
            <value>250</value>
            <value>6</value>
            <value>Main outcome and measures</value>
            <value>Methods</value>
            <value>The impact of age on IR, as calculated using homeostasis model assessment of IR (HOMA-IR) index, and
                several PCOS characteristics were evaluated.
            </value>
        </row>
        <row>
            <value>481</value>
            <value>250</value>
            <value>7</value>
            <value>Results</value>
            <value>Results</value>
            <value></value>
        </row>
        <row>
            <value>482</value>
            <value>250</value>
            <value>8</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Aging increases IR in obese but not in lean and overweight women with PCOS. As BMI and androgens are
                positively associated with HOMA-IR and androgens decline through time, it appears that if women with
                PCOS do not become obese they may exhibit a better metabolic profile during their reproductive years.
            </value>
        </row>
        <row>
            <value>483</value>
            <value>251</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Sea urchin gangliosides have been proved to contain neuritogenic activities, which related to their
                molecular compositions. This study reports a method utilizing reversed-phase chromatography coupled to
                mass spectrometry for structure investigation and molecular species determination of the
                monosialogangliosides from sea urchin Strongylocentrotus nudus. Two types of sulfated and nonsulfated
                monosialogangliosides were isolated from the sea urchin ovary. In MS(2) spectra of both nonsulfated
                monosialoganglioside and sulfated monosialoganglioside, 2-6 linked sialic acids were identified by the
                characteristic fragments of (0,4)A2-CO2 and (0,2)A1. Fragment ions at m/z 139.1 and m/z 169.1 of
                nonsulfated monosialoganglioside might be characteristic for 8-sulfated sialic acid residue. Retention
                time of the molecules was effectively used in the characterization of unknown molecules, and molecules
                that differ in mass by only 0.04Da were easily differentiated.
            </value>
        </row>
        <row>
            <value>484</value>
            <value>252</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>485</value>
            <value>253</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>MicroRNAs are short non-coding RNAs that play an important role in the regulation of gene expression.
                Hence, microRNAs are considered as potential targets for engineering of Chinese hamster ovary (CHO)
                cells to improve recombinant protein production. Here, we analyzed and compared the microRNA expression
                patterns of high, low, and non-producing recombinant CHO cell lines expressing two structurally
                different model proteins in order to identify microRNAs that are involved in heterologous protein
                synthesis and secretion and thus might be promising targets for cell engineering to increase
                productivity. To generate reproducible and comparable data, the cells were cultivated in a bioreactor
                under steady-state conditions. Global microRNA expression analysis showed that mature microRNAs were
                predominantly upregulated in the producing cell lines compared to the non-producer. Several microRNAs
                were significantly differentially expressed between high and low producers, but none of them commonly
                for both model proteins. The identification of target messenger RNAs (mRNAs) is essential to understand
                the biological function of microRNAs. Therefore, we negatively correlated microRNA and global mRNA
                expression data and combined them with computationally predicted and experimentally validated targets.
                However, statistical analysis of the identified microRNA-mRNA interactions indicated a considerable
                false positive rate. Our results and the comparison to published data suggest that the reaction of CHO
                cells to the heterologous protein expression is strongly product- and/or clone-specific. In addition,
                this study highlights the urgent need for reliable CHO-specific microRNA target prediction tools and
                experimentally validated target databases in order to facilitate functional analysis of high-throughput
                microRNA expression data in CHO cells.
            </value>
        </row>
        <row>
            <value>486</value>
            <value>254</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Objective: Carthamus tinctorius L. (Safflower) is a member of the asteraceae family which had been
                classified as a fertility regulator in the traditional medicine. The purpose of this study was to
                investigate its possible effects on the ovarian histomorphology and the levels of female reproductive
                hormones in the mice. Materials and Methods: Sixty adult female Balb/C mice were selected and randomly
                divided into one control and three experimental groups (n= 15). The control group received only
                distilled water, while experimental groups were administered intraperitoneally C. tinctorius extract at
                doses of 0.7, 1.4, and 2.8 mg/kg/day for 49 consecutive days. In the end of experiments, blood samples
                were collected and the sera were analyzed for the levels of FSH, LH, estrogen, and progesterone. Ovarian
                tissue samples were also taken and histomorphological changes of the ovaries were examined using optical
                microscope. The quantitative results were statistically analyzed by one-way ANOVA test. Results: The
                present findings showed that treatment with different concentrations of C. tinctorius extract reduced
                the number of ovarian follicles but number of atretic follicles showed an increase. The number and size
                of the corpora lutea were not affected by extract administration. In addition, in the treated mice with
                C. tinctorius extract, the thickness of the tunica albuginea was increased but the relative and absolute
                weights of the ovaries decreased significantly. Furthermore, the blood levels of the FSH and estrogen
                were decreased in the three experimental groups compared with those of the control animals. Conclusion:
                The present findings indicated that treatment with C. tinctorius extract has detrimental effects on the
                ovarian histomorphology and female reproductive hormones therefore popular consumption of this plant
                should be reconsidered.
            </value>
        </row>
        <row>
            <value>487</value>
            <value>255</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>488</value>
            <value>256</value>
            <value>1</value>
            <value>Unlabelled</value>
            <value></value>
            <value>Zi geese (Anser anser domestica) belong to the white geese and are excellent layers with a superior
                feed-to-egg conversion ratio. Quantitative gene expression analysis, such as Real-time qRT-PCR, will
                provide a good understanding of ovarian function during egg-laying and consequently improve egg
                production. However, we still don't know what reference genes in geese, which show stable expression,
                should be used for such quantitative analysis. In order to reveal such reference genes, the stability of
                seven genes were tested in five tissues of Zi geese. Methodology/Principal Findings: The relative
                transcription levels of genes encoding hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1),
                ?-actin (ACTB), ?-tubulin (TUB), glyceraldehyde-3-phosphate-dehydrogenase (GADPH), succinate
                dehydrogenase flavoprotein (SDH), 28S rRNA (28S) and 18S rRNA (18S) have been quantified in heart,
                liver, kidney, muscle and ovary in Zi geese respectively at different developmental stages (1 d, 2, 4, 6
                and 8 months). The expression stability of these genes was analyzed using geNorm, NormFinder and
                BestKeeper software.
            </value>
        </row>
        <row>
            <value>489</value>
            <value>256</value>
            <value>2</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>The expression of 28S in heart, GAPDH in liver and ovary, ACTB in kidney and HPRT1 in muscle are the
                most stable genes as identified by the three different analysis methods. Thus, these genes are
                recommended for use as candidate reference genes to compare mRNA transcription in various developmental
                stages of geese.
            </value>
        </row>
        <row>
            <value>490</value>
            <value>257</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Ski protein is implicated in proliferation/differentiation in a variety of cells. We had previously
                reported that Ski protein is present in granulosa cells of atretic follicles, but not in preovulatory
                follicles, suggesting that Ski has a role in apoptosis of granulosa cells. The alternative fate of
                granulosa cells other than apoptosis is to differentiate to luteal cells; however, it is unknown whether
                Ski is expressed and has a role in granulosa cells undergoing luteinization. Thus, the aim of the
                present study was to locate Ski protein in the rat ovary during luteinizationto predict the possible
                role of Ski. In order to examine the expression pattern of Ski protein along with the progress of
                luteinization, follicular growth was induced by administration of equine chorionic gonadtropin to
                immature female rats, and luteinization was induced by human chorionic gonadtropin treatment to mimic
                luteinizing hormone (LH) surge. While no Ski-positive granulosa cells were present in preovulatory
                follicle, Ski protein expression was induced in response to LH surge, and was maintained after the
                formation of the corpus luteum (CL). Though Ski protein is absent in granulosa cells of preovulatory
                follicle, its mRNA (c-Ski) was expressed and the level was unchanged even after LH surge. Taken
                together, these results demonstrated that Ski protein expression is induced in granulosa cells upon
                luteinization, and suggests that its expression is regulated post-transcriptionally.
            </value>
        </row>
        <row>
            <value>491</value>
            <value>258</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>This study was conducted to improve the yield of mature oocytes from in vitro-culture of ovarian
                primary follicles by optimizing follicle retrieval from neonatal mice of different ages. Primary
                follicles of 75 to 99 ?m in diameter were collected daily from 7- to 14-day-old neonatal mice, and
                subsequently cultured in ?-MEM medium. Number of primary follicles isolated, growth of the follicle
                during in vitro-culture and maturation of intrafollicular oocytes were monitored. Overall, mean number
                of preantral follicles per animal was improved from 10.7 to 88.7 as the age of follicle donors was
                increased from 7 to 14-day-old. Number of primary follicles was increased gradually up to 11-day-old
                (35.7 follicle per an animal), then reduced to 29 in 14-day-old (p = 0.0013). More follicles retrieved
                from 10-day-old or 11-day-old females maintained their morphological normality at the end of primary
                culture than the follicles retrieved from 9-day-old. Of those cultured, primary follicles retrieved from
                11-day-old mice yielded largest larger number of early secondary follicles than the follicles retrieved
                from in the other ages (39 vs. 13 to 29%). More than 3.3-times increase (0.86 to 2.86; p&lt;0.05) in an
                average number of mature oocytes per animal was observed in the group of 11-day-old, compared with
                9-day-old. However, no difference was found in the percentage of primary follicles developing into the
                pseudoantral stage (21 to 30%; p = 0.5222) and in the percentage of oocytes mucified (32 to 39%; p =
                0.5792). In conclusion, a positive correlation between retrieval time and follicle growth was detected,
                which influences the efficiency to derive mature oocytes by follicle culture.
            </value>
        </row>
        <row>
            <value>492</value>
            <value>259</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>Case report describes successful prenatal diagnosis of skeletal dysplasia in the first trimester of
                pregnancy in a female patient affected with X-linked dominat chondrodysplasia punctata (CDPX2). Her
                first pregnancy was terminated in the second trimester due to skeletal dysplasia of the foetus. The
                diagnosis in the following pregnancy was finished in the first trimester - before the end of the 13th
                gestational week. The diagnosis was established on the basis of ultrasonographic (US) examination and
                mutation analysis of the EBP gene in the material of chorionic villus sampling (CVS).Keywords: prenatal
                diagnosis, ultrasonograpy, X-linked dominant chondrodysplasia punctata, DNA analysis.
            </value>
        </row>
        <row>
            <value>493</value>
            <value>260</value>
            <value>1</value>
            <value></value>
            <value>Unlabelled</value>
            <value>This paper is concerned with the development process of human fetuses. Though the development process
                of human fetuses still includes many unknown issues, it is known that a certain harmonious relationship
                between the organs can be observed. This knowledge is based on our intuition, but we have no theory
                which clarifies these harmonized developments. The paper aims to give a mathematical understanding of
                the notion of harmonized development through the use of dilatation, which is a measure of the departure
                from conformal mapping. The asymptotics for dilatation have been developed using certain efficient
                models of quasiconformal mapping. The proposed method of dilatation is effectively applied to the human
                fetus data.
            </value>
        </row>
        <row>
            <value>494</value>
            <value>261</value>
            <value>1</value>
            <value>Objective</value>
            <value>Objective</value>
            <value>To generate reference charts for expected fetal growth in dichorionic diamniotic (DCDA) and
                monochorionic diamniotic (MCDA) twin pregnancies and to compare these with those from singleton
                pregnancies.
            </value>
        </row>
        <row>
            <value>495</value>
            <value>261</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value>This was a retrospective study of biometric measurements from serial ultrasound examinations of twin
                pregnancies in the second and third trimesters, from 14 weeks' gestation to term, collected by nine
                hospitals over a 10-year period. The measurements obtained at each examination included head
                circumference (HC), biparietal diameter (BPD), abdominal circumference (AC) and femur length (FL), in
                each fetus. Multilevel mixed effects statistical models were used to evaluate growth in each biometric
                variable in relation to gestational age, taking account of the serial examinations and the association
                between the two fetuses in each pregnancy, with separate models constructed for DCDA and MCDA
                pregnancies.
            </value>
        </row>
        <row>
            <value>496</value>
            <value>261</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>The final dataset for analysis included a total of 9866 second- and third-trimester ultrasound
                examinations in 1802 DCDA and 323 MCDA twin pregnancies, with a median of five scans per pregnancy
                (range, 1-14). For each variable, the mean value for DCDA twins was close to the reported values in
                singletons at 20-30 weeks and showed a decrease relative to singletons beyond 30 weeks. The differences
                were greater for AC and HC, for which the mean in twins was approximately equivalent to the 30th
                percentile in singletons at 18 weeks, the 35th percentile at 25 weeks and the 30th percentile at 35
                weeks. Fetuses in MCDA twin pregnancies displayed lower mean measurements in comparison to those in DCDA
                pregnancies throughout the gestational age range considered.
            </value>
        </row>
        <row>
            <value>497</value>
            <value>261</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>Ultrasound biometry shows a small but statistically significant reduction in fetal growth in twin
                pregnancies relative to that in singletons, particularly in the third trimester, with a more marked
                difference for MCDA pregnancies.
            </value>
        </row>
        <row>
            <value>498</value>
            <value>262</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>In the pancreas of fetuses at weeks 22-40 of prenatal development (n = 111) and of newborn infants
                who died during the first week of postnatal life (n = 38) the changes were detected that were
                characterized by exocrine part hypoplasia, retardation of acinar pancreatocyte differentiation,
                connective tissue outgrowth, pancreatic (Langerhans) islet hyperplasia and hypertrophy. The results of
                the study have shown that with the increase of the total risk sum of the perinatal period pathology
                development (expressed in balls), the relative content of the insular part of the organ and the number
                of large pancreatic islets (larger than 100 microm in diameter) decreased. The morphological features
                detected in this study indirectly reflect endo-ecologically discomfortable conditions of fetus
                development within the fetoplacental unit which increase the risk of polyendocrinopathy development and
                fetal intrauterine growth retardation. These polyendocrinopathies increase further the risk of endocrine
                disturbance occurence in childhood.
            </value>
        </row>
        <row>
            <value>499</value>
            <value>263</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>This experiment was conducted to evaluate the development of T cells in intrauterine growth retarded
                (IUGR) piglets at different gestational stages, and tentatively explore the relationship between T cells
                development and the Notch signaling pathway. A total of 18 crossbred (Landrace??Large white) primiparous
                sows were mated at similar weights and estruses and euthanized at d 60, 90 and 110 of gestation with six
                replicates for each time point. One IUGR and one normal fetus were picked from each litter. The T-cell
                subsets, mRNA expression of Delta-like1, Delta-like4, Jagged1, and Notch2 genes in the thymus were
                investigated. Compared to normal piglets, CD3(+)CD4(-)CD8(+) cells in IUGR fetuses at d 90 was 0.13%
                lower (p&lt;0.05). At d 110 of gestation CD8(+) T cells in IUGR fetuses was 0.19% lower (p&lt;0.05). The
                percentage of CD8(+) T cells was 3.14% lower (p&lt;0.05) of the total T cells in IUGR pigs at d 60. The
                abundance of Notch2 and Delta-like4 mRNA at d 110 was 20.93% higher and 0.77% (p&lt;0.05) lower, and
                Delta-like1 mRNA at d 90 was 0.19% (p&lt;0.05) higher compared to normal pigs. These results suggested
                that normal fetuses had a greater proportion of T-cell subsets at earlier gestation periods, and the
                Notch signaling pathway was likely partially responsible for these differences to some degree.
            </value>
        </row>
        <row>
            <value>500</value>
            <value>264</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>During embryo implantation in pigs, the uterine endometrium undergoes dramatic morphological and
                functional changes accompanied with dynamic gene expression. Since the greatest amount of embryonic
                losses occur during this period, it is essential to understand the expression and function of genes in
                the uterine endometrium. Although many reports have studied gene expression in the uterine endometrium
                during the estrous cycle and pregnancy, the pattern of global gene expression in the uterine endometrium
                in response to the presence of a conceptus (embryo/fetus and associated extraembryonic membranes) has
                not been completely determined. To better understand the expression of pregnancy-specific genes in the
                endometrium during the implantation period, we analyzed global gene expression in the endometrium on day
                (D) 12 and D15 of pregnancy and the estrous cycle using a microarray technique in order to identify
                differentially expressed endometrial genes between D12 of pregnancy and D12 of the estrous cycle and
                between D15 of pregnancy and D15 of the estrous cycle. Results showed that the global pattern of gene
                expression varied with pregnancy status. Among 23,937 genes analyzed, 99 and 213 up-regulated genes and
                92 and 231 down-regulated genes were identified as differentially expressed genes (DEGs) in the uterine
                endometrium on D12 and D15 of pregnancy compared to D12 and D15 of the estrous cycle, respectively.
                Functional annotation clustering analysis showed that those DEGs included genes involved in immunity,
                steroidogenesis, cell-to-cell interaction, and tissue remodeling. These findings suggest that the
                implantation process regulates differential endometrial gene expression to support the establishment of
                pregnancy in pigs. Further analysis of the genes identified in this study will provide insight into the
                cellular and molecular bases of the implantation process in pigs.
            </value>
        </row>
        <row>
            <value>501</value>
            <value>265</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>One of the main goals of small, medium and large farms is to improve the reproductive performance of
                rabbit does. Stocks of lower productivity can be improved by crossing with intensive breeds. A better
                nutritional status of both foetuses and suckling kits has a positive effect on their later productivity.
                Overfeeding young females before first mating can lead to conditions of fattiness. Using restricted
                feeding or higher fibre content in the feed and changing it for a higher level ad libitum feeding about
                one week prior to first mating leads to longer lifespan and higher productive level. Intensive
                reproductive rhythm creates a negative energy balance in does : they are unable to consume enough feed
                (energy) for the nutritional requirements of foetus and lactation, and therefore lose most of their fat
                reserves. Furthermore, primiparous does also expend energy because they are still growing. Under
                intensive conditions, the 42-d reproductive rhythm (re-mating 11 days after parturition) is recommended.
                Under extensive conditions, the 18 or 25-d mating interval with 35 to 42-d weaning could be suitable. On
                small farms, natural mating is favoured; on large farms AI is commonly employed. The main advantage of
                AI is the all-in, all-out system. Hormonal (PMSG) treatment is used with AI to increase receptivity on d
                11. Frequent and high level PMSG use can lead to higher anti-PMSG antibody rates. Lower level (max. 20
                IU) and less frequent PMSG injection or non-hormonal alternative methods (short dam-litter separation,
                changing nursing method or lighting programs) are recommended for this reason.
            </value>
        </row>
        <row>
            <value>502</value>
            <value>266</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>The experiment involved observations of 2,514 Holstein-Friesian cows to determine the effects of
                environmental factors (cow's age, calving season, weight and sex of calves, housing system) and genetic
                factors on gestation length in dairy cattle and the correlation between gestation length and other
                reproductive traits (calving ease, stillbirth rates and placental expulsion). Genetic parameters were
                estimated based on the sires of calved cows (indirect effect) and the sires of live-born calves (direct
                effect). The following factors were found to contribute to prolonged gestation: increasing cow's age,
                male fetuses and growing fetus weight. Optimal gestation length was determined in the range of 275-277
                days based on calving ease and stillbirth rates. The heritability of gestation length was estimated at
                0.201-0.210 by the direct effect and 0.055-0.073 by the indirect effect. The resulting genetic
                correlations suggest that the efforts to optimize (prolong) gestation length could exert an adverse
                influence on the breeding value of bulls by increasing perinatal mortality and calving difficulty. The
                standard errors of the investigated parameters were relatively high, suggesting that any attempts to
                modify gestation length for the purpose of improving calving ease and reducing stillbirth rates should
                be introduced with great caution.
            </value>
        </row>
        <row>
            <value>503</value>
            <value>267</value>
            <value>1</value>
            <value></value>
            <value></value>
            <value>Reproduction in ruminant species is a highly complex biological process requiring a dialogue between
                the developing conceptus (embryo-fetus and associated placental membranes) and maternal uterus which
                must be established during the peri-implantation period for pregnancy recognition signaling and
                regulation of gene expression by uterine epithelial and stromal cells. The uterus provide a
                microenvironment in which molecules secreted by uterine epithelia and transported into the uterine lumen
                represent histotroph, also known as the secretome, that are required for growth and development of the
                conceptus and receptivity of the uterus to implantation by the elongating conceptus. Pregnancy
                recognition signaling as related to sustaining the functional lifespan of the corpora lutea, is required
                to sustain the functional life-span of corpora lutea for production of progesterone which is essential
                for uterine functions supportive of implantation and placentation required for successful outcomes of
                pregnancy. It is within the peri-implantation period that most embryonic deaths occur in ruminants due
                to deficiencies attributed to uterine functions or failure of the conceptus to develop appropriately,
                signal pregnancy recognition and/or undergo implantation and placentation. The endocrine status of the
                pregnant ruminant and her nutritional status are critical for successful establishment and maintenance
                of pregnancy. The challenge is to understand the complexity of key mechanisms that are characteristic of
                successful reproduction in humans and animals and to use that knowledge to enhance fertility and
                reproductive health of ruminant species in livestock enterprises.
            </value>
        </row>
        <row>
            <value>504</value>
            <value>268</value>
            <value>1</value>
            <value>Introduction</value>
            <value>Background</value>
            <value>In pregnancy physiological mechanisms activated by maternal appetite contribute to adequate energy
                intake for the mother and for the fetus. The role of maternal appetite-related peptides and their
                possible association with neonatal energy stores and glucose metabolism have not been investigated as
                yet. The aim was to investigate, during pregnancy, the association of fasting maternal appetite-related
                hormones levels [ghrelin (active), GLP1 (active), total PYY and leptin] with neonatal waist, percent
                total body fat and insulin levels at birth.
            </value>
        </row>
        <row>
            <value>505</value>
            <value>268</value>
            <value>2</value>
            <value>Methods</value>
            <value>Methods</value>
            <value></value>
        </row>
        <row>
            <value>506</value>
            <value>268</value>
            <value>3</value>
            <value>Results</value>
            <value>Results</value>
            <value>During all three trimesters maternal weight correlated positively with percent total neonatal body
                fat while during the second and third trimesters it correlated positively with birth weight. The second
                trimester maternal active ghrelin levels correlated positively with neonatal waist and were its best
                positive predictor. The third trimester maternal active ghrelin levels correlated positively with
                neonatal waist and negatively with percent total neonatal body fat, fetal cord blood insulin levels and
                were the best negative predictor of the latter. The third trimester maternal leptin levels correlated
                negatively with neonatal waist.
            </value>
        </row>
        <row>
            <value>507</value>
            <value>268</value>
            <value>4</value>
            <value>Conclusions</value>
            <value>Conclusions</value>
            <value>During pregnancy circulating maternal active ghrelin, a pro-appetite hormone, is associated with
                neonatal visceral energy storage (as expressed by neonatal waist). By inhibiting glucose-driven maternal
                insulin secretion, ghrelin might ensure adequate fasting glucose and nutrient supplies to the fetus
                while limiting overall fetal adipose tissue deposition.
            </value>
        </row>
    </table>
    <table name="article_authors">
        <column>id</column>
        <column>article_id</column>
        <column>position</column>
        <column>last_name</column>
        <column>fore_name</column>
        <column>initials</column>
        <row>
            <value>1</value>
            <value>1</value>
            <value>1</value>
            <value></value>
            <value>Zeus</value>
            <value>Z</value>
        </row>
        <row>
            <value>2</value>
            <value>1</value>
            <value>2</value>
            <value>De la Cruz</value>
            <value>Miguel A</value>
            <value>MA</value>
        </row>
        <row>
            <value>3</value>
            <value>1</value>
            <value>3</value>
            <value>Carrillo-Casas</value>
            <value>Erika Margarita</value>
            <value>EM</value>
        </row>
        <row>
            <value>4</value>
            <value>1</value>
            <value>4</value>
            <value></value>
            <value>Laura</value>
            <value>L</value>
        </row>
        <row>
            <value>5</value>
            <value>1</value>
            <value>5</value>
            <value>Zhang</value>
            <value>Yushan</value>
            <value>Y</value>
        </row>
        <row>
            <value>6</value>
            <value>1</value>
            <value>6</value>
            <value></value>
            <value>Rigoberto</value>
            <value>R</value>
        </row>
        <row>
            <value>7</value>
            <value>1</value>
            <value>7</value>
            <value>Puente</value>
            <value></value>
            <value>JL</value>
        </row>
        <row>
            <value>8</value>
            <value>1</value>
            <value>8</value>
            <value>Daaka</value>
            <value>Yehia</value>
            <value>Y</value>
        </row>
        <row>
            <value>9</value>
            <value>1</value>
            <value>9</value>
            <value></value>
            <value>Jorge A</value>
            <value>JA</value>
        </row>
        <row>
            <value>10</value>
            <value>2</value>
            <value>1</value>
            <value>Min</value>
            <value>Kyung-Jin</value>
            <value>KJ</value>
        </row>
        <row>
            <value>11</value>
            <value>2</value>
            <value>2</value>
            <value>Kim</value>
            <value>Yeun-Sun</value>
            <value>YS</value>
        </row>
        <row>
            <value>12</value>
            <value>2</value>
            <value>3</value>
            <value>Hong</value>
            <value>Jin-Hwa</value>
            <value>JH</value>
        </row>
        <row>
            <value>13</value>
            <value>2</value>
            <value>4</value>
            <value>Lee</value>
            <value>Jae-Kwan</value>
            <value>JK</value>
        </row>
        <row>
            <value>14</value>
            <value>2</value>
            <value>5</value>
            <value>Yang</value>
            <value>Dae-Sik</value>
            <value>DS</value>
        </row>
        <row>
            <value>15</value>
            <value>3</value>
            <value>1</value>
            <value>Schippers</value>
            <value>Maaike G A</value>
            <value>MG</value>
        </row>
        <row>
            <value>16</value>
            <value>3</value>
            <value>2</value>
            <value>Bol</value>
            <value>Gijsbert H</value>
            <value>GH</value>
        </row>
        <row>
            <value>17</value>
            <value>3</value>
            <value>3</value>
            <value>de Leeuw</value>
            <value>Astrid A C</value>
            <value>AA</value>
        </row>
        <row>
            <value>18</value>
            <value>3</value>
            <value>4</value>
            <value>van der Heide</value>
            <value>Uulke A</value>
            <value>UA</value>
        </row>
        <row>
            <value>19</value>
            <value>3</value>
            <value>5</value>
            <value>Raaymakers</value>
            <value>Bas W</value>
            <value>BW</value>
        </row>
        <row>
            <value>20</value>
            <value>3</value>
            <value>6</value>
            <value>Verkooijen</value>
            <value>Helena M</value>
            <value>HM</value>
        </row>
        <row>
            <value>21</value>
            <value>3</value>
            <value>7</value>
            <value></value>
            <value>Ina M</value>
            <value>IM</value>
        </row>
        <row>
            <value>22</value>
            <value>4</value>
            <value>1</value>
            <value>Mullen</value>
            <value>Rachel D</value>
            <value>RD</value>
        </row>
        <row>
            <value>23</value>
            <value>4</value>
            <value>2</value>
            <value>Behringer</value>
            <value>Richard R</value>
            <value>RR</value>
        </row>
        <row>
            <value>24</value>
            <value>8</value>
            <value>1</value>
            <value>Silva</value>
            <value>Ninoska N</value>
            <value>NN</value>
        </row>
        <row>
            <value>25</value>
            <value>8</value>
            <value>2</value>
            <value>Eng</value>
            <value>Cathy</value>
            <value>C</value>
        </row>
        <row>
            <value>26</value>
            <value>9</value>
            <value>1</value>
            <value>Obara</value>
            <value>Mikitaka</value>
            <value>M</value>
        </row>
        <row>
            <value>27</value>
            <value>9</value>
            <value>2</value>
            <value>Hatakeyama</value>
            <value>Yuko</value>
            <value>Y</value>
        </row>
        <row>
            <value>28</value>
            <value>9</value>
            <value>3</value>
            <value>Shimizu</value>
            <value>Yasushi</value>
            <value>Y</value>
        </row>
        <row>
            <value>29</value>
            <value>10</value>
            <value>1</value>
            <value>Zeng</value>
            <value>Yu</value>
            <value>Y</value>
        </row>
        <row>
            <value>30</value>
            <value>10</value>
            <value>2</value>
            <value>Wu</value>
            <value>Yunjin</value>
            <value>Y</value>
        </row>
        <row>
            <value>31</value>
            <value>10</value>
            <value>3</value>
            <value>Zhu</value>
            <value>Xuyou</value>
            <value>X</value>
        </row>
        <row>
            <value>32</value>
            <value>10</value>
            <value>4</value>
            <value>Zhang</value>
            <value>Suxia</value>
            <value>S</value>
        </row>
        <row>
            <value>33</value>
            <value>10</value>
            <value>5</value>
            <value>Gu</value>
            <value>Pan</value>
            <value>P</value>
        </row>
        <row>
            <value>34</value>
            <value>10</value>
            <value>6</value>
            <value>Zhu</value>
            <value>Hailong</value>
            <value>H</value>
        </row>
        <row>
            <value>35</value>
            <value>10</value>
            <value>7</value>
            <value>Qiu</value>
            <value>Weizhe</value>
            <value>W</value>
        </row>
        <row>
            <value>36</value>
            <value>10</value>
            <value>8</value>
            <value>Yi</value>
            <value>Xianghua</value>
            <value>X</value>
        </row>
        <row>
            <value>37</value>
            <value>11</value>
            <value>1</value>
            <value></value>
            <value>M Gomes Salles</value>
            <value>MG</value>
        </row>
        <row>
            <value>38</value>
            <value>11</value>
            <value>2</value>
            <value>Pinheiro</value>
            <value>N M</value>
            <value>NM</value>
        </row>
        <row>
            <value>39</value>
            <value>11</value>
            <value>3</value>
            <value>Carboni</value>
            <value>S de Sales Costa Moreira</value>
            <value>Sde S</value>
        </row>
        <row>
            <value>40</value>
            <value>11</value>
            <value>4</value>
            <value>Rocha</value>
            <value>L P</value>
            <value>LP</value>
        </row>
        <row>
            <value>41</value>
            <value>11</value>
            <value>5</value>
            <value>Adad</value>
            <value>S J</value>
            <value>SJ</value>
        </row>
        <row>
            <value>42</value>
            <value>11</value>
            <value>6</value>
            <value>Maluf</value>
            <value>P J</value>
            <value>PJ</value>
        </row>
        <row>
            <value>43</value>
            <value>11</value>
            <value>7</value>
            <value>Murta</value>
            <value></value>
            <value>EF</value>
        </row>
        <row>
            <value>44</value>
            <value>11</value>
            <value>8</value>
            <value>Crema</value>
            <value>V O</value>
            <value>VO</value>
        </row>
        <row>
            <value>45</value>
            <value>12</value>
            <value>1</value>
            <value>Choi</value>
            <value>Seung Do</value>
            <value>SD</value>
        </row>
        <row>
            <value>46</value>
            <value>12</value>
            <value>2</value>
            <value>Kim</value>
            <value>Tae-Hee</value>
            <value>TH</value>
        </row>
        <row>
            <value>47</value>
            <value>12</value>
            <value>3</value>
            <value>Bae</value>
            <value>Dong Han</value>
            <value>DH</value>
        </row>
        <row>
            <value>48</value>
            <value>13</value>
            <value>1</value>
            <value>Wu</value>
            <value>Yang</value>
            <value>Y</value>
        </row>
        <row>
            <value>49</value>
            <value>13</value>
            <value>2</value>
            <value>Ji</value>
            <value>Jingkai</value>
            <value>J</value>
        </row>
        <row>
            <value>50</value>
            <value>13</value>
            <value>3</value>
            <value>Yang</value>
            <value>Ran</value>
            <value>R</value>
        </row>
        <row>
            <value>51</value>
            <value>13</value>
            <value>4</value>
            <value>Zhang</value>
            <value>Xiaoqiang</value>
            <value>X</value>
        </row>
        <row>
            <value>52</value>
            <value>13</value>
            <value>5</value>
            <value>Li</value>
            <value>Yuanhui</value>
            <value>Y</value>
        </row>
        <row>
            <value>53</value>
            <value>13</value>
            <value>6</value>
            <value>Pu</value>
            <value>Yuepu</value>
            <value>Y</value>
        </row>
        <row>
            <value>54</value>
            <value>13</value>
            <value>7</value>
            <value>Li</value>
            <value>Xinsong</value>
            <value>X</value>
        </row>
        <row>
            <value>55</value>
            <value>14</value>
            <value>1</value>
            <value>Bilyk</value>
            <value>O O</value>
            <value>OO</value>
        </row>
        <row>
            <value>56</value>
            <value>14</value>
            <value>2</value>
            <value>Pande</value>
            <value>N T</value>
            <value>NT</value>
        </row>
        <row>
            <value>57</value>
            <value>14</value>
            <value>3</value>
            <value>Pejovic</value>
            <value>T</value>
            <value>T</value>
        </row>
        <row>
            <value>58</value>
            <value>14</value>
            <value>4</value>
            <value>Buchinska</value>
            <value>L G</value>
            <value>LG</value>
        </row>
        <row>
            <value>59</value>
            <value>15</value>
            <value>1</value>
            <value>Wada</value>
            <value>Tomoyuki</value>
            <value>T</value>
        </row>
        <row>
            <value>60</value>
            <value>15</value>
            <value>2</value>
            <value>Anai</value>
            <value>Hirofumi</value>
            <value>H</value>
        </row>
        <row>
            <value>61</value>
            <value>15</value>
            <value>3</value>
            <value>Shuto</value>
            <value>Takashi</value>
            <value>T</value>
        </row>
        <row>
            <value>62</value>
            <value>15</value>
            <value>4</value>
            <value>Okamoto</value>
            <value>Keitaro</value>
            <value>K</value>
        </row>
        <row>
            <value>63</value>
            <value>15</value>
            <value>5</value>
            <value>Kawano</value>
            <value>Madoka</value>
            <value>M</value>
        </row>
        <row>
            <value>64</value>
            <value>15</value>
            <value>6</value>
            <value>Kozaki</value>
            <value>Satoshi</value>
            <value>S</value>
        </row>
        <row>
            <value>65</value>
            <value>15</value>
            <value>7</value>
            <value>Hirota</value>
            <value>Jun</value>
            <value>J</value>
        </row>
        <row>
            <value>66</value>
            <value>15</value>
            <value>8</value>
            <value>Miyamoto</value>
            <value>Shinji</value>
            <value>S</value>
        </row>
        <row>
            <value>67</value>
            <value>16</value>
            <value>1</value>
            <value>Meirovitz</value>
            <value>Mihai</value>
            <value>M</value>
        </row>
        <row>
            <value>68</value>
            <value>16</value>
            <value>2</value>
            <value>Gatt</value>
            <value>Dvir</value>
            <value>D</value>
        </row>
        <row>
            <value>69</value>
            <value>16</value>
            <value>3</value>
            <value>Dreiher</value>
            <value>Jacob</value>
            <value>J</value>
        </row>
        <row>
            <value>70</value>
            <value>16</value>
            <value>4</value>
            <value>Shaco-Levy</value>
            <value>Ruthy</value>
            <value>R</value>
        </row>
        <row>
            <value>71</value>
            <value>17</value>
            <value>1</value>
            <value>Izmaj??owicz</value>
            <value>Barbara</value>
            <value>B</value>
        </row>
        <row>
            <value>72</value>
            <value>17</value>
            <value>2</value>
            <value>Kornafel</value>
            <value>Jan</value>
            <value>J</value>
        </row>
        <row>
            <value>73</value>
            <value>17</value>
            <value>3</value>
            <value>B??aszczyk</value>
            <value>Jerzy</value>
            <value>J</value>
        </row>
        <row>
            <value>74</value>
            <value>18</value>
            <value>1</value>
            <value>Isoda</value>
            <value>Takuro</value>
            <value>T</value>
        </row>
        <row>
            <value>75</value>
            <value>18</value>
            <value>2</value>
            <value>BaBa</value>
            <value>Shingo</value>
            <value>S</value>
        </row>
        <row>
            <value>76</value>
            <value>18</value>
            <value>3</value>
            <value>Maruoka</value>
            <value>Yasuhiro</value>
            <value>Y</value>
        </row>
        <row>
            <value>77</value>
            <value>18</value>
            <value>4</value>
            <value>Kitamura</value>
            <value>Yoshiyuki</value>
            <value>Y</value>
        </row>
        <row>
            <value>78</value>
            <value>18</value>
            <value>5</value>
            <value>Nishie</value>
            <value>Akihiro</value>
            <value>A</value>
        </row>
        <row>
            <value>79</value>
            <value>18</value>
            <value>6</value>
            <value>Sasaki</value>
            <value>Masayuki</value>
            <value>M</value>
        </row>
        <row>
            <value>80</value>
            <value>18</value>
            <value>7</value>
            <value>Honda</value>
            <value>Hiroshi</value>
            <value>H</value>
        </row>
        <row>
            <value>81</value>
            <value>19</value>
            <value>1</value>
            <value>Koay</value>
            <value>M H E</value>
            <value>MH</value>
        </row>
        <row>
            <value>82</value>
            <value>19</value>
            <value>2</value>
            <value>Crook</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>83</value>
            <value>19</value>
            <value>3</value>
            <value>Stewart</value>
            <value>C J R</value>
            <value>CJ</value>
        </row>
        <row>
            <value>84</value>
            <value>20</value>
            <value>1</value>
            <value>Reich</value>
            <value>Olaf</value>
            <value>O</value>
        </row>
        <row>
            <value>85</value>
            <value>20</value>
            <value>2</value>
            <value>Fritsch</value>
            <value>Helga</value>
            <value>H</value>
        </row>
        <row>
            <value>86</value>
            <value>21</value>
            <value>1</value>
            <value>Sun</value>
            <value>Shengming</value>
            <value>S</value>
        </row>
        <row>
            <value>87</value>
            <value>21</value>
            <value>2</value>
            <value>Gu</value>
            <value>Zhimin</value>
            <value>Z</value>
        </row>
        <row>
            <value>88</value>
            <value>21</value>
            <value>3</value>
            <value>Fu</value>
            <value>Hongtuo</value>
            <value>H</value>
        </row>
        <row>
            <value>89</value>
            <value>21</value>
            <value>4</value>
            <value>Zhu</value>
            <value>Jian</value>
            <value>J</value>
        </row>
        <row>
            <value>90</value>
            <value>21</value>
            <value>5</value>
            <value>Xuan</value>
            <value>Fujun</value>
            <value>F</value>
        </row>
        <row>
            <value>91</value>
            <value>21</value>
            <value>6</value>
            <value>Ge</value>
            <value>Xianping</value>
            <value>X</value>
        </row>
        <row>
            <value>92</value>
            <value>22</value>
            <value>1</value>
            <value>Best</value>
            <value>Sarah A</value>
            <value>SA</value>
        </row>
        <row>
            <value>93</value>
            <value>22</value>
            <value>2</value>
            <value>Hutt</value>
            <value>Karla J</value>
            <value>KJ</value>
        </row>
        <row>
            <value>94</value>
            <value>22</value>
            <value>3</value>
            <value>Fu</value>
            <value>Nai Yang</value>
            <value>NY</value>
        </row>
        <row>
            <value>95</value>
            <value>22</value>
            <value>4</value>
            <value>Vaillant</value>
            <value></value>
            <value>F</value>
        </row>
        <row>
            <value>96</value>
            <value>22</value>
            <value>5</value>
            <value>Liew</value>
            <value>Seng H</value>
            <value>SH</value>
        </row>
        <row>
            <value>97</value>
            <value>22</value>
            <value>6</value>
            <value>Hartley</value>
            <value>Lynne</value>
            <value>L</value>
        </row>
        <row>
            <value>98</value>
            <value>22</value>
            <value>7</value>
            <value>Scott</value>
            <value>Clare L</value>
            <value>CL</value>
        </row>
        <row>
            <value>99</value>
            <value>22</value>
            <value>8</value>
            <value>Lindeman</value>
            <value>Geoffrey J</value>
            <value>GJ</value>
        </row>
        <row>
            <value>100</value>
            <value>22</value>
            <value>9</value>
            <value>Visvader</value>
            <value>Jane E</value>
            <value>JE</value>
        </row>
        <row>
            <value>101</value>
            <value>23</value>
            <value>1</value>
            <value>Sanches</value>
            <value>Gustavo S</value>
            <value>GS</value>
        </row>
        <row>
            <value>102</value>
            <value>23</value>
            <value>2</value>
            <value></value>
            <value>Marcos R</value>
            <value>MR</value>
        </row>
        <row>
            <value>103</value>
            <value>23</value>
            <value>3</value>
            <value>do Prado</value>
            <value>Angelo P</value>
            <value>AP</value>
        </row>
        <row>
            <value>104</value>
            <value>23</value>
            <value>4</value>
            <value>Allegretti</value>
            <value>Silmara M</value>
            <value>SM</value>
        </row>
        <row>
            <value>105</value>
            <value>23</value>
            <value>5</value>
            <value>Remedio</value>
            <value>Rafael N</value>
            <value>RN</value>
        </row>
        <row>
            <value>106</value>
            <value>23</value>
            <value>6</value>
            <value>Nunes</value>
            <value>Pablo H</value>
            <value>PH</value>
        </row>
        <row>
            <value>107</value>
            <value>23</value>
            <value>7</value>
            <value>Machado</value>
            <value>Rosangela Z</value>
            <value>RZ</value>
        </row>
        <row>
            <value>108</value>
            <value>23</value>
            <value>8</value>
            <value>Bechara</value>
            <value></value>
            <value>GH</value>
        </row>
        <row>
            <value>109</value>
            <value>23</value>
            <value>9</value>
            <value>Camargo-Mathias</value>
            <value>Maria I</value>
            <value>MI</value>
        </row>
        <row>
            <value>110</value>
            <value>24</value>
            <value>1</value>
            <value>Prizant</value>
            <value>Hen</value>
            <value>H</value>
        </row>
        <row>
            <value>111</value>
            <value>24</value>
            <value>2</value>
            <value>Gleicher</value>
            <value>Norbert</value>
            <value>N</value>
        </row>
        <row>
            <value>112</value>
            <value>24</value>
            <value>3</value>
            <value>Sen</value>
            <value>Aritro</value>
            <value>A</value>
        </row>
        <row>
            <value>113</value>
            <value>25</value>
            <value>1</value>
            <value>Anderson</value>
            <value>Richard A</value>
            <value>RA</value>
        </row>
        <row>
            <value>114</value>
            <value>26</value>
            <value>1</value>
            <value>Cengiz</value>
            <value></value>
            <value>H</value>
        </row>
        <row>
            <value>115</value>
            <value>26</value>
            <value>2</value>
            <value>Ekin</value>
            <value>Murat</value>
            <value>M</value>
        </row>
        <row>
            <value>116</value>
            <value>26</value>
            <value>3</value>
            <value>Dagdeviren</value>
            <value>Hediye</value>
            <value>H</value>
        </row>
        <row>
            <value>117</value>
            <value>26</value>
            <value>4</value>
            <value>Yildiz</value>
            <value></value>
            <value>S</value>
        </row>
        <row>
            <value>118</value>
            <value>26</value>
            <value>5</value>
            <value>Kaya</value>
            <value>Cihan</value>
            <value>C</value>
        </row>
        <row>
            <value>119</value>
            <value>26</value>
            <value>6</value>
            <value>Kanawati</value>
            <value>Ammar</value>
            <value>A</value>
        </row>
        <row>
            <value>120</value>
            <value>27</value>
            <value>1</value>
            <value>Shomali</value>
            <value>Tahoora</value>
            <value>T</value>
        </row>
        <row>
            <value>121</value>
            <value>27</value>
            <value>2</value>
            <value>Mosleh</value>
            <value>Najmeh</value>
            <value>N</value>
        </row>
        <row>
            <value>122</value>
            <value>27</value>
            <value>3</value>
            <value>Kamalpour</value>
            <value>Mohammad</value>
            <value>M</value>
        </row>
        <row>
            <value>123</value>
            <value>28</value>
            <value>1</value>
            <value>Rees</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>124</value>
            <value>28</value>
            <value>2</value>
            <value>Coulson</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>125</value>
            <value>28</value>
            <value>3</value>
            <value>Dunstan</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>126</value>
            <value>28</value>
            <value>4</value>
            <value>Evans</value>
            <value>W D</value>
            <value>WD</value>
        </row>
        <row>
            <value>127</value>
            <value>28</value>
            <value>5</value>
            <value>Blundell</value>
            <value>H L</value>
            <value>HL</value>
        </row>
        <row>
            <value>128</value>
            <value>28</value>
            <value>6</value>
            <value>Luzio</value>
            <value>S D</value>
            <value>SD</value>
        </row>
        <row>
            <value>129</value>
            <value>28</value>
            <value>7</value>
            <value>Dunseath</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>130</value>
            <value>28</value>
            <value>8</value>
            <value>Halcox</value>
            <value>J P</value>
            <value>JP</value>
        </row>
        <row>
            <value>131</value>
            <value>28</value>
            <value>9</value>
            <value>Fraser</value>
            <value>A G</value>
            <value>AG</value>
        </row>
        <row>
            <value>132</value>
            <value>28</value>
            <value>10</value>
            <value>Rees</value>
            <value>D A</value>
            <value>DA</value>
        </row>
        <row>
            <value>133</value>
            <value>29</value>
            <value>1</value>
            <value>Wang</value>
            <value>Wenxiang</value>
            <value>W</value>
        </row>
        <row>
            <value>134</value>
            <value>29</value>
            <value>2</value>
            <value>Sun</value>
            <value>Yan</value>
            <value>Y</value>
        </row>
        <row>
            <value>135</value>
            <value>29</value>
            <value>3</value>
            <value>Liu</value>
            <value>Jin</value>
            <value>J</value>
        </row>
        <row>
            <value>136</value>
            <value>29</value>
            <value>4</value>
            <value>Li</value>
            <value>Yuchen</value>
            <value>Y</value>
        </row>
        <row>
            <value>137</value>
            <value>29</value>
            <value>5</value>
            <value>Li</value>
            <value>Hong</value>
            <value>H</value>
        </row>
        <row>
            <value>138</value>
            <value>29</value>
            <value>6</value>
            <value>Xiao</value>
            <value>Shihua</value>
            <value>S</value>
        </row>
        <row>
            <value>139</value>
            <value>29</value>
            <value>7</value>
            <value>Weng</value>
            <value>Shaozheng</value>
            <value>S</value>
        </row>
        <row>
            <value>140</value>
            <value>29</value>
            <value>8</value>
            <value>Zhang</value>
            <value>Wenchang</value>
            <value>W</value>
        </row>
        <row>
            <value>141</value>
            <value>30</value>
            <value>1</value>
            <value>Nishimura</value>
            <value>Toshiya</value>
            <value>T</value>
        </row>
        <row>
            <value>142</value>
            <value>30</value>
            <value>2</value>
            <value>Tanaka</value>
            <value>Minoru</value>
            <value>M</value>
        </row>
        <row>
            <value>143</value>
            <value>31</value>
            <value>1</value>
            <value>Clajus</value>
            <value>Carolina</value>
            <value>C</value>
        </row>
        <row>
            <value>144</value>
            <value>31</value>
            <value>2</value>
            <value>Blasi</value>
            <value>Francesco</value>
            <value>F</value>
        </row>
        <row>
            <value>145</value>
            <value>31</value>
            <value>3</value>
            <value>Welte</value>
            <value>Tobias</value>
            <value>T</value>
        </row>
        <row>
            <value>146</value>
            <value>31</value>
            <value>4</value>
            <value>Greer</value>
            <value>Mark</value>
            <value>M</value>
        </row>
        <row>
            <value>147</value>
            <value>31</value>
            <value>5</value>
            <value>Fuehner</value>
            <value>Thomas</value>
            <value>T</value>
        </row>
        <row>
            <value>148</value>
            <value>31</value>
            <value>6</value>
            <value>Mantero</value>
            <value>Marco</value>
            <value>M</value>
        </row>
        <row>
            <value>149</value>
            <value>32</value>
            <value>1</value>
            <value>Xie</value>
            <value>Shangyun</value>
            <value>S</value>
        </row>
        <row>
            <value>150</value>
            <value>32</value>
            <value>2</value>
            <value>Wu</value>
            <value>Xiao</value>
            <value>X</value>
        </row>
        <row>
            <value>151</value>
            <value>32</value>
            <value>3</value>
            <value>Zhang</value>
            <value>Guoliang</value>
            <value>G</value>
        </row>
        <row>
            <value>152</value>
            <value>32</value>
            <value>4</value>
            <value>Xu</value>
            <value>Ke</value>
            <value>K</value>
        </row>
        <row>
            <value>153</value>
            <value>32</value>
            <value>5</value>
            <value>Bian</value>
            <value>Xiaoshan</value>
            <value>X</value>
        </row>
        <row>
            <value>154</value>
            <value>32</value>
            <value>6</value>
            <value>Zhang</value>
            <value>Shufang</value>
            <value>S</value>
        </row>
        <row>
            <value>155</value>
            <value>32</value>
            <value>7</value>
            <value>Ye</value>
            <value>Yongqing</value>
            <value>Y</value>
        </row>
        <row>
            <value>156</value>
            <value>33</value>
            <value>1</value>
            <value>Marcus</value>
            <value>Pamela M</value>
            <value>PM</value>
        </row>
        <row>
            <value>157</value>
            <value>33</value>
            <value>2</value>
            <value>Ogden</value>
            <value>Sheryl L</value>
            <value>SL</value>
        </row>
        <row>
            <value>158</value>
            <value>33</value>
            <value>3</value>
            <value>Gren</value>
            <value>Lisa H</value>
            <value>LH</value>
        </row>
        <row>
            <value>159</value>
            <value>33</value>
            <value>4</value>
            <value>Childs</value>
            <value>Jeffery C</value>
            <value>JC</value>
        </row>
        <row>
            <value>160</value>
            <value>33</value>
            <value>5</value>
            <value>Pretzel</value>
            <value>Shannon M</value>
            <value>SM</value>
        </row>
        <row>
            <value>161</value>
            <value>33</value>
            <value>6</value>
            <value>Lamerato</value>
            <value>Lois E</value>
            <value>LE</value>
        </row>
        <row>
            <value>162</value>
            <value>33</value>
            <value>7</value>
            <value>Walsh</value>
            <value>Kayo</value>
            <value>K</value>
        </row>
        <row>
            <value>163</value>
            <value>33</value>
            <value>8</value>
            <value>Rozjabek</value>
            <value>Heather M</value>
            <value>HM</value>
        </row>
        <row>
            <value>164</value>
            <value>33</value>
            <value>9</value>
            <value>Mabie</value>
            <value>Jerome</value>
            <value>J</value>
        </row>
        <row>
            <value>165</value>
            <value>33</value>
            <value>10</value>
            <value>Thomas</value>
            <value>Brett</value>
            <value>B</value>
        </row>
        <row>
            <value>166</value>
            <value>33</value>
            <value>11</value>
            <value>Riley</value>
            <value>Tom</value>
            <value>T</value>
        </row>
        <row>
            <value>167</value>
            <value>34</value>
            <value>1</value>
            <value>Rocca</value>
            <value>Joseph Della</value>
            <value>JD</value>
        </row>
        <row>
            <value>168</value>
            <value>34</value>
            <value>2</value>
            <value>Werner</value>
            <value>Michael E</value>
            <value>ME</value>
        </row>
        <row>
            <value>169</value>
            <value>34</value>
            <value>3</value>
            <value>Kramer</value>
            <value>Stephanie A</value>
            <value>SA</value>
        </row>
        <row>
            <value>170</value>
            <value>34</value>
            <value>4</value>
            <value>Huxford-Phillips</value>
            <value>Rachel C</value>
            <value>RC</value>
        </row>
        <row>
            <value>171</value>
            <value>34</value>
            <value>5</value>
            <value>Sukumar</value>
            <value>Rohit</value>
            <value>R</value>
        </row>
        <row>
            <value>172</value>
            <value>34</value>
            <value>6</value>
            <value>Cummings</value>
            <value>Natalie D</value>
            <value>ND</value>
        </row>
        <row>
            <value>173</value>
            <value>34</value>
            <value>7</value>
            <value>Vivero-Escoto</value>
            <value>Juan L</value>
            <value>JL</value>
        </row>
        <row>
            <value>174</value>
            <value>34</value>
            <value>8</value>
            <value>Wang</value>
            <value>Andrew Z</value>
            <value>AZ</value>
        </row>
        <row>
            <value>175</value>
            <value>34</value>
            <value>9</value>
            <value>Lin</value>
            <value>Wenbin</value>
            <value>W</value>
        </row>
        <row>
            <value>176</value>
            <value>35</value>
            <value>1</value>
            <value>Zheng</value>
            <value>Junfeng</value>
            <value>J</value>
        </row>
        <row>
            <value>177</value>
            <value>35</value>
            <value>2</value>
            <value>Chen</value>
            <value>Yan</value>
            <value>Y</value>
        </row>
        <row>
            <value>178</value>
            <value>35</value>
            <value>3</value>
            <value>Deng</value>
            <value>Fengyuan</value>
            <value>F</value>
        </row>
        <row>
            <value>179</value>
            <value>35</value>
            <value>4</value>
            <value>Huang</value>
            <value>Renliang</value>
            <value>R</value>
        </row>
        <row>
            <value>180</value>
            <value>35</value>
            <value>5</value>
            <value>Petersen</value>
            <value>Frank</value>
            <value>F</value>
        </row>
        <row>
            <value>181</value>
            <value>35</value>
            <value>6</value>
            <value>Ibrahim</value>
            <value>Saleh</value>
            <value>S</value>
        </row>
        <row>
            <value>182</value>
            <value>35</value>
            <value>7</value>
            <value>Yu</value>
            <value>Xinhua</value>
            <value>X</value>
        </row>
        <row>
            <value>183</value>
            <value>36</value>
            <value>1</value>
            <value>Johnson</value>
            <value>Larry</value>
            <value>L</value>
        </row>
        <row>
            <value>184</value>
            <value>36</value>
            <value>2</value>
            <value>Gaab</value>
            <value>Erin M</value>
            <value>EM</value>
        </row>
        <row>
            <value>185</value>
            <value>36</value>
            <value>3</value>
            <value>Sanchez</value>
            <value>Javier</value>
            <value>J</value>
        </row>
        <row>
            <value>186</value>
            <value>36</value>
            <value>4</value>
            <value>Bui</value>
            <value>Phuong Q</value>
            <value>PQ</value>
        </row>
        <row>
            <value>187</value>
            <value>36</value>
            <value>5</value>
            <value>Nobile</value>
            <value>Clarissa J</value>
            <value>CJ</value>
        </row>
        <row>
            <value>188</value>
            <value>36</value>
            <value>6</value>
            <value>Hoyer</value>
            <value>Katrina K</value>
            <value>KK</value>
        </row>
        <row>
            <value>189</value>
            <value>36</value>
            <value>7</value>
            <value>Peterson</value>
            <value>Michael W</value>
            <value>MW</value>
        </row>
        <row>
            <value>190</value>
            <value>36</value>
            <value>8</value>
            <value>Ojcius</value>
            <value>David M</value>
            <value>DM</value>
        </row>
        <row>
            <value>191</value>
            <value>37</value>
            <value>1</value>
            <value>Ozturk</value>
            <value>Ozge</value>
            <value>O</value>
        </row>
        <row>
            <value>192</value>
            <value>37</value>
            <value>2</value>
            <value>Koksal</value>
            <value>Deniz</value>
            <value>D</value>
        </row>
        <row>
            <value>193</value>
            <value>37</value>
            <value>3</value>
            <value>Emri</value>
            <value>Salih</value>
            <value>S</value>
        </row>
        <row>
            <value>194</value>
            <value>38</value>
            <value>1</value>
            <value>Kurishima</value>
            <value>Koichi</value>
            <value>K</value>
        </row>
        <row>
            <value>195</value>
            <value>38</value>
            <value>2</value>
            <value>Kagohashi</value>
            <value>Katsunori</value>
            <value>K</value>
        </row>
        <row>
            <value>196</value>
            <value>38</value>
            <value>3</value>
            <value>Satoh</value>
            <value>Hiroaki</value>
            <value>H</value>
        </row>
        <row>
            <value>197</value>
            <value>39</value>
            <value>1</value>
            <value>Kurishima</value>
            <value>Koichi</value>
            <value>K</value>
        </row>
        <row>
            <value>198</value>
            <value>39</value>
            <value>2</value>
            <value>Kagohashi</value>
            <value>Katsunori</value>
            <value>K</value>
        </row>
        <row>
            <value>199</value>
            <value>39</value>
            <value>3</value>
            <value>Taguchi</value>
            <value>Shijima</value>
            <value>S</value>
        </row>
        <row>
            <value>200</value>
            <value>39</value>
            <value>4</value>
            <value>Satoh</value>
            <value>Hiroaki</value>
            <value>H</value>
        </row>
        <row>
            <value>201</value>
            <value>40</value>
            <value>1</value>
            <value>Sayiner</value>
            <value>Abdullah</value>
            <value>A</value>
        </row>
        <row>
            <value>202</value>
            <value>40</value>
            <value>2</value>
            <value>Mirici</value>
            <value>Arzu</value>
            <value>A</value>
        </row>
        <row>
            <value>203</value>
            <value>40</value>
            <value>3</value>
            <value>Cilli</value>
            <value>Aykut</value>
            <value>A</value>
        </row>
        <row>
            <value>204</value>
            <value>40</value>
            <value>4</value>
            <value>Uzaslan</value>
            <value>Esra</value>
            <value>E</value>
        </row>
        <row>
            <value>205</value>
            <value>40</value>
            <value>5</value>
            <value>Akova</value>
            <value>Murat</value>
            <value>M</value>
        </row>
        <row>
            <value>206</value>
            <value>40</value>
            <value>6</value>
            <value>Ozhan</value>
            <value>Mustafa Hikmet</value>
            <value>MH</value>
        </row>
        <row>
            <value>207</value>
            <value>40</value>
            <value>7</value>
            <value>Kilinc</value>
            <value>O??uz</value>
            <value>O</value>
        </row>
        <row>
            <value>208</value>
            <value>41</value>
            <value>1</value>
            <value>Jayasena</value>
            <value>Channa N</value>
            <value>CN</value>
        </row>
        <row>
            <value>209</value>
            <value>41</value>
            <value>2</value>
            <value>Abbara</value>
            <value>Ali</value>
            <value>A</value>
        </row>
        <row>
            <value>210</value>
            <value>41</value>
            <value>3</value>
            <value>Comninos</value>
            <value>Alexander N</value>
            <value>AN</value>
        </row>
        <row>
            <value>211</value>
            <value>41</value>
            <value>4</value>
            <value>Nijher</value>
            <value>Gurjinder M K</value>
            <value>GM</value>
        </row>
        <row>
            <value>212</value>
            <value>41</value>
            <value>5</value>
            <value>Christopoulos</value>
            <value>Georgios</value>
            <value>G</value>
        </row>
        <row>
            <value>213</value>
            <value>41</value>
            <value>6</value>
            <value>Narayanaswamy</value>
            <value>Shakunthala</value>
            <value>S</value>
        </row>
        <row>
            <value>214</value>
            <value>41</value>
            <value>7</value>
            <value>Izzi-Engbeaya</value>
            <value>Chioma</value>
            <value>C</value>
        </row>
        <row>
            <value>215</value>
            <value>41</value>
            <value>8</value>
            <value>Sridharan</value>
            <value>Mathini</value>
            <value>M</value>
        </row>
        <row>
            <value>216</value>
            <value>41</value>
            <value>9</value>
            <value>Mason</value>
            <value>Alexina J</value>
            <value>AJ</value>
        </row>
        <row>
            <value>217</value>
            <value>41</value>
            <value>10</value>
            <value>Warwick</value>
            <value>Jane</value>
            <value>J</value>
        </row>
        <row>
            <value>218</value>
            <value>41</value>
            <value>11</value>
            <value>Ashby</value>
            <value>Deborah</value>
            <value>D</value>
        </row>
        <row>
            <value>219</value>
            <value>41</value>
            <value>12</value>
            <value>Ghatei</value>
            <value>Mohammad A</value>
            <value>MA</value>
        </row>
        <row>
            <value>220</value>
            <value>41</value>
            <value>13</value>
            <value>Bloom</value>
            <value>Stephen R</value>
            <value>SR</value>
        </row>
        <row>
            <value>221</value>
            <value>41</value>
            <value>14</value>
            <value>Carby</value>
            <value>Anna</value>
            <value>A</value>
        </row>
        <row>
            <value>222</value>
            <value>41</value>
            <value>15</value>
            <value>Trew</value>
            <value>Geoffrey H</value>
            <value>GH</value>
        </row>
        <row>
            <value>223</value>
            <value>41</value>
            <value>16</value>
            <value>Dhillo</value>
            <value>Waljit S</value>
            <value>WS</value>
        </row>
        <row>
            <value>224</value>
            <value>42</value>
            <value>1</value>
            <value>Kavitha</value>
            <value>K T</value>
            <value>KT</value>
        </row>
        <row>
            <value>225</value>
            <value>42</value>
            <value>2</value>
            <value>Latha</value>
            <value>B R</value>
            <value>BR</value>
        </row>
        <row>
            <value>226</value>
            <value>42</value>
            <value>3</value>
            <value>Bino Sundar</value>
            <value>S T</value>
            <value>ST</value>
        </row>
        <row>
            <value>227</value>
            <value>42</value>
            <value>4</value>
            <value>Jayathangaraj</value>
            <value>M G</value>
            <value>MG</value>
        </row>
        <row>
            <value>228</value>
            <value>42</value>
            <value>5</value>
            <value>Senthil Kumar</value>
            <value>K</value>
            <value>K</value>
        </row>
        <row>
            <value>229</value>
            <value>42</value>
            <value>6</value>
            <value>Sridhar</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>230</value>
            <value>42</value>
            <value>7</value>
            <value>Abdul Basith</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>231</value>
            <value>43</value>
            <value>1</value>
            <value>Huang</value>
            <value>Qiang</value>
            <value>Q</value>
        </row>
        <row>
            <value>232</value>
            <value>43</value>
            <value>2</value>
            <value>Zhang</value>
            <value>Miao</value>
            <value>M</value>
        </row>
        <row>
            <value>233</value>
            <value>43</value>
            <value>3</value>
            <value>Zhai</value>
            <value>Ren-You</value>
            <value>RY</value>
        </row>
        <row>
            <value>234</value>
            <value>44</value>
            <value>1</value>
            <value>Semczuk</value>
            <value>Andrzej</value>
            <value>A</value>
        </row>
        <row>
            <value>235</value>
            <value>44</value>
            <value>2</value>
            <value>Ignatov</value>
            <value>Atanas</value>
            <value>A</value>
        </row>
        <row>
            <value>236</value>
            <value>44</value>
            <value>3</value>
            <value>Obrzut</value>
            <value>Bogdan</value>
            <value>B</value>
        </row>
        <row>
            <value>237</value>
            <value>44</value>
            <value>4</value>
            <value>Reventos</value>
            <value>Jaume</value>
            <value>J</value>
        </row>
        <row>
            <value>238</value>
            <value>44</value>
            <value>5</value>
            <value>Rechberger</value>
            <value>Tomasz</value>
            <value>T</value>
        </row>
        <row>
            <value>239</value>
            <value>45</value>
            <value>1</value>
            <value>Buza</value>
            <value>Natalia</value>
            <value>N</value>
        </row>
        <row>
            <value>240</value>
            <value>45</value>
            <value>2</value>
            <value>Xu</value>
            <value>Fang</value>
            <value>F</value>
        </row>
        <row>
            <value>241</value>
            <value>45</value>
            <value>3</value>
            <value>Wu</value>
            <value>Weiqing</value>
            <value>W</value>
        </row>
        <row>
            <value>242</value>
            <value>45</value>
            <value>4</value>
            <value>Carr</value>
            <value>Ryan J</value>
            <value>RJ</value>
        </row>
        <row>
            <value>243</value>
            <value>45</value>
            <value>5</value>
            <value>Li</value>
            <value>Peining</value>
            <value>P</value>
        </row>
        <row>
            <value>244</value>
            <value>45</value>
            <value>6</value>
            <value>Hui</value>
            <value>Pei</value>
            <value>P</value>
        </row>
        <row>
            <value>245</value>
            <value>46</value>
            <value>1</value>
            <value>Kim</value>
            <value>Joo-Yeon</value>
            <value>JY</value>
        </row>
        <row>
            <value>246</value>
            <value>46</value>
            <value>2</value>
            <value>Park</value>
            <value>Do Youn</value>
            <value>do Y</value>
        </row>
        <row>
            <value>247</value>
            <value>46</value>
            <value>3</value>
            <value>Kim</value>
            <value>Gwang Ha</value>
            <value>GH</value>
        </row>
        <row>
            <value>248</value>
            <value>46</value>
            <value>4</value>
            <value>Jeon</value>
            <value>Tae-Yong</value>
            <value>TY</value>
        </row>
        <row>
            <value>249</value>
            <value>46</value>
            <value>5</value>
            <value>Lauwers</value>
            <value>Gregory Y</value>
            <value>GY</value>
        </row>
        <row>
            <value>250</value>
            <value>47</value>
            <value>1</value>
            <value>Sugawara</value>
            <value>Tae</value>
            <value>T</value>
        </row>
        <row>
            <value>251</value>
            <value>47</value>
            <value>2</value>
            <value>Ogawa</value>
            <value>Masaki</value>
            <value>M</value>
        </row>
        <row>
            <value>252</value>
            <value>47</value>
            <value>3</value>
            <value>Tanaka</value>
            <value>Toshinobu</value>
            <value>T</value>
        </row>
        <row>
            <value>253</value>
            <value>48</value>
            <value>1</value>
            <value>Hiradate</value>
            <value>Yuuki</value>
            <value>Y</value>
        </row>
        <row>
            <value>254</value>
            <value>48</value>
            <value>2</value>
            <value>Inoue</value>
            <value>Hiroki</value>
            <value>H</value>
        </row>
        <row>
            <value>255</value>
            <value>48</value>
            <value>3</value>
            <value>Kobayashi</value>
            <value>Norio</value>
            <value>N</value>
        </row>
        <row>
            <value>256</value>
            <value>48</value>
            <value>4</value>
            <value>Shirakata</value>
            <value>Yoshiki</value>
            <value>Y</value>
        </row>
        <row>
            <value>257</value>
            <value>48</value>
            <value>5</value>
            <value>Suzuki</value>
            <value>Yutaka</value>
            <value>Y</value>
        </row>
        <row>
            <value>258</value>
            <value>48</value>
            <value>6</value>
            <value>Gotoh</value>
            <value>Aina</value>
            <value>A</value>
        </row>
        <row>
            <value>259</value>
            <value>48</value>
            <value>7</value>
            <value>Roh</value>
            <value>Sang-Gun</value>
            <value>SG</value>
        </row>
        <row>
            <value>260</value>
            <value>48</value>
            <value>8</value>
            <value>Uchida</value>
            <value>Takafumi</value>
            <value>T</value>
        </row>
        <row>
            <value>261</value>
            <value>48</value>
            <value>9</value>
            <value>Katoh</value>
            <value>Kazuo</value>
            <value>K</value>
        </row>
        <row>
            <value>262</value>
            <value>48</value>
            <value>10</value>
            <value>Yoshida</value>
            <value>Manabu</value>
            <value>M</value>
        </row>
        <row>
            <value>263</value>
            <value>48</value>
            <value>11</value>
            <value>Sato</value>
            <value>Eimei</value>
            <value>E</value>
        </row>
        <row>
            <value>264</value>
            <value>48</value>
            <value>12</value>
            <value>Tanemura</value>
            <value>Kentaro</value>
            <value>K</value>
        </row>
        <row>
            <value>265</value>
            <value>49</value>
            <value>1</value>
            <value>Gu</value>
            <value>Angel</value>
            <value>A</value>
        </row>
        <row>
            <value>266</value>
            <value>49</value>
            <value>2</value>
            <value>Torres-Coronado</value>
            <value>Monica</value>
            <value>M</value>
        </row>
        <row>
            <value>267</value>
            <value>49</value>
            <value>3</value>
            <value>Tran</value>
            <value>Chy-Anh</value>
            <value>CA</value>
        </row>
        <row>
            <value>268</value>
            <value>49</value>
            <value>4</value>
            <value>Vu</value>
            <value>Hieu</value>
            <value>H</value>
        </row>
        <row>
            <value>269</value>
            <value>49</value>
            <value>5</value>
            <value>Epps</value>
            <value>Elizabeth W</value>
            <value>EW</value>
        </row>
        <row>
            <value>270</value>
            <value>49</value>
            <value>6</value>
            <value>Chung</value>
            <value>Janet</value>
            <value>J</value>
        </row>
        <row>
            <value>271</value>
            <value>49</value>
            <value>7</value>
            <value>Gonzalez</value>
            <value>Nancy</value>
            <value>N</value>
        </row>
        <row>
            <value>272</value>
            <value>49</value>
            <value>8</value>
            <value>Blanchard</value>
            <value>Suzette</value>
            <value>S</value>
        </row>
        <row>
            <value>273</value>
            <value>49</value>
            <value>9</value>
            <value>DiGiusto</value>
            <value>David L</value>
            <value>DL</value>
        </row>
        <row>
            <value>274</value>
            <value>50</value>
            <value>1</value>
            <value>Amsellem</value>
            <value></value>
            <value>V</value>
        </row>
        <row>
            <value>275</value>
            <value>50</value>
            <value>2</value>
            <value>Lipskaia</value>
            <value>Larissa</value>
            <value>L</value>
        </row>
        <row>
            <value>276</value>
            <value>50</value>
            <value>3</value>
            <value>Abid</value>
            <value>Shariq</value>
            <value>S</value>
        </row>
        <row>
            <value>277</value>
            <value>50</value>
            <value>4</value>
            <value>Poupel</value>
            <value>Lucie</value>
            <value>L</value>
        </row>
        <row>
            <value>278</value>
            <value>50</value>
            <value>5</value>
            <value>Houssaini</value>
            <value>Amal</value>
            <value>A</value>
        </row>
        <row>
            <value>279</value>
            <value>50</value>
            <value>6</value>
            <value>Quarck</value>
            <value>Rozenn</value>
            <value>R</value>
        </row>
        <row>
            <value>280</value>
            <value>50</value>
            <value>7</value>
            <value>Marcos</value>
            <value>Elisabeth</value>
            <value>E</value>
        </row>
        <row>
            <value>281</value>
            <value>50</value>
            <value>8</value>
            <value>Mouraret</value>
            <value>Nathalie</value>
            <value>N</value>
        </row>
        <row>
            <value>282</value>
            <value>50</value>
            <value>9</value>
            <value>Parpaleix</value>
            <value></value>
            <value>A</value>
        </row>
        <row>
            <value>283</value>
            <value>50</value>
            <value>10</value>
            <value>Bobe</value>
            <value></value>
            <value>R</value>
        </row>
        <row>
            <value>284</value>
            <value>50</value>
            <value>11</value>
            <value>Gary-Bobo</value>
            <value>Guillaume</value>
            <value>G</value>
        </row>
        <row>
            <value>285</value>
            <value>50</value>
            <value>12</value>
            <value>Saker</value>
            <value>Mirna</value>
            <value>M</value>
        </row>
        <row>
            <value>286</value>
            <value>50</value>
            <value>13</value>
            <value></value>
            <value>Jean-Luc</value>
            <value>JL</value>
        </row>
        <row>
            <value>287</value>
            <value>50</value>
            <value>14</value>
            <value>Gladwin</value>
            <value>Mark T</value>
            <value>MT</value>
        </row>
        <row>
            <value>288</value>
            <value>50</value>
            <value>15</value>
            <value>Norris</value>
            <value>Karen A</value>
            <value>KA</value>
        </row>
        <row>
            <value>289</value>
            <value>50</value>
            <value>16</value>
            <value>Delcroix</value>
            <value>Marion</value>
            <value>M</value>
        </row>
        <row>
            <value>290</value>
            <value>50</value>
            <value>17</value>
            <value></value>
            <value>Christophe</value>
            <value>C</value>
        </row>
        <row>
            <value>291</value>
            <value>50</value>
            <value>18</value>
            <value>Adnot</value>
            <value>Serge</value>
            <value>S</value>
        </row>
        <row>
            <value>292</value>
            <value>51</value>
            <value>1</value>
            <value>Adewumi</value>
            <value>A Adediran</value>
            <value>AA</value>
        </row>
        <row>
            <value>293</value>
            <value>51</value>
            <value>2</value>
            <value>Titilope</value>
            <value>A Adeyemo</value>
            <value>AA</value>
        </row>
        <row>
            <value>294</value>
            <value>51</value>
            <value>3</value>
            <value>Osamuedemen</value>
            <value>V Aghayere</value>
            <value>VA</value>
        </row>
        <row>
            <value>295</value>
            <value>51</value>
            <value>4</value>
            <value>Vincent</value>
            <value>O Osunkalu</value>
            <value>OO</value>
        </row>
        <row>
            <value>296</value>
            <value>51</value>
            <value>5</value>
            <value>Akinsegun</value>
            <value>A Akinbami</value>
            <value>AA</value>
        </row>
        <row>
            <value>297</value>
            <value>51</value>
            <value>6</value>
            <value>Dapus</value>
            <value>O Damulak</value>
            <value>OD</value>
        </row>
        <row>
            <value>298</value>
            <value>51</value>
            <value>7</value>
            <value>Sulaimon</value>
            <value>A Akanmu</value>
            <value>AA</value>
        </row>
        <row>
            <value>299</value>
            <value>52</value>
            <value>1</value>
            <value>Gadwalkar</value>
            <value>Srikant R</value>
            <value>SR</value>
        </row>
        <row>
            <value>300</value>
            <value>52</value>
            <value>2</value>
            <value>Deepa</value>
            <value>D V</value>
            <value>DV</value>
        </row>
        <row>
            <value>301</value>
            <value>52</value>
            <value>3</value>
            <value>Katageri</value>
            <value>Anand</value>
            <value>A</value>
        </row>
        <row>
            <value>302</value>
            <value>52</value>
            <value>4</value>
            <value>Murthy</value>
            <value>P Rama</value>
            <value>PR</value>
        </row>
        <row>
            <value>303</value>
            <value>52</value>
            <value>5</value>
            <value>Dhar</value>
            <value>Ravi</value>
            <value>R</value>
        </row>
        <row>
            <value>304</value>
            <value>53</value>
            <value>1</value>
            <value>Mohanram</value>
            <value>Venkatramanan</value>
            <value>V</value>
        </row>
        <row>
            <value>305</value>
            <value>53</value>
            <value>2</value>
            <value>Demberg</value>
            <value>Thorsten</value>
            <value>T</value>
        </row>
        <row>
            <value>306</value>
            <value>53</value>
            <value>3</value>
            <value>Tuero</value>
            <value>Iskra</value>
            <value>I</value>
        </row>
        <row>
            <value>307</value>
            <value>53</value>
            <value>4</value>
            <value>Vargas-Inchaustegui</value>
            <value>Diego</value>
            <value>D</value>
        </row>
        <row>
            <value>308</value>
            <value>53</value>
            <value>5</value>
            <value>Pavlakis</value>
            <value>George N</value>
            <value>GN</value>
        </row>
        <row>
            <value>309</value>
            <value>53</value>
            <value>6</value>
            <value>Felber</value>
            <value>Barbara K</value>
            <value>BK</value>
        </row>
        <row>
            <value>310</value>
            <value>53</value>
            <value>7</value>
            <value>Robert-Guroff</value>
            <value>Marjorie</value>
            <value>M</value>
        </row>
        <row>
            <value>311</value>
            <value>54</value>
            <value>1</value>
            <value>Colombo</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>312</value>
            <value>54</value>
            <value>2</value>
            <value>Strasser</value>
            <value>S I</value>
            <value>SI</value>
        </row>
        <row>
            <value>313</value>
            <value>54</value>
            <value>3</value>
            <value>Moreno</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>314</value>
            <value>54</value>
            <value>4</value>
            <value>Ferreira</value>
            <value>P A</value>
            <value>PA</value>
        </row>
        <row>
            <value>315</value>
            <value>54</value>
            <value>5</value>
            <value>Urbanek</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>316</value>
            <value>54</value>
            <value>6</value>
            <value></value>
            <value>I</value>
            <value>I</value>
        </row>
        <row>
            <value>317</value>
            <value>54</value>
            <value>7</value>
            <value>Abdurakmonov</value>
            <value>D</value>
            <value>D</value>
        </row>
        <row>
            <value>318</value>
            <value>54</value>
            <value>8</value>
            <value>Streinu-Cercel</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>319</value>
            <value>54</value>
            <value>9</value>
            <value>Verheyen</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>320</value>
            <value>54</value>
            <value>10</value>
            <value>Iraqi</value>
            <value>W</value>
            <value>W</value>
        </row>
        <row>
            <value>321</value>
            <value>54</value>
            <value>11</value>
            <value>DeMasi</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>322</value>
            <value>54</value>
            <value>12</value>
            <value>Hill</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>323</value>
            <value>54</value>
            <value>13</value>
            <value>Lonjon-Domanec</value>
            <value>I</value>
            <value>I</value>
        </row>
        <row>
            <value>324</value>
            <value>54</value>
            <value>14</value>
            <value>Wedemeyer</value>
            <value>H</value>
            <value>H</value>
        </row>
        <row>
            <value>325</value>
            <value>55</value>
            <value>1</value>
            <value>Savkovic</value>
            <value>Borislav</value>
            <value>B</value>
        </row>
        <row>
            <value>326</value>
            <value>55</value>
            <value>2</value>
            <value>Nichols</value>
            <value>James</value>
            <value>J</value>
        </row>
        <row>
            <value>327</value>
            <value>55</value>
            <value>3</value>
            <value>Birkett</value>
            <value>Donald</value>
            <value>D</value>
        </row>
        <row>
            <value>328</value>
            <value>55</value>
            <value>4</value>
            <value>Applegate</value>
            <value>Tanya</value>
            <value>T</value>
        </row>
        <row>
            <value>329</value>
            <value>55</value>
            <value>5</value>
            <value>Ledger</value>
            <value>Scott</value>
            <value>S</value>
        </row>
        <row>
            <value>330</value>
            <value>55</value>
            <value>6</value>
            <value>Symonds</value>
            <value>Geoff</value>
            <value>G</value>
        </row>
        <row>
            <value>331</value>
            <value>55</value>
            <value>7</value>
            <value>Murray</value>
            <value>John M</value>
            <value>JM</value>
        </row>
        <row>
            <value>332</value>
            <value>56</value>
            <value>1</value>
            <value>Carbonaro</value>
            <value>Denise A</value>
            <value>DA</value>
        </row>
        <row>
            <value>333</value>
            <value>56</value>
            <value>2</value>
            <value>Tarantal</value>
            <value>Alice F</value>
            <value>AF</value>
        </row>
        <row>
            <value>334</value>
            <value>56</value>
            <value>3</value>
            <value>Lee</value>
            <value>C Chang I</value>
            <value>CC</value>
        </row>
        <row>
            <value>335</value>
            <value>56</value>
            <value>4</value>
            <value>Martinez</value>
            <value>Michele</value>
            <value>M</value>
        </row>
        <row>
            <value>336</value>
            <value>56</value>
            <value>5</value>
            <value>Jin</value>
            <value>Xiangyang</value>
            <value>X</value>
        </row>
        <row>
            <value>337</value>
            <value>56</value>
            <value>6</value>
            <value>Wang</value>
            <value>Xiaoyan</value>
            <value>X</value>
        </row>
        <row>
            <value>338</value>
            <value>56</value>
            <value>7</value>
            <value>Hardee</value>
            <value>Cinnamon L</value>
            <value>CL</value>
        </row>
        <row>
            <value>339</value>
            <value>56</value>
            <value>8</value>
            <value>Geiger</value>
            <value>Sabine</value>
            <value>S</value>
        </row>
        <row>
            <value>340</value>
            <value>56</value>
            <value>9</value>
            <value>Kahl</value>
            <value>Christoph A</value>
            <value>CA</value>
        </row>
        <row>
            <value>341</value>
            <value>56</value>
            <value>10</value>
            <value>Kohn</value>
            <value>Donald B</value>
            <value>DB</value>
        </row>
        <row>
            <value>342</value>
            <value>57</value>
            <value>1</value>
            <value>Kenway-Lynch</value>
            <value>Carys S</value>
            <value>CS</value>
        </row>
        <row>
            <value>343</value>
            <value>57</value>
            <value>2</value>
            <value>Das</value>
            <value>Arpita</value>
            <value>A</value>
        </row>
        <row>
            <value>344</value>
            <value>57</value>
            <value>3</value>
            <value>Lackner</value>
            <value>Andrew A</value>
            <value>AA</value>
        </row>
        <row>
            <value>345</value>
            <value>57</value>
            <value>4</value>
            <value>Pahar</value>
            <value>Bapi</value>
            <value>B</value>
        </row>
        <row>
            <value>346</value>
            <value>58</value>
            <value>1</value>
            <value>Vargas-Inchaustegui</value>
            <value>Diego A</value>
            <value>DA</value>
        </row>
        <row>
            <value>347</value>
            <value>58</value>
            <value>2</value>
            <value>Tuero</value>
            <value>Iskra</value>
            <value>I</value>
        </row>
        <row>
            <value>348</value>
            <value>58</value>
            <value>3</value>
            <value>Mohanram</value>
            <value>Venkatramanan</value>
            <value>V</value>
        </row>
        <row>
            <value>349</value>
            <value>58</value>
            <value>4</value>
            <value>Musich</value>
            <value>Thomas</value>
            <value>T</value>
        </row>
        <row>
            <value>350</value>
            <value>58</value>
            <value>5</value>
            <value>Pegu</value>
            <value>Poonam</value>
            <value>P</value>
        </row>
        <row>
            <value>351</value>
            <value>58</value>
            <value>6</value>
            <value>Valentin</value>
            <value>Antonio</value>
            <value>A</value>
        </row>
        <row>
            <value>352</value>
            <value>58</value>
            <value>7</value>
            <value>Sui</value>
            <value>Yongjun</value>
            <value>Y</value>
        </row>
        <row>
            <value>353</value>
            <value>58</value>
            <value>8</value>
            <value>Rosati</value>
            <value>Margherita</value>
            <value>M</value>
        </row>
        <row>
            <value>354</value>
            <value>58</value>
            <value>9</value>
            <value>Bear</value>
            <value>Jenifer</value>
            <value>J</value>
        </row>
        <row>
            <value>355</value>
            <value>58</value>
            <value>10</value>
            <value>Venzon</value>
            <value>David J</value>
            <value>DJ</value>
        </row>
        <row>
            <value>356</value>
            <value>58</value>
            <value>11</value>
            <value>Kulkarni</value>
            <value>Viraj</value>
            <value>V</value>
        </row>
        <row>
            <value>357</value>
            <value>58</value>
            <value>12</value>
            <value>Alicea</value>
            <value>Candido</value>
            <value>C</value>
        </row>
        <row>
            <value>358</value>
            <value>58</value>
            <value>13</value>
            <value>Pilkington</value>
            <value>Guy R</value>
            <value>GR</value>
        </row>
        <row>
            <value>359</value>
            <value>58</value>
            <value>14</value>
            <value>Liyanage</value>
            <value>Namal P M</value>
            <value>NP</value>
        </row>
        <row>
            <value>360</value>
            <value>58</value>
            <value>15</value>
            <value>Demberg</value>
            <value>Thorsten</value>
            <value>T</value>
        </row>
        <row>
            <value>361</value>
            <value>58</value>
            <value>16</value>
            <value>Gordon</value>
            <value>Shari N</value>
            <value>SN</value>
        </row>
        <row>
            <value>362</value>
            <value>58</value>
            <value>17</value>
            <value>Wang</value>
            <value>Yichuan</value>
            <value>Y</value>
        </row>
        <row>
            <value>363</value>
            <value>58</value>
            <value>18</value>
            <value>Hogg</value>
            <value>Alison E</value>
            <value>AE</value>
        </row>
        <row>
            <value>364</value>
            <value>58</value>
            <value>19</value>
            <value>Frey</value>
            <value>Blake</value>
            <value>B</value>
        </row>
        <row>
            <value>365</value>
            <value>58</value>
            <value>20</value>
            <value>Patterson</value>
            <value>L Jean</value>
            <value>LJ</value>
        </row>
        <row>
            <value>366</value>
            <value>58</value>
            <value>21</value>
            <value>DiPasquale</value>
            <value>Janet</value>
            <value>J</value>
        </row>
        <row>
            <value>367</value>
            <value>58</value>
            <value>22</value>
            <value>Montefiori</value>
            <value>David C</value>
            <value>DC</value>
        </row>
        <row>
            <value>368</value>
            <value>58</value>
            <value>23</value>
            <value>Sardesai</value>
            <value>Niranjan Y</value>
            <value>NY</value>
        </row>
        <row>
            <value>369</value>
            <value>58</value>
            <value>24</value>
            <value>Reed</value>
            <value>Steven G</value>
            <value>SG</value>
        </row>
        <row>
            <value>370</value>
            <value>58</value>
            <value>25</value>
            <value>Berzofsky</value>
            <value>Jay A</value>
            <value>JA</value>
        </row>
        <row>
            <value>371</value>
            <value>58</value>
            <value>26</value>
            <value>Franchini</value>
            <value>Genoveffa</value>
            <value>G</value>
        </row>
        <row>
            <value>372</value>
            <value>58</value>
            <value>27</value>
            <value>Felber</value>
            <value>Barbara K</value>
            <value>BK</value>
        </row>
        <row>
            <value>373</value>
            <value>58</value>
            <value>28</value>
            <value>Pavlakis</value>
            <value>George N</value>
            <value>GN</value>
        </row>
        <row>
            <value>374</value>
            <value>58</value>
            <value>29</value>
            <value>Robert-Guroff</value>
            <value>Marjorie</value>
            <value>M</value>
        </row>
        <row>
            <value>375</value>
            <value>59</value>
            <value>1</value>
            <value>Coumailleau</value>
            <value>Pascal</value>
            <value>P</value>
        </row>
        <row>
            <value>376</value>
            <value>59</value>
            <value>2</value>
            <value>Pellegrini</value>
            <value>Elisabeth</value>
            <value>E</value>
        </row>
        <row>
            <value>377</value>
            <value>59</value>
            <value>3</value>
            <value>Adrio</value>
            <value></value>
            <value>F</value>
        </row>
        <row>
            <value>378</value>
            <value>59</value>
            <value>4</value>
            <value>Diotel</value>
            <value>Nicolas</value>
            <value>N</value>
        </row>
        <row>
            <value>379</value>
            <value>59</value>
            <value>5</value>
            <value>Cano-Nicolau</value>
            <value>Joel</value>
            <value>J</value>
        </row>
        <row>
            <value>380</value>
            <value>59</value>
            <value>6</value>
            <value>Nasri</value>
            <value>Ahmed</value>
            <value>A</value>
        </row>
        <row>
            <value>381</value>
            <value>59</value>
            <value>7</value>
            <value>Vaillant</value>
            <value>Colette</value>
            <value>C</value>
        </row>
        <row>
            <value>382</value>
            <value>59</value>
            <value>8</value>
            <value>Kah</value>
            <value>Olivier</value>
            <value>O</value>
        </row>
        <row>
            <value>383</value>
            <value>60</value>
            <value>1</value>
            <value>Ooi</value>
            <value>Yasuhiro</value>
            <value>Y</value>
        </row>
        <row>
            <value>384</value>
            <value>60</value>
            <value>2</value>
            <value>Inui-Yamamoto</value>
            <value>Chizuko</value>
            <value>C</value>
        </row>
        <row>
            <value>385</value>
            <value>60</value>
            <value>3</value>
            <value>Suzuki</value>
            <value>Takashi</value>
            <value>T</value>
        </row>
        <row>
            <value>386</value>
            <value>60</value>
            <value>4</value>
            <value>Nakadate</value>
            <value>Hiromichi</value>
            <value>H</value>
        </row>
        <row>
            <value>387</value>
            <value>60</value>
            <value>5</value>
            <value>Nagase</value>
            <value>Yoshitaka</value>
            <value>Y</value>
        </row>
        <row>
            <value>388</value>
            <value>60</value>
            <value>6</value>
            <value>Seiyama</value>
            <value>Akitoshi</value>
            <value>A</value>
        </row>
        <row>
            <value>389</value>
            <value>60</value>
            <value>7</value>
            <value>Yoshioka</value>
            <value>Yoshichika</value>
            <value>Y</value>
        </row>
        <row>
            <value>390</value>
            <value>60</value>
            <value>8</value>
            <value>Seki</value>
            <value>Junji</value>
            <value>J</value>
        </row>
        <row>
            <value>391</value>
            <value>61</value>
            <value>1</value>
            <value>Daschil</value>
            <value>Nina</value>
            <value>N</value>
        </row>
        <row>
            <value>392</value>
            <value>61</value>
            <value>2</value>
            <value>Humpel</value>
            <value>Christian</value>
            <value>C</value>
        </row>
        <row>
            <value>393</value>
            <value>62</value>
            <value>1</value>
            <value>Tseng</value>
            <value>To-Jung</value>
            <value>TJ</value>
        </row>
        <row>
            <value>394</value>
            <value>62</value>
            <value>2</value>
            <value>Hsieh</value>
            <value>Yu-Lin</value>
            <value>YL</value>
        </row>
        <row>
            <value>395</value>
            <value>62</value>
            <value>3</value>
            <value>Ko</value>
            <value>Miau-Hwa</value>
            <value>MH</value>
        </row>
        <row>
            <value>396</value>
            <value>62</value>
            <value>4</value>
            <value>Hsieh</value>
            <value>Sung-Tsang</value>
            <value>ST</value>
        </row>
        <row>
            <value>397</value>
            <value>63</value>
            <value>1</value>
            <value>Khailova</value>
            <value>Ljudmila S</value>
            <value>LS</value>
        </row>
        <row>
            <value>398</value>
            <value>63</value>
            <value>2</value>
            <value>Silachev</value>
            <value>Denis N</value>
            <value>DN</value>
        </row>
        <row>
            <value>399</value>
            <value>63</value>
            <value>3</value>
            <value>Rokitskaya</value>
            <value>Tatyana I</value>
            <value>TI</value>
        </row>
        <row>
            <value>400</value>
            <value>63</value>
            <value>4</value>
            <value>Avetisyan</value>
            <value>Armine V</value>
            <value>AV</value>
        </row>
        <row>
            <value>401</value>
            <value>63</value>
            <value>5</value>
            <value>Lyamsaev</value>
            <value>Konstantin G</value>
            <value>KG</value>
        </row>
        <row>
            <value>402</value>
            <value>63</value>
            <value>6</value>
            <value>Severina</value>
            <value>Inna I</value>
            <value>II</value>
        </row>
        <row>
            <value>403</value>
            <value>63</value>
            <value>7</value>
            <value>Il'yasova</value>
            <value>Tatyana M</value>
            <value>TM</value>
        </row>
        <row>
            <value>404</value>
            <value>63</value>
            <value>8</value>
            <value>Gulyaev</value>
            <value>Mikhail V</value>
            <value>MV</value>
        </row>
        <row>
            <value>405</value>
            <value>63</value>
            <value>9</value>
            <value>Dedukhova</value>
            <value>Vera I</value>
            <value>VI</value>
        </row>
        <row>
            <value>406</value>
            <value>63</value>
            <value>10</value>
            <value>Trendeleva</value>
            <value>Tatyana A</value>
            <value>TA</value>
        </row>
        <row>
            <value>407</value>
            <value>63</value>
            <value>11</value>
            <value>Plotnikov</value>
            <value>Egor Y</value>
            <value>EY</value>
        </row>
        <row>
            <value>408</value>
            <value>63</value>
            <value>12</value>
            <value>Zvyagilskaya</value>
            <value>Renata A</value>
            <value>RA</value>
        </row>
        <row>
            <value>409</value>
            <value>63</value>
            <value>13</value>
            <value>Chernyak</value>
            <value>Boris V</value>
            <value>BV</value>
        </row>
        <row>
            <value>410</value>
            <value>63</value>
            <value>14</value>
            <value>Zorov</value>
            <value>Dmitry B</value>
            <value>DB</value>
        </row>
        <row>
            <value>411</value>
            <value>63</value>
            <value>15</value>
            <value>Antonenko</value>
            <value>Yuri N</value>
            <value>YN</value>
        </row>
        <row>
            <value>412</value>
            <value>63</value>
            <value>16</value>
            <value>Skulachev</value>
            <value>Vladimir P</value>
            <value>VP</value>
        </row>
        <row>
            <value>413</value>
            <value>64</value>
            <value>1</value>
            <value>Haigh</value>
            <value>Cathryn L</value>
            <value>CL</value>
        </row>
        <row>
            <value>414</value>
            <value>64</value>
            <value>2</value>
            <value>Lawson</value>
            <value>Victoria A</value>
            <value>VA</value>
        </row>
        <row>
            <value>415</value>
            <value>64</value>
            <value>3</value>
            <value>Drew</value>
            <value>Simon C</value>
            <value>SC</value>
        </row>
        <row>
            <value>416</value>
            <value>65</value>
            <value>1</value>
            <value>Danovitch</value>
            <value>Judith H</value>
            <value>JH</value>
        </row>
        <row>
            <value>417</value>
            <value>65</value>
            <value>2</value>
            <value>Mills</value>
            <value>Candice M</value>
            <value>CM</value>
        </row>
        <row>
            <value>418</value>
            <value>66</value>
            <value>1</value>
            <value>Olszewski</value>
            <value>Pawel K</value>
            <value>PK</value>
        </row>
        <row>
            <value>419</value>
            <value>66</value>
            <value>2</value>
            <value>Ulrich</value>
            <value>Christine</value>
            <value>C</value>
        </row>
        <row>
            <value>420</value>
            <value>66</value>
            <value>3</value>
            <value>Ling</value>
            <value>Nicholas</value>
            <value>N</value>
        </row>
        <row>
            <value>421</value>
            <value>66</value>
            <value>4</value>
            <value>Allen</value>
            <value>Kerry</value>
            <value>K</value>
        </row>
        <row>
            <value>422</value>
            <value>66</value>
            <value>5</value>
            <value>Levine</value>
            <value>Allen S</value>
            <value>AS</value>
        </row>
        <row>
            <value>423</value>
            <value>67</value>
            <value>1</value>
            <value>Ewald</value>
            <value>Arne</value>
            <value>A</value>
        </row>
        <row>
            <value>424</value>
            <value>67</value>
            <value>2</value>
            <value>Avarvand</value>
            <value>Forooz Shahbazi</value>
            <value>FS</value>
        </row>
        <row>
            <value>425</value>
            <value>67</value>
            <value>3</value>
            <value>Nolte</value>
            <value>Guido</value>
            <value>G</value>
        </row>
        <row>
            <value>426</value>
            <value>68</value>
            <value>1</value>
            <value>Hulme</value>
            <value>Oliver J</value>
            <value>OJ</value>
        </row>
        <row>
            <value>427</value>
            <value>68</value>
            <value>2</value>
            <value>Skov</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>428</value>
            <value>68</value>
            <value>3</value>
            <value>Chadwick</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>429</value>
            <value>68</value>
            <value>4</value>
            <value>Siebner</value>
            <value>Hartwig R</value>
            <value>HR</value>
        </row>
        <row>
            <value>430</value>
            <value>68</value>
            <value>5</value>
            <value></value>
            <value>Thomas Z</value>
            <value>TZ</value>
        </row>
        <row>
            <value>431</value>
            <value>69</value>
            <value>1</value>
            <value>Jones</value>
            <value>Rena R</value>
            <value>RR</value>
        </row>
        <row>
            <value>432</value>
            <value>69</value>
            <value>2</value>
            <value>Yu</value>
            <value>Chu-Ling</value>
            <value>CL</value>
        </row>
        <row>
            <value>433</value>
            <value>69</value>
            <value>3</value>
            <value>Nuckols</value>
            <value>John R</value>
            <value>JR</value>
        </row>
        <row>
            <value>434</value>
            <value>69</value>
            <value>4</value>
            <value>Cerhan</value>
            <value>James R</value>
            <value>JR</value>
        </row>
        <row>
            <value>435</value>
            <value>69</value>
            <value>5</value>
            <value>Airola</value>
            <value>Matthew</value>
            <value>M</value>
        </row>
        <row>
            <value>436</value>
            <value>69</value>
            <value>6</value>
            <value>Ross</value>
            <value>Julie A</value>
            <value>JA</value>
        </row>
        <row>
            <value>437</value>
            <value>69</value>
            <value>7</value>
            <value>Robien</value>
            <value>Kim</value>
            <value>K</value>
        </row>
        <row>
            <value>438</value>
            <value>69</value>
            <value>8</value>
            <value>Ward</value>
            <value>Mary H</value>
            <value>MH</value>
        </row>
        <row>
            <value>439</value>
            <value>70</value>
            <value>1</value>
            <value>Portugal</value>
            <value>Rodrigo Doyle</value>
            <value>RD</value>
        </row>
        <row>
            <value>440</value>
            <value>70</value>
            <value>2</value>
            <value>Loureiro</value>
            <value>Monique M</value>
            <value>MM</value>
        </row>
        <row>
            <value>441</value>
            <value>70</value>
            <value>3</value>
            <value>Garnica</value>
            <value></value>
            <value>M</value>
        </row>
        <row>
            <value>442</value>
            <value>70</value>
            <value>4</value>
            <value>Pulcheri</value>
            <value>Wolmar</value>
            <value>W</value>
        </row>
        <row>
            <value>443</value>
            <value>70</value>
            <value>5</value>
            <value>Nucci</value>
            <value></value>
            <value>M</value>
        </row>
        <row>
            <value>444</value>
            <value>71</value>
            <value>1</value>
            <value>Cheng</value>
            <value>Jihua</value>
            <value>J</value>
        </row>
        <row>
            <value>445</value>
            <value>71</value>
            <value>2</value>
            <value>Talamo</value>
            <value>Giampaolo</value>
            <value>G</value>
        </row>
        <row>
            <value>446</value>
            <value>71</value>
            <value>3</value>
            <value>Malysz</value>
            <value>Jozef</value>
            <value>J</value>
        </row>
        <row>
            <value>447</value>
            <value>71</value>
            <value>4</value>
            <value>Ochmann</value>
            <value>Marlene</value>
            <value>M</value>
        </row>
        <row>
            <value>448</value>
            <value>71</value>
            <value>5</value>
            <value>Lamy</value>
            <value>Thierry</value>
            <value>T</value>
        </row>
        <row>
            <value>449</value>
            <value>71</value>
            <value>6</value>
            <value>Loughran</value>
            <value>Thomas P</value>
            <value>TP</value>
        </row>
        <row>
            <value>450</value>
            <value>72</value>
            <value>1</value>
            <value></value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>451</value>
            <value>72</value>
            <value>2</value>
            <value></value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>452</value>
            <value>72</value>
            <value>3</value>
            <value>Jarauta</value>
            <value>V</value>
            <value>V</value>
        </row>
        <row>
            <value>453</value>
            <value>72</value>
            <value>4</value>
            <value></value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>454</value>
            <value>72</value>
            <value>5</value>
            <value>Azaceta</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>455</value>
            <value>72</value>
            <value>6</value>
            <value>Palomera</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>456</value>
            <value>72</value>
            <value>7</value>
            <value>Pardo</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>457</value>
            <value>72</value>
            <value>8</value>
            <value>Anel</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>458</value>
            <value>72</value>
            <value>9</value>
            <value>Marzo</value>
            <value>I</value>
            <value>I</value>
        </row>
        <row>
            <value>459</value>
            <value>72</value>
            <value>10</value>
            <value>Naval</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>460</value>
            <value>73</value>
            <value>1</value>
            <value>Noell</value>
            <value>Claire M</value>
            <value>CM</value>
        </row>
        <row>
            <value>461</value>
            <value>73</value>
            <value>2</value>
            <value>Rose</value>
            <value>Elizabeth</value>
            <value>E</value>
        </row>
        <row>
            <value>462</value>
            <value>73</value>
            <value>3</value>
            <value>Nesbitt</value>
            <value>Lee T</value>
            <value>LT</value>
        </row>
        <row>
            <value>463</value>
            <value>74</value>
            <value>1</value>
            <value>Tagde</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>464</value>
            <value>74</value>
            <value>2</value>
            <value>Singh</value>
            <value>H</value>
            <value>H</value>
        </row>
        <row>
            <value>465</value>
            <value>74</value>
            <value>3</value>
            <value>Kang</value>
            <value>M H</value>
            <value>MH</value>
        </row>
        <row>
            <value>466</value>
            <value>74</value>
            <value>4</value>
            <value>Reynolds</value>
            <value>C P</value>
            <value>CP</value>
        </row>
        <row>
            <value>467</value>
            <value>75</value>
            <value>1</value>
            <value>D'Huyvetter</value>
            <value>Matthias</value>
            <value>M</value>
        </row>
        <row>
            <value>468</value>
            <value>75</value>
            <value>2</value>
            <value>Xavier</value>
            <value>Catarina</value>
            <value>C</value>
        </row>
        <row>
            <value>469</value>
            <value>75</value>
            <value>3</value>
            <value>Caveliers</value>
            <value>Vicky</value>
            <value>V</value>
        </row>
        <row>
            <value>470</value>
            <value>75</value>
            <value>4</value>
            <value>Lahoutte</value>
            <value>Tony</value>
            <value>T</value>
        </row>
        <row>
            <value>471</value>
            <value>75</value>
            <value>5</value>
            <value>Muyldermans</value>
            <value>Serge</value>
            <value>S</value>
        </row>
        <row>
            <value>472</value>
            <value>75</value>
            <value>6</value>
            <value>Devoogdt</value>
            <value>Nick</value>
            <value>N</value>
        </row>
        <row>
            <value>473</value>
            <value>76</value>
            <value>1</value>
            <value>Derlin</value>
            <value>Thorsten</value>
            <value>T</value>
        </row>
        <row>
            <value>474</value>
            <value>76</value>
            <value>2</value>
            <value>Bannas</value>
            <value>Peter</value>
            <value>P</value>
        </row>
        <row>
            <value>475</value>
            <value>77</value>
            <value>1</value>
            <value>Davran</value>
            <value>Ramazan</value>
            <value>R</value>
        </row>
        <row>
            <value>476</value>
            <value>77</value>
            <value>2</value>
            <value>Helvaci</value>
            <value>Mehmet Rami</value>
            <value>MR</value>
        </row>
        <row>
            <value>477</value>
            <value>77</value>
            <value>3</value>
            <value>Davarci</value>
            <value>Mursel</value>
            <value>M</value>
        </row>
        <row>
            <value>478</value>
            <value>78</value>
            <value>1</value>
            <value>Uz</value>
            <value>Burak</value>
            <value>B</value>
        </row>
        <row>
            <value>479</value>
            <value>78</value>
            <value>2</value>
            <value>Tatonyan</value>
            <value>Suzin ??atal</value>
            <value>S??</value>
        </row>
        <row>
            <value>480</value>
            <value>78</value>
            <value>3</value>
            <value>Sayito??lu</value>
            <value></value>
            <value>M</value>
        </row>
        <row>
            <value>481</value>
            <value>78</value>
            <value>4</value>
            <value>Erbilgin</value>
            <value></value>
            <value>Y</value>
        </row>
        <row>
            <value>482</value>
            <value>78</value>
            <value>5</value>
            <value>Hat?rnaz</value>
            <value>Ozden</value>
            <value>O</value>
        </row>
        <row>
            <value>483</value>
            <value>78</value>
            <value>6</value>
            <value>Aksu</value>
            <value>Salih</value>
            <value>S</value>
        </row>
        <row>
            <value>484</value>
            <value>78</value>
            <value>7</value>
            <value></value>
            <value>Yahya</value>
            <value>Y</value>
        </row>
        <row>
            <value>485</value>
            <value>78</value>
            <value>8</value>
            <value>Say?nalp</value>
            <value></value>
            <value>N</value>
        </row>
        <row>
            <value>486</value>
            <value>78</value>
            <value>9</value>
            <value></value>
            <value>Hakan</value>
            <value>H</value>
        </row>
        <row>
            <value>487</value>
            <value>78</value>
            <value>10</value>
            <value>Ozcebe</value>
            <value>Osman ?</value>
            <value>O?</value>
        </row>
        <row>
            <value>488</value>
            <value>78</value>
            <value>11</value>
            <value>Ozbek</value>
            <value>U??ur</value>
            <value>U</value>
        </row>
        <row>
            <value>489</value>
            <value>78</value>
            <value>12</value>
            <value>Haznedaro??lu</value>
            <value>Ibrahim C</value>
            <value>IC</value>
        </row>
        <row>
            <value>490</value>
            <value>79</value>
            <value>1</value>
            <value>Soukhtanloo</value>
            <value>Mohammad</value>
            <value>M</value>
        </row>
        <row>
            <value>491</value>
            <value>79</value>
            <value>2</value>
            <value>Talebian</value>
            <value>Elham</value>
            <value>E</value>
        </row>
        <row>
            <value>492</value>
            <value>79</value>
            <value>3</value>
            <value>Golchin</value>
            <value>Mehdi</value>
            <value>M</value>
        </row>
        <row>
            <value>493</value>
            <value>79</value>
            <value>4</value>
            <value>Mohammadi</value>
            <value>Mojgan</value>
            <value>M</value>
        </row>
        <row>
            <value>494</value>
            <value>79</value>
            <value>5</value>
            <value>Amirheidari</value>
            <value>Bagher</value>
            <value>B</value>
        </row>
        <row>
            <value>495</value>
            <value>80</value>
            <value>1</value>
            <value>Abdallah</value>
            <value>Emad</value>
            <value>E</value>
        </row>
        <row>
            <value>496</value>
            <value>80</value>
            <value>2</value>
            <value>Waked</value>
            <value>Emam</value>
            <value>E</value>
        </row>
        <row>
            <value>497</value>
            <value>81</value>
            <value>1</value>
            <value>Weng</value>
            <value>Yuhui</value>
            <value>Y</value>
        </row>
        <row>
            <value>498</value>
            <value>81</value>
            <value>2</value>
            <value>Shao</value>
            <value>Liang</value>
            <value>L</value>
        </row>
        <row>
            <value>499</value>
            <value>81</value>
            <value>3</value>
            <value>Ouyang</value>
            <value>Hongmei</value>
            <value>H</value>
        </row>
        <row>
            <value>500</value>
            <value>81</value>
            <value>4</value>
            <value>Liu</value>
            <value>Yuebo</value>
            <value>Y</value>
        </row>
        <row>
            <value>501</value>
            <value>81</value>
            <value>5</value>
            <value>Yao</value>
            <value>Jin</value>
            <value>J</value>
        </row>
        <row>
            <value>502</value>
            <value>81</value>
            <value>6</value>
            <value>Yang</value>
            <value>Hong</value>
            <value>H</value>
        </row>
        <row>
            <value>503</value>
            <value>81</value>
            <value>7</value>
            <value>Luo</value>
            <value>Yunjiao</value>
            <value>Y</value>
        </row>
        <row>
            <value>504</value>
            <value>81</value>
            <value>8</value>
            <value>Wang</value>
            <value>Hao</value>
            <value>H</value>
        </row>
        <row>
            <value>505</value>
            <value>81</value>
            <value>9</value>
            <value>Zhao</value>
            <value>Zhenyu</value>
            <value>Z</value>
        </row>
        <row>
            <value>506</value>
            <value>81</value>
            <value>10</value>
            <value>Mou</value>
            <value>Hong</value>
            <value>H</value>
        </row>
        <row>
            <value>507</value>
            <value>81</value>
            <value>11</value>
            <value>Zhou</value>
            <value>Zeping</value>
            <value>Z</value>
        </row>
        <row>
            <value>508</value>
            <value>81</value>
            <value>12</value>
            <value>Zhang</value>
            <value>You</value>
            <value>Y</value>
        </row>
        <row>
            <value>509</value>
            <value>82</value>
            <value>1</value>
            <value>Gu</value>
            <value>Ying</value>
            <value>Y</value>
        </row>
        <row>
            <value>510</value>
            <value>82</value>
            <value>2</value>
            <value>Ji</value>
            <value>Shun-dong</value>
            <value>SD</value>
        </row>
        <row>
            <value>511</value>
            <value>82</value>
            <value>3</value>
            <value>Zhao</value>
            <value>Yi-ming</value>
            <value>YM</value>
        </row>
        <row>
            <value>512</value>
            <value>82</value>
            <value>4</value>
            <value>Shen</value>
            <value>Fei</value>
            <value>F</value>
        </row>
        <row>
            <value>513</value>
            <value>82</value>
            <value>5</value>
            <value>Ruan</value>
            <value>Chang-geng</value>
            <value>CG</value>
        </row>
        <row>
            <value>514</value>
            <value>83</value>
            <value>1</value>
            <value>Liu</value>
            <value>Kun</value>
            <value>K</value>
        </row>
        <row>
            <value>515</value>
            <value>83</value>
            <value>2</value>
            <value>Luo</value>
            <value>Yun-Jiao</value>
            <value>YJ</value>
        </row>
        <row>
            <value>516</value>
            <value>83</value>
            <value>3</value>
            <value>Liu</value>
            <value>Yue-Bo</value>
            <value>YB</value>
        </row>
        <row>
            <value>517</value>
            <value>83</value>
            <value>4</value>
            <value>Yao</value>
            <value>Jin</value>
            <value>J</value>
        </row>
        <row>
            <value>518</value>
            <value>83</value>
            <value>5</value>
            <value>Yang</value>
            <value>Hong</value>
            <value>H</value>
        </row>
        <row>
            <value>519</value>
            <value>83</value>
            <value>6</value>
            <value>Mou</value>
            <value>Hong</value>
            <value>H</value>
        </row>
        <row>
            <value>520</value>
            <value>83</value>
            <value>7</value>
            <value>Huang</value>
            <value>Gui-Yun</value>
            <value>GY</value>
        </row>
        <row>
            <value>521</value>
            <value>83</value>
            <value>8</value>
            <value>Zhang</value>
            <value>You</value>
            <value>Y</value>
        </row>
        <row>
            <value>522</value>
            <value>84</value>
            <value>1</value>
            <value>Zhou</value>
            <value>Rong</value>
            <value>R</value>
        </row>
        <row>
            <value>523</value>
            <value>84</value>
            <value>2</value>
            <value>Sheng</value>
            <value>Hui-Ying</value>
            <value>HY</value>
        </row>
        <row>
            <value>524</value>
            <value>84</value>
            <value>3</value>
            <value>Tian</value>
            <value>Xin-Gui</value>
            <value>XG</value>
        </row>
        <row>
            <value>525</value>
            <value>84</value>
            <value>4</value>
            <value>Wang</value>
            <value>Chang-Bing</value>
            <value>CB</value>
        </row>
        <row>
            <value>526</value>
            <value>84</value>
            <value>5</value>
            <value>Gong</value>
            <value>Si-Tang</value>
            <value>ST</value>
        </row>
        <row>
            <value>527</value>
            <value>84</value>
            <value>6</value>
            <value>Chen</value>
            <value>Qiao-Lian</value>
            <value>QL</value>
        </row>
        <row>
            <value>528</value>
            <value>85</value>
            <value>1</value>
            <value>Wu</value>
            <value>Hong-ya</value>
            <value>HY</value>
        </row>
        <row>
            <value>529</value>
            <value>85</value>
            <value>2</value>
            <value>Wang</value>
            <value>Qin</value>
            <value>Q</value>
        </row>
        <row>
            <value>530</value>
            <value>85</value>
            <value>3</value>
            <value>Chen</value>
            <value>Yong-jing</value>
            <value>YJ</value>
        </row>
        <row>
            <value>531</value>
            <value>85</value>
            <value>4</value>
            <value>Xie</value>
            <value>Fang</value>
            <value>F</value>
        </row>
        <row>
            <value>532</value>
            <value>85</value>
            <value>5</value>
            <value>Mao</value>
            <value>Yi-xiang</value>
            <value>YX</value>
        </row>
        <row>
            <value>533</value>
            <value>85</value>
            <value>6</value>
            <value>Liu</value>
            <value>Gao-qin</value>
            <value>GQ</value>
        </row>
        <row>
            <value>534</value>
            <value>85</value>
            <value>7</value>
            <value>Zhang</value>
            <value>Xue-guang</value>
            <value>XG</value>
        </row>
        <row>
            <value>535</value>
            <value>86</value>
            <value>1</value>
            <value>Ding</value>
            <value>Yan-Song</value>
            <value>YS</value>
        </row>
        <row>
            <value>536</value>
            <value>86</value>
            <value>2</value>
            <value>Chen</value>
            <value>Wen-Ming</value>
            <value>WM</value>
        </row>
        <row>
            <value>537</value>
            <value>87</value>
            <value>1</value>
            <value></value>
            <value>Ernesto</value>
            <value>E</value>
        </row>
        <row>
            <value>538</value>
            <value>87</value>
            <value>2</value>
            <value>Vidriales</value>
            <value></value>
            <value>MB</value>
        </row>
        <row>
            <value>539</value>
            <value>87</value>
            <value>3</value>
            <value>Mateo</value>
            <value>Gema</value>
            <value>G</value>
        </row>
        <row>
            <value>540</value>
            <value>87</value>
            <value>4</value>
            <value></value>
            <value></value>
            <value>R</value>
        </row>
        <row>
            <value>541</value>
            <value>87</value>
            <value>5</value>
            <value>Mateos</value>
            <value>Maria-Victoria</value>
            <value>MV</value>
        </row>
        <row>
            <value>542</value>
            <value>87</value>
            <value>6</value>
            <value>de Coca</value>
            <value></value>
            <value>AG</value>
        </row>
        <row>
            <value>543</value>
            <value>87</value>
            <value>7</value>
            <value>Galende</value>
            <value>Josefina</value>
            <value>J</value>
        </row>
        <row>
            <value>544</value>
            <value>87</value>
            <value>8</value>
            <value></value>
            <value>Guillermo</value>
            <value>G</value>
        </row>
        <row>
            <value>545</value>
            <value>87</value>
            <value>9</value>
            <value>Alonso</value>
            <value></value>
            <value>JM</value>
        </row>
        <row>
            <value>546</value>
            <value>87</value>
            <value>10</value>
            <value>de Las Heras</value>
            <value>Natalia</value>
            <value>N</value>
        </row>
        <row>
            <value>547</value>
            <value>87</value>
            <value>11</value>
            <value></value>
            <value></value>
            <value>JM</value>
        </row>
        <row>
            <value>548</value>
            <value>87</value>
            <value>12</value>
            <value></value>
            <value>Alejandro</value>
            <value>A</value>
        </row>
        <row>
            <value>549</value>
            <value>87</value>
            <value>13</value>
            <value></value>
            <value>Consuelo</value>
            <value>C</value>
        </row>
        <row>
            <value>550</value>
            <value>87</value>
            <value>14</value>
            <value>Orfao</value>
            <value>Alberto</value>
            <value>A</value>
        </row>
        <row>
            <value>551</value>
            <value>87</value>
            <value>15</value>
            <value>San Miguel</value>
            <value></value>
            <value>JF</value>
        </row>
        <row>
            <value>552</value>
            <value>88</value>
            <value>1</value>
            <value>McCloskey</value>
            <value>E V</value>
            <value>EV</value>
        </row>
        <row>
            <value>553</value>
            <value>88</value>
            <value>2</value>
            <value>Guest</value>
            <value>J F</value>
            <value>JF</value>
        </row>
        <row>
            <value>554</value>
            <value>88</value>
            <value>3</value>
            <value>Kanis</value>
            <value>J A</value>
            <value>JA</value>
        </row>
        <row>
            <value>555</value>
            <value>89</value>
            <value>1</value>
            <value>Bel'ts</value>
            <value>E A</value>
            <value>EA</value>
        </row>
        <row>
            <value>556</value>
            <value>90</value>
            <value>1</value>
            <value>Wang</value>
            <value>Xin</value>
            <value>X</value>
        </row>
        <row>
            <value>557</value>
            <value>90</value>
            <value>2</value>
            <value>Li</value>
            <value>Xiaoyu</value>
            <value>X</value>
        </row>
        <row>
            <value>558</value>
            <value>90</value>
            <value>3</value>
            <value>Ma</value>
            <value>Jing</value>
            <value>J</value>
        </row>
        <row>
            <value>559</value>
            <value>90</value>
            <value>4</value>
            <value>Zhang</value>
            <value>Li</value>
            <value>L</value>
        </row>
        <row>
            <value>560</value>
            <value>90</value>
            <value>5</value>
            <value>Ma</value>
            <value>Ling</value>
            <value>L</value>
        </row>
        <row>
            <value>561</value>
            <value>90</value>
            <value>6</value>
            <value>Mi</value>
            <value>Zeyun</value>
            <value>Z</value>
        </row>
        <row>
            <value>562</value>
            <value>90</value>
            <value>7</value>
            <value>Zhou</value>
            <value>Jinming</value>
            <value>J</value>
        </row>
        <row>
            <value>563</value>
            <value>90</value>
            <value>8</value>
            <value>Guo</value>
            <value>Fei</value>
            <value>F</value>
        </row>
        <row>
            <value>564</value>
            <value>90</value>
            <value>9</value>
            <value>Kleiman</value>
            <value>Lawrence</value>
            <value>L</value>
        </row>
        <row>
            <value>565</value>
            <value>90</value>
            <value>10</value>
            <value>Cen</value>
            <value>Shan</value>
            <value>S</value>
        </row>
        <row>
            <value>566</value>
            <value>91</value>
            <value>1</value>
            <value>Jin</value>
            <value>Jill</value>
            <value>J</value>
        </row>
        <row>
            <value>567</value>
            <value>92</value>
            <value>1</value>
            <value>Johnson</value>
            <value>Anna Satcher</value>
            <value>AS</value>
        </row>
        <row>
            <value>568</value>
            <value>92</value>
            <value>2</value>
            <value>Hall</value>
            <value>H Irene</value>
            <value>HI</value>
        </row>
        <row>
            <value>569</value>
            <value>92</value>
            <value>3</value>
            <value>Hu</value>
            <value>Xiaohong</value>
            <value>X</value>
        </row>
        <row>
            <value>570</value>
            <value>92</value>
            <value>4</value>
            <value>Lansky</value>
            <value>Amy</value>
            <value>A</value>
        </row>
        <row>
            <value>571</value>
            <value>92</value>
            <value>5</value>
            <value>Holtgrave</value>
            <value>David R</value>
            <value>DR</value>
        </row>
        <row>
            <value>572</value>
            <value>92</value>
            <value>6</value>
            <value>Mermin</value>
            <value>Jonathan</value>
            <value>J</value>
        </row>
        <row>
            <value>573</value>
            <value>94</value>
            <value>1</value>
            <value></value>
            <value>Huldrych F</value>
            <value>HF</value>
        </row>
        <row>
            <value>574</value>
            <value>94</value>
            <value>2</value>
            <value>Aberg</value>
            <value>Judith A</value>
            <value>JA</value>
        </row>
        <row>
            <value>575</value>
            <value>94</value>
            <value>3</value>
            <value>Eron</value>
            <value>Joseph J</value>
            <value>JJ</value>
        </row>
        <row>
            <value>576</value>
            <value>94</value>
            <value>4</value>
            <value>Hoy</value>
            <value>Jennifer F</value>
            <value>JF</value>
        </row>
        <row>
            <value>577</value>
            <value>94</value>
            <value>5</value>
            <value>Telenti</value>
            <value>Amalio</value>
            <value>A</value>
        </row>
        <row>
            <value>578</value>
            <value>94</value>
            <value>6</value>
            <value>Benson</value>
            <value>Constance A</value>
            <value>CA</value>
        </row>
        <row>
            <value>579</value>
            <value>94</value>
            <value>7</value>
            <value>Burger</value>
            <value>David M</value>
            <value>DM</value>
        </row>
        <row>
            <value>580</value>
            <value>94</value>
            <value>8</value>
            <value>Cahn</value>
            <value>Pedro</value>
            <value>P</value>
        </row>
        <row>
            <value>581</value>
            <value>94</value>
            <value>9</value>
            <value>Gallant</value>
            <value>Joel E</value>
            <value>JE</value>
        </row>
        <row>
            <value>582</value>
            <value>94</value>
            <value>10</value>
            <value>Glesby</value>
            <value>Marshall J</value>
            <value>MJ</value>
        </row>
        <row>
            <value>583</value>
            <value>94</value>
            <value>11</value>
            <value>Reiss</value>
            <value>Peter</value>
            <value>P</value>
        </row>
        <row>
            <value>584</value>
            <value>94</value>
            <value>12</value>
            <value>Saag</value>
            <value>Michael S</value>
            <value>MS</value>
        </row>
        <row>
            <value>585</value>
            <value>94</value>
            <value>13</value>
            <value>Thomas</value>
            <value>David L</value>
            <value>DL</value>
        </row>
        <row>
            <value>586</value>
            <value>94</value>
            <value>14</value>
            <value>Jacobsen</value>
            <value>Donna M</value>
            <value>DM</value>
        </row>
        <row>
            <value>587</value>
            <value>94</value>
            <value>15</value>
            <value>Volberding</value>
            <value>Paul A</value>
            <value>PA</value>
        </row>
        <row>
            <value>588</value>
            <value>95</value>
            <value>1</value>
            <value>Marrazzo</value>
            <value>Jeanne M</value>
            <value>JM</value>
        </row>
        <row>
            <value>589</value>
            <value>95</value>
            <value>2</value>
            <value>Del Rio</value>
            <value>Carlos</value>
            <value>C</value>
        </row>
        <row>
            <value>590</value>
            <value>95</value>
            <value>3</value>
            <value>Holtgrave</value>
            <value>David R</value>
            <value>DR</value>
        </row>
        <row>
            <value>591</value>
            <value>95</value>
            <value>4</value>
            <value>Cohen</value>
            <value>Myron S</value>
            <value>MS</value>
        </row>
        <row>
            <value>592</value>
            <value>95</value>
            <value>5</value>
            <value>Kalichman</value>
            <value>Seth C</value>
            <value>SC</value>
        </row>
        <row>
            <value>593</value>
            <value>95</value>
            <value>6</value>
            <value>Mayer</value>
            <value>Kenneth H</value>
            <value>KH</value>
        </row>
        <row>
            <value>594</value>
            <value>95</value>
            <value>7</value>
            <value>Montaner</value>
            <value>Julio S G</value>
            <value>JS</value>
        </row>
        <row>
            <value>595</value>
            <value>95</value>
            <value>8</value>
            <value>Wheeler</value>
            <value>Darrell P</value>
            <value>DP</value>
        </row>
        <row>
            <value>596</value>
            <value>95</value>
            <value>9</value>
            <value>Grant</value>
            <value>Robert M</value>
            <value>RM</value>
        </row>
        <row>
            <value>597</value>
            <value>95</value>
            <value>10</value>
            <value>Grinsztejn</value>
            <value>Beatriz</value>
            <value>B</value>
        </row>
        <row>
            <value>598</value>
            <value>95</value>
            <value>11</value>
            <value>Kumarasamy</value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>599</value>
            <value>95</value>
            <value>12</value>
            <value>Shoptaw</value>
            <value>Steven</value>
            <value>S</value>
        </row>
        <row>
            <value>600</value>
            <value>95</value>
            <value>13</value>
            <value>Walensky</value>
            <value>Rochelle P</value>
            <value>RP</value>
        </row>
        <row>
            <value>601</value>
            <value>95</value>
            <value>14</value>
            <value>Dabis</value>
            <value>Francois</value>
            <value>F</value>
        </row>
        <row>
            <value>602</value>
            <value>95</value>
            <value>15</value>
            <value>Sugarman</value>
            <value>Jeremy</value>
            <value>J</value>
        </row>
        <row>
            <value>603</value>
            <value>95</value>
            <value>16</value>
            <value>Benson</value>
            <value>Constance A</value>
            <value>CA</value>
        </row>
        <row>
            <value>604</value>
            <value>96</value>
            <value>1</value>
            <value>Stanley</value>
            <value>Takara L</value>
            <value>TL</value>
        </row>
        <row>
            <value>605</value>
            <value>96</value>
            <value>2</value>
            <value>Feldpausch</value>
            <value>Meghan N</value>
            <value>MN</value>
        </row>
        <row>
            <value>606</value>
            <value>96</value>
            <value>3</value>
            <value>Oh</value>
            <value>Jinhee</value>
            <value>J</value>
        </row>
        <row>
            <value>607</value>
            <value>96</value>
            <value>4</value>
            <value>Branch</value>
            <value>Karen L</value>
            <value>KL</value>
        </row>
        <row>
            <value>608</value>
            <value>96</value>
            <value>5</value>
            <value>Lee</value>
            <value>Hang</value>
            <value>H</value>
        </row>
        <row>
            <value>609</value>
            <value>96</value>
            <value>6</value>
            <value>Torriani</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>610</value>
            <value>96</value>
            <value>7</value>
            <value>Grinspoon</value>
            <value>Steven K</value>
            <value>SK</value>
        </row>
        <row>
            <value>611</value>
            <value>97</value>
            <value>1</value>
            <value>MacPherson</value>
            <value>Peter</value>
            <value>P</value>
        </row>
        <row>
            <value>612</value>
            <value>97</value>
            <value>2</value>
            <value>Lalloo</value>
            <value>David G</value>
            <value>DG</value>
        </row>
        <row>
            <value>613</value>
            <value>97</value>
            <value>3</value>
            <value>Webb</value>
            <value>Emily L</value>
            <value>EL</value>
        </row>
        <row>
            <value>614</value>
            <value>97</value>
            <value>4</value>
            <value>Maheswaran</value>
            <value>Hendramoorthy</value>
            <value>H</value>
        </row>
        <row>
            <value>615</value>
            <value>97</value>
            <value>5</value>
            <value>Choko</value>
            <value>Augustine T</value>
            <value>AT</value>
        </row>
        <row>
            <value>616</value>
            <value>97</value>
            <value>6</value>
            <value>Makombe</value>
            <value>Simon D</value>
            <value>SD</value>
        </row>
        <row>
            <value>617</value>
            <value>97</value>
            <value>7</value>
            <value>Butterworth</value>
            <value>Anthony E</value>
            <value>AE</value>
        </row>
        <row>
            <value>618</value>
            <value>97</value>
            <value>8</value>
            <value>van Oosterhout</value>
            <value>Joep J</value>
            <value>JJ</value>
        </row>
        <row>
            <value>619</value>
            <value>97</value>
            <value>9</value>
            <value>Desmond</value>
            <value>Nicola</value>
            <value>N</value>
        </row>
        <row>
            <value>620</value>
            <value>97</value>
            <value>10</value>
            <value>Thindwa</value>
            <value>Deus</value>
            <value>D</value>
        </row>
        <row>
            <value>621</value>
            <value>97</value>
            <value>11</value>
            <value>Squire</value>
            <value>Stephen Bertel</value>
            <value>SB</value>
        </row>
        <row>
            <value>622</value>
            <value>97</value>
            <value>12</value>
            <value>Hayes</value>
            <value>Richard J</value>
            <value>RJ</value>
        </row>
        <row>
            <value>623</value>
            <value>97</value>
            <value>13</value>
            <value>Corbett</value>
            <value>Elizabeth L</value>
            <value>EL</value>
        </row>
        <row>
            <value>624</value>
            <value>98</value>
            <value>1</value>
            <value>Mugo</value>
            <value>Nelly R</value>
            <value>NR</value>
        </row>
        <row>
            <value>625</value>
            <value>98</value>
            <value>2</value>
            <value>Hong</value>
            <value>Ting</value>
            <value>T</value>
        </row>
        <row>
            <value>626</value>
            <value>98</value>
            <value>3</value>
            <value>Celum</value>
            <value>Connie</value>
            <value>C</value>
        </row>
        <row>
            <value>627</value>
            <value>98</value>
            <value>4</value>
            <value>Donnell</value>
            <value>Deborah</value>
            <value>D</value>
        </row>
        <row>
            <value>628</value>
            <value>98</value>
            <value>5</value>
            <value>Bukusi</value>
            <value>Elizabeth A</value>
            <value>EA</value>
        </row>
        <row>
            <value>629</value>
            <value>98</value>
            <value>6</value>
            <value>John-Stewart</value>
            <value>Grace</value>
            <value>G</value>
        </row>
        <row>
            <value>630</value>
            <value>98</value>
            <value>7</value>
            <value>Wangisi</value>
            <value>Jonathan</value>
            <value>J</value>
        </row>
        <row>
            <value>631</value>
            <value>98</value>
            <value>8</value>
            <value>Were</value>
            <value>Edwin</value>
            <value>E</value>
        </row>
        <row>
            <value>632</value>
            <value>98</value>
            <value>9</value>
            <value>Heffron</value>
            <value>Renee</value>
            <value>R</value>
        </row>
        <row>
            <value>633</value>
            <value>98</value>
            <value>10</value>
            <value>Matthews</value>
            <value>Lynn T</value>
            <value>LT</value>
        </row>
        <row>
            <value>634</value>
            <value>98</value>
            <value>11</value>
            <value>Morrison</value>
            <value>Susan</value>
            <value>S</value>
        </row>
        <row>
            <value>635</value>
            <value>98</value>
            <value>12</value>
            <value>Ngure</value>
            <value>Kenneth</value>
            <value>K</value>
        </row>
        <row>
            <value>636</value>
            <value>98</value>
            <value>13</value>
            <value>Baeten</value>
            <value>Jared M</value>
            <value>JM</value>
        </row>
        <row>
            <value>637</value>
            <value>98</value>
            <value>14</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>638</value>
            <value>99</value>
            <value>1</value>
            <value>Sulkowski</value>
            <value>Mark S</value>
            <value>MS</value>
        </row>
        <row>
            <value>639</value>
            <value>99</value>
            <value>2</value>
            <value>Naggie</value>
            <value>Susanna</value>
            <value>S</value>
        </row>
        <row>
            <value>640</value>
            <value>99</value>
            <value>3</value>
            <value>Lalezari</value>
            <value>Jacob</value>
            <value>J</value>
        </row>
        <row>
            <value>641</value>
            <value>99</value>
            <value>4</value>
            <value>Fessel</value>
            <value>Walford Jeffrey</value>
            <value>WJ</value>
        </row>
        <row>
            <value>642</value>
            <value>99</value>
            <value>5</value>
            <value>Mounzer</value>
            <value>Karam</value>
            <value>K</value>
        </row>
        <row>
            <value>643</value>
            <value>99</value>
            <value>6</value>
            <value>Shuhart</value>
            <value>Margaret</value>
            <value>M</value>
        </row>
        <row>
            <value>644</value>
            <value>99</value>
            <value>7</value>
            <value>Luetkemeyer</value>
            <value>Anne F</value>
            <value>AF</value>
        </row>
        <row>
            <value>645</value>
            <value>99</value>
            <value>8</value>
            <value>Asmuth</value>
            <value>David</value>
            <value>D</value>
        </row>
        <row>
            <value>646</value>
            <value>99</value>
            <value>9</value>
            <value>Gaggar</value>
            <value>Anuj</value>
            <value>A</value>
        </row>
        <row>
            <value>647</value>
            <value>99</value>
            <value>10</value>
            <value>Ni</value>
            <value>Liyun</value>
            <value>L</value>
        </row>
        <row>
            <value>648</value>
            <value>99</value>
            <value>11</value>
            <value>Svarovskaia</value>
            <value>Evguenia</value>
            <value>E</value>
        </row>
        <row>
            <value>649</value>
            <value>99</value>
            <value>12</value>
            <value>Brainard</value>
            <value>Diana M</value>
            <value>DM</value>
        </row>
        <row>
            <value>650</value>
            <value>99</value>
            <value>13</value>
            <value>Symonds</value>
            <value>William T</value>
            <value>WT</value>
        </row>
        <row>
            <value>651</value>
            <value>99</value>
            <value>14</value>
            <value>Subramanian</value>
            <value>G Mani</value>
            <value>GM</value>
        </row>
        <row>
            <value>652</value>
            <value>99</value>
            <value>15</value>
            <value>McHutchison</value>
            <value>John G</value>
            <value>JG</value>
        </row>
        <row>
            <value>653</value>
            <value>99</value>
            <value>16</value>
            <value>Rodriguez-Torres</value>
            <value>Maribel</value>
            <value>M</value>
        </row>
        <row>
            <value>654</value>
            <value>99</value>
            <value>17</value>
            <value>Dieterich</value>
            <value>Douglas</value>
            <value>D</value>
        </row>
        <row>
            <value>655</value>
            <value>99</value>
            <value>18</value>
            <value></value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>656</value>
            <value>100</value>
            <value>1</value>
            <value>Schmetzer</value>
            <value>Oliver</value>
            <value>O</value>
        </row>
        <row>
            <value>657</value>
            <value>100</value>
            <value>2</value>
            <value>Valentin</value>
            <value>Patricia</value>
            <value>P</value>
        </row>
        <row>
            <value>658</value>
            <value>100</value>
            <value>3</value>
            <value>Smorodchenko</value>
            <value>Anna</value>
            <value>A</value>
        </row>
        <row>
            <value>659</value>
            <value>100</value>
            <value>4</value>
            <value>Domenis</value>
            <value>Rossana</value>
            <value>R</value>
        </row>
        <row>
            <value>660</value>
            <value>100</value>
            <value>5</value>
            <value>Gri</value>
            <value>Giorgia</value>
            <value>G</value>
        </row>
        <row>
            <value>661</value>
            <value>100</value>
            <value>6</value>
            <value>Siebenhaar</value>
            <value>Frank</value>
            <value>F</value>
        </row>
        <row>
            <value>662</value>
            <value>100</value>
            <value>7</value>
            <value>Metz</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>663</value>
            <value>100</value>
            <value>8</value>
            <value>Maurer</value>
            <value>Marcus</value>
            <value>M</value>
        </row>
        <row>
            <value>664</value>
            <value>101</value>
            <value>1</value>
            <value>Far</value>
            <value>Rafat Mohebbi</value>
            <value>RM</value>
        </row>
        <row>
            <value>665</value>
            <value>101</value>
            <value>2</value>
            <value>Rad</value>
            <value>Fatemeh Samiee</value>
            <value>FS</value>
        </row>
        <row>
            <value>666</value>
            <value>101</value>
            <value>3</value>
            <value>Abdolazimi</value>
            <value>Zahra</value>
            <value>Z</value>
        </row>
        <row>
            <value>667</value>
            <value>101</value>
            <value>4</value>
            <value>Kohan</value>
            <value>Mohamad Mehdi Daneshi</value>
            <value>MM</value>
        </row>
        <row>
            <value>668</value>
            <value>102</value>
            <value>1</value>
            <value>Sidira</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>669</value>
            <value>102</value>
            <value>2</value>
            <value>Nikza</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>670</value>
            <value>102</value>
            <value>3</value>
            <value>Danis</value>
            <value>K</value>
            <value>K</value>
        </row>
        <row>
            <value>671</value>
            <value>102</value>
            <value>4</value>
            <value>Panagiotopoulos</value>
            <value>T</value>
            <value>T</value>
        </row>
        <row>
            <value>672</value>
            <value>102</value>
            <value>5</value>
            <value>Samara</value>
            <value>D</value>
            <value>D</value>
        </row>
        <row>
            <value>673</value>
            <value>102</value>
            <value>6</value>
            <value>Maltezou</value>
            <value>Hc</value>
            <value>H</value>
        </row>
        <row>
            <value>674</value>
            <value>102</value>
            <value>7</value>
            <value>Papa</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>675</value>
            <value>103</value>
            <value>1</value>
            <value>Zhou</value>
            <value>Liang</value>
            <value>L</value>
        </row>
        <row>
            <value>676</value>
            <value>103</value>
            <value>2</value>
            <value>Zhang</value>
            <value>Zhou</value>
            <value>Z</value>
        </row>
        <row>
            <value>677</value>
            <value>103</value>
            <value>3</value>
            <value>Shi</value>
            <value>Juan-Zi</value>
            <value>JZ</value>
        </row>
        <row>
            <value>678</value>
            <value>103</value>
            <value>4</value>
            <value>Liu</value>
            <value>Xiao-Hua</value>
            <value>XH</value>
        </row>
        <row>
            <value>679</value>
            <value>103</value>
            <value>5</value>
            <value>Shi</value>
            <value>Wen-Hao</value>
            <value>WH</value>
        </row>
        <row>
            <value>680</value>
            <value>103</value>
            <value>6</value>
            <value>Kou</value>
            <value>Hui</value>
            <value>H</value>
        </row>
        <row>
            <value>681</value>
            <value>103</value>
            <value>7</value>
            <value>Song</value>
            <value>Juan</value>
            <value>J</value>
        </row>
        <row>
            <value>682</value>
            <value>104</value>
            <value>1</value>
            <value>Aldamiz-Echevarria</value>
            <value>Covadonga</value>
            <value>C</value>
        </row>
        <row>
            <value>683</value>
            <value>104</value>
            <value>2</value>
            <value>Aguirre-Garcia</value>
            <value>Maria Soledad</value>
            <value>MS</value>
        </row>
        <row>
            <value>684</value>
            <value>105</value>
            <value>1</value>
            <value>Falcone</value>
            <value>Joseph A</value>
            <value>JA</value>
        </row>
        <row>
            <value>685</value>
            <value>105</value>
            <value>2</value>
            <value>Salameh</value>
            <value>Therese S</value>
            <value>TS</value>
        </row>
        <row>
            <value>686</value>
            <value>105</value>
            <value>3</value>
            <value>Yi</value>
            <value>Xiang</value>
            <value>X</value>
        </row>
        <row>
            <value>687</value>
            <value>105</value>
            <value>4</value>
            <value>Cordy</value>
            <value>Benjamin J</value>
            <value>BJ</value>
        </row>
        <row>
            <value>688</value>
            <value>105</value>
            <value>5</value>
            <value>Mortell</value>
            <value>William G</value>
            <value>WG</value>
        </row>
        <row>
            <value>689</value>
            <value>105</value>
            <value>6</value>
            <value>Kabanov</value>
            <value>Alexander V</value>
            <value>AV</value>
        </row>
        <row>
            <value>690</value>
            <value>105</value>
            <value>7</value>
            <value>Banks</value>
            <value>William A</value>
            <value>WA</value>
        </row>
        <row>
            <value>691</value>
            <value>106</value>
            <value>1</value>
            <value>DiCaro</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>692</value>
            <value>106</value>
            <value>2</value>
            <value>Cheung</value>
            <value>Wh</value>
            <value>W</value>
        </row>
        <row>
            <value>693</value>
            <value>106</value>
            <value>3</value>
            <value>Haidry</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>694</value>
            <value>106</value>
            <value>4</value>
            <value>Fini</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>695</value>
            <value>106</value>
            <value>5</value>
            <value>Keane</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>696</value>
            <value>106</value>
            <value>6</value>
            <value>Lovat</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>697</value>
            <value>106</value>
            <value>7</value>
            <value>Batterham</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>698</value>
            <value>106</value>
            <value>8</value>
            <value>Banks</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>699</value>
            <value>107</value>
            <value>1</value>
            <value>Cosgun</value>
            <value>Kadriye Nehir</value>
            <value>KN</value>
        </row>
        <row>
            <value>700</value>
            <value>107</value>
            <value>2</value>
            <value>Rahmig</value>
            <value>Susann</value>
            <value>S</value>
        </row>
        <row>
            <value>701</value>
            <value>107</value>
            <value>3</value>
            <value>Mende</value>
            <value>Nicole</value>
            <value>N</value>
        </row>
        <row>
            <value>702</value>
            <value>107</value>
            <value>4</value>
            <value>Reinke</value>
            <value></value>
            <value>S</value>
        </row>
        <row>
            <value>703</value>
            <value>107</value>
            <value>5</value>
            <value>Hauber</value>
            <value>Ilona</value>
            <value>I</value>
        </row>
        <row>
            <value>704</value>
            <value>107</value>
            <value>6</value>
            <value></value>
            <value>Carola</value>
            <value>C</value>
        </row>
        <row>
            <value>705</value>
            <value>107</value>
            <value>7</value>
            <value>Petzold</value>
            <value>Anke</value>
            <value>A</value>
        </row>
        <row>
            <value>706</value>
            <value>107</value>
            <value>8</value>
            <value>Weisbach</value>
            <value>Henry</value>
            <value>H</value>
        </row>
        <row>
            <value>707</value>
            <value>107</value>
            <value>9</value>
            <value>Heidkamp</value>
            <value>Gordon</value>
            <value>G</value>
        </row>
        <row>
            <value>708</value>
            <value>107</value>
            <value>10</value>
            <value>Purbojo</value>
            <value>Ariawan</value>
            <value>A</value>
        </row>
        <row>
            <value>709</value>
            <value>107</value>
            <value>11</value>
            <value>Cesnjevar</value>
            <value>Robert</value>
            <value>R</value>
        </row>
        <row>
            <value>710</value>
            <value>107</value>
            <value>12</value>
            <value>Platz</value>
            <value>Alexander</value>
            <value>A</value>
        </row>
        <row>
            <value>711</value>
            <value>107</value>
            <value>13</value>
            <value></value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>712</value>
            <value>107</value>
            <value>14</value>
            <value>Schmitz</value>
            <value>Marc</value>
            <value>M</value>
        </row>
        <row>
            <value>713</value>
            <value>107</value>
            <value>15</value>
            <value>Dudziak</value>
            <value>Diana</value>
            <value>D</value>
        </row>
        <row>
            <value>714</value>
            <value>107</value>
            <value>16</value>
            <value>Hauber</value>
            <value>Joachim</value>
            <value>J</value>
        </row>
        <row>
            <value>715</value>
            <value>107</value>
            <value>17</value>
            <value>Kirberg</value>
            <value></value>
            <value>J</value>
        </row>
        <row>
            <value>716</value>
            <value>107</value>
            <value>18</value>
            <value>Waskow</value>
            <value>Claudia</value>
            <value>C</value>
        </row>
        <row>
            <value>717</value>
            <value>108</value>
            <value>1</value>
            <value>Lund</value>
            <value>Troy C</value>
            <value>TC</value>
        </row>
        <row>
            <value>718</value>
            <value>108</value>
            <value>2</value>
            <value>Cathey</value>
            <value>Sara S</value>
            <value>SS</value>
        </row>
        <row>
            <value>719</value>
            <value>108</value>
            <value>3</value>
            <value>Miller</value>
            <value>Weston P</value>
            <value>WP</value>
        </row>
        <row>
            <value>720</value>
            <value>108</value>
            <value>4</value>
            <value>Eapen</value>
            <value>Mary</value>
            <value>M</value>
        </row>
        <row>
            <value>721</value>
            <value>108</value>
            <value>5</value>
            <value>Andreansky</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>722</value>
            <value>108</value>
            <value>6</value>
            <value>Dvorak</value>
            <value>Christopher C</value>
            <value>CC</value>
        </row>
        <row>
            <value>723</value>
            <value>108</value>
            <value>7</value>
            <value>Davis</value>
            <value>Jeffrey H</value>
            <value>JH</value>
        </row>
        <row>
            <value>724</value>
            <value>108</value>
            <value>8</value>
            <value>Dalal</value>
            <value>Jignesh D</value>
            <value>JD</value>
        </row>
        <row>
            <value>725</value>
            <value>108</value>
            <value>9</value>
            <value>Devine</value>
            <value>Steven M</value>
            <value>SM</value>
        </row>
        <row>
            <value>726</value>
            <value>108</value>
            <value>10</value>
            <value>Eames</value>
            <value>Gretchen M</value>
            <value>GM</value>
        </row>
        <row>
            <value>727</value>
            <value>108</value>
            <value>11</value>
            <value>Ferguson</value>
            <value>William S</value>
            <value>WS</value>
        </row>
        <row>
            <value>728</value>
            <value>108</value>
            <value>12</value>
            <value>Giller</value>
            <value>Roger H</value>
            <value>RH</value>
        </row>
        <row>
            <value>729</value>
            <value>108</value>
            <value>13</value>
            <value>He</value>
            <value>Wensheng</value>
            <value>W</value>
        </row>
        <row>
            <value>730</value>
            <value>108</value>
            <value>14</value>
            <value>Kurtzberg</value>
            <value>Joanne</value>
            <value>J</value>
        </row>
        <row>
            <value>731</value>
            <value>108</value>
            <value>15</value>
            <value>Krance</value>
            <value>Robert</value>
            <value>R</value>
        </row>
        <row>
            <value>732</value>
            <value>108</value>
            <value>16</value>
            <value>Katsanis</value>
            <value>Emmanuel</value>
            <value>E</value>
        </row>
        <row>
            <value>733</value>
            <value>108</value>
            <value>17</value>
            <value>Lewis</value>
            <value>Victor A</value>
            <value>VA</value>
        </row>
        <row>
            <value>734</value>
            <value>108</value>
            <value>18</value>
            <value>Sahdev</value>
            <value>Indira</value>
            <value>I</value>
        </row>
        <row>
            <value>735</value>
            <value>108</value>
            <value>19</value>
            <value>Orchard</value>
            <value>Paul J</value>
            <value>PJ</value>
        </row>
        <row>
            <value>736</value>
            <value>109</value>
            <value>1</value>
            <value>Kiviniemi</value>
            <value>Antti M</value>
            <value>AM</value>
        </row>
        <row>
            <value>737</value>
            <value>109</value>
            <value>2</value>
            <value>Tulppo</value>
            <value>Mikko P</value>
            <value>MP</value>
        </row>
        <row>
            <value>738</value>
            <value>109</value>
            <value>3</value>
            <value>Hautala</value>
            <value>Arto J</value>
            <value>AJ</value>
        </row>
        <row>
            <value>739</value>
            <value>109</value>
            <value>4</value>
            <value></value>
            <value>Juha S</value>
            <value>JS</value>
        </row>
        <row>
            <value>740</value>
            <value>109</value>
            <value>5</value>
            <value>Ylitalo</value>
            <value>Antti</value>
            <value>A</value>
        </row>
        <row>
            <value>741</value>
            <value>109</value>
            <value>6</value>
            <value></value>
            <value>Y Antero</value>
            <value>YA</value>
        </row>
        <row>
            <value>742</value>
            <value>109</value>
            <value>7</value>
            <value>Ukkola</value>
            <value>Olavi</value>
            <value>O</value>
        </row>
        <row>
            <value>743</value>
            <value>109</value>
            <value>8</value>
            <value>Huikuri</value>
            <value>Heikki V</value>
            <value>HV</value>
        </row>
        <row>
            <value>744</value>
            <value>110</value>
            <value>1</value>
            <value></value>
            <value>Lina Andrea</value>
            <value>LA</value>
        </row>
        <row>
            <value>745</value>
            <value>110</value>
            <value>2</value>
            <value></value>
            <value>Oscar</value>
            <value>O</value>
        </row>
        <row>
            <value>746</value>
            <value>110</value>
            <value>3</value>
            <value>Higuera</value>
            <value>Fernando</value>
            <value>F</value>
        </row>
        <row>
            <value>747</value>
            <value>111</value>
            <value>1</value>
            <value></value>
            <value>Diego</value>
            <value>D</value>
        </row>
        <row>
            <value>748</value>
            <value>111</value>
            <value>2</value>
            <value></value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>749</value>
            <value>111</value>
            <value>3</value>
            <value></value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>750</value>
            <value>111</value>
            <value>4</value>
            <value></value>
            <value>M A</value>
            <value>MA</value>
        </row>
        <row>
            <value>751</value>
            <value>111</value>
            <value>5</value>
            <value>Montejano</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>752</value>
            <value>112</value>
            <value>1</value>
            <value>Nafishah</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>753</value>
            <value>112</value>
            <value>2</value>
            <value>Asiah</value>
            <value>M Nor</value>
            <value>MN</value>
        </row>
        <row>
            <value>754</value>
            <value>112</value>
            <value>3</value>
            <value>Syimah</value>
            <value>A T Nur</value>
            <value>AT</value>
        </row>
        <row>
            <value>755</value>
            <value>112</value>
            <value>4</value>
            <value>Mohd Zahari</value>
            <value>T H</value>
            <value>TH</value>
        </row>
        <row>
            <value>756</value>
            <value>112</value>
            <value>5</value>
            <value>Yasmin</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>757</value>
            <value>112</value>
            <value>6</value>
            <value>Normi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>758</value>
            <value>112</value>
            <value>7</value>
            <value>Anza</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>759</value>
            <value>112</value>
            <value>8</value>
            <value>Shahnaz</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>760</value>
            <value>112</value>
            <value>9</value>
            <value>Narazah</value>
            <value>M Y</value>
            <value>MY</value>
        </row>
        <row>
            <value>761</value>
            <value>113</value>
            <value>1</value>
            <value>Hung</value>
            <value>Huey-Shan</value>
            <value>HS</value>
        </row>
        <row>
            <value>762</value>
            <value>113</value>
            <value>2</value>
            <value>Yang</value>
            <value>Yi-Chun</value>
            <value>YC</value>
        </row>
        <row>
            <value>763</value>
            <value>113</value>
            <value>3</value>
            <value>Lin</value>
            <value>Yu-Chun</value>
            <value>YC</value>
        </row>
        <row>
            <value>764</value>
            <value>113</value>
            <value>4</value>
            <value>Lin</value>
            <value>Shinn-Zong</value>
            <value>SZ</value>
        </row>
        <row>
            <value>765</value>
            <value>113</value>
            <value>5</value>
            <value>Kao</value>
            <value>Wei-Chien</value>
            <value>WC</value>
        </row>
        <row>
            <value>766</value>
            <value>113</value>
            <value>6</value>
            <value>Hsieh</value>
            <value>Hsien-Hsu</value>
            <value>HH</value>
        </row>
        <row>
            <value>767</value>
            <value>113</value>
            <value>7</value>
            <value>Chu</value>
            <value>Mei-Yun</value>
            <value>MY</value>
        </row>
        <row>
            <value>768</value>
            <value>113</value>
            <value>8</value>
            <value>Fu</value>
            <value>Ru-Huei</value>
            <value>RH</value>
        </row>
        <row>
            <value>769</value>
            <value>113</value>
            <value>9</value>
            <value>Hsu</value>
            <value>Shan-hui</value>
            <value>SH</value>
        </row>
        <row>
            <value>770</value>
            <value>114</value>
            <value>1</value>
            <value>Sondeen</value>
            <value>Jill L</value>
            <value>JL</value>
        </row>
        <row>
            <value>771</value>
            <value>114</value>
            <value>2</value>
            <value>Prince</value>
            <value>Malcolm D</value>
            <value>MD</value>
        </row>
        <row>
            <value>772</value>
            <value>114</value>
            <value>3</value>
            <value>Polykratis</value>
            <value>Irene A</value>
            <value>IA</value>
        </row>
        <row>
            <value>773</value>
            <value>114</value>
            <value>4</value>
            <value>Hernandez</value>
            <value>Orlando</value>
            <value>O</value>
        </row>
        <row>
            <value>774</value>
            <value>114</value>
            <value>5</value>
            <value>Torres-Mendoza</value>
            <value>Jaime</value>
            <value>J</value>
        </row>
        <row>
            <value>775</value>
            <value>114</value>
            <value>6</value>
            <value>De Guzman</value>
            <value>Rodolfo</value>
            <value>R</value>
        </row>
        <row>
            <value>776</value>
            <value>114</value>
            <value>7</value>
            <value>Aden</value>
            <value>James K</value>
            <value>JK</value>
        </row>
        <row>
            <value>777</value>
            <value>114</value>
            <value>8</value>
            <value>Dubick</value>
            <value>Michael A</value>
            <value>MA</value>
        </row>
        <row>
            <value>778</value>
            <value>115</value>
            <value>1</value>
            <value>Guilcher</value>
            <value>Gregory M T</value>
            <value>GM</value>
        </row>
        <row>
            <value>779</value>
            <value>115</value>
            <value>2</value>
            <value>Fernandez</value>
            <value>Conrad V</value>
            <value>CV</value>
        </row>
        <row>
            <value>780</value>
            <value>115</value>
            <value>3</value>
            <value>Joffe</value>
            <value>Steven</value>
            <value>S</value>
        </row>
        <row>
            <value>781</value>
            <value>116</value>
            <value>1</value>
            <value>Yi</value>
            <value>Chun-Hui</value>
            <value>CH</value>
        </row>
        <row>
            <value>782</value>
            <value>116</value>
            <value>2</value>
            <value>La Vega-Talbott</value>
            <value>Maite</value>
            <value>M</value>
        </row>
        <row>
            <value>783</value>
            <value>116</value>
            <value>3</value>
            <value>Friedman</value>
            <value>Mark T</value>
            <value>MT</value>
        </row>
        <row>
            <value>784</value>
            <value>117</value>
            <value>1</value>
            <value>Young</value>
            <value>Wise</value>
            <value>W</value>
        </row>
        <row>
            <value>785</value>
            <value>118</value>
            <value>1</value>
            <value>Al-Riyami</value>
            <value>Arwa Z</value>
            <value>AZ</value>
        </row>
        <row>
            <value>786</value>
            <value>118</value>
            <value>2</value>
            <value>Al-Mahrooqi</value>
            <value>Sabah</value>
            <value>S</value>
        </row>
        <row>
            <value>787</value>
            <value>118</value>
            <value>3</value>
            <value>Al-Hinai</value>
            <value>Sumaiya</value>
            <value>S</value>
        </row>
        <row>
            <value>788</value>
            <value>118</value>
            <value>4</value>
            <value>Al-Hosni</value>
            <value>Saif</value>
            <value>S</value>
        </row>
        <row>
            <value>789</value>
            <value>118</value>
            <value>5</value>
            <value>Al-Madhani</value>
            <value>Ali</value>
            <value>A</value>
        </row>
        <row>
            <value>790</value>
            <value>118</value>
            <value>6</value>
            <value>Daar</value>
            <value>Shahina</value>
            <value>S</value>
        </row>
        <row>
            <value>791</value>
            <value>119</value>
            <value>1</value>
            <value>Brown</value>
            <value>L J</value>
            <value>LJ</value>
        </row>
        <row>
            <value>792</value>
            <value>119</value>
            <value>2</value>
            <value>Rosatte</value>
            <value>R C</value>
            <value>RC</value>
        </row>
        <row>
            <value>793</value>
            <value>119</value>
            <value>3</value>
            <value>Fehlner-Gardiner</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>794</value>
            <value>119</value>
            <value>4</value>
            <value>Ellison</value>
            <value>J A</value>
            <value>JA</value>
        </row>
        <row>
            <value>795</value>
            <value>119</value>
            <value>5</value>
            <value>Jackson</value>
            <value>F R</value>
            <value>FR</value>
        </row>
        <row>
            <value>796</value>
            <value>119</value>
            <value>6</value>
            <value>Bachmann</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>797</value>
            <value>119</value>
            <value>7</value>
            <value>Taylor</value>
            <value>J S</value>
            <value>JS</value>
        </row>
        <row>
            <value>798</value>
            <value>119</value>
            <value>8</value>
            <value>Franka</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>799</value>
            <value>119</value>
            <value>9</value>
            <value>Donovan</value>
            <value>D</value>
            <value>D</value>
        </row>
        <row>
            <value>800</value>
            <value>120</value>
            <value>1</value>
            <value>Gotts</value>
            <value>Jeffrey Earl</value>
            <value>JE</value>
        </row>
        <row>
            <value>801</value>
            <value>120</value>
            <value>2</value>
            <value>Abbott</value>
            <value>Jason</value>
            <value>J</value>
        </row>
        <row>
            <value>802</value>
            <value>120</value>
            <value>3</value>
            <value>Matthay</value>
            <value>Michael A</value>
            <value>MA</value>
        </row>
        <row>
            <value>803</value>
            <value>121</value>
            <value>1</value>
            <value>Ozdo??u</value>
            <value>Hakan</value>
            <value>H</value>
        </row>
        <row>
            <value>804</value>
            <value>121</value>
            <value>2</value>
            <value>Yeral</value>
            <value>Mahmut</value>
            <value>M</value>
        </row>
        <row>
            <value>805</value>
            <value>121</value>
            <value>3</value>
            <value>Bo??a</value>
            <value>Can</value>
            <value>C</value>
        </row>
        <row>
            <value>806</value>
            <value>121</value>
            <value>4</value>
            <value>Kozano??lu</value>
            <value>Ilknur</value>
            <value>I</value>
        </row>
        <row>
            <value>807</value>
            <value>122</value>
            <value>1</value>
            <value>Javanbakht</value>
            <value>Javad</value>
            <value>J</value>
        </row>
        <row>
            <value>808</value>
            <value>122</value>
            <value>2</value>
            <value>Hosseini</value>
            <value>Ehsan</value>
            <value>E</value>
        </row>
        <row>
            <value>809</value>
            <value>122</value>
            <value>3</value>
            <value>Karimi</value>
            <value>Shahram</value>
            <value>S</value>
        </row>
        <row>
            <value>810</value>
            <value>122</value>
            <value>4</value>
            <value>Hassan</value>
            <value>Mehdi Aghamohammad</value>
            <value>MA</value>
        </row>
        <row>
            <value>811</value>
            <value>122</value>
            <value>5</value>
            <value>Sabbagh</value>
            <value>Atefeh</value>
            <value>A</value>
        </row>
        <row>
            <value>812</value>
            <value>122</value>
            <value>6</value>
            <value>Mousavi</value>
            <value>Shadi</value>
            <value>S</value>
        </row>
        <row>
            <value>813</value>
            <value>122</value>
            <value>7</value>
            <value>Fattahi</value>
            <value>Roohollah</value>
            <value>R</value>
        </row>
        <row>
            <value>814</value>
            <value>122</value>
            <value>8</value>
            <value>Khaki</value>
            <value>Fariba</value>
            <value>F</value>
        </row>
        <row>
            <value>815</value>
            <value>122</value>
            <value>9</value>
            <value>Shafiee</value>
            <value>Radmehr</value>
            <value>R</value>
        </row>
        <row>
            <value>816</value>
            <value>123</value>
            <value>1</value>
            <value>Driss</value>
            <value>Nadia</value>
            <value>N</value>
        </row>
        <row>
            <value>817</value>
            <value>123</value>
            <value>2</value>
            <value>Mellouli</value>
            <value>Fethi</value>
            <value>F</value>
        </row>
        <row>
            <value>818</value>
            <value>123</value>
            <value>3</value>
            <value>Ben Yahia</value>
            <value>Ahlem</value>
            <value>A</value>
        </row>
        <row>
            <value>819</value>
            <value>123</value>
            <value>4</value>
            <value>Touzi</value>
            <value>Henda</value>
            <value>H</value>
        </row>
        <row>
            <value>820</value>
            <value>123</value>
            <value>5</value>
            <value>Barbouche</value>
            <value>Mohamed-Ridha</value>
            <value>MR</value>
        </row>
        <row>
            <value>821</value>
            <value>123</value>
            <value>6</value>
            <value>Triki</value>
            <value>Henda</value>
            <value>H</value>
        </row>
        <row>
            <value>822</value>
            <value>123</value>
            <value>7</value>
            <value>Bejaoui</value>
            <value>Mohamed</value>
            <value>M</value>
        </row>
        <row>
            <value>823</value>
            <value>124</value>
            <value>1</value>
            <value>Brissot</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>824</value>
            <value>124</value>
            <value>2</value>
            <value>Gomez</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>825</value>
            <value>124</value>
            <value>3</value>
            <value>Aline-Fardin</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>826</value>
            <value>124</value>
            <value>4</value>
            <value>Lalande</value>
            <value>V</value>
            <value>V</value>
        </row>
        <row>
            <value>827</value>
            <value>124</value>
            <value>5</value>
            <value>Lapusan</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>828</value>
            <value>124</value>
            <value>6</value>
            <value>Isnard</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>829</value>
            <value>124</value>
            <value>7</value>
            <value>Legrand</value>
            <value>O</value>
            <value>O</value>
        </row>
        <row>
            <value>830</value>
            <value>124</value>
            <value>8</value>
            <value>Meynard</value>
            <value>J-L</value>
            <value>JL</value>
        </row>
        <row>
            <value>831</value>
            <value>124</value>
            <value>9</value>
            <value>Rubio</value>
            <value>M-T</value>
            <value>MT</value>
        </row>
        <row>
            <value>832</value>
            <value>124</value>
            <value>10</value>
            <value>Mohty</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>833</value>
            <value>125</value>
            <value>1</value>
            <value>Takizawa</value>
            <value>Sho</value>
            <value>S</value>
        </row>
        <row>
            <value>834</value>
            <value>125</value>
            <value>2</value>
            <value>Kaneyama</value>
            <value>Tomoki</value>
            <value>T</value>
        </row>
        <row>
            <value>835</value>
            <value>125</value>
            <value>3</value>
            <value>Tsugane</value>
            <value>Sayaka</value>
            <value>S</value>
        </row>
        <row>
            <value>836</value>
            <value>125</value>
            <value>4</value>
            <value>Takeichi</value>
            <value>Naoya</value>
            <value>N</value>
        </row>
        <row>
            <value>837</value>
            <value>125</value>
            <value>5</value>
            <value>Yanagisawa</value>
            <value>Satoshi</value>
            <value>S</value>
        </row>
        <row>
            <value>838</value>
            <value>125</value>
            <value>6</value>
            <value>Ichikawa</value>
            <value>Motoki</value>
            <value>M</value>
        </row>
        <row>
            <value>839</value>
            <value>125</value>
            <value>7</value>
            <value>Yagita</value>
            <value>Hideo</value>
            <value>H</value>
        </row>
        <row>
            <value>840</value>
            <value>125</value>
            <value>8</value>
            <value>Kim</value>
            <value>Byung S</value>
            <value>BS</value>
        </row>
        <row>
            <value>841</value>
            <value>125</value>
            <value>9</value>
            <value>Koh</value>
            <value>Chang-Sung</value>
            <value>CS</value>
        </row>
        <row>
            <value>842</value>
            <value>126</value>
            <value>1</value>
            <value>Luff</value>
            <value>Jennifer A</value>
            <value>JA</value>
        </row>
        <row>
            <value>843</value>
            <value>126</value>
            <value>2</value>
            <value>Yuan</value>
            <value>Hang</value>
            <value>H</value>
        </row>
        <row>
            <value>844</value>
            <value>126</value>
            <value>3</value>
            <value>Kennedy</value>
            <value>Douglas</value>
            <value>D</value>
        </row>
        <row>
            <value>845</value>
            <value>126</value>
            <value>4</value>
            <value>Schlegel</value>
            <value>Richard</value>
            <value>R</value>
        </row>
        <row>
            <value>846</value>
            <value>126</value>
            <value>5</value>
            <value>Felsburg</value>
            <value>Peter</value>
            <value>P</value>
        </row>
        <row>
            <value>847</value>
            <value>126</value>
            <value>6</value>
            <value>Moore</value>
            <value>Peter F</value>
            <value>PF</value>
        </row>
        <row>
            <value>848</value>
            <value>127</value>
            <value>1</value>
            <value>Kaplan</value>
            <value>Jason B</value>
            <value>JB</value>
        </row>
        <row>
            <value>849</value>
            <value>127</value>
            <value>2</value>
            <value>Guitart</value>
            <value>Joan</value>
            <value>J</value>
        </row>
        <row>
            <value>850</value>
            <value>127</value>
            <value>3</value>
            <value>Giles</value>
            <value>Francis J</value>
            <value>FJ</value>
        </row>
        <row>
            <value>851</value>
            <value>128</value>
            <value>1</value>
            <value>Greco</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>852</value>
            <value>128</value>
            <value>2</value>
            <value>Mancini</value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>853</value>
            <value>128</value>
            <value>3</value>
            <value>Peccatori</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>854</value>
            <value>128</value>
            <value>4</value>
            <value>Cieri</value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>855</value>
            <value>128</value>
            <value>5</value>
            <value>Vago</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>856</value>
            <value>128</value>
            <value>6</value>
            <value>Giglio</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>857</value>
            <value>128</value>
            <value>7</value>
            <value>Morelli</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>858</value>
            <value>128</value>
            <value>8</value>
            <value>Ghidoli</value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>859</value>
            <value>128</value>
            <value>9</value>
            <value>Carletti</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>860</value>
            <value>128</value>
            <value>10</value>
            <value>Levati</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>861</value>
            <value>128</value>
            <value>11</value>
            <value>Crucitti</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>862</value>
            <value>128</value>
            <value>12</value>
            <value>Sala</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>863</value>
            <value>128</value>
            <value>13</value>
            <value>Lupo Stanghellini</value>
            <value>M T</value>
            <value>MT</value>
        </row>
        <row>
            <value>864</value>
            <value>128</value>
            <value>14</value>
            <value>Lorentino</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>865</value>
            <value>128</value>
            <value>15</value>
            <value>Forcina</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>866</value>
            <value>128</value>
            <value>16</value>
            <value>Pavesi</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>867</value>
            <value>128</value>
            <value>17</value>
            <value>Carrabba</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>868</value>
            <value>128</value>
            <value>18</value>
            <value>Marktel</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>869</value>
            <value>128</value>
            <value>19</value>
            <value>Assanelli</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>870</value>
            <value>128</value>
            <value>20</value>
            <value>Marcatti</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>871</value>
            <value>128</value>
            <value>21</value>
            <value>Bernardi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>872</value>
            <value>128</value>
            <value>22</value>
            <value>Corti</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>873</value>
            <value>128</value>
            <value>23</value>
            <value>Doglioni</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>874</value>
            <value>128</value>
            <value>24</value>
            <value>Scarpellini</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>875</value>
            <value>128</value>
            <value>25</value>
            <value>Burioni</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>876</value>
            <value>128</value>
            <value>26</value>
            <value>Bonini</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>877</value>
            <value>128</value>
            <value>27</value>
            <value>Clementi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>878</value>
            <value>128</value>
            <value>28</value>
            <value>Ciceri</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>879</value>
            <value>129</value>
            <value>1</value>
            <value>Morgado</value>
            <value>Pedro</value>
            <value>P</value>
        </row>
        <row>
            <value>880</value>
            <value>129</value>
            <value>2</value>
            <value>Sudarshana</value>
            <value>Dattanand M</value>
            <value>DM</value>
        </row>
        <row>
            <value>881</value>
            <value>129</value>
            <value>3</value>
            <value>Gov</value>
            <value>Lanny</value>
            <value>L</value>
        </row>
        <row>
            <value>882</value>
            <value>129</value>
            <value>4</value>
            <value>Harker</value>
            <value>Katherine S</value>
            <value>KS</value>
        </row>
        <row>
            <value>883</value>
            <value>129</value>
            <value>5</value>
            <value>Lam</value>
            <value>Tonika</value>
            <value>T</value>
        </row>
        <row>
            <value>884</value>
            <value>129</value>
            <value>6</value>
            <value>Casali</value>
            <value>Paolo</value>
            <value>P</value>
        </row>
        <row>
            <value>885</value>
            <value>129</value>
            <value>7</value>
            <value>Boyle</value>
            <value>Jon P</value>
            <value>JP</value>
        </row>
        <row>
            <value>886</value>
            <value>129</value>
            <value>8</value>
            <value>Lodoen</value>
            <value>Melissa B</value>
            <value>MB</value>
        </row>
        <row>
            <value>887</value>
            <value>130</value>
            <value>1</value>
            <value>Sun</value>
            <value>Jing</value>
            <value>J</value>
        </row>
        <row>
            <value>888</value>
            <value>130</value>
            <value>2</value>
            <value>Zhang</value>
            <value>Ting</value>
            <value>T</value>
        </row>
        <row>
            <value>889</value>
            <value>130</value>
            <value>3</value>
            <value>Zhang</value>
            <value>Panpan</value>
            <value>P</value>
        </row>
        <row>
            <value>890</value>
            <value>130</value>
            <value>4</value>
            <value>Lv</value>
            <value>Linlin</value>
            <value>L</value>
        </row>
        <row>
            <value>891</value>
            <value>130</value>
            <value>5</value>
            <value>Wang</value>
            <value>Yanzhi</value>
            <value>Y</value>
        </row>
        <row>
            <value>892</value>
            <value>130</value>
            <value>6</value>
            <value>Zhang</value>
            <value>Jing</value>
            <value>J</value>
        </row>
        <row>
            <value>893</value>
            <value>130</value>
            <value>7</value>
            <value>Li</value>
            <value>Shu</value>
            <value>S</value>
        </row>
        <row>
            <value>894</value>
            <value>131</value>
            <value>1</value>
            <value>Ha</value>
            <value>Jung Min</value>
            <value>JM</value>
        </row>
        <row>
            <value>895</value>
            <value>131</value>
            <value>2</value>
            <value>Kim</value>
            <value>Eun</value>
            <value>E</value>
        </row>
        <row>
            <value>896</value>
            <value>131</value>
            <value>3</value>
            <value>Lee</value>
            <value>Woo Joo</value>
            <value>WJ</value>
        </row>
        <row>
            <value>897</value>
            <value>131</value>
            <value>4</value>
            <value>Hwang</value>
            <value>Ji-Won</value>
            <value>JW</value>
        </row>
        <row>
            <value>898</value>
            <value>131</value>
            <value>5</value>
            <value>Yune</value>
            <value>Sehyo</value>
            <value>S</value>
        </row>
        <row>
            <value>899</value>
            <value>131</value>
            <value>6</value>
            <value>Ko</value>
            <value>Young Hyeh</value>
            <value>YH</value>
        </row>
        <row>
            <value>900</value>
            <value>131</value>
            <value>7</value>
            <value>Choi</value>
            <value>Joon Young</value>
            <value>JY</value>
        </row>
        <row>
            <value>901</value>
            <value>131</value>
            <value>8</value>
            <value>Kim</value>
            <value>Seok Jin</value>
            <value>SJ</value>
        </row>
        <row>
            <value>902</value>
            <value>131</value>
            <value>9</value>
            <value>Kim</value>
            <value>Won Seog</value>
            <value>WS</value>
        </row>
        <row>
            <value>903</value>
            <value>132</value>
            <value>1</value>
            <value>Yessayan</value>
            <value>Lenar</value>
            <value>L</value>
        </row>
        <row>
            <value>904</value>
            <value>132</value>
            <value>2</value>
            <value>Yee</value>
            <value>Jerry</value>
            <value>J</value>
        </row>
        <row>
            <value>905</value>
            <value>132</value>
            <value>3</value>
            <value>Zasuwa</value>
            <value>Gary</value>
            <value>G</value>
        </row>
        <row>
            <value>906</value>
            <value>132</value>
            <value>4</value>
            <value>Frinak</value>
            <value>Stan</value>
            <value>S</value>
        </row>
        <row>
            <value>907</value>
            <value>132</value>
            <value>5</value>
            <value>Besarab</value>
            <value>Anatole</value>
            <value>A</value>
        </row>
        <row>
            <value>908</value>
            <value>133</value>
            <value>1</value>
            <value>Zheng</value>
            <value>Yulong</value>
            <value>Y</value>
        </row>
        <row>
            <value>909</value>
            <value>133</value>
            <value>2</value>
            <value>Fang</value>
            <value>Weijia</value>
            <value>W</value>
        </row>
        <row>
            <value>910</value>
            <value>133</value>
            <value>3</value>
            <value>Mao</value>
            <value>Chenyu</value>
            <value>C</value>
        </row>
        <row>
            <value>911</value>
            <value>133</value>
            <value>4</value>
            <value>Qian</value>
            <value>Joing</value>
            <value>J</value>
        </row>
        <row>
            <value>912</value>
            <value>133</value>
            <value>5</value>
            <value>Zhao</value>
            <value>Peng</value>
            <value>P</value>
        </row>
        <row>
            <value>913</value>
            <value>133</value>
            <value>6</value>
            <value>Zhang</value>
            <value>Xiaochen</value>
            <value>X</value>
        </row>
        <row>
            <value>914</value>
            <value>133</value>
            <value>7</value>
            <value>Jiang</value>
            <value>Haiping</value>
            <value>H</value>
        </row>
        <row>
            <value>915</value>
            <value>133</value>
            <value>8</value>
            <value>Zheng</value>
            <value>Yi</value>
            <value>Y</value>
        </row>
        <row>
            <value>916</value>
            <value>133</value>
            <value>9</value>
            <value>Xu</value>
            <value>Nong</value>
            <value>N</value>
        </row>
        <row>
            <value>917</value>
            <value>134</value>
            <value>1</value>
            <value>Avivi</value>
            <value>Irit</value>
            <value>I</value>
        </row>
        <row>
            <value>918</value>
            <value>134</value>
            <value>2</value>
            <value>Wittmann</value>
            <value>Talya</value>
            <value>T</value>
        </row>
        <row>
            <value>919</value>
            <value>134</value>
            <value>3</value>
            <value>Henig</value>
            <value>Israel</value>
            <value>I</value>
        </row>
        <row>
            <value>920</value>
            <value>134</value>
            <value>4</value>
            <value>Kra-Oz</value>
            <value>Zipora</value>
            <value>Z</value>
        </row>
        <row>
            <value>921</value>
            <value>134</value>
            <value>5</value>
            <value>Cohen</value>
            <value>Moran Szwarcwort</value>
            <value>MS</value>
        </row>
        <row>
            <value>922</value>
            <value>134</value>
            <value>6</value>
            <value>Zuckerman</value>
            <value>Tsila</value>
            <value>T</value>
        </row>
        <row>
            <value>923</value>
            <value>134</value>
            <value>7</value>
            <value>Horowitz</value>
            <value>Netanel A</value>
            <value>NA</value>
        </row>
        <row>
            <value>924</value>
            <value>134</value>
            <value>8</value>
            <value>Benyamini</value>
            <value>Noam</value>
            <value>N</value>
        </row>
        <row>
            <value>925</value>
            <value>135</value>
            <value>1</value>
            <value>Al-Ajmi</value>
            <value>Nouf</value>
            <value>N</value>
        </row>
        <row>
            <value>926</value>
            <value>135</value>
            <value>2</value>
            <value>Saretzki</value>
            <value>Gabriele</value>
            <value>G</value>
        </row>
        <row>
            <value>927</value>
            <value>135</value>
            <value>3</value>
            <value>Miles</value>
            <value>Colin</value>
            <value>C</value>
        </row>
        <row>
            <value>928</value>
            <value>135</value>
            <value>4</value>
            <value>Spyridopoulos</value>
            <value>Ioakim</value>
            <value>I</value>
        </row>
        <row>
            <value>929</value>
            <value>136</value>
            <value>1</value>
            <value>Hamamura</value>
            <value>Kazunori</value>
            <value>K</value>
        </row>
        <row>
            <value>930</value>
            <value>136</value>
            <value>2</value>
            <value>Chen</value>
            <value>Andy</value>
            <value>A</value>
        </row>
        <row>
            <value>931</value>
            <value>136</value>
            <value>3</value>
            <value>Nishimura</value>
            <value>Akinobu</value>
            <value>A</value>
        </row>
        <row>
            <value>932</value>
            <value>136</value>
            <value>4</value>
            <value>Tanjung</value>
            <value>Nancy</value>
            <value>N</value>
        </row>
        <row>
            <value>933</value>
            <value>136</value>
            <value>5</value>
            <value>Sudo</value>
            <value>Akihiro</value>
            <value>A</value>
        </row>
        <row>
            <value>934</value>
            <value>136</value>
            <value>6</value>
            <value>Yokota</value>
            <value>Hiroki</value>
            <value>H</value>
        </row>
        <row>
            <value>935</value>
            <value>137</value>
            <value>1</value>
            <value>Laskin</value>
            <value>Benjamin L</value>
            <value>BL</value>
        </row>
        <row>
            <value>936</value>
            <value>137</value>
            <value>2</value>
            <value>Nehus</value>
            <value>Edward</value>
            <value>E</value>
        </row>
        <row>
            <value>937</value>
            <value>137</value>
            <value>3</value>
            <value>Goebel</value>
            <value>Jens</value>
            <value>J</value>
        </row>
        <row>
            <value>938</value>
            <value>137</value>
            <value>4</value>
            <value>Furth</value>
            <value>Susan</value>
            <value>S</value>
        </row>
        <row>
            <value>939</value>
            <value>137</value>
            <value>5</value>
            <value>Davies</value>
            <value>Stella M</value>
            <value>SM</value>
        </row>
        <row>
            <value>940</value>
            <value>137</value>
            <value>6</value>
            <value>Jodele</value>
            <value>Sonata</value>
            <value>S</value>
        </row>
        <row>
            <value>941</value>
            <value>138</value>
            <value>1</value>
            <value>Garcia-Bonilla</value>
            <value>Lidia</value>
            <value>L</value>
        </row>
        <row>
            <value>942</value>
            <value>138</value>
            <value>2</value>
            <value>Moore</value>
            <value>Jamie M</value>
            <value>JM</value>
        </row>
        <row>
            <value>943</value>
            <value>138</value>
            <value>3</value>
            <value>Racchumi</value>
            <value>Gianfranco</value>
            <value>G</value>
        </row>
        <row>
            <value>944</value>
            <value>138</value>
            <value>4</value>
            <value>Zhou</value>
            <value>Ping</value>
            <value>P</value>
        </row>
        <row>
            <value>945</value>
            <value>138</value>
            <value>5</value>
            <value>Butler</value>
            <value>Jason M</value>
            <value>JM</value>
        </row>
        <row>
            <value>946</value>
            <value>138</value>
            <value>6</value>
            <value>Iadecola</value>
            <value>Costantino</value>
            <value>C</value>
        </row>
        <row>
            <value>947</value>
            <value>138</value>
            <value>7</value>
            <value>Anrather</value>
            <value>Josef</value>
            <value>J</value>
        </row>
        <row>
            <value>948</value>
            <value>139</value>
            <value>1</value>
            <value>Garg</value>
            <value>Ravi K</value>
            <value>RK</value>
        </row>
        <row>
            <value>949</value>
            <value>139</value>
            <value>2</value>
            <value>Rennert</value>
            <value>Robert C</value>
            <value>RC</value>
        </row>
        <row>
            <value>950</value>
            <value>139</value>
            <value>3</value>
            <value>Duscher</value>
            <value>Dominik</value>
            <value>D</value>
        </row>
        <row>
            <value>951</value>
            <value>139</value>
            <value>4</value>
            <value>Sorkin</value>
            <value>Michael</value>
            <value>M</value>
        </row>
        <row>
            <value>952</value>
            <value>139</value>
            <value>5</value>
            <value>Kosaraju</value>
            <value>Revanth</value>
            <value>R</value>
        </row>
        <row>
            <value>953</value>
            <value>139</value>
            <value>6</value>
            <value>Auerbach</value>
            <value>Lauren J</value>
            <value>LJ</value>
        </row>
        <row>
            <value>954</value>
            <value>139</value>
            <value>7</value>
            <value>Lennon</value>
            <value>James</value>
            <value>J</value>
        </row>
        <row>
            <value>955</value>
            <value>139</value>
            <value>8</value>
            <value>Chung</value>
            <value>Michael T</value>
            <value>MT</value>
        </row>
        <row>
            <value>956</value>
            <value>139</value>
            <value>9</value>
            <value>Paik</value>
            <value>Kevin</value>
            <value>K</value>
        </row>
        <row>
            <value>957</value>
            <value>139</value>
            <value>10</value>
            <value>Nimpf</value>
            <value>Johannes</value>
            <value>J</value>
        </row>
        <row>
            <value>958</value>
            <value>139</value>
            <value>11</value>
            <value>Rajadas</value>
            <value>Jayakumar</value>
            <value>J</value>
        </row>
        <row>
            <value>959</value>
            <value>139</value>
            <value>12</value>
            <value>Longaker</value>
            <value>Michael T</value>
            <value>MT</value>
        </row>
        <row>
            <value>960</value>
            <value>139</value>
            <value>13</value>
            <value>Gurtner</value>
            <value>Geoffrey C</value>
            <value>GC</value>
        </row>
        <row>
            <value>961</value>
            <value>140</value>
            <value>1</value>
            <value>Kolomeyer</value>
            <value>Anton M</value>
            <value>AM</value>
        </row>
        <row>
            <value>962</value>
            <value>140</value>
            <value>2</value>
            <value>Seery</value>
            <value>Christopher W</value>
            <value>CW</value>
        </row>
        <row>
            <value>963</value>
            <value>140</value>
            <value>3</value>
            <value>Emami-Naeimi</value>
            <value>Parisa</value>
            <value>P</value>
        </row>
        <row>
            <value>964</value>
            <value>140</value>
            <value>4</value>
            <value>Zarbin</value>
            <value>Marco A</value>
            <value>MA</value>
        </row>
        <row>
            <value>965</value>
            <value>140</value>
            <value>5</value>
            <value>Fechtner</value>
            <value>Robert D</value>
            <value>RD</value>
        </row>
        <row>
            <value>966</value>
            <value>140</value>
            <value>6</value>
            <value>Bhagat</value>
            <value>Neelakshi</value>
            <value>N</value>
        </row>
        <row>
            <value>967</value>
            <value>141</value>
            <value>1</value>
            <value>Wang</value>
            <value>Fengzhen</value>
            <value>F</value>
        </row>
        <row>
            <value>968</value>
            <value>141</value>
            <value>2</value>
            <value>Chen</value>
            <value>Li</value>
            <value>L</value>
        </row>
        <row>
            <value>969</value>
            <value>141</value>
            <value>3</value>
            <value>Zhang</value>
            <value>Dongsheng</value>
            <value>D</value>
        </row>
        <row>
            <value>970</value>
            <value>141</value>
            <value>4</value>
            <value>Jiang</value>
            <value>Sunmin</value>
            <value>S</value>
        </row>
        <row>
            <value>971</value>
            <value>141</value>
            <value>5</value>
            <value>Shi</value>
            <value>Kun</value>
            <value>K</value>
        </row>
        <row>
            <value>972</value>
            <value>141</value>
            <value>6</value>
            <value>Huang</value>
            <value>Yuan</value>
            <value>Y</value>
        </row>
        <row>
            <value>973</value>
            <value>141</value>
            <value>7</value>
            <value>Li</value>
            <value>Rui</value>
            <value>R</value>
        </row>
        <row>
            <value>974</value>
            <value>141</value>
            <value>8</value>
            <value>Xu</value>
            <value>Qunwei</value>
            <value>Q</value>
        </row>
        <row>
            <value>975</value>
            <value>142</value>
            <value>1</value>
            <value>Gage</value>
            <value>Philip J</value>
            <value>PJ</value>
        </row>
        <row>
            <value>976</value>
            <value>142</value>
            <value>2</value>
            <value>Kuang</value>
            <value>Chen</value>
            <value>C</value>
        </row>
        <row>
            <value>977</value>
            <value>142</value>
            <value>3</value>
            <value>Zacharias</value>
            <value>Amanda L</value>
            <value>AL</value>
        </row>
        <row>
            <value>978</value>
            <value>143</value>
            <value>1</value>
            <value>Wang</value>
            <value>Dajiang</value>
            <value>D</value>
        </row>
        <row>
            <value>979</value>
            <value>143</value>
            <value>2</value>
            <value>Yu</value>
            <value>Jifeng</value>
            <value>J</value>
        </row>
        <row>
            <value>980</value>
            <value>143</value>
            <value>3</value>
            <value>Tian</value>
            <value>Lei</value>
            <value>L</value>
        </row>
        <row>
            <value>981</value>
            <value>143</value>
            <value>4</value>
            <value>Wang</value>
            <value>Liqiang</value>
            <value>L</value>
        </row>
        <row>
            <value>982</value>
            <value>143</value>
            <value>5</value>
            <value>Huang</value>
            <value>Yifei</value>
            <value>Y</value>
        </row>
        <row>
            <value>983</value>
            <value>144</value>
            <value>1</value>
            <value>Tarkkanen</value>
            <value>Ahti H A</value>
            <value>AH</value>
        </row>
        <row>
            <value>984</value>
            <value>144</value>
            <value>2</value>
            <value></value>
            <value>Tero T</value>
            <value>TT</value>
        </row>
        <row>
            <value>985</value>
            <value>145</value>
            <value>1</value>
            <value>Li</value>
            <value>Jingjing</value>
            <value>J</value>
        </row>
        <row>
            <value>986</value>
            <value>145</value>
            <value>2</value>
            <value>Lin</value>
            <value>Xiaoti</value>
            <value>X</value>
        </row>
        <row>
            <value>987</value>
            <value>145</value>
            <value>3</value>
            <value>Yu</value>
            <value>Minbin</value>
            <value>M</value>
        </row>
        <row>
            <value>988</value>
            <value>146</value>
            <value>1</value>
            <value>Wygnanski-Jaffe</value>
            <value>Tamara</value>
            <value>T</value>
        </row>
        <row>
            <value>989</value>
            <value>146</value>
            <value>2</value>
            <value>Spierer</value>
            <value>Abraham</value>
            <value>A</value>
        </row>
        <row>
            <value>990</value>
            <value>146</value>
            <value>3</value>
            <value>Melamed</value>
            <value>Shlomo</value>
            <value>S</value>
        </row>
        <row>
            <value>991</value>
            <value>146</value>
            <value>4</value>
            <value>Ben-Zion</value>
            <value>Itay</value>
            <value>I</value>
        </row>
        <row>
            <value>992</value>
            <value>147</value>
            <value>1</value>
            <value>Omodaka</value>
            <value>Kazuko</value>
            <value>K</value>
        </row>
        <row>
            <value>993</value>
            <value>147</value>
            <value>2</value>
            <value>Kurimoto</value>
            <value>Takuji</value>
            <value>T</value>
        </row>
        <row>
            <value>994</value>
            <value>147</value>
            <value>3</value>
            <value>Nakamura</value>
            <value>Orie</value>
            <value>O</value>
        </row>
        <row>
            <value>995</value>
            <value>147</value>
            <value>4</value>
            <value>Sato</value>
            <value>Kota</value>
            <value>K</value>
        </row>
        <row>
            <value>996</value>
            <value>147</value>
            <value>5</value>
            <value>Yasuda</value>
            <value>Masayuki</value>
            <value>M</value>
        </row>
        <row>
            <value>997</value>
            <value>147</value>
            <value>6</value>
            <value>Tanaka</value>
            <value>Yuji</value>
            <value>Y</value>
        </row>
        <row>
            <value>998</value>
            <value>147</value>
            <value>7</value>
            <value>Himori</value>
            <value>Noriko</value>
            <value>N</value>
        </row>
        <row>
            <value>999</value>
            <value>147</value>
            <value>8</value>
            <value>Yokoyama</value>
            <value>Yu</value>
            <value>Y</value>
        </row>
        <row>
            <value>1000</value>
            <value>147</value>
            <value>9</value>
            <value>Nakazawa</value>
            <value>Toru</value>
            <value>T</value>
        </row>
        <row>
            <value>1001</value>
            <value>148</value>
            <value>1</value>
            <value>Huang</value>
            <value>Luoxiu</value>
            <value>L</value>
        </row>
        <row>
            <value>1002</value>
            <value>148</value>
            <value>2</value>
            <value>Balsara</value>
            <value>Rashna D</value>
            <value>RD</value>
        </row>
        <row>
            <value>1003</value>
            <value>148</value>
            <value>3</value>
            <value>Castellino</value>
            <value>Francis J</value>
            <value>FJ</value>
        </row>
        <row>
            <value>1004</value>
            <value>149</value>
            <value>1</value>
            <value>Siaudvytyte</value>
            <value>Lina</value>
            <value>L</value>
        </row>
        <row>
            <value>1005</value>
            <value>149</value>
            <value>2</value>
            <value>Januleviciene</value>
            <value>Ingrida</value>
            <value>I</value>
        </row>
        <row>
            <value>1006</value>
            <value>149</value>
            <value>3</value>
            <value>Ragauskas</value>
            <value>Arminas</value>
            <value>A</value>
        </row>
        <row>
            <value>1007</value>
            <value>149</value>
            <value>4</value>
            <value>Bartusis</value>
            <value>Laimonas</value>
            <value>L</value>
        </row>
        <row>
            <value>1008</value>
            <value>149</value>
            <value>5</value>
            <value>Siesky</value>
            <value>Brent</value>
            <value>B</value>
        </row>
        <row>
            <value>1009</value>
            <value>149</value>
            <value>6</value>
            <value>Harris</value>
            <value>Alon</value>
            <value>A</value>
        </row>
        <row>
            <value>1010</value>
            <value>150</value>
            <value>1</value>
            <value>Turalba</value>
            <value>Angela V</value>
            <value>AV</value>
        </row>
        <row>
            <value>1011</value>
            <value>150</value>
            <value>2</value>
            <value>Pasquale</value>
            <value>Louis R</value>
            <value>LR</value>
        </row>
        <row>
            <value>1012</value>
            <value>151</value>
            <value>1</value>
            <value>Sato</value>
            <value>Tomoki</value>
            <value>T</value>
        </row>
        <row>
            <value>1013</value>
            <value>151</value>
            <value>2</value>
            <value>Hirata</value>
            <value>Akira</value>
            <value>A</value>
        </row>
        <row>
            <value>1014</value>
            <value>151</value>
            <value>3</value>
            <value>Mizoguchi</value>
            <value>Takanori</value>
            <value>T</value>
        </row>
        <row>
            <value>1015</value>
            <value>152</value>
            <value>1</value>
            <value>Saunders</value>
            <value>Luke J</value>
            <value>LJ</value>
        </row>
        <row>
            <value>1016</value>
            <value>152</value>
            <value>2</value>
            <value>Russell</value>
            <value>Richard A</value>
            <value>RA</value>
        </row>
        <row>
            <value>1017</value>
            <value>152</value>
            <value>3</value>
            <value>Kirwan</value>
            <value>James F</value>
            <value>JF</value>
        </row>
        <row>
            <value>1018</value>
            <value>152</value>
            <value>4</value>
            <value>McNaught</value>
            <value>Andrew I</value>
            <value>AI</value>
        </row>
        <row>
            <value>1019</value>
            <value>152</value>
            <value>5</value>
            <value>Crabb</value>
            <value>David P</value>
            <value>DP</value>
        </row>
        <row>
            <value>1020</value>
            <value>153</value>
            <value>1</value>
            <value>Wesselink</value>
            <value>Christiaan</value>
            <value>C</value>
        </row>
        <row>
            <value>1021</value>
            <value>153</value>
            <value>2</value>
            <value>Jansonius</value>
            <value>Nomdo M</value>
            <value>NM</value>
        </row>
        <row>
            <value>1022</value>
            <value>154</value>
            <value>1</value>
            <value>Dorbandt</value>
            <value>Daniel M</value>
            <value>DM</value>
        </row>
        <row>
            <value>1023</value>
            <value>154</value>
            <value>2</value>
            <value>Moore</value>
            <value>Phillip A</value>
            <value>PA</value>
        </row>
        <row>
            <value>1024</value>
            <value>154</value>
            <value>3</value>
            <value>Myrna</value>
            <value>Kathern E</value>
            <value>KE</value>
        </row>
        <row>
            <value>1025</value>
            <value>155</value>
            <value>1</value>
            <value>Rommel</value>
            <value>K P</value>
            <value>KP</value>
        </row>
        <row>
            <value>1026</value>
            <value>155</value>
            <value>2</value>
            <value>Baum</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1027</value>
            <value>155</value>
            <value>3</value>
            <value>Mende</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1028</value>
            <value>155</value>
            <value>4</value>
            <value>Desch</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>1029</value>
            <value>155</value>
            <value>5</value>
            <value>Gutberlet</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1030</value>
            <value>155</value>
            <value>6</value>
            <value>Schuler</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1031</value>
            <value>155</value>
            <value>7</value>
            <value>Thiele</value>
            <value>H</value>
            <value>H</value>
        </row>
        <row>
            <value>1032</value>
            <value>155</value>
            <value>8</value>
            <value>Eitel</value>
            <value>I</value>
            <value>I</value>
        </row>
        <row>
            <value>1033</value>
            <value>156</value>
            <value>1</value>
            <value>Kim</value>
            <value>Dong Hun</value>
            <value>DH</value>
        </row>
        <row>
            <value>1034</value>
            <value>156</value>
            <value>2</value>
            <value>Choi</value>
            <value>Dong-Hyun</value>
            <value>DH</value>
        </row>
        <row>
            <value>1035</value>
            <value>156</value>
            <value>3</value>
            <value>Kim</value>
            <value>Hyun-Wook</value>
            <value>HW</value>
        </row>
        <row>
            <value>1036</value>
            <value>156</value>
            <value>4</value>
            <value>Choi</value>
            <value>Seo-Won</value>
            <value>SW</value>
        </row>
        <row>
            <value>1037</value>
            <value>156</value>
            <value>5</value>
            <value>Kim</value>
            <value>Bo-Bae</value>
            <value>BB</value>
        </row>
        <row>
            <value>1038</value>
            <value>156</value>
            <value>6</value>
            <value>Chung</value>
            <value>Joong-Wha</value>
            <value>JW</value>
        </row>
        <row>
            <value>1039</value>
            <value>156</value>
            <value>7</value>
            <value>Koh</value>
            <value>Young-Youp</value>
            <value>YY</value>
        </row>
        <row>
            <value>1040</value>
            <value>156</value>
            <value>8</value>
            <value>Chang</value>
            <value>Kyong-Sig</value>
            <value>KS</value>
        </row>
        <row>
            <value>1041</value>
            <value>156</value>
            <value>9</value>
            <value>Hong</value>
            <value>Soon-Pyo</value>
            <value>SP</value>
        </row>
        <row>
            <value>1042</value>
            <value>157</value>
            <value>1</value>
            <value>Duan</value>
            <value>Wenting</value>
            <value>W</value>
        </row>
        <row>
            <value>1043</value>
            <value>157</value>
            <value>2</value>
            <value>Ma</value>
            <value>Xianghong</value>
            <value>X</value>
        </row>
        <row>
            <value>1044</value>
            <value>157</value>
            <value>3</value>
            <value>Cui</value>
            <value>Lijun</value>
            <value>L</value>
        </row>
        <row>
            <value>1045</value>
            <value>158</value>
            <value>1</value>
            <value>Taniwaki</value>
            <value>Masanori</value>
            <value>M</value>
        </row>
        <row>
            <value>1046</value>
            <value>158</value>
            <value>2</value>
            <value>Stefanini</value>
            <value>Giulio G</value>
            <value>GG</value>
        </row>
        <row>
            <value>1047</value>
            <value>158</value>
            <value>3</value>
            <value></value>
            <value>Lorenz</value>
            <value>L</value>
        </row>
        <row>
            <value>1048</value>
            <value>158</value>
            <value>4</value>
            <value>Brugaletta</value>
            <value>Salvatore</value>
            <value>S</value>
        </row>
        <row>
            <value>1049</value>
            <value>158</value>
            <value>5</value>
            <value>Cequier</value>
            <value>Angel</value>
            <value>A</value>
        </row>
        <row>
            <value>1050</value>
            <value>158</value>
            <value>6</value>
            <value>Dik</value>
            <value>Heg</value>
            <value>H</value>
        </row>
        <row>
            <value>1051</value>
            <value>158</value>
            <value>7</value>
            <value></value>
            <value></value>
            <value>A</value>
        </row>
        <row>
            <value>1052</value>
            <value>158</value>
            <value>8</value>
            <value></value>
            <value>Henning</value>
            <value>H</value>
        </row>
        <row>
            <value>1053</value>
            <value>158</value>
            <value>9</value>
            <value>Serra</value>
            <value>Antonio</value>
            <value>A</value>
        </row>
        <row>
            <value>1054</value>
            <value>158</value>
            <value>10</value>
            <value>Ostoijic</value>
            <value>Miodrag</value>
            <value>M</value>
        </row>
        <row>
            <value>1055</value>
            <value>158</value>
            <value>11</value>
            <value>Hernandez-Antolin</value>
            <value>Rosana</value>
            <value>R</value>
        </row>
        <row>
            <value>1056</value>
            <value>158</value>
            <value>12</value>
            <value>Baumbach</value>
            <value>Andreas</value>
            <value>A</value>
        </row>
        <row>
            <value>1057</value>
            <value>158</value>
            <value>13</value>
            <value></value>
            <value>Stefan</value>
            <value>S</value>
        </row>
        <row>
            <value>1058</value>
            <value>158</value>
            <value>14</value>
            <value></value>
            <value>Peter</value>
            <value>P</value>
        </row>
        <row>
            <value>1059</value>
            <value>158</value>
            <value>15</value>
            <value>Mainar</value>
            <value>Vicente</value>
            <value>V</value>
        </row>
        <row>
            <value>1060</value>
            <value>158</value>
            <value>16</value>
            <value>Sabate</value>
            <value>Manel</value>
            <value>M</value>
        </row>
        <row>
            <value>1061</value>
            <value>158</value>
            <value>17</value>
            <value>Windecker</value>
            <value>Stephan</value>
            <value>S</value>
        </row>
        <row>
            <value>1062</value>
            <value>159</value>
            <value>1</value>
            <value>Toth</value>
            <value>Gabor G</value>
            <value>GG</value>
        </row>
        <row>
            <value>1063</value>
            <value>159</value>
            <value>2</value>
            <value>Kala</value>
            <value>Petr</value>
            <value>P</value>
        </row>
        <row>
            <value>1064</value>
            <value>159</value>
            <value>3</value>
            <value>Lansky</value>
            <value>Alexandra</value>
            <value>A</value>
        </row>
        <row>
            <value>1065</value>
            <value>159</value>
            <value>4</value>
            <value>Baumbach</value>
            <value>Andreas</value>
            <value>A</value>
        </row>
        <row>
            <value>1066</value>
            <value>160</value>
            <value>1</value>
            <value>Dong</value>
            <value>Mei</value>
            <value>M</value>
        </row>
        <row>
            <value>1067</value>
            <value>160</value>
            <value>2</value>
            <value>Mu</value>
            <value>Nan</value>
            <value>N</value>
        </row>
        <row>
            <value>1068</value>
            <value>160</value>
            <value>3</value>
            <value>Ren</value>
            <value>Faxin</value>
            <value>F</value>
        </row>
        <row>
            <value>1069</value>
            <value>160</value>
            <value>4</value>
            <value>Sun</value>
            <value>Xiaojian</value>
            <value>X</value>
        </row>
        <row>
            <value>1070</value>
            <value>160</value>
            <value>5</value>
            <value>Li</value>
            <value>Fengli</value>
            <value>F</value>
        </row>
        <row>
            <value>1071</value>
            <value>160</value>
            <value>6</value>
            <value>Zhang</value>
            <value>Chuanhuan</value>
            <value>C</value>
        </row>
        <row>
            <value>1072</value>
            <value>160</value>
            <value>7</value>
            <value>Yang</value>
            <value>Jun</value>
            <value>J</value>
        </row>
        <row>
            <value>1073</value>
            <value>161</value>
            <value>1</value>
            <value>Uslu</value>
            <value>Nevzat</value>
            <value>N</value>
        </row>
        <row>
            <value>1074</value>
            <value>161</value>
            <value>2</value>
            <value>Gul</value>
            <value>Mehmet</value>
            <value>M</value>
        </row>
        <row>
            <value>1075</value>
            <value>161</value>
            <value>3</value>
            <value>Cakmak</value>
            <value>Huseyin Altug</value>
            <value>HA</value>
        </row>
        <row>
            <value>1076</value>
            <value>161</value>
            <value>4</value>
            <value>Atam</value>
            <value>Ali</value>
            <value>A</value>
        </row>
        <row>
            <value>1077</value>
            <value>161</value>
            <value>5</value>
            <value>Pusuroglu</value>
            <value>Hamdi</value>
            <value>H</value>
        </row>
        <row>
            <value>1078</value>
            <value>161</value>
            <value>6</value>
            <value>Satilmisoglu</value>
            <value>Hulusi</value>
            <value>H</value>
        </row>
        <row>
            <value>1079</value>
            <value>161</value>
            <value>7</value>
            <value>Akkaya</value>
            <value>Emre</value>
            <value>E</value>
        </row>
        <row>
            <value>1080</value>
            <value>161</value>
            <value>8</value>
            <value>Aksu</value>
            <value>Hale Unal</value>
            <value>HU</value>
        </row>
        <row>
            <value>1081</value>
            <value>161</value>
            <value>9</value>
            <value>Kalkan</value>
            <value>Ali Kemal</value>
            <value>AK</value>
        </row>
        <row>
            <value>1082</value>
            <value>161</value>
            <value>10</value>
            <value>Surgit</value>
            <value>Ozgur</value>
            <value>O</value>
        </row>
        <row>
            <value>1083</value>
            <value>161</value>
            <value>11</value>
            <value>Erturk</value>
            <value>Mehmet</value>
            <value>M</value>
        </row>
        <row>
            <value>1084</value>
            <value>161</value>
            <value>12</value>
            <value>Aksu</value>
            <value>Huseyin</value>
            <value>H</value>
        </row>
        <row>
            <value>1085</value>
            <value>161</value>
            <value>13</value>
            <value>Eksik</value>
            <value>Abdurrahman</value>
            <value>A</value>
        </row>
        <row>
            <value>1086</value>
            <value>162</value>
            <value>1</value>
            <value>Zhao</value>
            <value>Shijie</value>
            <value>S</value>
        </row>
        <row>
            <value>1087</value>
            <value>162</value>
            <value>2</value>
            <value>Qi</value>
            <value>Guoxian</value>
            <value>G</value>
        </row>
        <row>
            <value>1088</value>
            <value>162</value>
            <value>3</value>
            <value>Tian</value>
            <value>Wen</value>
            <value>W</value>
        </row>
        <row>
            <value>1089</value>
            <value>162</value>
            <value>4</value>
            <value>Chen</value>
            <value>Ling</value>
            <value>L</value>
        </row>
        <row>
            <value>1090</value>
            <value>162</value>
            <value>5</value>
            <value>Sun</value>
            <value>Yujiao</value>
            <value>Y</value>
        </row>
        <row>
            <value>1091</value>
            <value>163</value>
            <value>1</value>
            <value>Akgul</value>
            <value>Ozgur</value>
            <value>O</value>
        </row>
        <row>
            <value>1092</value>
            <value>163</value>
            <value>2</value>
            <value>Uyarel</value>
            <value>Huseyin</value>
            <value>H</value>
        </row>
        <row>
            <value>1093</value>
            <value>163</value>
            <value>3</value>
            <value>Pusuroglu</value>
            <value>Hamdi</value>
            <value>H</value>
        </row>
        <row>
            <value>1094</value>
            <value>163</value>
            <value>4</value>
            <value>Surgit</value>
            <value>Ozgur</value>
            <value>O</value>
        </row>
        <row>
            <value>1095</value>
            <value>163</value>
            <value>5</value>
            <value>Turen</value>
            <value>Selahattin</value>
            <value>S</value>
        </row>
        <row>
            <value>1096</value>
            <value>163</value>
            <value>6</value>
            <value>Erturk</value>
            <value>Mehmet</value>
            <value>M</value>
        </row>
        <row>
            <value>1097</value>
            <value>163</value>
            <value>7</value>
            <value>Ayhan</value>
            <value>Erkan</value>
            <value>E</value>
        </row>
        <row>
            <value>1098</value>
            <value>163</value>
            <value>8</value>
            <value>Bulut</value>
            <value>Umit</value>
            <value>U</value>
        </row>
        <row>
            <value>1099</value>
            <value>163</value>
            <value>9</value>
            <value>Baycan</value>
            <value>Omer Faruk</value>
            <value>OF</value>
        </row>
        <row>
            <value>1100</value>
            <value>163</value>
            <value>10</value>
            <value>Demir</value>
            <value>Ali Riza</value>
            <value>AR</value>
        </row>
        <row>
            <value>1101</value>
            <value>163</value>
            <value>11</value>
            <value>Uslu</value>
            <value>Nevzat</value>
            <value>N</value>
        </row>
        <row>
            <value>1102</value>
            <value>164</value>
            <value>1</value>
            <value></value>
            <value>Ilker</value>
            <value>I</value>
        </row>
        <row>
            <value>1103</value>
            <value>164</value>
            <value>2</value>
            <value>Aykan</value>
            <value>Ahmet Ca??r?</value>
            <value>AC</value>
        </row>
        <row>
            <value>1104</value>
            <value>164</value>
            <value>3</value>
            <value></value>
            <value>Tayyar</value>
            <value>T</value>
        </row>
        <row>
            <value>1105</value>
            <value>164</value>
            <value>4</value>
            <value>Boyac?</value>
            <value>Faruk</value>
            <value>F</value>
        </row>
        <row>
            <value>1106</value>
            <value>164</value>
            <value>5</value>
            <value>Kalayc?o??lu</value>
            <value>Ezgi</value>
            <value>E</value>
        </row>
        <row>
            <value>1107</value>
            <value>164</value>
            <value>6</value>
            <value>Hatem</value>
            <value>Engin</value>
            <value>E</value>
        </row>
        <row>
            <value>1108</value>
            <value>164</value>
            <value>7</value>
            <value>Bilgin</value>
            <value>Murat</value>
            <value>M</value>
        </row>
        <row>
            <value>1109</value>
            <value>164</value>
            <value>8</value>
            <value>Celik</value>
            <value></value>
            <value>S</value>
        </row>
        <row>
            <value>1110</value>
            <value>165</value>
            <value>1</value>
            <value>Zitelli</value>
            <value>Kristine</value>
            <value>K</value>
        </row>
        <row>
            <value>1111</value>
            <value>165</value>
            <value>2</value>
            <value>Fernandes</value>
            <value>Neil</value>
            <value>N</value>
        </row>
        <row>
            <value>1112</value>
            <value>165</value>
            <value>3</value>
            <value>Adams</value>
            <value>Brian B</value>
            <value>BB</value>
        </row>
        <row>
            <value>1113</value>
            <value>166</value>
            <value>1</value>
            <value>Zhu</value>
            <value>Xianmin</value>
            <value>X</value>
        </row>
        <row>
            <value>1114</value>
            <value>166</value>
            <value>2</value>
            <value>Guan</value>
            <value>Jun</value>
            <value>J</value>
        </row>
        <row>
            <value>1115</value>
            <value>166</value>
            <value>3</value>
            <value>Xu</value>
            <value>Jinhuan</value>
            <value>J</value>
        </row>
        <row>
            <value>1116</value>
            <value>166</value>
            <value>4</value>
            <value>Wei</value>
            <value>Jia</value>
            <value>J</value>
        </row>
        <row>
            <value>1117</value>
            <value>166</value>
            <value>5</value>
            <value>Jiang</value>
            <value>Lijun</value>
            <value>L</value>
        </row>
        <row>
            <value>1118</value>
            <value>166</value>
            <value>6</value>
            <value>Yin</value>
            <value>Jin</value>
            <value>J</value>
        </row>
        <row>
            <value>1119</value>
            <value>166</value>
            <value>7</value>
            <value>Zhao</value>
            <value>Lei</value>
            <value>L</value>
        </row>
        <row>
            <value>1120</value>
            <value>166</value>
            <value>8</value>
            <value>Zhang</value>
            <value>Yicheng</value>
            <value>Y</value>
        </row>
        <row>
            <value>1121</value>
            <value>167</value>
            <value>1</value>
            <value>Miyazawa</value>
            <value>Yuri</value>
            <value>Y</value>
        </row>
        <row>
            <value>1122</value>
            <value>167</value>
            <value>2</value>
            <value>Tahara</value>
            <value>Kenichi</value>
            <value>K</value>
        </row>
        <row>
            <value>1123</value>
            <value>167</value>
            <value>3</value>
            <value>Yuzuriha</value>
            <value>Akinori</value>
            <value>A</value>
        </row>
        <row>
            <value>1124</value>
            <value>167</value>
            <value>4</value>
            <value>Mihara</value>
            <value>Masahiro</value>
            <value>M</value>
        </row>
        <row>
            <value>1125</value>
            <value>167</value>
            <value>5</value>
            <value>Toyama</value>
            <value>Kohtaro</value>
            <value>K</value>
        </row>
        <row>
            <value>1126</value>
            <value>167</value>
            <value>6</value>
            <value>Yokohama</value>
            <value>Akihiko</value>
            <value>A</value>
        </row>
        <row>
            <value>1127</value>
            <value>167</value>
            <value>7</value>
            <value>Handa</value>
            <value>Hiroshi</value>
            <value>H</value>
        </row>
        <row>
            <value>1128</value>
            <value>167</value>
            <value>8</value>
            <value>Jinbo</value>
            <value>Takahiro</value>
            <value>T</value>
        </row>
        <row>
            <value>1129</value>
            <value>168</value>
            <value>1</value>
            <value>Ghauri</value>
            <value>Rooha Ijaz</value>
            <value>RI</value>
        </row>
        <row>
            <value>1130</value>
            <value>168</value>
            <value>2</value>
            <value>Naveed</value>
            <value>Muhammad</value>
            <value>M</value>
        </row>
        <row>
            <value>1131</value>
            <value>168</value>
            <value>3</value>
            <value>Mannan</value>
            <value>Jovaria</value>
            <value>J</value>
        </row>
        <row>
            <value>1132</value>
            <value>169</value>
            <value>1</value>
            <value>Suarez Martinez-Falero</value>
            <value>Beatriz</value>
            <value>B</value>
        </row>
        <row>
            <value>1133</value>
            <value>169</value>
            <value>2</value>
            <value>Gillmore</value>
            <value>Roopinder</value>
            <value>R</value>
        </row>
        <row>
            <value>1134</value>
            <value>170</value>
            <value>1</value>
            <value>Agrawal</value>
            <value>Pallavi</value>
            <value>P</value>
        </row>
        <row>
            <value>1135</value>
            <value>170</value>
            <value>2</value>
            <value>Sharma</value>
            <value>Prashant</value>
            <value>P</value>
        </row>
        <row>
            <value>1136</value>
            <value>170</value>
            <value>3</value>
            <value>Narang</value>
            <value>Vikram</value>
            <value>V</value>
        </row>
        <row>
            <value>1137</value>
            <value>170</value>
            <value>4</value>
            <value>Varma</value>
            <value>Neelam</value>
            <value>N</value>
        </row>
        <row>
            <value>1138</value>
            <value>170</value>
            <value>5</value>
            <value>Malhotra</value>
            <value>Pankaj</value>
            <value>P</value>
        </row>
        <row>
            <value>1139</value>
            <value>170</value>
            <value>6</value>
            <value>Varma</value>
            <value>Subhash</value>
            <value>S</value>
        </row>
        <row>
            <value>1140</value>
            <value>171</value>
            <value>1</value>
            <value>Henniger</value>
            <value>Pauline</value>
            <value>P</value>
        </row>
        <row>
            <value>1141</value>
            <value>171</value>
            <value>2</value>
            <value>Henniger</value>
            <value>Thomas</value>
            <value>T</value>
        </row>
        <row>
            <value>1142</value>
            <value>171</value>
            <value>3</value>
            <value>Seehusen</value>
            <value>Frauke</value>
            <value>F</value>
        </row>
        <row>
            <value>1143</value>
            <value>171</value>
            <value>4</value>
            <value>Distl</value>
            <value>Ottmar</value>
            <value>O</value>
        </row>
        <row>
            <value>1144</value>
            <value>171</value>
            <value>5</value>
            <value>Ganter</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>1145</value>
            <value>172</value>
            <value>1</value>
            <value>Hangai</value>
            <value>Sho</value>
            <value>S</value>
        </row>
        <row>
            <value>1146</value>
            <value>172</value>
            <value>2</value>
            <value>Yoshimi</value>
            <value>Akihide</value>
            <value>A</value>
        </row>
        <row>
            <value>1147</value>
            <value>172</value>
            <value>3</value>
            <value>Hosoi</value>
            <value>Atsuko</value>
            <value>A</value>
        </row>
        <row>
            <value>1148</value>
            <value>172</value>
            <value>4</value>
            <value>Matsusaka</value>
            <value>Keisuke</value>
            <value>K</value>
        </row>
        <row>
            <value>1149</value>
            <value>172</value>
            <value>5</value>
            <value>Ichikawa</value>
            <value>Motoshi</value>
            <value>M</value>
        </row>
        <row>
            <value>1150</value>
            <value>172</value>
            <value>6</value>
            <value>Fukayama</value>
            <value>Masashi</value>
            <value>M</value>
        </row>
        <row>
            <value>1151</value>
            <value>172</value>
            <value>7</value>
            <value>Kurokawa</value>
            <value>Mineo</value>
            <value>M</value>
        </row>
        <row>
            <value>1152</value>
            <value>173</value>
            <value>1</value>
            <value>Bajaj</value>
            <value>Puneet</value>
            <value>P</value>
        </row>
        <row>
            <value>1153</value>
            <value>173</value>
            <value>2</value>
            <value>Clement</value>
            <value>Jincy</value>
            <value>J</value>
        </row>
        <row>
            <value>1154</value>
            <value>173</value>
            <value>3</value>
            <value>Bayerl</value>
            <value>Michael G</value>
            <value>MG</value>
        </row>
        <row>
            <value>1155</value>
            <value>173</value>
            <value>4</value>
            <value>Kalra</value>
            <value>Neelu</value>
            <value>N</value>
        </row>
        <row>
            <value>1156</value>
            <value>173</value>
            <value>5</value>
            <value>Craig</value>
            <value>Timothy J</value>
            <value>TJ</value>
        </row>
        <row>
            <value>1157</value>
            <value>173</value>
            <value>6</value>
            <value>Ishmael</value>
            <value>Faoud T</value>
            <value>FT</value>
        </row>
        <row>
            <value>1158</value>
            <value>174</value>
            <value>1</value>
            <value>Chang</value>
            <value>Jei wen</value>
            <value>Jw</value>
        </row>
        <row>
            <value>1159</value>
            <value>174</value>
            <value>2</value>
            <value>Sageshima</value>
            <value>Junichiro</value>
            <value>J</value>
        </row>
        <row>
            <value>1160</value>
            <value>174</value>
            <value>3</value>
            <value>Ciancio</value>
            <value>Gaetano</value>
            <value>G</value>
        </row>
        <row>
            <value>1161</value>
            <value>174</value>
            <value>4</value>
            <value>Mattiazzi</value>
            <value>Adela</value>
            <value>A</value>
        </row>
        <row>
            <value>1162</value>
            <value>174</value>
            <value>5</value>
            <value>Chen</value>
            <value>Linda</value>
            <value>L</value>
        </row>
        <row>
            <value>1163</value>
            <value>174</value>
            <value>6</value>
            <value>Tsai</value>
            <value>Hsin-Lin</value>
            <value>HL</value>
        </row>
        <row>
            <value>1164</value>
            <value>174</value>
            <value>7</value>
            <value>Ruiz</value>
            <value>Phillip</value>
            <value>P</value>
        </row>
        <row>
            <value>1165</value>
            <value>174</value>
            <value>8</value>
            <value>Burke</value>
            <value>George W</value>
            <value>GW</value>
        </row>
        <row>
            <value>1166</value>
            <value>175</value>
            <value>1</value>
            <value>Rajendran</value>
            <value>Aruna</value>
            <value>A</value>
        </row>
        <row>
            <value>1167</value>
            <value>175</value>
            <value>2</value>
            <value>Trehan</value>
            <value>Amita</value>
            <value>A</value>
        </row>
        <row>
            <value>1168</value>
            <value>175</value>
            <value>3</value>
            <value>Ahluwalia</value>
            <value>Jasmina</value>
            <value>J</value>
        </row>
        <row>
            <value>1169</value>
            <value>175</value>
            <value>4</value>
            <value>Marwaha</value>
            <value>Ram Kumar</value>
            <value>RK</value>
        </row>
        <row>
            <value>1170</value>
            <value>176</value>
            <value>1</value>
            <value>Liu</value>
            <value>Wen-Cheng</value>
            <value>WC</value>
        </row>
        <row>
            <value>1171</value>
            <value>176</value>
            <value>2</value>
            <value>Chen</value>
            <value>Hsiang-Cheng</value>
            <value>HC</value>
        </row>
        <row>
            <value>1172</value>
            <value>176</value>
            <value>3</value>
            <value>Chen</value>
            <value>Jin-Shuen</value>
            <value>JS</value>
        </row>
        <row>
            <value>1173</value>
            <value>177</value>
            <value>1</value>
            <value>Karapinar</value>
            <value>Deniz Yilmaz</value>
            <value>DY</value>
        </row>
        <row>
            <value>1174</value>
            <value>177</value>
            <value>2</value>
            <value>Karada??</value>
            <value>Nihal</value>
            <value>N</value>
        </row>
        <row>
            <value>1175</value>
            <value>177</value>
            <value>3</value>
            <value>Yazici</value>
            <value>Pinar</value>
            <value>P</value>
        </row>
        <row>
            <value>1176</value>
            <value>177</value>
            <value>4</value>
            <value>Polat</value>
            <value></value>
            <value>SH</value>
        </row>
        <row>
            <value>1177</value>
            <value>177</value>
            <value>5</value>
            <value>Karapinar</value>
            <value></value>
            <value>B</value>
        </row>
        <row>
            <value>1178</value>
            <value>178</value>
            <value>1</value>
            <value>Yamamoto</value>
            <value>Nobuyuki</value>
            <value>N</value>
        </row>
        <row>
            <value>1179</value>
            <value>178</value>
            <value>2</value>
            <value>Nishimura</value>
            <value>Noriyuki</value>
            <value>N</value>
        </row>
        <row>
            <value>1180</value>
            <value>178</value>
            <value>3</value>
            <value>Takeuchi</value>
            <value>Mai</value>
            <value>M</value>
        </row>
        <row>
            <value>1181</value>
            <value>178</value>
            <value>4</value>
            <value>Ito</value>
            <value>Tomoo</value>
            <value>T</value>
        </row>
        <row>
            <value>1182</value>
            <value>178</value>
            <value>5</value>
            <value>Yokozaki</value>
            <value>Hiroshi</value>
            <value>H</value>
        </row>
        <row>
            <value>1183</value>
            <value>178</value>
            <value>6</value>
            <value>Hirase</value>
            <value>Satoshi</value>
            <value>S</value>
        </row>
        <row>
            <value>1184</value>
            <value>178</value>
            <value>7</value>
            <value>Kubokawa</value>
            <value>Ikuko</value>
            <value>I</value>
        </row>
        <row>
            <value>1185</value>
            <value>178</value>
            <value>8</value>
            <value>Mori</value>
            <value>Takeshi</value>
            <value>T</value>
        </row>
        <row>
            <value>1186</value>
            <value>178</value>
            <value>9</value>
            <value>Yanai</value>
            <value>Tomoko</value>
            <value>T</value>
        </row>
        <row>
            <value>1187</value>
            <value>178</value>
            <value>10</value>
            <value>Hayakawa</value>
            <value>Akira</value>
            <value>A</value>
        </row>
        <row>
            <value>1188</value>
            <value>178</value>
            <value>11</value>
            <value>Takeshima</value>
            <value>Yasuhiro</value>
            <value>Y</value>
        </row>
        <row>
            <value>1189</value>
            <value>178</value>
            <value>12</value>
            <value>Nishio</value>
            <value>Hisahide</value>
            <value>H</value>
        </row>
        <row>
            <value>1190</value>
            <value>178</value>
            <value>13</value>
            <value>Matsuo</value>
            <value>Masafumi</value>
            <value>M</value>
        </row>
        <row>
            <value>1191</value>
            <value>178</value>
            <value>14</value>
            <value>Imadome</value>
            <value>Ken-Ichi</value>
            <value>KI</value>
        </row>
        <row>
            <value>1192</value>
            <value>178</value>
            <value>15</value>
            <value>Iijima</value>
            <value>Kazumoto</value>
            <value>K</value>
        </row>
        <row>
            <value>1193</value>
            <value>179</value>
            <value>1</value>
            <value>Kataria</value>
            <value>Rachna</value>
            <value>R</value>
        </row>
        <row>
            <value>1194</value>
            <value>179</value>
            <value>2</value>
            <value>Shah</value>
            <value>Ira</value>
            <value>I</value>
        </row>
        <row>
            <value>1195</value>
            <value>180</value>
            <value>1</value>
            <value>Siminas</value>
            <value>Sotirios</value>
            <value>S</value>
        </row>
        <row>
            <value>1196</value>
            <value>180</value>
            <value>2</value>
            <value>Caswell</value>
            <value>Mark</value>
            <value>M</value>
        </row>
        <row>
            <value>1197</value>
            <value>180</value>
            <value>3</value>
            <value>Kenny</value>
            <value>Simon E</value>
            <value>SE</value>
        </row>
        <row>
            <value>1198</value>
            <value>181</value>
            <value>1</value>
            <value>Abeni</value>
            <value>Chiara</value>
            <value>C</value>
        </row>
        <row>
            <value>1199</value>
            <value>181</value>
            <value>2</value>
            <value>Rota</value>
            <value>Luigina</value>
            <value>L</value>
        </row>
        <row>
            <value>1200</value>
            <value>181</value>
            <value>3</value>
            <value>Ogliosi</value>
            <value>Chiara</value>
            <value>C</value>
        </row>
        <row>
            <value>1201</value>
            <value>181</value>
            <value>4</value>
            <value>Bertocchi</value>
            <value>Paola</value>
            <value>P</value>
        </row>
        <row>
            <value>1202</value>
            <value>181</value>
            <value>5</value>
            <value>Centurini</value>
            <value>Pietro Berra</value>
            <value>PB</value>
        </row>
        <row>
            <value>1203</value>
            <value>181</value>
            <value>6</value>
            <value>Zaniboni</value>
            <value>Alberto</value>
            <value>A</value>
        </row>
        <row>
            <value>1204</value>
            <value>182</value>
            <value>1</value>
            <value>Rangaswamy</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1205</value>
            <value>182</value>
            <value>2</value>
            <value>Prabhu</value>
            <value></value>
            <value></value>
        </row>
        <row>
            <value>1206</value>
            <value>182</value>
            <value>3</value>
            <value>Nandini</value>
            <value>N M</value>
            <value>NM</value>
        </row>
        <row>
            <value>1207</value>
            <value>182</value>
            <value>4</value>
            <value>Manjunath</value>
            <value>G V</value>
            <value>GV</value>
        </row>
        <row>
            <value>1208</value>
            <value>183</value>
            <value>1</value>
            <value>Tsai</value>
            <value>An-Swen</value>
            <value>AS</value>
        </row>
        <row>
            <value>1209</value>
            <value>183</value>
            <value>2</value>
            <value>Ko</value>
            <value>Chung-Wang</value>
            <value>CW</value>
        </row>
        <row>
            <value>1210</value>
            <value>183</value>
            <value>3</value>
            <value>Yeh</value>
            <value>Hong-Zen</value>
            <value>HZ</value>
        </row>
        <row>
            <value>1211</value>
            <value>183</value>
            <value>4</value>
            <value>Chang</value>
            <value>Chi-Sen</value>
            <value>CS</value>
        </row>
        <row>
            <value>1212</value>
            <value>183</value>
            <value>5</value>
            <value>Wang</value>
            <value>Ren Ching</value>
            <value>RC</value>
        </row>
        <row>
            <value>1213</value>
            <value>184</value>
            <value>1</value>
            <value></value>
            <value>Vivian</value>
            <value>V</value>
        </row>
        <row>
            <value>1214</value>
            <value>184</value>
            <value>2</value>
            <value>Calado</value>
            <value>Rita</value>
            <value>R</value>
        </row>
        <row>
            <value>1215</value>
            <value>184</value>
            <value>3</value>
            <value></value>
            <value></value>
            <value>MJ</value>
        </row>
        <row>
            <value>1216</value>
            <value>184</value>
            <value>4</value>
            <value></value>
            <value>Anabela</value>
            <value>A</value>
        </row>
        <row>
            <value>1217</value>
            <value>184</value>
            <value>5</value>
            <value>Morais</value>
            <value>Anabela</value>
            <value>A</value>
        </row>
        <row>
            <value>1218</value>
            <value>185</value>
            <value>1</value>
            <value>Jarfaut</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1219</value>
            <value>185</value>
            <value>2</value>
            <value>Santucci</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1220</value>
            <value>185</value>
            <value>3</value>
            <value></value>
            <value>D</value>
            <value>D</value>
        </row>
        <row>
            <value>1221</value>
            <value>185</value>
            <value>4</value>
            <value>Herbrecht</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1222</value>
            <value>186</value>
            <value>1</value>
            <value>Takahashi</value>
            <value>Hiroyoshi</value>
            <value>H</value>
        </row>
        <row>
            <value>1223</value>
            <value>186</value>
            <value>2</value>
            <value>Koh</value>
            <value>Katsuyoshi</value>
            <value>K</value>
        </row>
        <row>
            <value>1224</value>
            <value>186</value>
            <value>3</value>
            <value>Yasui</value>
            <value>Naoko</value>
            <value>N</value>
        </row>
        <row>
            <value>1225</value>
            <value>186</value>
            <value>4</value>
            <value>Mori</value>
            <value>Makiko</value>
            <value>M</value>
        </row>
        <row>
            <value>1226</value>
            <value>186</value>
            <value>5</value>
            <value>Akiyama</value>
            <value>Kosuke</value>
            <value>K</value>
        </row>
        <row>
            <value>1227</value>
            <value>186</value>
            <value>6</value>
            <value>Seki</value>
            <value>Masafumi</value>
            <value>M</value>
        </row>
        <row>
            <value>1228</value>
            <value>186</value>
            <value>7</value>
            <value>Kato</value>
            <value>Motohiro</value>
            <value>M</value>
        </row>
        <row>
            <value>1229</value>
            <value>186</value>
            <value>8</value>
            <value>Kagimoto</value>
            <value>Seiichi</value>
            <value>S</value>
        </row>
        <row>
            <value>1230</value>
            <value>186</value>
            <value>9</value>
            <value>Oh-Ishi</value>
            <value>Tsutomu</value>
            <value>T</value>
        </row>
        <row>
            <value>1231</value>
            <value>186</value>
            <value>10</value>
            <value>Hanada</value>
            <value>Ryoji</value>
            <value>R</value>
        </row>
        <row>
            <value>1232</value>
            <value>187</value>
            <value>1</value>
            <value>Ahn</value>
            <value>Jin Young</value>
            <value>JY</value>
        </row>
        <row>
            <value>1233</value>
            <value>187</value>
            <value>2</value>
            <value>Seok</value>
            <value>Soon Ja</value>
            <value>SJ</value>
        </row>
        <row>
            <value>1234</value>
            <value>187</value>
            <value>3</value>
            <value>Song</value>
            <value>Je Eun</value>
            <value>JE</value>
        </row>
        <row>
            <value>1235</value>
            <value>187</value>
            <value>4</value>
            <value>Choi</value>
            <value>Jung Ho</value>
            <value>JH</value>
        </row>
        <row>
            <value>1236</value>
            <value>187</value>
            <value>5</value>
            <value>Han</value>
            <value>Sang Hoon</value>
            <value>SH</value>
        </row>
        <row>
            <value>1237</value>
            <value>187</value>
            <value>6</value>
            <value>Choi</value>
            <value>Jun Yong</value>
            <value>JY</value>
        </row>
        <row>
            <value>1238</value>
            <value>187</value>
            <value>7</value>
            <value>Kim</value>
            <value>Chang Oh</value>
            <value>CO</value>
        </row>
        <row>
            <value>1239</value>
            <value>187</value>
            <value>8</value>
            <value>Song</value>
            <value>Young Goo</value>
            <value>YG</value>
        </row>
        <row>
            <value>1240</value>
            <value>187</value>
            <value>9</value>
            <value>Kim</value>
            <value>June Myung</value>
            <value>JM</value>
        </row>
        <row>
            <value>1241</value>
            <value>188</value>
            <value>1</value>
            <value>Balta</value>
            <value>Gunay</value>
            <value>G</value>
        </row>
        <row>
            <value>1242</value>
            <value>188</value>
            <value>2</value>
            <value>Topcuoglu</value>
            <value>Sevilay</value>
            <value>S</value>
        </row>
        <row>
            <value>1243</value>
            <value>188</value>
            <value>3</value>
            <value>Gursoy</value>
            <value>Tugba</value>
            <value>T</value>
        </row>
        <row>
            <value>1244</value>
            <value>188</value>
            <value>4</value>
            <value>Gurgey</value>
            <value>Aytemiz</value>
            <value>A</value>
        </row>
        <row>
            <value>1245</value>
            <value>188</value>
            <value>5</value>
            <value>Ovali</value>
            <value>Fahri</value>
            <value>F</value>
        </row>
        <row>
            <value>1246</value>
            <value>189</value>
            <value>1</value>
            <value>Sevinc</value>
            <value>Ferda</value>
            <value>F</value>
        </row>
        <row>
            <value>1247</value>
            <value>189</value>
            <value>2</value>
            <value>Sevinc</value>
            <value>Mutlu</value>
            <value>M</value>
        </row>
        <row>
            <value>1248</value>
            <value>189</value>
            <value>3</value>
            <value>Ekici</value>
            <value>Ozlem Derinbay</value>
            <value>OD</value>
        </row>
        <row>
            <value>1249</value>
            <value>189</value>
            <value>4</value>
            <value>Yildiz</value>
            <value>Ramazan</value>
            <value>R</value>
        </row>
        <row>
            <value>1250</value>
            <value>189</value>
            <value>5</value>
            <value>Isik</value>
            <value>Nermin</value>
            <value>N</value>
        </row>
        <row>
            <value>1251</value>
            <value>189</value>
            <value>6</value>
            <value>Aydogdu</value>
            <value>Ugur</value>
            <value>U</value>
        </row>
        <row>
            <value>1252</value>
            <value>190</value>
            <value>1</value>
            <value>Sulko</value>
            <value>Jerzy</value>
            <value>J</value>
        </row>
        <row>
            <value>1253</value>
            <value>191</value>
            <value>1</value>
            <value>Karvunidis</value>
            <value>Thomas</value>
            <value>T</value>
        </row>
        <row>
            <value>1254</value>
            <value>191</value>
            <value>2</value>
            <value>Chvojka</value>
            <value>Jiri</value>
            <value>J</value>
        </row>
        <row>
            <value>1255</value>
            <value>191</value>
            <value>3</value>
            <value>Lysak</value>
            <value>Daniel</value>
            <value>D</value>
        </row>
        <row>
            <value>1256</value>
            <value>191</value>
            <value>4</value>
            <value>Sykora</value>
            <value>Roman</value>
            <value>R</value>
        </row>
        <row>
            <value>1257</value>
            <value>191</value>
            <value>5</value>
            <value>Krouzecky</value>
            <value>Ales</value>
            <value>A</value>
        </row>
        <row>
            <value>1258</value>
            <value>191</value>
            <value>6</value>
            <value>Radej</value>
            <value>Jaroslav</value>
            <value>J</value>
        </row>
        <row>
            <value>1259</value>
            <value>191</value>
            <value>7</value>
            <value>Novak</value>
            <value>Ivan</value>
            <value>I</value>
        </row>
        <row>
            <value>1260</value>
            <value>191</value>
            <value>8</value>
            <value>Matejovic</value>
            <value>Martin</value>
            <value>M</value>
        </row>
        <row>
            <value>1261</value>
            <value>192</value>
            <value>1</value>
            <value>Keddis</value>
            <value>Mira</value>
            <value>M</value>
        </row>
        <row>
            <value>1262</value>
            <value>192</value>
            <value>2</value>
            <value>Leung</value>
            <value>Nelson</value>
            <value>N</value>
        </row>
        <row>
            <value>1263</value>
            <value>192</value>
            <value>3</value>
            <value>Herrmann</value>
            <value>Sandra</value>
            <value>S</value>
        </row>
        <row>
            <value>1264</value>
            <value>192</value>
            <value>4</value>
            <value>El-Zoghby</value>
            <value>Ziad</value>
            <value>Z</value>
        </row>
        <row>
            <value>1265</value>
            <value>192</value>
            <value>5</value>
            <value>Sethi</value>
            <value>Sanjeev</value>
            <value>S</value>
        </row>
        <row>
            <value>1266</value>
            <value>193</value>
            <value>1</value>
            <value>Garbay</value>
            <value>Delphine</value>
            <value>D</value>
        </row>
        <row>
            <value>1267</value>
            <value>193</value>
            <value>2</value>
            <value>Durrieu</value>
            <value></value>
            <value>F</value>
        </row>
        <row>
            <value>1268</value>
            <value>193</value>
            <value>3</value>
            <value>Bui</value>
            <value>Binh</value>
            <value>B</value>
        </row>
        <row>
            <value>1269</value>
            <value>193</value>
            <value>4</value>
            <value>Italiano</value>
            <value>Antoine</value>
            <value>A</value>
        </row>
        <row>
            <value>1270</value>
            <value>194</value>
            <value>1</value>
            <value>Sharma</value>
            <value>Hema</value>
            <value>H</value>
        </row>
        <row>
            <value>1271</value>
            <value>194</value>
            <value>2</value>
            <value>Keshavan</value>
            <value>Ashvini</value>
            <value>A</value>
        </row>
        <row>
            <value>1272</value>
            <value>194</value>
            <value>3</value>
            <value>Little</value>
            <value>Mark Alan</value>
            <value>MA</value>
        </row>
        <row>
            <value>1273</value>
            <value>194</value>
            <value>4</value>
            <value>Cross</value>
            <value>Jennifer</value>
            <value>J</value>
        </row>
        <row>
            <value>1274</value>
            <value>194</value>
            <value>5</value>
            <value>Lipman</value>
            <value>Marc C</value>
            <value>MC</value>
        </row>
        <row>
            <value>1275</value>
            <value>194</value>
            <value>6</value>
            <value>Talukdar</value>
            <value>Sabrina</value>
            <value>S</value>
        </row>
        <row>
            <value>1276</value>
            <value>194</value>
            <value>7</value>
            <value>Hopkins</value>
            <value>Susan</value>
            <value>S</value>
        </row>
        <row>
            <value>1277</value>
            <value>195</value>
            <value>1</value>
            <value>Giri</value>
            <value>Prabhas Prasun</value>
            <value>PP</value>
        </row>
        <row>
            <value>1278</value>
            <value>195</value>
            <value>2</value>
            <value>Pal</value>
            <value>Priyankar</value>
            <value>P</value>
        </row>
        <row>
            <value>1279</value>
            <value>195</value>
            <value>3</value>
            <value>Ghosh</value>
            <value>Apurba</value>
            <value>A</value>
        </row>
        <row>
            <value>1280</value>
            <value>195</value>
            <value>4</value>
            <value>Sinha</value>
            <value>Rajiv</value>
            <value>R</value>
        </row>
        <row>
            <value>1281</value>
            <value>196</value>
            <value>1</value>
            <value>Fardet</value>
            <value>Laurence</value>
            <value>L</value>
        </row>
        <row>
            <value>1282</value>
            <value>196</value>
            <value>2</value>
            <value>Galicier</value>
            <value>Lionel</value>
            <value>L</value>
        </row>
        <row>
            <value>1283</value>
            <value>196</value>
            <value>3</value>
            <value>Lambotte</value>
            <value>Olivier</value>
            <value>O</value>
        </row>
        <row>
            <value>1284</value>
            <value>196</value>
            <value>4</value>
            <value>Marzac</value>
            <value>Christophe</value>
            <value>C</value>
        </row>
        <row>
            <value>1285</value>
            <value>196</value>
            <value>5</value>
            <value>Aumont</value>
            <value>Cedric</value>
            <value>C</value>
        </row>
        <row>
            <value>1286</value>
            <value>196</value>
            <value>6</value>
            <value>Chahwan</value>
            <value>Doumit</value>
            <value>D</value>
        </row>
        <row>
            <value>1287</value>
            <value>196</value>
            <value>7</value>
            <value>Coppo</value>
            <value>Paul</value>
            <value>P</value>
        </row>
        <row>
            <value>1288</value>
            <value>196</value>
            <value>8</value>
            <value>Hejblum</value>
            <value>Gilles</value>
            <value>G</value>
        </row>
        <row>
            <value>1289</value>
            <value>197</value>
            <value>1</value>
            <value>Klein</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>1290</value>
            <value>197</value>
            <value>2</value>
            <value>Schmidt</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>1291</value>
            <value>197</value>
            <value>3</value>
            <value></value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1292</value>
            <value>197</value>
            <value>4</value>
            <value>Pletz</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1293</value>
            <value>197</value>
            <value>5</value>
            <value>Harz</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>1294</value>
            <value>197</value>
            <value>6</value>
            <value>Dirsch</value>
            <value>O</value>
            <value>O</value>
        </row>
        <row>
            <value>1295</value>
            <value>197</value>
            <value>7</value>
            <value>Fritzenwanger</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1296</value>
            <value>197</value>
            <value>8</value>
            <value>Stallmach</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1297</value>
            <value>198</value>
            <value>1</value>
            <value>Morano</value>
            <value>Salvatore Giacomo</value>
            <value>SG</value>
        </row>
        <row>
            <value>1298</value>
            <value>198</value>
            <value>2</value>
            <value>Coppola</value>
            <value>Lorenzo</value>
            <value>L</value>
        </row>
        <row>
            <value>1299</value>
            <value>198</value>
            <value>3</value>
            <value>Latagliata</value>
            <value>Roberto</value>
            <value>R</value>
        </row>
        <row>
            <value>1300</value>
            <value>198</value>
            <value>4</value>
            <value>Berneschi</value>
            <value>Paola</value>
            <value>P</value>
        </row>
        <row>
            <value>1301</value>
            <value>198</value>
            <value>5</value>
            <value>Chistolini</value>
            <value>Antonio</value>
            <value>A</value>
        </row>
        <row>
            <value>1302</value>
            <value>198</value>
            <value>6</value>
            <value>Micozzi</value>
            <value>Alessandra</value>
            <value>A</value>
        </row>
        <row>
            <value>1303</value>
            <value>198</value>
            <value>7</value>
            <value>Girmenia</value>
            <value>Corrado</value>
            <value>C</value>
        </row>
        <row>
            <value>1304</value>
            <value>198</value>
            <value>8</value>
            <value>Breccia</value>
            <value>Massimo</value>
            <value>M</value>
        </row>
        <row>
            <value>1305</value>
            <value>198</value>
            <value>9</value>
            <value>Brunetti</value>
            <value>Gregorio</value>
            <value>G</value>
        </row>
        <row>
            <value>1306</value>
            <value>198</value>
            <value>10</value>
            <value>Massaro</value>
            <value>Fulvio</value>
            <value>F</value>
        </row>
        <row>
            <value>1307</value>
            <value>198</value>
            <value>11</value>
            <value>Rosa</value>
            <value>Giovanni</value>
            <value>G</value>
        </row>
        <row>
            <value>1308</value>
            <value>198</value>
            <value>12</value>
            <value>Guerrisi</value>
            <value>Pietro</value>
            <value>P</value>
        </row>
        <row>
            <value>1309</value>
            <value>198</value>
            <value>13</value>
            <value>Mandelli</value>
            <value>Franco</value>
            <value>F</value>
        </row>
        <row>
            <value>1310</value>
            <value>198</value>
            <value>14</value>
            <value></value>
            <value>Roberto</value>
            <value>R</value>
        </row>
        <row>
            <value>1311</value>
            <value>198</value>
            <value>15</value>
            <value>Alimena</value>
            <value>Giuliana</value>
            <value>G</value>
        </row>
        <row>
            <value>1312</value>
            <value>199</value>
            <value>1</value>
            <value>Li</value>
            <value>Jing</value>
            <value>J</value>
        </row>
        <row>
            <value>1313</value>
            <value>199</value>
            <value>2</value>
            <value>Wang</value>
            <value>Qian</value>
            <value>Q</value>
        </row>
        <row>
            <value>1314</value>
            <value>199</value>
            <value>3</value>
            <value>Zheng</value>
            <value>Wenjie</value>
            <value>W</value>
        </row>
        <row>
            <value>1315</value>
            <value>199</value>
            <value>4</value>
            <value>Ma</value>
            <value>Jie</value>
            <value>J</value>
        </row>
        <row>
            <value>1316</value>
            <value>199</value>
            <value>5</value>
            <value>Zhang</value>
            <value>Wei</value>
            <value>W</value>
        </row>
        <row>
            <value>1317</value>
            <value>199</value>
            <value>6</value>
            <value>Wang</value>
            <value>Wenze</value>
            <value>W</value>
        </row>
        <row>
            <value>1318</value>
            <value>199</value>
            <value>7</value>
            <value>Tian</value>
            <value>Xinping</value>
            <value>X</value>
        </row>
        <row>
            <value>1319</value>
            <value>200</value>
            <value>1</value>
            <value>Adamkovich</value>
            <value></value>
            <value>N</value>
        </row>
        <row>
            <value>1320</value>
            <value>200</value>
            <value>2</value>
            <value></value>
            <value></value>
            <value>M</value>
        </row>
        <row>
            <value>1321</value>
            <value>200</value>
            <value>3</value>
            <value></value>
            <value></value>
            <value>L</value>
        </row>
        <row>
            <value>1322</value>
            <value>200</value>
            <value>4</value>
            <value>Bagdi</value>
            <value>Enik??</value>
            <value>E</value>
        </row>
        <row>
            <value>1323</value>
            <value>200</value>
            <value>5</value>
            <value></value>
            <value>Zita</value>
            <value>Z</value>
        </row>
        <row>
            <value>1324</value>
            <value>201</value>
            <value>1</value>
            <value>Croker</value>
            <value>Ben A</value>
            <value>BA</value>
        </row>
        <row>
            <value>1325</value>
            <value>201</value>
            <value>2</value>
            <value>O'Donnell</value>
            <value>Joanne A</value>
            <value>JA</value>
        </row>
        <row>
            <value>1326</value>
            <value>201</value>
            <value>3</value>
            <value>Gerlic</value>
            <value>Motti</value>
            <value>M</value>
        </row>
        <row>
            <value>1327</value>
            <value>202</value>
            <value>1</value>
            <value>Hamidieh</value>
            <value>Amir Ali</value>
            <value>AA</value>
        </row>
        <row>
            <value>1328</value>
            <value>202</value>
            <value>2</value>
            <value>Pourpak</value>
            <value>Zahra</value>
            <value>Z</value>
        </row>
        <row>
            <value>1329</value>
            <value>202</value>
            <value>3</value>
            <value>Hashemi</value>
            <value>Susan</value>
            <value>S</value>
        </row>
        <row>
            <value>1330</value>
            <value>202</value>
            <value>4</value>
            <value>Yari</value>
            <value>Kolsoum</value>
            <value>K</value>
        </row>
        <row>
            <value>1331</value>
            <value>202</value>
            <value>5</value>
            <value>Fazlollahi</value>
            <value>Mohammad Reza</value>
            <value>MR</value>
        </row>
        <row>
            <value>1332</value>
            <value>202</value>
            <value>6</value>
            <value>Movahedi</value>
            <value>Masoud</value>
            <value>M</value>
        </row>
        <row>
            <value>1333</value>
            <value>202</value>
            <value>7</value>
            <value>Behfar</value>
            <value>Maryam</value>
            <value>M</value>
        </row>
        <row>
            <value>1334</value>
            <value>202</value>
            <value>8</value>
            <value>Moin</value>
            <value>Mostafa</value>
            <value>M</value>
        </row>
        <row>
            <value>1335</value>
            <value>202</value>
            <value>9</value>
            <value>Ghavamzadeh</value>
            <value>Ardeshir</value>
            <value>A</value>
        </row>
        <row>
            <value>1336</value>
            <value>203</value>
            <value>1</value>
            <value>Lehmann</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1337</value>
            <value>203</value>
            <value>2</value>
            <value>Huber</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>1338</value>
            <value>203</value>
            <value>3</value>
            <value></value>
            <value>T</value>
            <value>T</value>
        </row>
        <row>
            <value>1339</value>
            <value>203</value>
            <value>4</value>
            <value>Fleck</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1340</value>
            <value>204</value>
            <value>1</value>
            <value>Hatfield</value>
            <value>Kimberley Joanne</value>
            <value>KJ</value>
        </row>
        <row>
            <value>1341</value>
            <value>204</value>
            <value>2</value>
            <value>Lassalle</value>
            <value>Philippe</value>
            <value>P</value>
        </row>
        <row>
            <value>1342</value>
            <value>204</value>
            <value>3</value>
            <value>Leiva</value>
            <value>Rafael Alexander</value>
            <value>RA</value>
        </row>
        <row>
            <value>1343</value>
            <value>204</value>
            <value>4</value>
            <value></value>
            <value>Roald</value>
            <value>R</value>
        </row>
        <row>
            <value>1344</value>
            <value>204</value>
            <value>5</value>
            <value>Wendelboe</value>
            <value>??ystein</value>
            <value>??</value>
        </row>
        <row>
            <value>1345</value>
            <value>204</value>
            <value>6</value>
            <value>Bruserud</value>
            <value>??ystein</value>
            <value>??</value>
        </row>
        <row>
            <value>1346</value>
            <value>205</value>
            <value>1</value>
            <value>Garrett</value>
            <value>Jared</value>
            <value>J</value>
        </row>
        <row>
            <value>1347</value>
            <value>205</value>
            <value>2</value>
            <value>Klimberg</value>
            <value>V Suzanne</value>
            <value>VS</value>
        </row>
        <row>
            <value>1348</value>
            <value>205</value>
            <value>3</value>
            <value>Anaissie</value>
            <value>Elias</value>
            <value>E</value>
        </row>
        <row>
            <value>1349</value>
            <value>205</value>
            <value>4</value>
            <value>Barlogie</value>
            <value>Bart</value>
            <value>B</value>
        </row>
        <row>
            <value>1350</value>
            <value>205</value>
            <value>5</value>
            <value>Turnage</value>
            <value>Richard</value>
            <value>R</value>
        </row>
        <row>
            <value>1351</value>
            <value>205</value>
            <value>6</value>
            <value>Badgwell</value>
            <value>Brian D</value>
            <value>BD</value>
        </row>
        <row>
            <value>1352</value>
            <value>206</value>
            <value>1</value>
            <value>Young</value>
            <value>Pablo</value>
            <value>P</value>
        </row>
        <row>
            <value>1353</value>
            <value>206</value>
            <value>2</value>
            <value>Peroni</value>
            <value>Jose</value>
            <value>J</value>
        </row>
        <row>
            <value>1354</value>
            <value>206</value>
            <value>3</value>
            <value>Finn</value>
            <value></value>
            <value>BC</value>
        </row>
        <row>
            <value>1355</value>
            <value>206</value>
            <value>4</value>
            <value>Venditti</value>
            <value>Julio E</value>
            <value>JE</value>
        </row>
        <row>
            <value>1356</value>
            <value>206</value>
            <value>5</value>
            <value>Preiti</value>
            <value></value>
            <value>V</value>
        </row>
        <row>
            <value>1357</value>
            <value>206</value>
            <value>6</value>
            <value>Bullorsky</value>
            <value>Eduardo</value>
            <value>E</value>
        </row>
        <row>
            <value>1358</value>
            <value>206</value>
            <value>7</value>
            <value>Bruetman</value>
            <value>Julio E</value>
            <value>JE</value>
        </row>
        <row>
            <value>1359</value>
            <value>207</value>
            <value>1</value>
            <value>Raschke</value>
            <value>Robert A</value>
            <value>RA</value>
        </row>
        <row>
            <value>1360</value>
            <value>207</value>
            <value>2</value>
            <value>Garcia-Orr</value>
            <value>Roxanne</value>
            <value>R</value>
        </row>
        <row>
            <value>1361</value>
            <value>208</value>
            <value>1</value>
            <value>Okabe</value>
            <value>Toshimasa</value>
            <value>T</value>
        </row>
        <row>
            <value>1362</value>
            <value>208</value>
            <value>2</value>
            <value>Shah</value>
            <value>Gunjan</value>
            <value>G</value>
        </row>
        <row>
            <value>1363</value>
            <value>208</value>
            <value>3</value>
            <value>Mendoza</value>
            <value>Vinia</value>
            <value>V</value>
        </row>
        <row>
            <value>1364</value>
            <value>208</value>
            <value>4</value>
            <value>Hirani</value>
            <value>Amyn</value>
            <value>A</value>
        </row>
        <row>
            <value>1365</value>
            <value>208</value>
            <value>5</value>
            <value>Baram</value>
            <value>Michael</value>
            <value>M</value>
        </row>
        <row>
            <value>1366</value>
            <value>208</value>
            <value>6</value>
            <value>Marik</value>
            <value>Paul</value>
            <value>P</value>
        </row>
        <row>
            <value>1367</value>
            <value>209</value>
            <value>1</value>
            <value>Al-Hamoudi</value>
            <value>Waleed</value>
            <value>W</value>
        </row>
        <row>
            <value>1368</value>
            <value>209</value>
            <value>2</value>
            <value>Mohamed</value>
            <value>Hazem</value>
            <value>H</value>
        </row>
        <row>
            <value>1369</value>
            <value>209</value>
            <value>3</value>
            <value>Abaalkhail</value>
            <value>Faisal</value>
            <value>F</value>
        </row>
        <row>
            <value>1370</value>
            <value>209</value>
            <value>4</value>
            <value>Kamel</value>
            <value>Yaser</value>
            <value>Y</value>
        </row>
        <row>
            <value>1371</value>
            <value>209</value>
            <value>5</value>
            <value>Al-Masri</value>
            <value>Nasser</value>
            <value>N</value>
        </row>
        <row>
            <value>1372</value>
            <value>209</value>
            <value>6</value>
            <value>Allam</value>
            <value>Naglaa</value>
            <value>N</value>
        </row>
        <row>
            <value>1373</value>
            <value>209</value>
            <value>7</value>
            <value>Alqahtani</value>
            <value>Saleh</value>
            <value>S</value>
        </row>
        <row>
            <value>1374</value>
            <value>209</value>
            <value>8</value>
            <value>Al-Sofayan</value>
            <value>Mohammed</value>
            <value>M</value>
        </row>
        <row>
            <value>1375</value>
            <value>209</value>
            <value>9</value>
            <value>Khalaf</value>
            <value>Hatem</value>
            <value>H</value>
        </row>
        <row>
            <value>1376</value>
            <value>209</value>
            <value>10</value>
            <value>Al-Sebayel</value>
            <value>Mohammed</value>
            <value>M</value>
        </row>
        <row>
            <value>1377</value>
            <value>209</value>
            <value>11</value>
            <value>Al-Jedai</value>
            <value>Ahmed</value>
            <value>A</value>
        </row>
        <row>
            <value>1378</value>
            <value>209</value>
            <value>12</value>
            <value>Abdo</value>
            <value>Ayman</value>
            <value>A</value>
        </row>
        <row>
            <value>1379</value>
            <value>210</value>
            <value>1</value>
            <value>Panda</value>
            <value>Dipanjan</value>
            <value>D</value>
        </row>
        <row>
            <value>1380</value>
            <value>210</value>
            <value>2</value>
            <value>Gupta</value>
            <value>Nidhi</value>
            <value>N</value>
        </row>
        <row>
            <value>1381</value>
            <value>210</value>
            <value>3</value>
            <value>Gupta</value>
            <value>Ritu</value>
            <value>R</value>
        </row>
        <row>
            <value>1382</value>
            <value>210</value>
            <value>4</value>
            <value>Bakhshi</value>
            <value>Sameer</value>
            <value>S</value>
        </row>
        <row>
            <value>1383</value>
            <value>211</value>
            <value>1</value>
            <value>Eisele</value>
            <value>Lewin</value>
            <value>L</value>
        </row>
        <row>
            <value>1384</value>
            <value>211</value>
            <value>2</value>
            <value></value>
            <value>Florian</value>
            <value>F</value>
        </row>
        <row>
            <value>1385</value>
            <value>211</value>
            <value>3</value>
            <value>Ebeling</value>
            <value>Peter</value>
            <value>P</value>
        </row>
        <row>
            <value>1386</value>
            <value>211</value>
            <value>4</value>
            <value>Nabring</value>
            <value>Jens</value>
            <value>J</value>
        </row>
        <row>
            <value>1387</value>
            <value>211</value>
            <value>5</value>
            <value></value>
            <value>Ulrich</value>
            <value>U</value>
        </row>
        <row>
            <value>1388</value>
            <value>211</value>
            <value>6</value>
            <value></value>
            <value>Jan</value>
            <value>J</value>
        </row>
        <row>
            <value>1389</value>
            <value>212</value>
            <value>1</value>
            <value>Charoo</value>
            <value>Bashir A</value>
            <value>BA</value>
        </row>
        <row>
            <value>1390</value>
            <value>212</value>
            <value>2</value>
            <value>Iqbal</value>
            <value>Javeed I</value>
            <value>JI</value>
        </row>
        <row>
            <value>1391</value>
            <value>212</value>
            <value>3</value>
            <value>Iqbal</value>
            <value>Qazi</value>
            <value>Q</value>
        </row>
        <row>
            <value>1392</value>
            <value>212</value>
            <value>4</value>
            <value>Mushtaq</value>
            <value>Sheikh</value>
            <value>S</value>
        </row>
        <row>
            <value>1393</value>
            <value>212</value>
            <value>5</value>
            <value>Bhat</value>
            <value>Abdul W</value>
            <value>AW</value>
        </row>
        <row>
            <value>1394</value>
            <value>212</value>
            <value>6</value>
            <value>Nawaz</value>
            <value>Imtiyaz</value>
            <value>I</value>
        </row>
        <row>
            <value>1395</value>
            <value>213</value>
            <value>1</value>
            <value>Saadi</value>
            <value>Tarek</value>
            <value>T</value>
        </row>
        <row>
            <value>1396</value>
            <value>213</value>
            <value>2</value>
            <value>Rosenbaum</value>
            <value>Hana</value>
            <value>H</value>
        </row>
        <row>
            <value>1397</value>
            <value>213</value>
            <value>3</value>
            <value>Veitsman</value>
            <value>Ella</value>
            <value>E</value>
        </row>
        <row>
            <value>1398</value>
            <value>213</value>
            <value>4</value>
            <value>Baruch</value>
            <value>Yaacov</value>
            <value>Y</value>
        </row>
        <row>
            <value>1399</value>
            <value>214</value>
            <value>1</value>
            <value></value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>1400</value>
            <value>214</value>
            <value>2</value>
            <value></value>
            <value>M A</value>
            <value>MA</value>
        </row>
        <row>
            <value>1401</value>
            <value>214</value>
            <value>3</value>
            <value></value>
            <value>I</value>
            <value>I</value>
        </row>
        <row>
            <value>1402</value>
            <value>214</value>
            <value>4</value>
            <value></value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>1403</value>
            <value>215</value>
            <value>1</value>
            <value>Karapinar</value>
            <value></value>
            <value>B</value>
        </row>
        <row>
            <value>1404</value>
            <value>215</value>
            <value>2</value>
            <value>Yilmaz</value>
            <value>Deniz</value>
            <value>D</value>
        </row>
        <row>
            <value>1405</value>
            <value>215</value>
            <value>3</value>
            <value>Balkan</value>
            <value>Can</value>
            <value>C</value>
        </row>
        <row>
            <value>1406</value>
            <value>215</value>
            <value>4</value>
            <value>Akin</value>
            <value>Mehmet</value>
            <value>M</value>
        </row>
        <row>
            <value>1407</value>
            <value>215</value>
            <value>5</value>
            <value>Ay</value>
            <value>Yilmaz</value>
            <value>Y</value>
        </row>
        <row>
            <value>1408</value>
            <value>215</value>
            <value>6</value>
            <value>Kvakli</value>
            <value>Kaan</value>
            <value>K</value>
        </row>
        <row>
            <value>1409</value>
            <value>216</value>
            <value>1</value>
            <value>Leung</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1410</value>
            <value>216</value>
            <value>2</value>
            <value>Piatkov</value>
            <value>I</value>
            <value>I</value>
        </row>
        <row>
            <value>1411</value>
            <value>216</value>
            <value>3</value>
            <value>Rochester</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>1412</value>
            <value>216</value>
            <value>4</value>
            <value>Boyages</value>
            <value>S C</value>
            <value>SC</value>
        </row>
        <row>
            <value>1413</value>
            <value>216</value>
            <value>5</value>
            <value>Leong</value>
            <value>R W L</value>
            <value>RW</value>
        </row>
        <row>
            <value>1414</value>
            <value>217</value>
            <value>1</value>
            <value>Castillo</value>
            <value>Leticia</value>
            <value>L</value>
        </row>
        <row>
            <value>1415</value>
            <value>217</value>
            <value>2</value>
            <value>Carcillo</value>
            <value>Joseph</value>
            <value>J</value>
        </row>
        <row>
            <value>1416</value>
            <value>218</value>
            <value>1</value>
            <value>Mistry</value>
            <value>Pramod K</value>
            <value>PK</value>
        </row>
        <row>
            <value>1417</value>
            <value>218</value>
            <value>2</value>
            <value>Sadan</value>
            <value>Sara</value>
            <value>S</value>
        </row>
        <row>
            <value>1418</value>
            <value>218</value>
            <value>3</value>
            <value>Yang</value>
            <value>Ruhua</value>
            <value>R</value>
        </row>
        <row>
            <value>1419</value>
            <value>218</value>
            <value>4</value>
            <value>Yee</value>
            <value>John</value>
            <value>J</value>
        </row>
        <row>
            <value>1420</value>
            <value>218</value>
            <value>5</value>
            <value>Yang</value>
            <value>Mei</value>
            <value>M</value>
        </row>
        <row>
            <value>1421</value>
            <value>219</value>
            <value>1</value>
            <value>Emanuel</value>
            <value>Patrick O</value>
            <value>PO</value>
        </row>
        <row>
            <value>1422</value>
            <value>219</value>
            <value>2</value>
            <value>Sternberg</value>
            <value>Lauren J</value>
            <value>LJ</value>
        </row>
        <row>
            <value>1423</value>
            <value>219</value>
            <value>3</value>
            <value>Phelps</value>
            <value>Robert G</value>
            <value>RG</value>
        </row>
        <row>
            <value>1424</value>
            <value>220</value>
            <value>1</value>
            <value>Kleinert</value>
            <value>Maria Mercedes</value>
            <value>MM</value>
        </row>
        <row>
            <value>1425</value>
            <value>220</value>
            <value>2</value>
            <value>Garate</value>
            <value>Gonzalo</value>
            <value>G</value>
        </row>
        <row>
            <value>1426</value>
            <value>220</value>
            <value>3</value>
            <value>Osatnik</value>
            <value>Javier</value>
            <value>J</value>
        </row>
        <row>
            <value>1427</value>
            <value>220</value>
            <value>4</value>
            <value>Cicco</value>
            <value>Juan</value>
            <value>J</value>
        </row>
        <row>
            <value>1428</value>
            <value>220</value>
            <value>5</value>
            <value>Hunter</value>
            <value>Barbara</value>
            <value>B</value>
        </row>
        <row>
            <value>1429</value>
            <value>220</value>
            <value>6</value>
            <value>Soria</value>
            <value>Elisa J</value>
            <value>EJ</value>
        </row>
        <row>
            <value>1430</value>
            <value>221</value>
            <value>1</value>
            <value>Ptaszy??ska</value>
            <value>Joanna</value>
            <value>J</value>
        </row>
        <row>
            <value>1431</value>
            <value>221</value>
            <value>2</value>
            <value>Rapa??a</value>
            <value>Ma??gorzata</value>
            <value>M</value>
        </row>
        <row>
            <value>1432</value>
            <value>221</value>
            <value>3</value>
            <value>Mi??kiewicz</value>
            <value>Piotr</value>
            <value>P</value>
        </row>
        <row>
            <value>1433</value>
            <value>221</value>
            <value>4</value>
            <value></value>
            <value>Agnieszka</value>
            <value>A</value>
        </row>
        <row>
            <value>1434</value>
            <value>221</value>
            <value>5</value>
            <value>Godzi??ski</value>
            <value>Jan</value>
            <value>J</value>
        </row>
        <row>
            <value>1435</value>
            <value>222</value>
            <value>1</value>
            <value>Talwalkar</value>
            <value>Jayant A</value>
            <value>JA</value>
        </row>
        <row>
            <value>1436</value>
            <value>222</value>
            <value>2</value>
            <value>Angulo</value>
            <value>Paul</value>
            <value>P</value>
        </row>
        <row>
            <value>1437</value>
            <value>222</value>
            <value>3</value>
            <value>Keach</value>
            <value>Jill C</value>
            <value>JC</value>
        </row>
        <row>
            <value>1438</value>
            <value>222</value>
            <value>4</value>
            <value>Petz</value>
            <value>Janice L</value>
            <value>JL</value>
        </row>
        <row>
            <value>1439</value>
            <value>222</value>
            <value>5</value>
            <value>Jorgensen</value>
            <value>Roberta A</value>
            <value>RA</value>
        </row>
        <row>
            <value>1440</value>
            <value>222</value>
            <value>6</value>
            <value>Lindor</value>
            <value>Keith D</value>
            <value>KD</value>
        </row>
        <row>
            <value>1441</value>
            <value>223</value>
            <value>1</value>
            <value>Latagliata</value>
            <value>Roberto</value>
            <value>R</value>
        </row>
        <row>
            <value>1442</value>
            <value>223</value>
            <value>2</value>
            <value>Roberto</value>
            <value>Latagliata</value>
            <value>L</value>
        </row>
        <row>
            <value>1443</value>
            <value>223</value>
            <value>3</value>
            <value>Breccia</value>
            <value>Massimo</value>
            <value>M</value>
        </row>
        <row>
            <value>1444</value>
            <value>223</value>
            <value>4</value>
            <value>Massimo</value>
            <value>Breccia</value>
            <value>B</value>
        </row>
        <row>
            <value>1445</value>
            <value>223</value>
            <value>5</value>
            <value>Carmosino</value>
            <value>Ida</value>
            <value>I</value>
        </row>
        <row>
            <value>1446</value>
            <value>223</value>
            <value>6</value>
            <value>Ida</value>
            <value>Carmosino</value>
            <value>C</value>
        </row>
        <row>
            <value>1447</value>
            <value>223</value>
            <value>7</value>
            <value>Sarlo</value>
            <value>Chiara</value>
            <value>C</value>
        </row>
        <row>
            <value>1448</value>
            <value>223</value>
            <value>8</value>
            <value>Chiara</value>
            <value>Sarlo</value>
            <value>S</value>
        </row>
        <row>
            <value>1449</value>
            <value>223</value>
            <value>9</value>
            <value>Montefusco</value>
            <value>Enrico</value>
            <value>E</value>
        </row>
        <row>
            <value>1450</value>
            <value>223</value>
            <value>10</value>
            <value>Enrico</value>
            <value>Montefusco</value>
            <value>M</value>
        </row>
        <row>
            <value>1451</value>
            <value>223</value>
            <value>11</value>
            <value>Mancini</value>
            <value>Marco</value>
            <value>M</value>
        </row>
        <row>
            <value>1452</value>
            <value>223</value>
            <value>12</value>
            <value>Marco</value>
            <value>Mancini</value>
            <value>M</value>
        </row>
        <row>
            <value>1453</value>
            <value>223</value>
            <value>13</value>
            <value>Natalino</value>
            <value>Fiammetta</value>
            <value>F</value>
        </row>
        <row>
            <value>1454</value>
            <value>223</value>
            <value>14</value>
            <value>Fiammetta</value>
            <value>Natalino</value>
            <value>N</value>
        </row>
        <row>
            <value>1455</value>
            <value>223</value>
            <value>15</value>
            <value>Chistolini</value>
            <value>Antonio</value>
            <value>A</value>
        </row>
        <row>
            <value>1456</value>
            <value>223</value>
            <value>16</value>
            <value>Antonio</value>
            <value>Chistolini</value>
            <value>C</value>
        </row>
        <row>
            <value>1457</value>
            <value>223</value>
            <value>17</value>
            <value>De Cuia</value>
            <value>Rosa</value>
            <value>R</value>
        </row>
        <row>
            <value>1458</value>
            <value>223</value>
            <value>18</value>
            <value>Rosa</value>
            <value>De Cuia</value>
            <value>de C</value>
        </row>
        <row>
            <value>1459</value>
            <value>223</value>
            <value>19</value>
            <value>Russo</value>
            <value>Eleonora</value>
            <value>E</value>
        </row>
        <row>
            <value>1460</value>
            <value>223</value>
            <value>20</value>
            <value>Eleonora</value>
            <value>Russo</value>
            <value>R</value>
        </row>
        <row>
            <value>1461</value>
            <value>223</value>
            <value>21</value>
            <value>Morano</value>
            <value>Giacomo Salvatore</value>
            <value>GS</value>
        </row>
        <row>
            <value>1462</value>
            <value>223</value>
            <value>22</value>
            <value>Giacomo</value>
            <value>Morano Salvatore</value>
            <value>MS</value>
        </row>
        <row>
            <value>1463</value>
            <value>223</value>
            <value>23</value>
            <value>Biondo</value>
            <value>Francesca</value>
            <value>F</value>
        </row>
        <row>
            <value>1464</value>
            <value>223</value>
            <value>24</value>
            <value>Francesca</value>
            <value>Biondo</value>
            <value>B</value>
        </row>
        <row>
            <value>1465</value>
            <value>223</value>
            <value>25</value>
            <value>Spadea</value>
            <value>Antonio</value>
            <value>A</value>
        </row>
        <row>
            <value>1466</value>
            <value>223</value>
            <value>26</value>
            <value>Antonio</value>
            <value>Spadea</value>
            <value>S</value>
        </row>
        <row>
            <value>1467</value>
            <value>223</value>
            <value>27</value>
            <value>Mandelli</value>
            <value>Franco</value>
            <value>F</value>
        </row>
        <row>
            <value>1468</value>
            <value>223</value>
            <value>28</value>
            <value>Franco</value>
            <value>Mandelli</value>
            <value>M</value>
        </row>
        <row>
            <value>1469</value>
            <value>223</value>
            <value>29</value>
            <value>Alimena</value>
            <value>Giuliana</value>
            <value>G</value>
        </row>
        <row>
            <value>1470</value>
            <value>223</value>
            <value>30</value>
            <value>Giuliana</value>
            <value>Alimena</value>
            <value>A</value>
        </row>
        <row>
            <value>1471</value>
            <value>224</value>
            <value>1</value>
            <value>Matt</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1472</value>
            <value>224</value>
            <value>2</value>
            <value>Bernet</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>1473</value>
            <value>224</value>
            <value>3</value>
            <value>Habicht</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1474</value>
            <value>224</value>
            <value>4</value>
            <value>Gambazzi</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>1475</value>
            <value>224</value>
            <value>5</value>
            <value>Passweg</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1476</value>
            <value>224</value>
            <value>6</value>
            <value>Gratwohl</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1477</value>
            <value>224</value>
            <value>7</value>
            <value>Tamm</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1478</value>
            <value>224</value>
            <value>8</value>
            <value>Zerkowski</value>
            <value>H-R</value>
            <value>HR</value>
        </row>
        <row>
            <value>1479</value>
            <value>225</value>
            <value>1</value>
            <value>Luppi</value>
            <value>Mario</value>
            <value>M</value>
        </row>
        <row>
            <value>1480</value>
            <value>225</value>
            <value>2</value>
            <value>Barozzi</value>
            <value>Patrizia</value>
            <value>P</value>
        </row>
        <row>
            <value>1481</value>
            <value>225</value>
            <value>3</value>
            <value>Rasini</value>
            <value>Valeria</value>
            <value>V</value>
        </row>
        <row>
            <value>1482</value>
            <value>225</value>
            <value>4</value>
            <value>Riva</value>
            <value>Giovanni</value>
            <value>G</value>
        </row>
        <row>
            <value>1483</value>
            <value>225</value>
            <value>5</value>
            <value>Re</value>
            <value>Alessandro</value>
            <value>A</value>
        </row>
        <row>
            <value>1484</value>
            <value>225</value>
            <value>6</value>
            <value>Rossi</value>
            <value>Giuseppe</value>
            <value>G</value>
        </row>
        <row>
            <value>1485</value>
            <value>225</value>
            <value>7</value>
            <value>Setti</value>
            <value>Gisella</value>
            <value>G</value>
        </row>
        <row>
            <value>1486</value>
            <value>225</value>
            <value>8</value>
            <value>Sandrini</value>
            <value>Silvio</value>
            <value>S</value>
        </row>
        <row>
            <value>1487</value>
            <value>225</value>
            <value>9</value>
            <value>Facchetti</value>
            <value>Fabio</value>
            <value>F</value>
        </row>
        <row>
            <value>1488</value>
            <value>225</value>
            <value>10</value>
            <value>Torelli</value>
            <value>Giuseppe</value>
            <value>G</value>
        </row>
        <row>
            <value>1489</value>
            <value>226</value>
            <value>1</value>
            <value>Akpek</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1490</value>
            <value>226</value>
            <value>2</value>
            <value>McAneny</value>
            <value>D</value>
            <value>D</value>
        </row>
        <row>
            <value>1491</value>
            <value>226</value>
            <value>3</value>
            <value>Weintraub</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>1492</value>
            <value>227</value>
            <value>1</value>
            <value>de Smit</value>
            <value>A J</value>
            <value>AJ</value>
        </row>
        <row>
            <value>1493</value>
            <value>227</value>
            <value>2</value>
            <value>Bouma</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1494</value>
            <value>227</value>
            <value>3</value>
            <value>de Kluijver</value>
            <value>E P</value>
            <value>EP</value>
        </row>
        <row>
            <value>1495</value>
            <value>227</value>
            <value>4</value>
            <value>Terpstra</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>1496</value>
            <value>227</value>
            <value>5</value>
            <value>Moormann</value>
            <value>R J</value>
            <value>RJ</value>
        </row>
        <row>
            <value>1497</value>
            <value>228</value>
            <value>1</value>
            <value>Luppi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1498</value>
            <value>228</value>
            <value>2</value>
            <value>Barozzi</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1499</value>
            <value>228</value>
            <value>3</value>
            <value>Schulz</value>
            <value>T F</value>
            <value>TF</value>
        </row>
        <row>
            <value>1500</value>
            <value>228</value>
            <value>4</value>
            <value>Setti</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1501</value>
            <value>228</value>
            <value>5</value>
            <value>Staskus</value>
            <value>K</value>
            <value>K</value>
        </row>
        <row>
            <value>1502</value>
            <value>228</value>
            <value>6</value>
            <value>Trovato</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1503</value>
            <value>228</value>
            <value>7</value>
            <value>Narni</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>1504</value>
            <value>228</value>
            <value>8</value>
            <value>Donelli</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1505</value>
            <value>228</value>
            <value>9</value>
            <value>Maiorana</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1506</value>
            <value>228</value>
            <value>10</value>
            <value>Marasca</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1507</value>
            <value>228</value>
            <value>11</value>
            <value>Sandrini</value>
            <value>S</value>
            <value>S</value>
        </row>
        <row>
            <value>1508</value>
            <value>228</value>
            <value>12</value>
            <value>Torelli</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1509</value>
            <value>229</value>
            <value>1</value>
            <value>Nishimura</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1510</value>
            <value>229</value>
            <value>2</value>
            <value>Tsukahara</value>
            <value>H</value>
            <value>H</value>
        </row>
        <row>
            <value>1511</value>
            <value>229</value>
            <value>3</value>
            <value>Hiraoka</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1512</value>
            <value>229</value>
            <value>4</value>
            <value>Osaka</value>
            <value>Y</value>
            <value>Y</value>
        </row>
        <row>
            <value>1513</value>
            <value>229</value>
            <value>5</value>
            <value>Ohshima</value>
            <value>Y</value>
            <value>Y</value>
        </row>
        <row>
            <value>1514</value>
            <value>229</value>
            <value>6</value>
            <value>Tanizawa</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1515</value>
            <value>229</value>
            <value>7</value>
            <value>Mayumi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1516</value>
            <value>230</value>
            <value>1</value>
            <value>Elliott</value>
            <value>M A</value>
            <value>MA</value>
        </row>
        <row>
            <value>1517</value>
            <value>230</value>
            <value>2</value>
            <value>Chen</value>
            <value>M G</value>
            <value>MG</value>
        </row>
        <row>
            <value>1518</value>
            <value>230</value>
            <value>3</value>
            <value>Silverstein</value>
            <value>M N</value>
            <value>MN</value>
        </row>
        <row>
            <value>1519</value>
            <value>230</value>
            <value>4</value>
            <value>Tefferi</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1520</value>
            <value>231</value>
            <value>1</value>
            <value>Toren</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1521</value>
            <value>231</value>
            <value>2</value>
            <value>Nagler</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1522</value>
            <value>231</value>
            <value>3</value>
            <value>Nagler</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1523</value>
            <value>232</value>
            <value>1</value>
            <value>Ly</value>
            <value>B</value>
            <value>B</value>
        </row>
        <row>
            <value>1524</value>
            <value>232</value>
            <value>2</value>
            <value></value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1525</value>
            <value>232</value>
            <value>3</value>
            <value>Bergheim</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1526</value>
            <value>232</value>
            <value>4</value>
            <value>Dahl</value>
            <value>I M</value>
            <value>IM</value>
        </row>
        <row>
            <value>1527</value>
            <value>232</value>
            <value>5</value>
            <value></value>
            <value>K A</value>
            <value>KA</value>
        </row>
        <row>
            <value>1528</value>
            <value>232</value>
            <value>6</value>
            <value></value>
            <value>B</value>
            <value>B</value>
        </row>
        <row>
            <value>1529</value>
            <value>233</value>
            <value>1</value>
            <value>Emilia</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1530</value>
            <value>233</value>
            <value>2</value>
            <value>Luppi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1531</value>
            <value>233</value>
            <value>3</value>
            <value>Ferrari</value>
            <value>M G</value>
            <value>MG</value>
        </row>
        <row>
            <value>1532</value>
            <value>233</value>
            <value>4</value>
            <value>Barozzi</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1533</value>
            <value>233</value>
            <value>5</value>
            <value>Marasca</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1534</value>
            <value>233</value>
            <value>6</value>
            <value>Torelli</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1535</value>
            <value>234</value>
            <value>1</value>
            <value>Koduri</value>
            <value>P R</value>
            <value>PR</value>
        </row>
        <row>
            <value>1536</value>
            <value>234</value>
            <value>2</value>
            <value>Chundi</value>
            <value>V</value>
            <value>V</value>
        </row>
        <row>
            <value>1537</value>
            <value>234</value>
            <value>3</value>
            <value>DeMarais</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1538</value>
            <value>234</value>
            <value>4</value>
            <value>Mizock</value>
            <value>B A</value>
            <value>BA</value>
        </row>
        <row>
            <value>1539</value>
            <value>234</value>
            <value>5</value>
            <value>Patel</value>
            <value>A R</value>
            <value>AR</value>
        </row>
        <row>
            <value>1540</value>
            <value>234</value>
            <value>6</value>
            <value>Weinstein</value>
            <value>R A</value>
            <value>RA</value>
        </row>
        <row>
            <value>1541</value>
            <value>235</value>
            <value>1</value>
            <value></value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1542</value>
            <value>235</value>
            <value>2</value>
            <value></value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1543</value>
            <value>235</value>
            <value>3</value>
            <value></value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>1544</value>
            <value>235</value>
            <value>4</value>
            <value></value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1545</value>
            <value>235</value>
            <value>5</value>
            <value></value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>1546</value>
            <value>236</value>
            <value>1</value>
            <value>Lehne</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1547</value>
            <value>236</value>
            <value>2</value>
            <value>Hannisdal</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>1548</value>
            <value>236</value>
            <value>3</value>
            <value>Langholm</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1549</value>
            <value>236</value>
            <value>4</value>
            <value>Nome</value>
            <value>O</value>
            <value>O</value>
        </row>
        <row>
            <value>1550</value>
            <value>237</value>
            <value>1</value>
            <value>Dunn</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1551</value>
            <value>237</value>
            <value>2</value>
            <value>Shih</value>
            <value>L Y</value>
            <value>LY</value>
        </row>
        <row>
            <value>1552</value>
            <value>237</value>
            <value>3</value>
            <value>Liaw</value>
            <value>S J</value>
            <value>SJ</value>
        </row>
        <row>
            <value>1553</value>
            <value>238</value>
            <value>1</value>
            <value>Lang</value>
            <value>E</value>
            <value>E</value>
        </row>
        <row>
            <value>1554</value>
            <value>238</value>
            <value>2</value>
            <value>Schmid</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1555</value>
            <value>238</value>
            <value>3</value>
            <value>Fauser</value>
            <value>A A</value>
            <value>AA</value>
        </row>
        <row>
            <value>1556</value>
            <value>239</value>
            <value>1</value>
            <value>Lamm</value>
            <value>D L</value>
            <value>DL</value>
        </row>
        <row>
            <value>1557</value>
            <value>239</value>
            <value>2</value>
            <value>Stogdill</value>
            <value>V D</value>
            <value>VD</value>
        </row>
        <row>
            <value>1558</value>
            <value>239</value>
            <value>3</value>
            <value>Stogdill</value>
            <value>B J</value>
            <value>BJ</value>
        </row>
        <row>
            <value>1559</value>
            <value>239</value>
            <value>4</value>
            <value>Crispen</value>
            <value>R G</value>
            <value>RG</value>
        </row>
        <row>
            <value>1560</value>
            <value>240</value>
            <value>1</value>
            <value>Gyger</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1561</value>
            <value>240</value>
            <value>2</value>
            <value>Forest</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>1562</value>
            <value>240</value>
            <value>3</value>
            <value>Vuong</value>
            <value>T E</value>
            <value>TE</value>
        </row>
        <row>
            <value>1563</value>
            <value>240</value>
            <value>4</value>
            <value>Perreault</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>1564</value>
            <value>240</value>
            <value>5</value>
            <value>Lavallee</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1565</value>
            <value>240</value>
            <value>6</value>
            <value>Lacombe</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1566</value>
            <value>240</value>
            <value>7</value>
            <value>Boileau</value>
            <value>J</value>
            <value>J</value>
        </row>
        <row>
            <value>1567</value>
            <value>240</value>
            <value>8</value>
            <value>D'Angelo</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1568</value>
            <value>241</value>
            <value>1</value>
            <value>Garrison</value>
            <value>R N</value>
            <value>RN</value>
        </row>
        <row>
            <value>1569</value>
            <value>241</value>
            <value>2</value>
            <value>McCoy</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1570</value>
            <value>241</value>
            <value>3</value>
            <value>Winkler</value>
            <value>C</value>
            <value>C</value>
        </row>
        <row>
            <value>1571</value>
            <value>241</value>
            <value>4</value>
            <value>Yam</value>
            <value>L</value>
            <value>L</value>
        </row>
        <row>
            <value>1572</value>
            <value>241</value>
            <value>5</value>
            <value>Fry</value>
            <value>D E</value>
            <value>DE</value>
        </row>
        <row>
            <value>1573</value>
            <value>242</value>
            <value>1</value>
            <value>Slavin</value>
            <value>R E</value>
            <value>RE</value>
        </row>
        <row>
            <value>1574</value>
            <value>242</value>
            <value>2</value>
            <value>Dias</value>
            <value>M A</value>
            <value>MA</value>
        </row>
        <row>
            <value>1575</value>
            <value>242</value>
            <value>3</value>
            <value>Saral</value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1576</value>
            <value>243</value>
            <value>1</value>
            <value>Bhatnagar</value>
            <value>Shishir Kumar</value>
            <value>SK</value>
        </row>
        <row>
            <value>1577</value>
            <value>243</value>
            <value>2</value>
            <value>Chandra</value>
            <value>Jagdish</value>
            <value>J</value>
        </row>
        <row>
            <value>1578</value>
            <value>243</value>
            <value>3</value>
            <value>Narayan</value>
            <value>Shashi</value>
            <value>S</value>
        </row>
        <row>
            <value>1579</value>
            <value>243</value>
            <value>4</value>
            <value>Sharma</value>
            <value>Sunita</value>
            <value>S</value>
        </row>
        <row>
            <value>1580</value>
            <value>243</value>
            <value>5</value>
            <value>Singh</value>
            <value>Varinder</value>
            <value>V</value>
        </row>
        <row>
            <value>1581</value>
            <value>243</value>
            <value>6</value>
            <value>Dutta</value>
            <value>Ashok Kumar</value>
            <value>AK</value>
        </row>
        <row>
            <value>1582</value>
            <value>244</value>
            <value>1</value>
            <value>Zeb Jan</value>
            <value>Anwar</value>
            <value>A</value>
        </row>
        <row>
            <value>1583</value>
            <value>244</value>
            <value>2</value>
            <value>Zahid</value>
            <value>Bakhtyar</value>
            <value>B</value>
        </row>
        <row>
            <value>1584</value>
            <value>244</value>
            <value>3</value>
            <value>Ahmad</value>
            <value>Samreen</value>
            <value>S</value>
        </row>
        <row>
            <value>1585</value>
            <value>244</value>
            <value>4</value>
            <value>Gul</value>
            <value>Zahid</value>
            <value>Z</value>
        </row>
        <row>
            <value>1586</value>
            <value>245</value>
            <value>1</value>
            <value>Wu</value>
            <value>Jun</value>
            <value>J</value>
        </row>
        <row>
            <value>1587</value>
            <value>245</value>
            <value>2</value>
            <value>Cheng</value>
            <value>Yi-Fei</value>
            <value>YF</value>
        </row>
        <row>
            <value>1588</value>
            <value>245</value>
            <value>3</value>
            <value>Zhang</value>
            <value>Le-Ping</value>
            <value>LP</value>
        </row>
        <row>
            <value>1589</value>
            <value>245</value>
            <value>4</value>
            <value>Liu</value>
            <value>Gui-Lan</value>
            <value>GL</value>
        </row>
        <row>
            <value>1590</value>
            <value>245</value>
            <value>5</value>
            <value>Lu</value>
            <value>Ai-Dong</value>
            <value>AD</value>
        </row>
        <row>
            <value>1591</value>
            <value>245</value>
            <value>6</value>
            <value>Jia</value>
            <value>Yue-Ping</value>
            <value>YP</value>
        </row>
        <row>
            <value>1592</value>
            <value>245</value>
            <value>7</value>
            <value>Wang</value>
            <value>Bin</value>
            <value>B</value>
        </row>
        <row>
            <value>1593</value>
            <value>246</value>
            <value>1</value>
            <value>Memon</value>
            <value>Shazia</value>
            <value>S</value>
        </row>
        <row>
            <value>1594</value>
            <value>246</value>
            <value>2</value>
            <value>Shaikh</value>
            <value>Salma</value>
            <value>S</value>
        </row>
        <row>
            <value>1595</value>
            <value>246</value>
            <value>3</value>
            <value>Nizamani</value>
            <value>M Akbar A</value>
            <value>MA</value>
        </row>
        <row>
            <value>1596</value>
            <value>247</value>
            <value>1</value>
            <value></value>
            <value>V</value>
            <value>V</value>
        </row>
        <row>
            <value>1597</value>
            <value>247</value>
            <value>2</value>
            <value></value>
            <value>R</value>
            <value>R</value>
        </row>
        <row>
            <value>1598</value>
            <value>247</value>
            <value>3</value>
            <value>Ayerza Lerchundi</value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1599</value>
            <value>247</value>
            <value>4</value>
            <value></value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1600</value>
            <value>247</value>
            <value>5</value>
            <value>Prados Madrona</value>
            <value>D</value>
            <value>D</value>
        </row>
        <row>
            <value>1601</value>
            <value>248</value>
            <value>1</value>
            <value>Garewal</value>
            <value>G</value>
            <value>G</value>
        </row>
        <row>
            <value>1602</value>
            <value>248</value>
            <value>2</value>
            <value>Marwaha</value>
            <value>N</value>
            <value>N</value>
        </row>
        <row>
            <value>1603</value>
            <value>248</value>
            <value>3</value>
            <value>Marwaha</value>
            <value>R K</value>
            <value>RK</value>
        </row>
        <row>
            <value>1604</value>
            <value>248</value>
            <value>4</value>
            <value>Das</value>
            <value>K C</value>
            <value>KC</value>
        </row>
        <row>
            <value>1605</value>
            <value>249</value>
            <value>1</value>
            <value>K??epelka</value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1606</value>
            <value>250</value>
            <value>1</value>
            <value>Livadas</value>
            <value>Sarantis</value>
            <value>S</value>
        </row>
        <row>
            <value>1607</value>
            <value>250</value>
            <value>2</value>
            <value>Kollias</value>
            <value>Anastasios</value>
            <value>A</value>
        </row>
        <row>
            <value>1608</value>
            <value>250</value>
            <value>3</value>
            <value>Panidis</value>
            <value>Dimitrios</value>
            <value>D</value>
        </row>
        <row>
            <value>1609</value>
            <value>250</value>
            <value>4</value>
            <value>Diamanti-Kandarakis</value>
            <value>Evanthia</value>
            <value>E</value>
        </row>
        <row>
            <value>1610</value>
            <value>251</value>
            <value>1</value>
            <value>Cong</value>
            <value>Pei-Xu</value>
            <value>PX</value>
        </row>
        <row>
            <value>1611</value>
            <value>251</value>
            <value>2</value>
            <value>Gao</value>
            <value>Rui-Chang</value>
            <value>RC</value>
        </row>
        <row>
            <value>1612</value>
            <value>251</value>
            <value>3</value>
            <value>Xue</value>
            <value>Chang-Hu</value>
            <value>CH</value>
        </row>
        <row>
            <value>1613</value>
            <value>251</value>
            <value>4</value>
            <value>Li</value>
            <value>Zhao-Jie</value>
            <value>ZJ</value>
        </row>
        <row>
            <value>1614</value>
            <value>251</value>
            <value>5</value>
            <value>Zhang</value>
            <value>Hong-Wei</value>
            <value>HW</value>
        </row>
        <row>
            <value>1615</value>
            <value>251</value>
            <value>6</value>
            <value>Khan</value>
            <value>Muhammad Naseem</value>
            <value>MN</value>
        </row>
        <row>
            <value>1616</value>
            <value>251</value>
            <value>7</value>
            <value>Xue</value>
            <value>Yong</value>
            <value>Y</value>
        </row>
        <row>
            <value>1617</value>
            <value>251</value>
            <value>8</value>
            <value>Sugawara</value>
            <value>Tatsuya</value>
            <value>T</value>
        </row>
        <row>
            <value>1618</value>
            <value>251</value>
            <value>9</value>
            <value>Xu</value>
            <value>Jie</value>
            <value>J</value>
        </row>
        <row>
            <value>1619</value>
            <value>252</value>
            <value>1</value>
            <value>Haider</value>
            <value>Shehla</value>
            <value>S</value>
        </row>
        <row>
            <value>1620</value>
            <value>252</value>
            <value>2</value>
            <value>Mannan</value>
            <value>Nighat</value>
            <value>N</value>
        </row>
        <row>
            <value>1621</value>
            <value>252</value>
            <value>3</value>
            <value>Khan</value>
            <value>Ayesha</value>
            <value>A</value>
        </row>
        <row>
            <value>1622</value>
            <value>252</value>
            <value>4</value>
            <value>Qureshi</value>
            <value>Masood A</value>
            <value>MA</value>
        </row>
        <row>
            <value>1623</value>
            <value>253</value>
            <value>1</value>
            <value>Maccani</value>
            <value>Andreas</value>
            <value>A</value>
        </row>
        <row>
            <value>1624</value>
            <value>253</value>
            <value>2</value>
            <value>Hackl</value>
            <value>Matthias</value>
            <value>M</value>
        </row>
        <row>
            <value>1625</value>
            <value>253</value>
            <value>3</value>
            <value>Leitner</value>
            <value>Christian</value>
            <value>C</value>
        </row>
        <row>
            <value>1626</value>
            <value>253</value>
            <value>4</value>
            <value>Steinfellner</value>
            <value>Willibald</value>
            <value>W</value>
        </row>
        <row>
            <value>1627</value>
            <value>253</value>
            <value>5</value>
            <value>Graf</value>
            <value>Alexandra B</value>
            <value>AB</value>
        </row>
        <row>
            <value>1628</value>
            <value>253</value>
            <value>6</value>
            <value>Tatto</value>
            <value>Nadine E</value>
            <value>NE</value>
        </row>
        <row>
            <value>1629</value>
            <value>253</value>
            <value>7</value>
            <value>Karbiener</value>
            <value>Michael</value>
            <value>M</value>
        </row>
        <row>
            <value>1630</value>
            <value>253</value>
            <value>8</value>
            <value>Scheideler</value>
            <value>Marcel</value>
            <value>M</value>
        </row>
        <row>
            <value>1631</value>
            <value>253</value>
            <value>9</value>
            <value>Grillari</value>
            <value>Johannes</value>
            <value>J</value>
        </row>
        <row>
            <value>1632</value>
            <value>253</value>
            <value>10</value>
            <value>Mattanovich</value>
            <value>Diethard</value>
            <value>D</value>
        </row>
        <row>
            <value>1633</value>
            <value>253</value>
            <value>11</value>
            <value>Kunert</value>
            <value>Renate</value>
            <value>R</value>
        </row>
        <row>
            <value>1634</value>
            <value>253</value>
            <value>12</value>
            <value>Borth</value>
            <value>Nicole</value>
            <value>N</value>
        </row>
        <row>
            <value>1635</value>
            <value>253</value>
            <value>13</value>
            <value>Grabherr</value>
            <value>Reingard</value>
            <value>R</value>
        </row>
        <row>
            <value>1636</value>
            <value>253</value>
            <value>14</value>
            <value>Ernst</value>
            <value>Wolfgang</value>
            <value>W</value>
        </row>
        <row>
            <value>1637</value>
            <value>254</value>
            <value>1</value>
            <value>Louei Monfared</value>
            <value>Ali</value>
            <value>A</value>
        </row>
        <row>
            <value>1638</value>
            <value>254</value>
            <value>2</value>
            <value>Salati</value>
            <value>Amir Parviz</value>
            <value>AP</value>
        </row>
        <row>
            <value>1639</value>
            <value>255</value>
            <value>1</value>
            <value>Mahmoudi</value>
            <value>Zahra</value>
            <value>Z</value>
        </row>
        <row>
            <value>1640</value>
            <value>255</value>
            <value>2</value>
            <value>Soleimani</value>
            <value>Masoud</value>
            <value>M</value>
        </row>
        <row>
            <value>1641</value>
            <value>255</value>
            <value>3</value>
            <value>Saidi</value>
            <value>Abbas</value>
            <value>A</value>
        </row>
        <row>
            <value>1642</value>
            <value>255</value>
            <value>4</value>
            <value>Khamisipour</value>
            <value>Gholamreza</value>
            <value>G</value>
        </row>
        <row>
            <value>1643</value>
            <value>255</value>
            <value>5</value>
            <value>Azizsoltani</value>
            <value>Arezoo</value>
            <value>A</value>
        </row>
        <row>
            <value>1644</value>
            <value>256</value>
            <value>1</value>
            <value>Ji</value>
            <value>Hong</value>
            <value>H</value>
        </row>
        <row>
            <value>1645</value>
            <value>256</value>
            <value>2</value>
            <value>Wang</value>
            <value>Jianfa</value>
            <value>J</value>
        </row>
        <row>
            <value>1646</value>
            <value>256</value>
            <value>3</value>
            <value>Liu</value>
            <value>Juxiong</value>
            <value>J</value>
        </row>
        <row>
            <value>1647</value>
            <value>256</value>
            <value>4</value>
            <value>Guo</value>
            <value>Jingru</value>
            <value>J</value>
        </row>
        <row>
            <value>1648</value>
            <value>256</value>
            <value>5</value>
            <value>Wang</value>
            <value>Zhongwei</value>
            <value>Z</value>
        </row>
        <row>
            <value>1649</value>
            <value>256</value>
            <value>6</value>
            <value>Zhang</value>
            <value>Xu</value>
            <value>X</value>
        </row>
        <row>
            <value>1650</value>
            <value>256</value>
            <value>7</value>
            <value>Guo</value>
            <value>Li</value>
            <value>L</value>
        </row>
        <row>
            <value>1651</value>
            <value>256</value>
            <value>8</value>
            <value>Yang</value>
            <value>Huanmin</value>
            <value>H</value>
        </row>
        <row>
            <value>1652</value>
            <value>257</value>
            <value>1</value>
            <value>Kim</value>
            <value>Hyun</value>
            <value>H</value>
        </row>
        <row>
            <value>1653</value>
            <value>257</value>
            <value>2</value>
            <value>Kim</value>
            <value>Dong Hun</value>
            <value>DH</value>
        </row>
        <row>
            <value>1654</value>
            <value>257</value>
            <value>3</value>
            <value>Park</value>
            <value>Soo Bong</value>
            <value>SB</value>
        </row>
        <row>
            <value>1655</value>
            <value>257</value>
            <value>4</value>
            <value>Ko</value>
            <value>Yeoung-Gyu</value>
            <value>YG</value>
        </row>
        <row>
            <value>1656</value>
            <value>257</value>
            <value>5</value>
            <value>Kim</value>
            <value>Sung-Woo</value>
            <value>SW</value>
        </row>
        <row>
            <value>1657</value>
            <value>257</value>
            <value>6</value>
            <value>Do</value>
            <value>Yoon Jun</value>
            <value>YJ</value>
        </row>
        <row>
            <value>1658</value>
            <value>257</value>
            <value>7</value>
            <value>Park</value>
            <value>Jae-Hong</value>
            <value>JH</value>
        </row>
        <row>
            <value>1659</value>
            <value>257</value>
            <value>8</value>
            <value>Yang</value>
            <value>Boh-Suk</value>
            <value>BS</value>
        </row>
        <row>
            <value>1660</value>
            <value>258</value>
            <value>1</value>
            <value>Choi</value>
            <value>J H</value>
            <value>JH</value>
        </row>
        <row>
            <value>1661</value>
            <value>258</value>
            <value>2</value>
            <value>Yoo</value>
            <value>C R</value>
            <value>CR</value>
        </row>
        <row>
            <value>1662</value>
            <value>258</value>
            <value>3</value>
            <value>Ahn</value>
            <value>J Y</value>
            <value>JY</value>
        </row>
        <row>
            <value>1663</value>
            <value>258</value>
            <value>4</value>
            <value>Park</value>
            <value>J H</value>
            <value>JH</value>
        </row>
        <row>
            <value>1664</value>
            <value>258</value>
            <value>5</value>
            <value>Lim</value>
            <value>J M</value>
            <value>JM</value>
        </row>
        <row>
            <value>1665</value>
            <value>259</value>
            <value>1</value>
            <value></value>
            <value>P</value>
            <value>P</value>
        </row>
        <row>
            <value>1666</value>
            <value>259</value>
            <value>2</value>
            <value></value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1667</value>
            <value>259</value>
            <value>3</value>
            <value></value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1668</value>
            <value>259</value>
            <value>4</value>
            <value></value>
            <value>M</value>
            <value>M</value>
        </row>
        <row>
            <value>1669</value>
            <value>260</value>
            <value>1</value>
            <value>Naito</value>
            <value>Kanta</value>
            <value>K</value>
        </row>
        <row>
            <value>1670</value>
            <value>260</value>
            <value>2</value>
            <value>Notsu</value>
            <value>Akifumi</value>
            <value>A</value>
        </row>
        <row>
            <value>1671</value>
            <value>260</value>
            <value>3</value>
            <value>Udagawa</value>
            <value>Jun</value>
            <value>J</value>
        </row>
        <row>
            <value>1672</value>
            <value>260</value>
            <value>4</value>
            <value>Otani</value>
            <value>Hiroki</value>
            <value>H</value>
        </row>
        <row>
            <value>1673</value>
            <value>261</value>
            <value>1</value>
            <value>Stirrup</value>
            <value>O T</value>
            <value>OT</value>
        </row>
        <row>
            <value>1674</value>
            <value>261</value>
            <value>2</value>
            <value>Khalil</value>
            <value>A</value>
            <value>A</value>
        </row>
        <row>
            <value>1675</value>
            <value>261</value>
            <value>3</value>
            <value>D'Antonio</value>
            <value>F</value>
            <value>F</value>
        </row>
        <row>
            <value>1676</value>
            <value>261</value>
            <value>4</value>
            <value>Thilaganathan</value>
            <value>B</value>
            <value>B</value>
        </row>
        <row>
            <value>1677</value>
            <value>263</value>
            <value>1</value>
            <value>Lin</value>
            <value>Yan</value>
            <value>Y</value>
        </row>
        <row>
            <value>1678</value>
            <value>263</value>
            <value>2</value>
            <value>Wang</value>
            <value>Junjun</value>
            <value>J</value>
        </row>
        <row>
            <value>1679</value>
            <value>263</value>
            <value>3</value>
            <value>Wang</value>
            <value>Xiaoqiu</value>
            <value>X</value>
        </row>
        <row>
            <value>1680</value>
            <value>263</value>
            <value>4</value>
            <value>Wu</value>
            <value>Weizong</value>
            <value>W</value>
        </row>
        <row>
            <value>1681</value>
            <value>263</value>
            <value>5</value>
            <value>Lai</value>
            <value>Changhua</value>
            <value>C</value>
        </row>
        <row>
            <value>1682</value>
            <value>264</value>
            <value>1</value>
            <value>Kim</value>
            <value>Mingoo</value>
            <value>M</value>
        </row>
        <row>
            <value>1683</value>
            <value>264</value>
            <value>2</value>
            <value>Seo</value>
            <value>Heewon</value>
            <value>H</value>
        </row>
        <row>
            <value>1684</value>
            <value>264</value>
            <value>3</value>
            <value>Choi</value>
            <value>Yohan</value>
            <value>Y</value>
        </row>
        <row>
            <value>1685</value>
            <value>264</value>
            <value>4</value>
            <value>Shim</value>
            <value>Jangsoo</value>
            <value>J</value>
        </row>
        <row>
            <value>1686</value>
            <value>264</value>
            <value>5</value>
            <value>Kim</value>
            <value>Heebal</value>
            <value>H</value>
        </row>
        <row>
            <value>1687</value>
            <value>264</value>
            <value>6</value>
            <value>Lee</value>
            <value>Chang-Kyu</value>
            <value>CK</value>
        </row>
        <row>
            <value>1688</value>
            <value>264</value>
            <value>7</value>
            <value>Ka</value>
            <value>Hakhyun</value>
            <value>H</value>
        </row>
        <row>
            <value>1689</value>
            <value>265</value>
            <value>1</value>
            <value>Szendr??</value>
            <value>Zs</value>
            <value>Z</value>
        </row>
        <row>
            <value>1690</value>
            <value>265</value>
            <value>2</value>
            <value>Szendr??</value>
            <value>K</value>
            <value>K</value>
        </row>
        <row>
            <value>1691</value>
            <value>265</value>
            <value>3</value>
            <value>Zotte</value>
            <value>A Dalle</value>
            <value>AD</value>
        </row>
        <row>
            <value>1692</value>
            <value>266</value>
            <value>1</value>
            <value>Nogalski</value>
            <value>Zenon</value>
            <value>Z</value>
        </row>
        <row>
            <value>1693</value>
            <value>266</value>
            <value>2</value>
            <value>Piwczy??ski</value>
            <value>Dariusz</value>
            <value>D</value>
        </row>
        <row>
            <value>1694</value>
            <value>267</value>
            <value>1</value>
            <value>Bazer</value>
            <value>Fuller W</value>
            <value>FW</value>
        </row>
        <row>
            <value>1695</value>
            <value>267</value>
            <value>2</value>
            <value>Song</value>
            <value>Gwonhwa</value>
            <value>G</value>
        </row>
        <row>
            <value>1696</value>
            <value>267</value>
            <value>3</value>
            <value>Thatcher</value>
            <value>William W</value>
            <value>WW</value>
        </row>
        <row>
            <value>1697</value>
            <value>268</value>
            <value>1</value>
            <value>Valsamakis</value>
            <value>Georgios</value>
            <value>G</value>
        </row>
        <row>
            <value>1698</value>
            <value>268</value>
            <value>2</value>
            <value>Papatheodorou</value>
            <value>Dimitrios C</value>
            <value>DC</value>
        </row>
        <row>
            <value>1699</value>
            <value>268</value>
            <value>3</value>
            <value>Naoum</value>
            <value>Aikaterini</value>
            <value>A</value>
        </row>
        <row>
            <value>1700</value>
            <value>268</value>
            <value>4</value>
            <value>Margeli</value>
            <value>Alexandra</value>
            <value>A</value>
        </row>
        <row>
            <value>1701</value>
            <value>268</value>
            <value>5</value>
            <value>Papassotiriou</value>
            <value>Ioannis</value>
            <value>I</value>
        </row>
        <row>
            <value>1702</value>
            <value>268</value>
            <value>6</value>
            <value>Kapantais</value>
            <value>Efthymios</value>
            <value>E</value>
        </row>
        <row>
            <value>1703</value>
            <value>268</value>
            <value>7</value>
            <value>Creatsas</value>
            <value>George</value>
            <value>G</value>
        </row>
        <row>
            <value>1704</value>
            <value>268</value>
            <value>8</value>
            <value>Kumar</value>
            <value>Sudhesh</value>
            <value>S</value>
        </row>
        <row>
            <value>1705</value>
            <value>268</value>
            <value>9</value>
            <value>Mastorakos</value>
            <value>George</value>
            <value>G</value>
        </row>
    </table>
    <table name="articles">
        <column>id</column>
        <column>indexer_id</column>
        <column>volume</column>
        <column>issue</column>
        <column>pages</column>
        <column>year</column>
        <column>month</column>
        <column>day</column>
        <column>journal_id</column>
        <column>title</column>
        <column>pub_status</column>
        <row>
            <value>1</value>
            <value>PMID25036370</value>
            <value>9</value>
            <value>7</value>
            <value>e101200</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>1</value>
            <value>Production of the Escherichia coli Common Pilus by Uropathogenic E. coli Is Associated with Adherence
                to HeLa and HTB-4 Cells and Invasion of Mouse Bladder Urothelium.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>2</value>
            <value>PMID25035664</value>
            <value>26</value>
            <value>3</value>
            <value>351-4</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>2</value>
            <value>Primary malignant melanoma of uterine cervix: a suggestion of new scheme of treatment combination.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>3</value>
            <value>PMID25034933</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>14</value>
            <value>3</value>
            <value>Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with
                cervical cancer.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>4</value>
            <value>PMID25033758</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>12</value>
            <value>4</value>
            <value></value>
            <value>0</value>
        </row>
        <row>
            <value>5</value>
            <value>PMID25033689</value>
            <value>60</value>
            <value>3</value>
            <value>348-51</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>5</value>
            <value>[The risk of neoplastic processes transformation in cervix uteri].</value>
            <value>1</value>
        </row>
        <row>
            <value>6</value>
            <value>PMID25033680</value>
            <value>60</value>
            <value>3</value>
            <value>298-305</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>5</value>
            <value>[Effectiveness of the model used for screening and early diagnosis of cervical cancer in Karelia].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>7</value>
            <value>PMID25033675</value>
            <value>60</value>
            <value>3</value>
            <value>263-6</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>5</value>
            <value>[Cervical intraepithelial neoplasia combined with pregnancy: diagnosis, management, outcomes].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>8</value>
            <value>PMID25031942</value>
            <value>3</value>
            <value>3</value>
            <value>161-9</value>
            <value>2012</value>
            <value>May</value>
            <value></value>
            <value>6</value>
            <value>Management of refractory metastatic anal squamous cell carcinoma following disease progression on
                traditional chemoradiation therapy.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>9</value>
            <value>PMID25032058</value>
            <value>4</value>
            <value>1</value>
            <value>37-40</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>7</value>
            <value>Vaginal Myomectomy for Semipedunculated Cervical Myoma during Pregnancy.</value>
            <value>1</value>
        </row>
        <row>
            <value>10</value>
            <value>PMID25030871</value>
            <value>43</value>
            <value>5</value>
            <value>339-40</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>8</value>
            <value>[Mesonephric hyperplasia in uterine cervix: report of two cases].</value>
            <value>1</value>
        </row>
        <row>
            <value>11</value>
            <value>PMID24984542</value>
            <value>35</value>
            <value>3</value>
            <value>284-8</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>9</value>
            <value>GTPases Rho distribution in intraepithelial and invasive neoplasias of the uterine cervix.</value>
            <value>1</value>
        </row>
        <row>
            <value>12</value>
            <value>PMID24984539</value>
            <value>35</value>
            <value>3</value>
            <value>270-3</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>9</value>
            <value>Cervical intraepithelial neoplasia based on array comparative genomic hybridization.</value>
            <value>1</value>
        </row>
        <row>
            <value>13</value>
            <value>PMID24981025</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>1</value>
            <value>10</value>
            <value>Galactosylated 2-hydroxypropyl methacrylamide-s-3-guanidinopropyl methacrylamide copolymer as small
                hairpin RNA carrier for inhibiting human telomerase reverse transcriptase expression.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>14</value>
            <value>PMID24980768</value>
            <value>36</value>
            <value>2</value>
            <value>121-4</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>11</value>
            <value>The frequency of human papilloma virus types 16, 18 in upper genital tract of women at high risk of
                developing ovarian cancer.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>15</value>
            <value>PMID24980145</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>1</value>
            <value>12</value>
            <value>Difficult preoperative diagnosis in a case of rapidly progressive carcinomatous pericarditis.</value>
            <value>0</value>
        </row>
        <row>
            <value>16</value>
            <value>PMID24979836</value>
            <value>16</value>
            <value>5</value>
            <value>303-6</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>13</value>
            <value>Uterine cervix conization based on Pap smear results: the "see and treat" approach.</value>
            <value>1</value>
        </row>
        <row>
            <value>17</value>
            <value>PMID24979516</value>
            <value>23</value>
            <value>3</value>
            <value>433-40</value>
            <value>2014</value>
            <value>May-Jun</value>
            <value></value>
            <value>14</value>
            <value>Multiple neoplasms among cervical cancer patients in the material of the lower silesian cancer
                registry.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>18</value>
            <value>PMID24978344</value>
            <value>39</value>
            <value>8</value>
            <value>680-4</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>15</value>
            <value>Nabothian Cyst a Predominant Cause of False-Positive Iodine Uptake in Uterus: Comparison of SPECT/CT
                and Pelvic MRI.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>19</value>
            <value>PMID24977742</value>
            <value>46</value>
            <value>5</value>
            <value>433-8</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>16</value>
            <value>Fascin expression in cervical normal squamous epithelium, cervical intraepithelial neoplasia, and
                superficially invasive (stage IA1) squamous carcinoma of the cervix.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>20</value>
            <value>PMID24977630</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>20</value>
            <value>17</value>
            <value>The Developmental Origin of Cervical and Vaginal Epithelium and Their Clinical Consequences: A
                Systematic Review.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>21</value>
            <value>PMID25038282</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>18</value>
            <value>Identification and characterization of a Macrobrachium nipponense ferritin subunit regulated by iron
                ion and pathogen challenge.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>22</value>
            <value>PMID25038044</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>19</value>
            <value>Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary.</value>
            <value>0</value>
        </row>
        <row>
            <value>23</value>
            <value>PMID25037744</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>19</value>
            <value>20</value>
            <value>Oocyte maturation in the sloth's giant tick Amblyomma varium (Acari: Ixodidae) in an ecological
                context.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>24</value>
            <value>PMID25037707</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>21</value>
            <value>Androgen actions in the ovary: balance is key.</value>
            <value>0</value>
        </row>
        <row>
            <value>25</value>
            <value>PMID25036649</value>
            <value>155</value>
            <value>8</value>
            <value>2751-3</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>22</value>
            <value>Brainwork in the ovary: kisspeptin and BDNF signaling converge to ensure oocyte survival.</value>
            <value>1</value>
        </row>
        <row>
            <value>26</value>
            <value>PMID25036408</value>
            <value>180C</value>
            <value></value>
            <value>46-50</value>
            <value>2014</value>
            <value>Jun</value>
            <value>28</value>
            <value>23</value>
            <value></value>
            <value>0</value>
        </row>
        <row>
            <value>27</value>
            <value>PMID25035863</value>
            <value>3</value>
            <value>2</value>
            <value>126-9</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>24</value>
            <value>Screening of Different Organs of Rats for HCA2 Receptor mRNA.</value>
            <value>1</value>
        </row>
        <row>
            <value>28</value>
            <value>PMID25035436</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>17</value>
            <value>25</value>
            <value>Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and
                abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>29</value>
            <value>PMID25035168</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>14</value>
            <value>26</value>
            <value>Soy isoflavones administered to rats from weaning until sexual maturity affect ovarian follicle
                development by inducing apoptosis.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>30</value>
            <value>PMID25034975</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>12</value>
            <value>4</value>
            <value>Gonadal Development in Fish.</value>
            <value>0</value>
        </row>
        <row>
            <value>31</value>
            <value>PMID25038552</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>27</value>
            <value>Therapeutic approach to respiratory infections in lung transplantation.</value>
            <value>0</value>
        </row>
        <row>
            <value>32</value>
            <value>PMID25038546</value>
            <value>290</value>
            <value>2</value>
            <value>185-9</value>
            <value>2014</value>
            <value>Jun</value>
            <value>18</value>
            <value>28</value>
            <value>Remarkable regression of a lung recurrence from an undifferentiated embryonal sarcoma of the liver
                treated with a DC vaccine combined with immune cells: A case report.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>33</value>
            <value>PMID25038532</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>29</value>
            <value>Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian
                (PLCO) Cancer Screening Trial.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>34</value>
            <value>PMID25038495</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>30</value>
            <value>Polysilsesquioxane Nanoparticles for Triggered Release of Cisplatin and Effective Cancer
                Chemoradiotherapy.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>35</value>
            <value>PMID25038446</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>31</value>
            <value>mtDNA sequence, phylogeny and evolution of laboratory mice.</value>
            <value>0</value>
        </row>
        <row>
            <value>36</value>
            <value>PMID25038397</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>32</value>
            <value>Valley Fever: Danger Lurking in a Dust Cloud.</value>
            <value>0</value>
        </row>
        <row>
            <value>37</value>
            <value>PMID25038391</value>
            <value>62</value>
            <value>2</value>
            <value>174-6</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>33</value>
            <value>Tracheoesophageal fistula in a treatment naive patient with lung cancer.</value>
            <value>1</value>
        </row>
        <row>
            <value>38</value>
            <value>PMID25038390</value>
            <value>62</value>
            <value>2</value>
            <value>172-3</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>33</value>
            <value>Lung cancer superimposed opacity of aortic arch.</value>
            <value>1</value>
        </row>
        <row>
            <value>39</value>
            <value>PMID25038389</value>
            <value>62</value>
            <value>2</value>
            <value>170-1</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>33</value>
            <value>FDG-PET/CT scan in a skin metastasis from lung cancer.</value>
            <value>1</value>
        </row>
        <row>
            <value>40</value>
            <value>PMID25038386</value>
            <value>62</value>
            <value>2</value>
            <value>154-9</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>33</value>
            <value>[The risk of pneumococcal diseases in lung diseases and the importance of adult vaccination.]</value>
            <value>1</value>
        </row>
        <row>
            <value>41</value>
            <value>PMID25036713</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>34</value>
            <value>Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.</value>
            <value>0</value>
        </row>
        <row>
            <value>42</value>
            <value>PMID25035588</value>
            <value>38</value>
            <value>3</value>
            <value>293-6</value>
            <value>2014</value>
            <value>Sep</value>
            <value></value>
            <value>35</value>
            <value>Kalicephalus sp. in a captive Russell's viper: a case report.</value>
            <value>1</value>
        </row>
        <row>
            <value>43</value>
            <value>PMID25035091</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>30</value>
            <value>36</value>
            <value>The use of contrast-enhanced magnetic resonance imaging to diagnose cesarean scar pregnancies.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>44</value>
            <value>PMID25033979</value>
            <value>87</value>
            <value>4</value>
            <value>193-204</value>
            <value>2014</value>
            <value>Jul</value>
            <value>11</value>
            <value>37</value>
            <value></value>
            <value>0</value>
        </row>
        <row>
            <value>45</value>
            <value>PMID25033729</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>5</value>
            <value>38</value>
            <value>Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array
                comparative genomic hybridization study.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>46</value>
            <value>PMID25032253</value>
            <value>65</value>
            <value>1</value>
            <value>90-9</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>39</value>
            <value>Does clear cell carcinoma of stomach exist? Clinicopathological and prognostic significance of clear
                cell changes in gastric adenocarcinomas.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>47</value>
            <value>PMID25032052</value>
            <value>4</value>
            <value>1</value>
            <value>9-12</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>7</value>
            <value>Repair of Uterine Rupture during Second Trimester Leading to Successful Pregnancy Outcome: Case Study
                and Literature's Review.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>48</value>
            <value>PMID25031361</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>40</value>
            <value>Neurotensin Enhances Sperm Capacitation and Acrosome Reaction in Mice.</value>
            <value>0</value>
        </row>
        <row>
            <value>49</value>
            <value>PMID25003230</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>8</value>
            <value>41</value>
            <value>Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised
                following short-term culture in the presence of an aryl hydrocarbon receptor antagonist.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>50</value>
            <value>PMID24993099</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>3</value>
            <value>42</value>
            <value>CCR5 as a Treatment Target in Pulmonary Arterial Hypertension.</value>
            <value>0</value>
        </row>
        <row>
            <value>51</value>
            <value>PMID24970973</value>
            <value>55</value>
            <value>1</value>
            <value>63-6</value>
            <value>2014</value>
            <value>Jan</value>
            <value></value>
            <value>43</value>
            <value>Prevalence of HIV-related autoimmune haemolytic anaemia in Lagos, Nigeria.</value>
            <value>1</value>
        </row>
        <row>
            <value>52</value>
            <value>PMID24968551</value>
            <value>61</value>
            <value>12</value>
            <value>910-2</value>
            <value>2013</value>
            <value>Dec</value>
            <value></value>
            <value>44</value>
            <value>Primary human parvovirus B19 infection in an HIV infected patient on antiretroviral therapy.</value>
            <value>1</value>
        </row>
        <row>
            <value>53</value>
            <value>PMID24953216</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>19</value>
            <value>45</value>
            <value>Improved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus
                macaques.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>54</value>
            <value>PMID24946280</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>16</value>
            <value>46</value>
            <value>Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The
                International Telaprevir Access Program.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>55</value>
            <value>PMID24945407</value>
            <value>10</value>
            <value>6</value>
            <value>e1003681</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>47</value>
            <value>A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+
                T cells.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>56</value>
            <value>PMID24925206</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>13</value>
            <value>48</value>
            <value>Effects of Vector Backbone and Pseudotype on Lentiviral Vector-Mediated Gene Transfer: Studies in
                Infant ADA-Deficient Mice and Rhesus Monkeys.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>57</value>
            <value>PMID24920807</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>11</value>
            <value>49</value>
            <value>Cytokine/chemokine responses in activated CD4+ and CD8+ T-cells isolated from peripheral blood, bone
                marrow and axillary lymph node during acute simian immunodeficiency virus infection.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>58</value>
            <value>PMID24907411</value>
            <value>153</value>
            <value>2</value>
            <value>308-22</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>50</value>
            <value>Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel
                combinatorial approaches for enhancing responses.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>59</value>
            <value>PMID25038582</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>51</value>
            <value>Aromatase, estrogen receptors and brain development in fish and amphibians.</value>
            <value>0</value>
        </row>
        <row>
            <value>60</value>
            <value>PMID25038563</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>52</value>
            <value>In vivo Magnetic Resonance Imaging at 11.7 Tesla Visualized the Effects of Neonatal Transection of
                Infraorbital Nerve upon Primary and Secondary Trigeminal Pathways in Rats.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>61</value>
            <value>PMID25038562</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>52</value>
            <value>Nifedipine and nimodipine protect dopaminergic substantia nigra neurons against axotomy-induced cell
                death in rat vibrosections via modulating inflammatory responses.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>62</value>
            <value>PMID25038561</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>52</value>
            <value>Redistribution of voltage-gated sodium channels after nerve decompression contributes to relieve
                neuropathic pain in chronic constriction injury.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>63</value>
            <value>PMID25038514</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>51</value>
            <value>A short-chain alkyl derivative of Rhodamine 19 acts as a mild uncoupler of mitochondria and a
                neuroprotector.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>64</value>
            <value>PMID25038450</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>53</value>
            <value>Blood vessel cell death during prion disease: implications for disease management and infection
                control.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>65</value>
            <value>PMID25038449</value>
            <value>128C</value>
            <value></value>
            <value>1-20</value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>54</value>
            <value>How familiar characters influence children's judgments about information and products.</value>
            <value>0</value>
        </row>
        <row>
            <value>66</value>
            <value>PMID25038444</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>55</value>
            <value>A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice:
                Insights into changes in c-Fos immunoreactivity.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>67</value>
            <value>PMID25038442</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>56</value>
            <value>Wedge MUSIC: A novel approach to examine experimental differences of brain source connectivity
                patterns from EEG/MEG data.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>68</value>
            <value>PMID25038440</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>56</value>
            <value>Sparse Encoding of Automatic Visual Association in Hippocampal Networks.</value>
            <value>0</value>
        </row>
        <row>
            <value>69</value>
            <value>PMID25038451</value>
            <value>133C</value>
            <value></value>
            <value>353-61</value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>57</value>
            <value>Farm residence and lymphohematopoietic cancers in the Iowa Women?s Health Study.</value>
            <value>0</value>
        </row>
        <row>
            <value>70</value>
            <value>PMID25037887</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>12</value>
            <value>58</value>
            <value>Feasibility and Outcome of the Hyper-CVAD Regimen in Patients With Adult Acute Lymphoblastic
                Leukemia.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>71</value>
            <value>PMID25037886</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>12</value>
            <value>58</value>
            <value>Report of 6 Cases of Large Granular Lymphocytic Leukemia and Plasma Cell Dyscrasia.</value>
            <value>0</value>
        </row>
        <row>
            <value>72</value>
            <value>PMID25037851</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>19</value>
            <value>59</value>
            <value>Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>73</value>
            <value>PMID25037813</value>
            <value>71</value>
            <value>2</value>
            <value>e50-2</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>60</value>
            <value>Merkel cell carcinoma presenting as right leg edema in a multiple myeloma patient.</value>
            <value>1</value>
        </row>
        <row>
            <value>74</value>
            <value>PMID25036800</value>
            <value>4</value>
            <value></value>
            <value>e229</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>61</value>
            <value>The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan
                activity against preclinical models of multiple myeloma.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>75</value>
            <value>PMID25035968</value>
            <value></value>
            <value></value>
            <value>1-16</value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>62</value>
            <value>Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.</value>
            <value>0</value>
        </row>
        <row>
            <value>76</value>
            <value>PMID25035830</value>
            <value>5</value>
            <value>3</value>
            <value>272-82</value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>63</value>
            <value>Imaging of multiple myeloma: Current concepts.</value>
            <value>1</value>
        </row>
        <row>
            <value>77</value>
            <value>PMID25035786</value>
            <value>7</value>
            <value>6</value>
            <value>1603-6</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>64</value>
            <value>Left renal atrophy.</value>
            <value>1</value>
        </row>
        <row>
            <value>78</value>
            <value>PMID25035670</value>
            <value>31</value>
            <value>2</value>
            <value>136-42</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>65</value>
            <value>Local Renin-Angiotensin system in normal hematopoietic and multiple myeloma-related progenitor
                cells.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>79</value>
            <value>PMID24350626</value>
            <value>35</value>
            <value>4</value>
            <value>335-43</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>66</value>
            <value>Production and characterization of monoclonal antibodies against aflatoxin B1.</value>
            <value>1</value>
        </row>
        <row>
            <value>80</value>
            <value>PMID24029260</value>
            <value>24</value>
            <value>5</value>
            <value>950-8</value>
            <value>2013</value>
            <value>Sep</value>
            <value></value>
            <value>67</value>
            <value>Incidence and clinical outcome of renal amyloidosis: a retrospective study.</value>
            <value>1</value>
        </row>
        <row>
            <value>81</value>
            <value>PMID22407148</value>
            <value>27</value>
            <value>6</value>
            <value>1815-22</value>
            <value>2012</value>
            <value>Jun</value>
            <value></value>
            <value>68</value>
            <value>A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple
                myeloma model.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>82</value>
            <value>PMID21651867</value>
            <value>27</value>
            <value>6</value>
            <value>650-2</value>
            <value>2011</value>
            <value>Jun</value>
            <value></value>
            <value>69</value>
            <value>[Development, identification and function assay of monoclonal antibody against platelet membrane
                glycoprotein Ib].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>83</value>
            <value>PMID19698225</value>
            <value>17</value>
            <value>4</value>
            <value>898-902</value>
            <value>2009</value>
            <value>Aug</value>
            <value></value>
            <value>70</value>
            <value>[Construction of eukaryotic expressing vector of multiple myeloma mucin-1 and its expression in COS-7
                cells in vitro].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>84</value>
            <value>PMID18583250</value>
            <value>28</value>
            <value>6</value>
            <value>1008-10</value>
            <value>2008</value>
            <value>Jun</value>
            <value></value>
            <value>71</value>
            <value>[Preparation and characterization of specific monoclonal antibodies against hexon of HAdV 3].</value>
            <value>1</value>
        </row>
        <row>
            <value>85</value>
            <value>PMID17618572</value>
            <value>23</value>
            <value>8</value>
            <value>757-60</value>
            <value>2007</value>
            <value>Aug</value>
            <value></value>
            <value>69</value>
            <value>[Preparation and characterization of two novel functional monoclonal antibodies against human
                OX40L].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>86</value>
            <value>PMID17605870</value>
            <value>15</value>
            <value>3</value>
            <value>581-5</value>
            <value>2007</value>
            <value>Jun</value>
            <value></value>
            <value>70</value>
            <value>[Anti-myloma activity of T cell activated by dentritic cells loading antigen of U266 cells].</value>
            <value>1</value>
        </row>
        <row>
            <value>87</value>
            <value>PMID17576818</value>
            <value>110</value>
            <value>7</value>
            <value>2586-92</value>
            <value>2007</value>
            <value>Oct</value>
            <value>1</value>
            <value>72</value>
            <value>New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and
                smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>88</value>
            <value>PMID11511021</value>
            <value>61</value>
            <value>9</value>
            <value>1253-74</value>
            <value>2001</value>
            <value></value>
            <value></value>
            <value>73</value>
            <value>The clinical and cost considerations of bisphosphonates in preventing bone complications in patients
                with metastatic breast cancer or multiple myeloma.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>89</value>
            <value>PMID4244427</value>
            <value>42</value>
            <value>4</value>
            <value>78</value>
            <value>1968</value>
            <value>Apr</value>
            <value></value>
            <value>74</value>
            <value>[Dermatitis caused by soap].</value>
            <value>1</value>
        </row>
        <row>
            <value>90</value>
            <value>PMID25038404</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>75</value>
            <value>Human APOBEC3F Incorporation into Human Immunodeficiency Virus Type 1 Particles.</value>
            <value>0</value>
        </row>
        <row>
            <value>91</value>
            <value>PMID25038373</value>
            <value>312</value>
            <value>4</value>
            <value>452</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Medications to Prevent HIV Infection.</value>
            <value>1</value>
        </row>
        <row>
            <value>92</value>
            <value>PMID25038362</value>
            <value>312</value>
            <value>4</value>
            <value>432-4</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Trends in Diagnoses of HIV Infection in the United States, 2002-2011.</value>
            <value>1</value>
        </row>
        <row>
            <value>93</value>
            <value>PMID25038361</value>
            <value>312</value>
            <value>4</value>
            <value>428-9</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Dolutegravir (Tivicay) for HIV.</value>
            <value>1</value>
        </row>
        <row>
            <value>94</value>
            <value>PMID25038359</value>
            <value>312</value>
            <value>4</value>
            <value>410-25</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral
                Society-USA Panel.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>95</value>
            <value>PMID25038358</value>
            <value>312</value>
            <value>4</value>
            <value>390-409</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>HIV Prevention in Clinical Care Settings: 2014 Recommendations of the International Antiviral
                Society-USA Panel.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>96</value>
            <value>PMID25038357</value>
            <value>312</value>
            <value>4</value>
            <value>380-9</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat
                Accumulation: A Randomized Clinical Trial.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>97</value>
            <value>PMID25038356</value>
            <value>312</value>
            <value>4</value>
            <value>372-9</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Effect of Optional Home Initiation of HIV Care Following HIV Self-testing on Antiretroviral Therapy
                Initiation Among Adults in Malawi: A Randomized Clinical Trial.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>98</value>
            <value>PMID25038355</value>
            <value>312</value>
            <value>4</value>
            <value>362-71</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention: A
                Randomized Clinical Trial.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>99</value>
            <value>PMID25038354</value>
            <value>312</value>
            <value>4</value>
            <value>353-61</value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>76</value>
            <value>Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection.</value>
            <value>1</value>
        </row>
        <row>
            <value>100</value>
            <value>PMID25038510</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>45</value>
            <value>A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast
                cells (PSCMCs).
            </value>
            <value>0</value>
        </row>
        <row>
            <value>101</value>
            <value>PMID25035674</value>
            <value>31</value>
            <value>2</value>
            <value>161-7</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>65</value>
            <value>Determination of rate and causes of wastage of blood and blood products in Iranian hospitals.</value>
            <value>1</value>
        </row>
        <row>
            <value>102</value>
            <value>PMID25031510</value>
            <value>17</value>
            <value>4</value>
            <value>322-5</value>
            <value>2013</value>
            <value>Oct</value>
            <value></value>
            <value>77</value>
            <value>Prevalence of Crimean-Congo hemorrhagic fever virus antibodies in Greek residents in the area where
                the AP92 strain was isolated.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>103</value>
            <value>PMID25029858</value>
            <value>20</value>
            <value>6</value>
            <value>523-6</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>78</value>
            <value>[Influence factors on the cryosurvival rate of post-thaw spermatozoa from sperm donors].</value>
            <value>1</value>
        </row>
        <row>
            <value>104</value>
            <value>PMID25029059</value>
            <value>22</value>
            <value>3</value>
            <value>467-75</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>79</value>
            <value>A behavior model for blood donors and marketing strategies to retain and attract them.</value>
            <value>1</value>
        </row>
        <row>
            <value>105</value>
            <value>PMID25027317</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>15</value>
            <value>80</value>
            <value>Intranasal administration as a route for drug delivery to the brain: Evidence for a unique pathway
                for albumin.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>106</value>
            <value>PMID25021471</value>
            <value>63 Suppl 1</value>
            <value></value>
            <value>A118-9</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>81</value>
            <value>PTU-181???Relationship Between Barrett's Oesophagus And Abdominal Adiposity Or Bmi And Activated
                Pathways In Progression To Cancer.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>107</value>
            <value>PMID25017720</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>9</value>
            <value>82</value>
            <value>Kit Regulates HSC Engraftment across the Human-Mouse Species Barrier.</value>
            <value>0</value>
        </row>
        <row>
            <value>108</value>
            <value>PMID25016194</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>9</value>
            <value>83</value>
            <value>Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease.</value>
            <value>0</value>
        </row>
        <row>
            <value>109</value>
            <value>PMID25015692</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>6</value>
            <value>84</value>
            <value>Prognostic Significance of Impaired Baroreflex Sensitivity Assessed from Phase IV of the Valsalva
                Maneuver in a Population-Based Sample of Middle-Aged Subjects.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>110</value>
            <value>PMID24839834</value>
            <value>60</value>
            <value>5</value>
            <value>869-71</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>85</value>
            <value>Prevalence of antibodies against transfusion-transmissible infections (TTI) in blood donors from the
                Colombian eastern region.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>111</value>
            <value>PMID24839369</value>
            <value>30</value>
            <value>2</value>
            <value>135-8</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>86</value>
            <value>Hemolytic disease of the newborn due to anti-jkb: case report and review of the literature.</value>
            <value>1</value>
        </row>
        <row>
            <value>112</value>
            <value>PMID24839364</value>
            <value>30</value>
            <value>2</value>
            <value>105-10</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>86</value>
            <value>Rate of seroconversion in repeat blood donors at the national blood centre, kuala lumpur.</value>
            <value>1</value>
        </row>
        <row>
            <value>113</value>
            <value>PMID24836305</value>
            <value>35</value>
            <value>25</value>
            <value>6810-21</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>87</value>
            <value>Regulation of human endothelial progenitor cell maturation by polyurethane nanocomposites.</value>
            <value>1</value>
        </row>
        <row>
            <value>114</value>
            <value>PMID24827574</value>
            <value>53</value>
            <value>3</value>
            <value>307-16</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>88</value>
            <value>Blood-banking techniques for plateletpheresis in swine.</value>
            <value>1</value>
        </row>
        <row>
            <value>115</value>
            <value>PMID24825373</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>May</value>
            <value>13</value>
            <value>89</value>
            <value>Are hybrid umbilical cord blood banks really the best of both worlds?</value>
            <value>0</value>
        </row>
        <row>
            <value>116</value>
            <value>PMID24824150</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>May</value>
            <value>13</value>
            <value>90</value>
            <value>Treatment of acute disseminated encephalomyelitis with plasmapheresis in a 16-year-old female, a case
                report and literature review.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>117</value>
            <value>PMID24816442</value>
            <value>23</value>
            <value>4-5</value>
            <value>407-15</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>91</value>
            <value>Plasma-depleted versus red cell-reduced umbilical cord blood.</value>
            <value>1</value>
        </row>
        <row>
            <value>118</value>
            <value>PMID24816438</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Apr</value>
            <value>21</value>
            <value>92</value>
            <value>Transfusion therapy and alloimmunization in Thalassemia Intermedia: A 10 year experience at a
                tertiary care university hospital.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>119</value>
            <value>PMID24814554</value>
            <value>32</value>
            <value>29</value>
            <value>3675-9</value>
            <value>2014</value>
            <value>Jun</value>
            <value>17</value>
            <value>93</value>
            <value></value>
            <value>1</value>
        </row>
        <row>
            <value>120</value>
            <value>PMID25038188</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>94</value>
            <value>Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to
                mesenchymal stem cell therapy.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>121</value>
            <value>PMID25035677</value>
            <value>31</value>
            <value>2</value>
            <value>181-3</value>
            <value>2014</value>
            <value>Jun</value>
            <value></value>
            <value>65</value>
            <value>Use of mesenchymal cells to modulate immune suppression and immune reconstruction in a patient with
                aplastic anemia complicated by invasive sino-orbital aspergillosis.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>122</value>
            <value>PMID25035597</value>
            <value>38</value>
            <value>3</value>
            <value>334-6</value>
            <value>2014</value>
            <value>Sep</value>
            <value></value>
            <value>35</value>
            <value>A new report on the occurrence of clinico-histopathological diagnostic criteria for
                Spinodiplotriaena.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>123</value>
            <value>PMID25031436</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>95</value>
            <value>Sequential asymptomatic enterovirus infections in a patient with MHC class II primary
                immunodeficiency.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>124</value>
            <value>PMID25029233</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>14</value>
            <value>96</value>
            <value>Report of disseminated Mycobacterium haemophilum infection after double cord blood allo-SCT.</value>
            <value>0</value>
        </row>
        <row>
            <value>125</value>
            <value>PMID25027060</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>27</value>
            <value>97</value>
            <value>Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis
                virus-induced demyelinating disease.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>126</value>
            <value>PMID25025687</value>
            <value>9</value>
            <value>7</value>
            <value>e102033</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>1</value>
            <value>Keratinocyte Antiviral Response to Poly(dA:dT) Stimulation and Papillomavirus Infection in a Canine
                Model of X-Linked Severe Combined Immunodeficiency.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>127</value>
            <value>PMID25025372</value>
            <value>7</value>
            <value>4</value>
            <value>481-93</value>
            <value>2014</value>
            <value>Aug</value>
            <value></value>
            <value>98</value>
            <value>Targeted therapies for cutaneous T-cell lymphomas.</value>
            <value>1</value>
        </row>
        <row>
            <value>128</value>
            <value>PMID25024994</value>
            <value>6</value>
            <value>2</value>
            <value>119-24</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>99</value>
            <value>Early molecular diagnosis of aspergillosis in a patient with acute myeloid leukaemia.</value>
            <value>1</value>
        </row>
        <row>
            <value>129</value>
            <value>PMID25024369</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>14</value>
            <value>100</value>
            <value>Type II Toxoplasma gondii induction of CD40 on infected macrophages enhances IL-12 responses.</value>
            <value>0</value>
        </row>
        <row>
            <value>130</value>
            <value>PMID25038933</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>20</value>
            <value>101</value>
            <value>Overexpression of the PLAP-1 gene inhibits the differentiation of BMSCs into osteoblast-like cells.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>131</value>
            <value>PMID25038766</value>
            <value>46</value>
            <value>3</value>
            <value>307-11</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>102</value>
            <value>Unusual manifestation of intravascular large B-cell lymphoma: severe hypercalcemia with parathyroid
                hormone-related protein.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>132</value>
            <value>PMID25038614</value>
            <value>15</value>
            <value>1</value>
            <value>119</value>
            <value>2014</value>
            <value>Jul</value>
            <value>19</value>
            <value>103</value>
            <value>Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease
                patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>133</value>
            <value>PMID25038612</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>20</value>
            <value>104</value>
            <value>Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine
                and platinum in advanced gastric cancer: a phase II study.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>134</value>
            <value>PMID25038519</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>105</value>
            <value>Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell
                transplantation-can preemptive detection of John Cunningham virus be useful?
            </value>
            <value>0</value>
        </row>
        <row>
            <value>135</value>
            <value>PMID25038516</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>17</value>
            <value>106</value>
            <value>Dietary restriction ameliorates haematopoietic ageing independent of telomerase, whilst lack of
                telomerase and short telomeres exacerbates the ageing phenotype.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>136</value>
            <value>PMID25038457</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>107</value>
            <value>Predicting and validating the pathway of Wnt3a-driven suppression of osteoclastogenesis.</value>
            <value>0</value>
        </row>
        <row>
            <value>137</value>
            <value>PMID25038395</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>83</value>
            <value>Estimated versus measured glomerular filtration rate in children prior to hematopoietic cell
                transplantation.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>138</value>
            <value>PMID25038255</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>108</value>
            <value>Inducible Nitric Oxide Synthase in Neutrophils and Endothelium Contributes to Ischemic Brain Injury
                in Mice.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>139</value>
            <value>PMID25038246</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>109</value>
            <value>Capillary Force Seeding of Hydrogels for Adipose-Derived Stem Cell Delivery in Wounds.</value>
            <value>0</value>
        </row>
        <row>
            <value>140</value>
            <value>PMID25046391</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>110</value>
            <value>COMBINED PARS PLANA VITRECTOMY AND PARS PLANA BAERVELDT TUBE PLACEMENT IN EYES WITH NEOVASCULAR
                GLAUCOMA.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>141</value>
            <value>PMID25045926</value>
            <value></value>
            <value></value>
            <value>1-10</value>
            <value>2014</value>
            <value>Jul</value>
            <value>21</value>
            <value>111</value>
            <value>Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the
                treatment of glaucoma: vitro and vivo study.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>142</value>
            <value>PMID25044936</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>16</value>
            <value>112</value>
            <value>The homeodomain transcription factor PITX2 is required for specifying correct cell fates and
                establishing angiogenic privilege in the developing cornea.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>143</value>
            <value>PMID25044142</value>
            <value></value>
            <value></value>
            <value>0</value>
            <value>2014</value>
            <value>Jul</value>
            <value>4</value>
            <value>113</value>
            <value>Effectiveness of transscleral cyclophotocoagulation as adjuvant therapy for refractory glaucoma in
                keratoprosthesis patients.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>144</value>
            <value>PMID25044141</value>
            <value></value>
            <value></value>
            <value>0</value>
            <value>2014</value>
            <value>Jul</value>
            <value>21</value>
            <value>113</value>
            <value>Vascular comorbidity in patients with low-tension glaucoma.</value>
            <value>0</value>
        </row>
        <row>
            <value>145</value>
            <value>PMID25044139</value>
            <value></value>
            <value></value>
            <value>0</value>
            <value>2014</value>
            <value>Jul</value>
            <value>8</value>
            <value>113</value>
            <value>Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications
                in chronic angle-closure glaucoma.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>146</value>
            <value>PMID25044138</value>
            <value></value>
            <value></value>
            <value>0</value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>113</value>
            <value>The effect of oral propranolol on intraocular pressure in infants with Sturge-Weber syndrome
                glaucoma.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>147</value>
            <value>PMID25044131</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>9</value>
            <value>114</value>
            <value>Artemin augments survival and axon regeneration in axotomized retinal ganglion cells.</value>
            <value>0</value>
        </row>
        <row>
            <value>148</value>
            <value>PMID25043917</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>10</value>
            <value>114</value>
            <value>Synthetic conantokin peptides potently inhibit N-methyl-D-aspartate receptor-mediated currents of
                retinal ganglion cells.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>149</value>
            <value>PMID25043873</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>115</value>
            <value>Update in intracranial pressure evaluation methods and translaminar pressure gradient role in
                glaucoma.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>150</value>
            <value>PMID25050061</value>
            <value>8</value>
            <value></value>
            <value>1311-6</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>116</value>
            <value>Hypertensive phase and early complications after Ahmed glaucoma valve implantation with
                intraoperative subtenon triamcinolone acetonide.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>151</value>
            <value>PMID25050060</value>
            <value>8</value>
            <value></value>
            <value>1301-10</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>116</value>
            <value></value>
            <value>1</value>
        </row>
        <row>
            <value>152</value>
            <value>PMID25048828</value>
            <value>55</value>
            <value>7</value>
            <value>4475</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>117</value>
            <value>Author Response: Predicting and Preventing Visual Impairment and Blindness by Incorporating
                Individual Progression Velocity in Glaucoma Care.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>153</value>
            <value>PMID25048827</value>
            <value>55</value>
            <value>7</value>
            <value>4470-4</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>117</value>
            <value>Predicting and Preventing Visual Impairment and Blindness by Incorporating Individual Progression
                Velocity in Glaucoma Care.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>154</value>
            <value>PMID25047064</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>22</value>
            <value>118</value>
            <value>Outcome of conjunctival flap repair for corneal defects with and without an acellular submucosa
                implant in 73 canine eyes.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>155</value>
            <value>PMID25049315</value>
            <value>100</value>
            <value>16</value>
            <value>1257-63</value>
            <value>2014</value>
            <value>Aug</value>
            <value>15</value>
            <value>119</value>
            <value>Prognostic significance and relationship of worst lead residual ST segment elevation with myocardial
                damage assessed by cardiovascular MRI in myocardial infarction.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>156</value>
            <value>PMID25045293</value>
            <value>29</value>
            <value>4</value>
            <value>454-65</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>120</value>
            <value>Prediction of infarct severity from triiodothyronine levels in patients with ST-elevation myocardial
                infarction.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>157</value>
            <value>PMID25042919</value>
            <value>42</value>
            <value>5</value>
            <value>400-5</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>121</value>
            <value>[Association between fragmented QRS complexes and imperfect ST-segment resolution in patients with
                ST-elevation myocardial infarction after primary percutaneous coronary intervention].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>158</value>
            <value>PMID25042419</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>18</value>
            <value>122</value>
            <value>Predictors of adverse events among patients undergoing primary percutaneous coronary intervention:
                insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>159</value>
            <value>PMID25042272</value>
            <value>10</value>
            <value>3</value>
            <value>411-2</value>
            <value>2014</value>
            <value>Jul</value>
            <value>20</value>
            <value>122</value>
            <value>Will this trial change my practice? PRAMI - treatment of bystander coronary lesions in patients
                undergoing primary PCI for acute STEMI.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>160</value>
            <value>PMID25041222</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>19</value>
            <value>123</value>
            <value>Prospective Study of Effects of Endogenous Estrogens on Myocardial No-Reflow Risk in Postmenopausal
                Women with Acute Myocardial Infarction.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>161</value>
            <value>PMID25041063</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>17</value>
            <value>124</value>
            <value>The Assessment of Relationship between Fragmented QRS Complex and Left Ventricular Wall Motion Score
                Index in Patients with ST Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary
                Intervention.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>162</value>
            <value>PMID25041036</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>8</value>
            <value>123</value>
            <value>Effect of Intracoronary Nitroprusside in Preventing No Reflow Phenomenon during Primary Percutaneous
                Coronary Intervention: A Meta-Analysis.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>163</value>
            <value>PMID25040877</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>7</value>
            <value>124</value>
            <value>Predictive Value of a Fragmented QRS Complex in Patients Undergoing Primary Angioplasty for ST
                Elevation Myocardial Infarction.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>164</value>
            <value>PMID25036322</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Apr</value>
            <value>8</value>
            <value>125</value>
            <value>The relationship between C-reactive protein and the lapse of time since the onset of the symptoms
                after acute myocardial infarction: an prospective-observational study.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>165</value>
            <value>PMID25039354</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>11</value>
            <value>126</value>
            <value>Eosinophilic folliculitis occurring after stem cell transplant for acute lymphoblastic leukemia: a
                case report and review.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>166</value>
            <value>PMID24931461</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jun</value>
            <value>12</value>
            <value>127</value>
            <value>Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an
                immunosuppressive therapy regimen option for severe aplastic anemia in adults.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>167</value>
            <value>PMID24881923</value>
            <value>55</value>
            <value>5</value>
            <value>563-9</value>
            <value>2014</value>
            <value>May</value>
            <value></value>
            <value>128</value>
            <value>Clinical experience of bendamustine for adult Langerhans cell sarcoma.</value>
            <value>1</value>
        </row>
        <row>
            <value>168</value>
            <value>PMID24709246</value>
            <value>24</value>
            <value>4</value>
            <value>285-7</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>129</value>
            <value>Congenital amegakaryocytic thrombocytopenic purpura (CAMT).</value>
            <value>1</value>
        </row>
        <row>
            <value>169</value>
            <value>PMID24700034</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>130</value>
            <value>A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>170</value>
            <value>PMID24554832</value>
            <value>30</value>
            <value>1</value>
            <value>72-4</value>
            <value>2014</value>
            <value>Mar</value>
            <value></value>
            <value>86</value>
            <value>Gelatinous Marrow Transformation in an Imatinib-Treated CML Patient with Pancytopenia Following
                Severe Sepsis.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>171</value>
            <value>PMID24490345</value>
            <value>127</value>
            <value>1-2</value>
            <value>61-9</value>
            <value>2014</value>
            <value>Jan-Feb</value>
            <value></value>
            <value>131</value>
            <value>Causes of death in calves with experimentally induced bovine neonatal pancytopenia (BNP).</value>
            <value>1</value>
        </row>
        <row>
            <value>172</value>
            <value>PMID24481938</value>
            <value>99</value>
            <value>4</value>
            <value>523-6</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>132</value>
            <value>An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level
                of IFN-? production.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>173</value>
            <value>PMID24433602</value>
            <value>35</value>
            <value>1</value>
            <value>78-82</value>
            <value>2014</value>
            <value>Jan-Feb</value>
            <value></value>
            <value>133</value>
            <value>High-grade fever and pancytopenia in an adult patient with common variable immune deficiency.</value>
            <value>1</value>
        </row>
        <row>
            <value>174</value>
            <value>PMID24433450</value>
            <value>28</value>
            <value>2</value>
            <value>217-22</value>
            <value>2014</value>
            <value>Feb</value>
            <value></value>
            <value>134</value>
            <value>Successful treatment for graft-versus-host disease after pancreas transplantation.</value>
            <value>1</value>
        </row>
        <row>
            <value>175</value>
            <value>PMID24426366</value>
            <value>29</value>
            <value>3</value>
            <value>167-70</value>
            <value>2013</value>
            <value>Sep</value>
            <value></value>
            <value>86</value>
            <value>Severe systemic infection masking underlying childhood leukemia.</value>
            <value>1</value>
        </row>
        <row>
            <value>176</value>
            <value>PMID24413728</value>
            <value>8</value>
            <value>1</value>
            <value>81-4</value>
            <value>2014</value>
            <value>Jan</value>
            <value></value>
            <value>135</value>
            <value>Clinical dilemma over low-dose methotrexate therapy in dialysis patients: a case report and review of
                literature.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>177</value>
            <value>PMID24383917</value>
            <value>31</value>
            <value>3</value>
            <value>282-4</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>136</value>
            <value>Trichosporon asahii, sepsis, and secondary hemophagocytic lymphohistiocytosis in children with
                hematologic malignancy.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>178</value>
            <value>PMID24169729</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2013</value>
            <value>Oct</value>
            <value>30</value>
            <value>137</value>
            <value>The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated
                post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>179</value>
            <value>PMID24047883</value>
            <value>25</value>
            <value>5</value>
            <value>387-8</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>138</value>
            <value>Coagulase-negative staphylococci in an HIV-infected child causing pancytopaenia.</value>
            <value>1</value>
        </row>
        <row>
            <value>180</value>
            <value>PMID23895965</value>
            <value>48</value>
            <value>7</value>
            <value>1514-9</value>
            <value>2013</value>
            <value>Jul</value>
            <value></value>
            <value>139</value>
            <value>Hemophagocytic lymphohistiocytosis mimicking surgical symptoms and complications: lessons learned
                from four cases.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>181</value>
            <value>PMID23855909</value>
            <value>7</value>
            <value></value>
            <value>185</value>
            <value>2013</value>
            <value></value>
            <value></value>
            <value>140</value>
            <value>Correlation among Streptococcus bovis, endocarditis and septicemia in a patient with advanced colon
                cancer: a case report.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>182</value>
            <value>PMID23741821</value>
            <value>110</value>
            <value>8</value>
            <value>560-2, 566</value>
            <value>2012</value>
            <value>Aug</value>
            <value></value>
            <value>141</value>
            <value>Bone marrow examination in pancytopenia.</value>
            <value>1</value>
        </row>
        <row>
            <value>183</value>
            <value>PMID23497971</value>
            <value>76</value>
            <value>3</value>
            <value>169-72</value>
            <value>2013</value>
            <value>Mar</value>
            <value></value>
            <value>142</value>
            <value>Peripheral T-cell lymphoma of the colon associated with hemophagocytic lymphohistiocytosis.</value>
            <value>1</value>
        </row>
        <row>
            <value>184</value>
            <value>PMID23413287</value>
            <value>2013</value>
            <value></value>
            <value></value>
            <value>2013</value>
            <value></value>
            <value></value>
            <value>130</value>
            <value>Hepatitis-associated aplastic anaemia: a poor prognosis.</value>
            <value>1</value>
        </row>
        <row>
            <value>185</value>
            <value>PMID23332768</value>
            <value>43</value>
            <value>1</value>
            <value>39-41</value>
            <value>2013</value>
            <value>Jan</value>
            <value></value>
            <value>143</value>
            <value>Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin.</value>
            <value>1</value>
        </row>
        <row>
            <value>186</value>
            <value>PMID23257675</value>
            <value>53</value>
            <value>11</value>
            <value>1926-31</value>
            <value>2012</value>
            <value>Nov</value>
            <value></value>
            <value>128</value>
            <value>[Severe aplastic anemia following living-donor liver transplantation for fluminant hepatitis].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>187</value>
            <value>PMID23225831</value>
            <value>54</value>
            <value>1</value>
            <value>265-8</value>
            <value>2013</value>
            <value>Jan</value>
            <value>1</value>
            <value>144</value>
            <value>Two cases of mushroom poisoning by Podostroma cornu-damae.</value>
            <value>1</value>
        </row>
        <row>
            <value>188</value>
            <value>PMID23073042</value>
            <value>35</value>
            <value>8</value>
            <value>e332-4</value>
            <value>2013</value>
            <value>Nov</value>
            <value></value>
            <value>145</value>
            <value>Association of nonimmune hydrops fetalis with familial hemophagocytic lymphohistiocytosis in
                identical twin neonates with perforin His222Arg (c665A&gt;G) mutation.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>189</value>
            <value>PMID22889552</value>
            <value>191</value>
            <value>1-2</value>
            <value>35-43</value>
            <value>2013</value>
            <value>Jan</value>
            <value>16</value>
            <value>146</value>
            <value>Babesia ovis infections: detailed clinical and laboratory observations in the pre- and post-treatment
                periods of 97 field cases.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>190</value>
            <value>PMID22610142</value>
            <value>22</value>
            <value>2</value>
            <value>170-4</value>
            <value>2013</value>
            <value>Mar</value>
            <value></value>
            <value>147</value>
            <value>Diagnostic difficulties: chronic recurrent multifocal osteomyelitis and lymphoma. One or two
                diseases?
            </value>
            <value>1</value>
        </row>
        <row>
            <value>191</value>
            <value>PMID22584795</value>
            <value>38</value>
            <value>8</value>
            <value>1336-44</value>
            <value>2012</value>
            <value>Aug</value>
            <value></value>
            <value>148</value>
            <value>Septic shock and chemotherapy-induced cytopenia: effects on microcirculation.</value>
            <value>1</value>
        </row>
        <row>
            <value>192</value>
            <value>PMID22405484</value>
            <value>59</value>
            <value>6</value>
            <value>886-90</value>
            <value>2012</value>
            <value>Jun</value>
            <value></value>
            <value>149</value>
            <value>Adenovirus-induced interstitial nephritis following umbilical cord blood transplant for chronic
                lymphocytic leukemia.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>193</value>
            <value>PMID22310344</value>
            <value>35</value>
            <value>1-2</value>
            <value>40-2</value>
            <value>2012</value>
            <value></value>
            <value></value>
            <value>150</value>
            <value>Bone marrow metastases in a patient with primary mediastinal non-seminomatous germ cell tumor - an
                unusual pattern of relapse.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>194</value>
            <value>PMID22250755</value>
            <value>34</value>
            <value>3</value>
            <value>378-82</value>
            <value>2012</value>
            <value></value>
            <value></value>
            <value>151</value>
            <value>Fortuitous vasculitis.</value>
            <value>1</value>
        </row>
        <row>
            <value>195</value>
            <value>PMID22193223</value>
            <value>33</value>
            <value>5</value>
            <value>1363-6</value>
            <value>2013</value>
            <value>May</value>
            <value></value>
            <value>152</value>
            <value>Infection-associated haemophagocytic lymphohistiocytosis: a case series using steroids only protocol
                for management.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>196</value>
            <value>PMID24782338</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Apr</value>
            <value>29</value>
            <value>153</value>
            <value>Development and validation of a score for the diagnosis of reactive hemophagocytic syndrome
                (HScore).
            </value>
            <value>0</value>
        </row>
        <row>
            <value>197</value>
            <value>PMID24718941</value>
            <value>52</value>
            <value>4</value>
            <value>354-9</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>154</value>
            <value>Fulminant gastrointestinal bleeding caused by EBV-triggered hemophagocytic lymphohistiocytosis:
                report of a case.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>198</value>
            <value>PMID24678388</value>
            <value>6</value>
            <value>1</value>
            <value>e2014011</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>155</value>
            <value>Early and late complications related to central venous catheters in hematological malignancies: a
                retrospective analysis of 1102 patients.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>199</value>
            <value>PMID24646466</value>
            <value>93</value>
            <value>2</value>
            <value>100-5</value>
            <value>2014</value>
            <value>Mar</value>
            <value></value>
            <value>156</value>
            <value>Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients.</value>
            <value>1</value>
        </row>
        <row>
            <value>200</value>
            <value>PMID24613776</value>
            <value>155</value>
            <value>11</value>
            <value>414-9</value>
            <value>2014</value>
            <value>Mar</value>
            <value>16</value>
            <value>157</value>
            <value>[Large granular lymphocytic leukemia. A rare disease with personalized treatment options].</value>
            <value>1</value>
        </row>
        <row>
            <value>201</value>
            <value>PMID24556409</value>
            <value>26</value>
            <value></value>
            <value>128-37</value>
            <value>2014</value>
            <value>Feb</value>
            <value></value>
            <value>158</value>
            <value>Pyroptotic death storms and cytopenia.</value>
            <value>1</value>
        </row>
        <row>
            <value>202</value>
            <value>PMID24330187</value>
            <value>92</value>
            <value>4</value>
            <value>331-6</value>
            <value>2014</value>
            <value>Apr</value>
            <value></value>
            <value>159</value>
            <value>Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation
                in primary hemophagocytic lymphohistiocytosis.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>203</value>
            <value>PMID22836385</value>
            <value>71</value>
            <value>8</value>
            <value>701-6</value>
            <value>2012</value>
            <value>Oct</value>
            <value></value>
            <value>160</value>
            <value>[Macrophage activation syndrome].</value>
            <value>1</value>
        </row>
        <row>
            <value>204</value>
            <value>PMID22183069</value>
            <value>16</value>
            <value>6</value>
            <value>351-6</value>
            <value>2011</value>
            <value>Nov</value>
            <value></value>
            <value>161</value>
            <value>Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid
                leukemia.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>205</value>
            <value>PMID21788006</value>
            <value>203</value>
            <value>2</value>
            <value>127-31</value>
            <value>2012</value>
            <value>Feb</value>
            <value></value>
            <value>162</value>
            <value>The surgical management of abdominal pain in the multiple myeloma patient.</value>
            <value>1</value>
        </row>
        <row>
            <value>206</value>
            <value>PMID21773661</value>
            <value>139</value>
            <value>2</value>
            <value>224-9</value>
            <value>2011</value>
            <value>Feb</value>
            <value></value>
            <value>163</value>
            <value>[Hemophagocytic syndrome. Report of four cases].</value>
            <value>1</value>
        </row>
        <row>
            <value>207</value>
            <value>PMID21737492</value>
            <value>140</value>
            <value>4</value>
            <value>933-8</value>
            <value>2011</value>
            <value>Oct</value>
            <value></value>
            <value>164</value>
            <value>Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic
                inflammatory response syndrome, severe sepsis, and septic shock in adults.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>208</value>
            <value>PMID21257627</value>
            <value>27</value>
            <value>1</value>
            <value>58-64</value>
            <value>2012</value>
            <value>Feb</value>
            <value></value>
            <value>165</value>
            <value>What intensivists need to know about hemophagocytic syndrome: an underrecognized cause of death in
                adult intensive care units.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>209</value>
            <value>PMID21221800</value>
            <value>56</value>
            <value>6</value>
            <value>1848-52</value>
            <value>2011</value>
            <value>Jun</value>
            <value></value>
            <value>166</value>
            <value>Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of
                pegylated interferon alfa-2a and ribavirin.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>210</value>
            <value>PMID21178710</value>
            <value>33</value>
            <value>1</value>
            <value>59-61</value>
            <value>2011</value>
            <value>Jan</value>
            <value></value>
            <value>145</value>
            <value>Pediatric myelodysplastic syndrome with cytoplasmic vacuolation in myeloid precursors.</value>
            <value>1</value>
        </row>
        <row>
            <value>211</value>
            <value>PMID21124036</value>
            <value>33</value>
            <value>12</value>
            <value>658-64</value>
            <value>2010</value>
            <value></value>
            <value></value>
            <value>150</value>
            <value>Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is
                feasible and reduces hospital treatment costs.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>212</value>
            <value>PMID20118059</value>
            <value>2</value>
            <value>2</value>
            <value>349-53</value>
            <value>2009</value>
            <value></value>
            <value></value>
            <value>167</value>
            <value>Nosocomial sepsis-induced late onset thrombocytopenia in a neonatal tertiary care unit: a prospective
                study.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>213</value>
            <value>PMID20093936</value>
            <value>22</value>
            <value>8</value>
            <value>1019-21</value>
            <value>2010</value>
            <value>Aug</value>
            <value></value>
            <value>168</value>
            <value>Gaucher's disease type I: a disease masked by the presence of abnormal laboratory tests common to
                primary liver disease.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>214</value>
            <value>PMID20042206</value>
            <value>52</value>
            <value>1</value>
            <value>76-80</value>
            <value>2010</value>
            <value>Jan-Feb</value>
            <value></value>
            <value>169</value>
            <value>[Familial hemophagocytic lymphohistiocytosis: Neuroradiological findings].</value>
            <value>1</value>
        </row>
        <row>
            <value>215</value>
            <value>PMID19433941</value>
            <value>10</value>
            <value>3</value>
            <value>285-90</value>
            <value>2009</value>
            <value>May</value>
            <value></value>
            <value>170</value>
            <value>An unusual cause of multiple organ dysfunction syndrome in the pediatric intensive care unit:
                hemophagocytic lymphohistiocytosis.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>216</value>
            <value>PMID19356188</value>
            <value>39</value>
            <value>2</value>
            <value>121-6</value>
            <value>2009</value>
            <value>Feb</value>
            <value></value>
            <value>171</value>
            <value>Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine
                induced myelosuppression.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>217</value>
            <value>PMID19325510</value>
            <value>10</value>
            <value>3</value>
            <value>387-92</value>
            <value>2009</value>
            <value>May</value>
            <value></value>
            <value>170</value>
            <value>Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response
                syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate
                phenotypes on a spectrum of inflammation.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>218</value>
            <value>PMID17492645</value>
            <value>82</value>
            <value>8</value>
            <value>697-701</value>
            <value>2007</value>
            <value>Aug</value>
            <value></value>
            <value>172</value>
            <value>Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among
                hematologists-oncologists and an opportunity for early diagnosis and intervention.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>219</value>
            <value>PMID17483661</value>
            <value>6</value>
            <value>3</value>
            <value>147-9</value>
            <value>2007</value>
            <value>May-Jun</value>
            <value></value>
            <value>173</value>
            <value>Griscelli syndrome.</value>
            <value>1</value>
        </row>
        <row>
            <value>220</value>
            <value>PMID17408021</value>
            <value>67</value>
            <value>1</value>
            <value>49-52</value>
            <value>2007</value>
            <value></value>
            <value></value>
            <value>174</value>
            <value>[Reactive hemophagocytic syndrome in critical care patients. Report of 4 cases].</value>
            <value>1</value>
        </row>
        <row>
            <value>221</value>
            <value>PMID17317910</value>
            <value>10</value>
            <value>3 Pt 1</value>
            <value>793-801</value>
            <value>2006</value>
            <value>Jul-Sep</value>
            <value></value>
            <value>175</value>
            <value>[Surgical treatment for malignancies in children--is prolonged bone marrow suppression an absolute
                contraindication for surgical procedures?].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>222</value>
            <value>PMID15667487</value>
            <value>100</value>
            <value>2</value>
            <value>308-12</value>
            <value>2005</value>
            <value>Feb</value>
            <value></value>
            <value>176</value>
            <value>Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.</value>
            <value>1</value>
        </row>
        <row>
            <value>223</value>
            <value>PMID15661264</value>
            <value>29</value>
            <value>3</value>
            <value>287-91</value>
            <value>2005</value>
            <value>Mar</value>
            <value></value>
            <value>177</value>
            <value>Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate
                treatment.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>224</value>
            <value>PMID14502460</value>
            <value>51</value>
            <value>4</value>
            <value>221-5</value>
            <value>2003</value>
            <value>Aug</value>
            <value></value>
            <value>178</value>
            <value>Short- and long-term outcome after lung resection for invasive pulmonary aspergillosis.</value>
            <value>1</value>
        </row>
        <row>
            <value>225</value>
            <value>PMID12134112</value>
            <value>74</value>
            <value>1</value>
            <value>131-2</value>
            <value>2002</value>
            <value>Jul</value>
            <value>15</value>
            <value>179</value>
            <value>Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient
                successfully treated with foscarnet.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>226</value>
            <value>PMID11344482</value>
            <value>77</value>
            <value>1</value>
            <value>42-8</value>
            <value>2001</value>
            <value>May</value>
            <value></value>
            <value>180</value>
            <value>Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis
                of 26 cases.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>227</value>
            <value>PMID11182497</value>
            <value>78</value>
            <value>4</value>
            <value>307-17</value>
            <value>2001</value>
            <value>Feb</value>
            <value>26</value>
            <value>181</value>
            <value>Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a
                single vaccination.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>228</value>
            <value>PMID11070102</value>
            <value>343</value>
            <value>19</value>
            <value>1378-85</value>
            <value>2000</value>
            <value>Nov</value>
            <value>9</value>
            <value>182</value>
            <value>Bone marrow failure associated with human herpesvirus 8 infection after transplantation.</value>
            <value>1</value>
        </row>
        <row>
            <value>229</value>
            <value>PMID10878402</value>
            <value>20</value>
            <value>3</value>
            <value>208-11</value>
            <value>2000</value>
            <value>May-Jun</value>
            <value></value>
            <value>183</value>
            <value>Systemic inflammatory response syndrome and acute renal failure associated with Hemophilus influenzae
                septic meningitis.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>230</value>
            <value>PMID9827926</value>
            <value>103</value>
            <value>2</value>
            <value>505-11</value>
            <value>1998</value>
            <value>Nov</value>
            <value></value>
            <value>184</value>
            <value>Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid
                metaplasia.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>231</value>
            <value>PMID9789219</value>
            <value>15</value>
            <value>2</value>
            <value>113-8</value>
            <value>1998</value>
            <value>Jul</value>
            <value></value>
            <value>185</value>
            <value>Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated
                with major haematological toxicities.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>232</value>
            <value>PMID9485617</value>
            <value>118</value>
            <value>2</value>
            <value>228-32</value>
            <value>1998</value>
            <value>Jan</value>
            <value>20</value>
            <value>186</value>
            <value>[Chronic lymphatic leukemia. A population-based study of symptoms, findings, complications and choice
                of treatment].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>233</value>
            <value>PMID9334931</value>
            <value>53</value>
            <value>2</value>
            <value>182-4</value>
            <value>1997</value>
            <value>Oct</value>
            <value></value>
            <value>187</value>
            <value>Hepatitis C virus-induced leuko-thrombocytopenia and haemolysis.</value>
            <value>1</value>
        </row>
        <row>
            <value>234</value>
            <value>PMID8749633</value>
            <value>21</value>
            <value>6</value>
            <value>1463-5</value>
            <value>1995</value>
            <value>Dec</value>
            <value></value>
            <value>188</value>
            <value>Reactive hemophagocytic syndrome: a new presentation of disseminated histoplasmosis in patients with
                AIDS.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>235</value>
            <value>PMID8578701</value>
            <value>41</value>
            <value>10</value>
            <value>692-5</value>
            <value>1995</value>
            <value>Oct</value>
            <value></value>
            <value>189</value>
            <value>[G-CSF (Neupogen Roche) in the treatment of patients with chronic aplastic anemia with severe
                neutropenia].
            </value>
            <value>1</value>
        </row>
        <row>
            <value>236</value>
            <value>PMID8039121</value>
            <value>74</value>
            <value>3</value>
            <value>933-9</value>
            <value>1994</value>
            <value>Aug</value>
            <value>1</value>
            <value>190</value>
            <value>A 10-year experience with splenectomy in patients with malignant non-Hodgkin's lymphoma at the
                Norwegian Radium Hospital.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>237</value>
            <value>PMID1683381</value>
            <value>90</value>
            <value>9</value>
            <value>831-5</value>
            <value>1991</value>
            <value>Sep</value>
            <value></value>
            <value>191</value>
            <value>Paroxysmal nocturnal hemoglobinuria: analysis of 40 cases.</value>
            <value>1</value>
        </row>
        <row>
            <value>238</value>
            <value>PMID2149045</value>
            <value>76 Suppl 2</value>
            <value></value>
            <value>14-8</value>
            <value>1990</value>
            <value>Dec</value>
            <value></value>
            <value>184</value>
            <value>A clinical trial on efficacy and safety of teicoplanin in combination with beta-lactams and
                aminoglycosides in the treatment of severe sepsis of patients undergoing allogeneic/autologous bone
                marrow transplantation.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>239</value>
            <value>PMID3511286</value>
            <value>135</value>
            <value>2</value>
            <value>272-4</value>
            <value>1986</value>
            <value>Feb</value>
            <value></value>
            <value>192</value>
            <value>Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>240</value>
            <value>PMID6466572</value>
            <value>58</value>
            <value>1</value>
            <value>61-9</value>
            <value>1984</value>
            <value>Sep</value>
            <value></value>
            <value>184</value>
            <value>Therapy-induced preleukaemia in patients treated for Hodgkin's lymphoma: clinical and therapeutic
                relevance of sequential chromosome banding studies.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>241</value>
            <value>PMID6465689</value>
            <value>50</value>
            <value>8</value>
            <value>428-32</value>
            <value>1984</value>
            <value>Aug</value>
            <value></value>
            <value>193</value>
            <value>Splenectomy in hematologic malignancy.</value>
            <value>1</value>
        </row>
        <row>
            <value>242</value>
            <value>PMID709532</value>
            <value>42</value>
            <value>4</value>
            <value>1747-59</value>
            <value>1978</value>
            <value>Oct</value>
            <value></value>
            <value>190</value>
            <value>Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic
                protocols: a clinical-pathologic study of 33 patients.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>243</value>
            <value>PMID16014764</value>
            <value>51</value>
            <value>4</value>
            <value>236-9</value>
            <value>2005</value>
            <value>Aug</value>
            <value></value>
            <value>194</value>
            <value>Pancytopenia in children: etiological profile.</value>
            <value>1</value>
        </row>
        <row>
            <value>244</value>
            <value>PMID24353710</value>
            <value>29</value>
            <value>5</value>
            <value>1153-7</value>
            <value>2013</value>
            <value>Sep</value>
            <value></value>
            <value>195</value>
            <value>Pancytopenia in children: A 6-year spectrum of patients admitted to Pediatric Department of Rehman
                Medical Institute, Peshawar.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>245</value>
            <value>PMID21924019</value>
            <value>13</value>
            <value>9</value>
            <value>718-21</value>
            <value>2011</value>
            <value>Sep</value>
            <value></value>
            <value>196</value>
            <value>[Clinical features and etiological spectrum in children with pancytopenia].</value>
            <value>1</value>
        </row>
        <row>
            <value>246</value>
            <value>PMID18460245</value>
            <value>18</value>
            <value>3</value>
            <value>163-7</value>
            <value>2008</value>
            <value>Mar</value>
            <value></value>
            <value>197</value>
            <value>Etiological spectrum of pancytopenia based on bone marrow examination in children.</value>
            <value>1</value>
        </row>
        <row>
            <value>247</value>
            <value>PMID2325464</value>
            <value>94</value>
            <value>4</value>
            <value>130-4</value>
            <value>1990</value>
            <value>Feb</value>
            <value>3</value>
            <value>198</value>
            <value>[Reactive hemophagocytic syndrome: analysis of a series of 7 cases].</value>
            <value>1</value>
        </row>
        <row>
            <value>248</value>
            <value>PMID2055619</value>
            <value>28</value>
            <value>1</value>
            <value>79-81</value>
            <value>1991</value>
            <value>Jan</value>
            <value></value>
            <value>199</value>
            <value>Bone marrow necrosis and pancytopenia associated with gram negative septicemia.</value>
            <value>1</value>
        </row>
        <row>
            <value>249</value>
            <value>PMID25054962</value>
            <value>79</value>
            <value>3</value>
            <value>242-6</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>200</value>
            <value>[Myo-inositol in the treatment of polycystic ovary syndrome.]</value>
            <value>1</value>
        </row>
        <row>
            <value>250</value>
            <value>PMID25053727</value>
            <value>171</value>
            <value>3</value>
            <value>301-9</value>
            <value>2014</value>
            <value>Sep</value>
            <value></value>
            <value>201</value>
            <value>Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary
                syndrome: evidence from 1345 women with the syndrome.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>251</value>
            <value>PMID25053082</value>
            <value>166C</value>
            <value></value>
            <value>473-8</value>
            <value>2015</value>
            <value>Jan</value>
            <value>1</value>
            <value>202</value>
            <value>Molecular species analysis of monosialogangliosides from sea urchin Strongylocentrotus nudus by
                RPLC-ESI-MS/MS.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>252</value>
            <value>PMID25052966</value>
            <value>24</value>
            <value>7</value>
            <value>463-6</value>
            <value>2014</value>
            <value>Jul</value>
            <value></value>
            <value>129</value>
            <value>Influence of anthropometric measurements on abnormal gonadotropin secretion in women with polycystic
                ovary syndrome.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>253</value>
            <value>PMID25052466</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>203</value>
            <value>Identification of microRNAs specific for high producer CHO cell lines using steady-state
                cultivation.
            </value>
            <value>0</value>
        </row>
        <row>
            <value>254</value>
            <value>PMID25050271</value>
            <value>3</value>
            <value>2</value>
            <value>171-7</value>
            <value>2013</value>
            <value></value>
            <value></value>
            <value>204</value>
            <value>Effects of Carthamus tinctorius L. on the ovarian histomorphology and the female reproductive
                hormones in mice.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>255</value>
            <value>PMID25050267</value>
            <value>3</value>
            <value>2</value>
            <value>135-42</value>
            <value>2013</value>
            <value></value>
            <value></value>
            <value>204</value>
            <value>Effects of Foeniculum vulgare ethanol extract on osteogenesis in human mecenchymal stem cells.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>256</value>
            <value>PMID25049806</value>
            <value>26</value>
            <value>3</value>
            <value>423-32</value>
            <value>2013</value>
            <value>Mar</value>
            <value></value>
            <value>205</value>
            <value>Selection of Reliable Reference Genes for Real-time qRT-PCR Analysis of Zi Geese (Anser anser
                domestica) Gene Expression.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>257</value>
            <value>PMID25049607</value>
            <value>25</value>
            <value>5</value>
            <value>635-41</value>
            <value>2012</value>
            <value>May</value>
            <value></value>
            <value>205</value>
            <value>Induction of Ski Protein Expression upon Luteinization in Rat Granulosa Cells.</value>
            <value>1</value>
        </row>
        <row>
            <value>258</value>
            <value>PMID25049606</value>
            <value>25</value>
            <value>5</value>
            <value>629-34</value>
            <value>2012</value>
            <value>May</value>
            <value></value>
            <value>205</value>
            <value>Growth of Ovarian Primary Follicles Retrieved from Neonates of Different Ages and Derivation of
                Mature Oocytes Following In vitro-Culture.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>259</value>
            <value>PMID25054955</value>
            <value>79</value>
            <value>3</value>
            <value>193-7</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>200</value>
            <value>[Prenatal diagnosis of skeletal dysplasia in first trimester of pregnancy X-linked dominant
                chondrodysplasia punctata.]
            </value>
            <value>1</value>
        </row>
        <row>
            <value>260</value>
            <value>PMID25053611</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>22</value>
            <value>206</value>
            <value>Statistical analysis with dilatation for development process of human fetuses.</value>
            <value>0</value>
        </row>
        <row>
            <value>261</value>
            <value>PMID25052857</value>
            <value></value>
            <value></value>
            <value></value>
            <value>2014</value>
            <value>Jul</value>
            <value>23</value>
            <value>207</value>
            <value>Fetal growth reference ranges in twin pregnancy: analysis of the Southwest Thames Obstetric.</value>
            <value>0</value>
        </row>
        <row>
            <value>262</value>
            <value>PMID25051799</value>
            <value>145</value>
            <value>1</value>
            <value>38-42</value>
            <value>2014</value>
            <value></value>
            <value></value>
            <value>208</value>
            <value>[Pancreas structure in fetuses and newborn infants who died in the perinatal period].</value>
            <value>1</value>
        </row>
        <row>
            <value>263</value>
            <value>PMID25049796</value>
            <value>26</value>
            <value>3</value>
            <value>343-8</value>
            <value>2013</value>
            <value>Mar</value>
            <value></value>
            <value>205</value>
            <value>T Cells Development Is Different between Thymus from Normal and Intrauterine Growth Restricted Pig
                Fetus at Different Gestational Stage.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>264</value>
            <value>PMID25049669</value>
            <value>25</value>
            <value>8</value>
            <value>1102-16</value>
            <value>2012</value>
            <value>Aug</value>
            <value></value>
            <value>205</value>
            <value>Microarray Analysis of Gene Expression in the Uterine Endometrium during the Implantation Period in
                Pigs.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>265</value>
            <value>PMID25049621</value>
            <value>25</value>
            <value>5</value>
            <value>738-48</value>
            <value>2012</value>
            <value>May</value>
            <value></value>
            <value>205</value>
            <value>Management of reproduction on small, medium and large rabbit farms: a review.</value>
            <value>1</value>
        </row>
        <row>
            <value>266</value>
            <value>PMID25049473</value>
            <value>25</value>
            <value>1</value>
            <value>22-7</value>
            <value>2012</value>
            <value>Jan</value>
            <value></value>
            <value>205</value>
            <value>Association of length of pregnancy with other reproductive traits in dairy cattle.</value>
            <value>1</value>
        </row>
        <row>
            <value>267</value>
            <value>PMID25049471</value>
            <value>25</value>
            <value>1</value>
            <value>1-16</value>
            <value>2012</value>
            <value>Jan</value>
            <value></value>
            <value>205</value>
            <value>Roles of conceptus secretory proteins in establishment and maintenance of pregnancy in ruminants.
            </value>
            <value>1</value>
        </row>
        <row>
            <value>268</value>
            <value>PMID25051539</value>
            <value>90</value>
            <value>9</value>
            <value>487-92</value>
            <value>2014</value>
            <value>Jul</value>
            <value>19</value>
            <value>209</value>
            <value>Neonatal birth waist is positively predicted by second trimester maternal active ghrelin, a
                pro-appetite hormone, and negatively associated with third trimester maternal leptin, a pro-satiety
                hormone.
            </value>
            <value>0</value>
        </row>
    </table>
    <table name="collection_articles">
        <column>collection_id</column>
        <column>article_id</column>
        <column>position</column>
        <row>
            <value>16</value>
            <value>1</value>
            <value>1</value>
        </row>
        <row>
            <value>17</value>
            <value>21</value>
            <value>1</value>
        </row>
        <row>
            <value>17</value>
            <value>22</value>
            <value>2</value>
        </row>
        <row>
            <value>17</value>
            <value>23</value>
            <value>3</value>
        </row>
        <row>
            <value>17</value>
            <value>25</value>
            <value>4</value>
        </row>
        <row>
            <value>19</value>
            <value>31</value>
            <value>1</value>
        </row>
        <row>
            <value>19</value>
            <value>32</value>
            <value>2</value>
        </row>
        <row>
            <value>19</value>
            <value>35</value>
            <value>3</value>
        </row>
        <row>
            <value>20</value>
            <value>23</value>
            <value>1</value>
        </row>
        <row>
            <value>20</value>
            <value>43</value>
            <value>2</value>
        </row>
        <row>
            <value>20</value>
            <value>42</value>
            <value>3</value>
        </row>
        <row>
            <value>20</value>
            <value>4</value>
            <value>4</value>
        </row>
        <row>
            <value>20</value>
            <value>47</value>
            <value>5</value>
        </row>
        <row>
            <value>20</value>
            <value>46</value>
            <value>6</value>
        </row>
        <row>
            <value>20</value>
            <value>41</value>
            <value>7</value>
        </row>
        <row>
            <value>20</value>
            <value>45</value>
            <value>8</value>
        </row>
        <row>
            <value>21</value>
            <value>59</value>
            <value>1</value>
        </row>
        <row>
            <value>21</value>
            <value>60</value>
            <value>2</value>
        </row>
        <row>
            <value>26</value>
            <value>243</value>
            <value>1</value>
        </row>
        <row>
            <value>26</value>
            <value>246</value>
            <value>2</value>
        </row>
        <row>
            <value>26</value>
            <value>248</value>
            <value>3</value>
        </row>
        <row>
            <value>27</value>
            <value>261</value>
            <value>1</value>
        </row>
        <row>
            <value>27</value>
            <value>260</value>
            <value>2</value>
        </row>
        <row>
            <value>27</value>
            <value>259</value>
            <value>3</value>
        </row>
        <row>
            <value>27</value>
            <value>262</value>
            <value>4</value>
        </row>
        <row>
            <value>27</value>
            <value>263</value>
            <value>5</value>
        </row>
    </table>
    <table name="collections">
        <column>id</column>
        <column>user_id</column>
        <column>name</column>
        <column>created_on</column>
        <column>updated_on</column>
        <column>deleted</column>
        <row>
            <value>16</value>
            <value>3</value>
            <value>rwss abc</value>
            <value>2014-07-20 19:14:27</value>
            <value>2014-07-20 19:19:42</value>
            <value>0</value>
        </row>
        <row>
            <value>17</value>
            <value>2</value>
            <value>ovary</value>
            <value>2014-07-20 19:14:28</value>
            <value>2014-07-20 19:15:53</value>
            <value>0</value>
        </row>
        <row>
            <value>19</value>
            <value>2</value>
            <value>lung</value>
            <value>2014-07-20 19:17:18</value>
            <value>2014-07-20 19:18:12</value>
            <value>0</value>
        </row>
        <row>
            <value>20</value>
            <value>2</value>
            <value>uterus</value>
            <value>2014-07-20 19:21:54</value>
            <null/>
            <value>0</value>
        </row>
        <row>
            <value>21</value>
            <value>2</value>
            <value>brain</value>
            <value>2014-07-20 19:25:02</value>
            <null/>
            <value>0</value>
        </row>
        <row>
            <value>26</value>
            <value>1</value>
            <value>Pancytopenia in septicemia</value>
            <value>2014-07-24 01:00:37</value>
            <value>2014-07-24 01:07:57</value>
            <value>0</value>
        </row>
        <row>
            <value>27</value>
            <value>2</value>
            <value>foetus</value>
            <value>2014-07-24 18:55:25</value>
            <null/>
            <value>0</value>
        </row>
    </table>
    <table name="journals">
        <column>id</column>
        <column>issn</column>
        <column>title</column>
        <column>abbr</column>
        <row>
            <value>1</value>
            <value>1932-6203</value>
            <value>PloS one</value>
            <value>PLoS ONE</value>
        </row>
        <row>
            <value>2</value>
            <value>1000-9604</value>
            <value>Chinese journal of cancer research = Chung-kuo yen cheng yen chiu</value>
            <value>Chin J Cancer Res</value>
        </row>
        <row>
            <value>3</value>
            <value>1879-0887</value>
            <value>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
            </value>
            <value>Radiother Oncol</value>
        </row>
        <row>
            <value>4</value>
            <value>1661-5433</value>
            <value>Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology
                of sex determination and differentiation
            </value>
            <value>Sex Dev</value>
        </row>
        <row>
            <value>5</value>
            <value>0507-3758</value>
            <value>Voprosy onkologii</value>
            <value>Vopr Onkol</value>
        </row>
        <row>
            <value>6</value>
            <value>2150-0878</value>
            <value>Journal of the advanced practitioner in oncology</value>
            <value>J Adv Pract Oncol</value>
        </row>
        <row>
            <value>7</value>
            <value>2157-6998</value>
            <value>AJP reports</value>
            <value>AJP Rep</value>
        </row>
        <row>
            <value>8</value>
            <value>0529-5807</value>
            <value>Zhonghua bing li xue za zhi Chinese journal of pathology</value>
            <value>Zhonghua Bing Li Xue Za Zhi</value>
        </row>
        <row>
            <value>9</value>
            <value>0392-2936</value>
            <value>European journal of gynaecological oncology</value>
            <value>Eur J Gynaecol Oncol</value>
        </row>
        <row>
            <value>10</value>
            <value>1521-2254</value>
            <value>The journal of gene medicine</value>
            <value>J Gene Med</value>
        </row>
        <row>
            <value>11</value>
            <value>1812-9269</value>
            <value>Experimental oncology</value>
            <value>Exp Oncol</value>
        </row>
        <row>
            <value>12</value>
            <value>1863-6713</value>
            <value>General thoracic and cardiovascular surgery</value>
            <value>Gen Thorac Cardiovasc Surg</value>
        </row>
        <row>
            <value>13</value>
            <value>1565-1088</value>
            <value>The Israel Medical Association journal : IMAJ</value>
            <value>Isr Med Assoc J</value>
        </row>
        <row>
            <value>14</value>
            <value>1899-5276</value>
            <value>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</value>
            <value>Adv Clin Exp Med</value>
        </row>
        <row>
            <value>15</value>
            <value>1536-0229</value>
            <value>Clinical nuclear medicine</value>
            <value>Clin Nucl Med</value>
        </row>
        <row>
            <value>16</value>
            <value>1465-3931</value>
            <value>Pathology</value>
            <value>Pathology</value>
        </row>
        <row>
            <value>17</value>
            <value>1526-0976</value>
            <value>Journal of lower genital tract disease</value>
            <value>J Low Genit Tract Dis</value>
        </row>
        <row>
            <value>18</value>
            <value>1095-9947</value>
            <value>Fish &amp; shellfish immunology</value>
            <value>Fish Shellfish Immunol</value>
        </row>
        <row>
            <value>19</value>
            <value>1477-9129</value>
            <value>Development (Cambridge, England)</value>
            <value>Development</value>
        </row>
        <row>
            <value>20</value>
            <value>1572-9702</value>
            <value>Experimental &amp; applied acarology</value>
            <value>Exp Appl Acarol</value>
        </row>
        <row>
            <value>21</value>
            <value>1479-6805</value>
            <value>The Journal of endocrinology</value>
            <value>J Endocrinol</value>
        </row>
        <row>
            <value>22</value>
            <value>1945-7170</value>
            <value>Endocrinology</value>
            <value>Endocrinology</value>
        </row>
        <row>
            <value>23</value>
            <value>1872-7654</value>
            <value>European journal of obstetrics, gynecology, and reproductive biology</value>
            <value>Eur J Obstet Gynecol Reprod Biol</value>
        </row>
        <row>
            <value>24</value>
            <value>2251-9637</value>
            <value>International journal of molecular and cellular medicine</value>
            <value>Int J Mol Cell Med</value>
        </row>
        <row>
            <value>25</value>
            <value>1460-2350</value>
            <value>Human reproduction (Oxford, England)</value>
            <value>Hum Reprod</value>
        </row>
        <row>
            <value>26</value>
            <value>1873-6351</value>
            <value>Food and chemical toxicology : an international journal published for the British Industrial
                Biological Research Association
            </value>
            <value>Food Chem Toxicol</value>
        </row>
        <row>
            <value>27</value>
            <value>1522-9629</value>
            <value>Pulmonary pharmacology &amp; therapeutics</value>
            <value>Pulm Pharmacol Ther</value>
        </row>
        <row>
            <value>28</value>
            <value>1090-2163</value>
            <value>Cellular immunology</value>
            <value>Cell Immunol</value>
        </row>
        <row>
            <value>29</value>
            <value>1096-0260</value>
            <value>Preventive medicine</value>
            <value>Prev Med</value>
        </row>
        <row>
            <value>30</value>
            <value>1549-9642</value>
            <value>Nanomedicine : nanotechnology, biology, and medicine</value>
            <value>Nanomedicine</value>
        </row>
        <row>
            <value>31</value>
            <value>1872-8278</value>
            <value>Mitochondrion</value>
            <value>Mitochondrion</value>
        </row>
        <row>
            <value>32</value>
            <value>1769-714X</value>
            <value>Microbes and infection / Institut Pasteur</value>
            <value>Microbes Infect</value>
        </row>
        <row>
            <value>33</value>
            <value>0494-1373</value>
            <value>Tuberkuloz ve toraks</value>
            <value>Tuberk Toraks</value>
        </row>
        <row>
            <value>34</value>
            <value>1558-8238</value>
            <value>The Journal of clinical investigation</value>
            <value>J Clin Invest</value>
        </row>
        <row>
            <value>35</value>
            <value>0971-7196</value>
            <value>Journal of parasitic diseases : official organ of the Indian Society for Parasitology</value>
            <value>J Parasit Dis</value>
        </row>
        <row>
            <value>36</value>
            <value>1879-3479</value>
            <value>International journal of gynaecology and obstetrics: the official organ of the International
                Federation of Gynaecology and Obstetrics
            </value>
            <value>Int J Gynaecol Obstet</value>
        </row>
        <row>
            <value>37</value>
            <value>1423-0232</value>
            <value>Oncology</value>
            <value>Oncology</value>
        </row>
        <row>
            <value>38</value>
            <value>1532-8392</value>
            <value>Human pathology</value>
            <value>Hum Pathol</value>
        </row>
        <row>
            <value>39</value>
            <value>1365-2559</value>
            <value>Histopathology</value>
            <value>Histopathology</value>
        </row>
        <row>
            <value>40</value>
            <value>1529-7268</value>
            <value>Biology of reproduction</value>
            <value>Biol Reprod</value>
        </row>
        <row>
            <value>41</value>
            <value>1946-6544</value>
            <value>Human gene therapy methods</value>
            <value>Hum Gene Ther Methods</value>
        </row>
        <row>
            <value>42</value>
            <value>1524-4539</value>
            <value>Circulation</value>
            <value>Circulation</value>
        </row>
        <row>
            <value>43</value>
            <value>0300-1652</value>
            <value>Nigerian medical journal : journal of the Nigeria Medical Association</value>
            <value>Niger Med J</value>
        </row>
        <row>
            <value>44</value>
            <value>0004-5772</value>
            <value>The Journal of the Association of Physicians of India</value>
            <value>J Assoc Physicians India</value>
        </row>
        <row>
            <value>45</value>
            <value>1872-7905</value>
            <value>Journal of immunological methods</value>
            <value>J Immunol Methods</value>
        </row>
        <row>
            <value>46</value>
            <value>1600-0641</value>
            <value>Journal of hepatology</value>
            <value>J Hepatol</value>
        </row>
        <row>
            <value>47</value>
            <value>1553-7358</value>
            <value>PLoS computational biology</value>
            <value>PLoS Comput Biol</value>
        </row>
        <row>
            <value>48</value>
            <value>1525-0024</value>
            <value>Molecular therapy : the journal of the American Society of Gene Therapy</value>
            <value>Mol Ther</value>
        </row>
        <row>
            <value>49</value>
            <value>1098-5514</value>
            <value>Journal of virology</value>
            <value>J Virol</value>
        </row>
        <row>
            <value>50</value>
            <value>1521-7035</value>
            <value>Clinical immunology (Orlando, Fla.)</value>
            <value>Clin Immunol</value>
        </row>
        <row>
            <value>51</value>
            <value>0006-3002</value>
            <value>Biochimica et biophysica acta</value>
            <value>Biochim Biophys Acta</value>
        </row>
        <row>
            <value>52</value>
            <value>1872-6240</value>
            <value>Brain research</value>
            <value>Brain Res</value>
        </row>
        <row>
            <value>53</value>
            <value>1873-2399</value>
            <value>Experimental hematology</value>
            <value>Exp Hematol</value>
        </row>
        <row>
            <value>54</value>
            <value>1096-0457</value>
            <value>Journal of experimental child psychology</value>
            <value>J Exp Child Psychol</value>
        </row>
        <row>
            <value>55</value>
            <value>1873-5177</value>
            <value>Pharmacology, biochemistry, and behavior</value>
            <value>Pharmacol Biochem Behav</value>
        </row>
        <row>
            <value>56</value>
            <value>1095-9572</value>
            <value>NeuroImage</value>
            <value>Neuroimage</value>
        </row>
        <row>
            <value>57</value>
            <value>1096-0953</value>
            <value>Environmental research</value>
            <value>Environ Res</value>
        </row>
        <row>
            <value>58</value>
            <value>2152-2669</value>
            <value>Clinical lymphoma, myeloma &amp; leukemia</value>
            <value>Clin Lymphoma Myeloma Leuk</value>
        </row>
        <row>
            <value>59</value>
            <value>1699-3055</value>
            <value>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology
                Societies and of the National Cancer Institute of Mexico
            </value>
            <value>Clin Transl Oncol</value>
        </row>
        <row>
            <value>60</value>
            <value>1097-6787</value>
            <value>Journal of the American Academy of Dermatology</value>
            <value>J Am Acad Dermatol</value>
        </row>
        <row>
            <value>61</value>
            <value>2044-5385</value>
            <value>Blood cancer journal</value>
            <value>Blood Cancer J</value>
        </row>
        <row>
            <value>62</value>
            <value>1744-7593</value>
            <value>Expert opinion on drug delivery</value>
            <value>Expert Opin Drug Deliv</value>
        </row>
        <row>
            <value>63</value>
            <value>2218-5836</value>
            <value>World journal of orthopedics</value>
            <value>World J Orthop</value>
        </row>
        <row>
            <value>64</value>
            <value>1940-5901</value>
            <value>International journal of clinical and experimental medicine</value>
            <value>Int J Clin Exp Med</value>
        </row>
        <row>
            <value>65</value>
            <value>1300-7777</value>
            <value>Turkish journal of haematology : official journal of Turkish Society of Haematology</value>
            <value>Turk J Haematol</value>
        </row>
        <row>
            <value>66</value>
            <value>1532-4230</value>
            <value>Journal of immunoassay &amp; immunochemistry</value>
            <value>J Immunoassay Immunochem</value>
        </row>
        <row>
            <value>67</value>
            <value>1319-2442</value>
            <value>Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center
                for Organ Transplantation, Saudi Arabia
            </value>
            <value>Saudi J Kidney Dis Transpl</value>
        </row>
        <row>
            <value>68</value>
            <value>1791-2431</value>
            <value>Oncology reports</value>
            <value>Oncol Rep</value>
        </row>
        <row>
            <value>69</value>
            <value>1007-8738</value>
            <value>Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology</value>
            <value>Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</value>
        </row>
        <row>
            <value>70</value>
            <value>1009-2137</value>
            <value>Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental
                hematology / Chinese Association of Pathophysiology
            </value>
            <value>Zhongguo Shi Yan Xue Ye Xue Za Zhi</value>
        </row>
        <row>
            <value>71</value>
            <value>1673-4254</value>
            <value>Nan fang yi ke da xue xue bao = Journal of Southern Medical University</value>
            <value>Nan Fang Yi Ke Da Xue Xue Bao</value>
        </row>
        <row>
            <value>72</value>
            <value>0006-4971</value>
            <value>Blood</value>
            <value>Blood</value>
        </row>
        <row>
            <value>73</value>
            <value>0012-6667</value>
            <value>Drugs</value>
            <value>Drugs</value>
        </row>
        <row>
            <value>74</value>
            <value>0042-4609</value>
            <value>Vestnik dermatologii i venerologii</value>
            <value>Vestn Dermatol Venerol</value>
        </row>
        <row>
            <value>75</value>
            <value>1872-7492</value>
            <value>Virus research</value>
            <value>Virus Res</value>
        </row>
        <row>
            <value>76</value>
            <value>1538-3598</value>
            <value>JAMA : the journal of the American Medical Association</value>
            <value>JAMA</value>
        </row>
        <row>
            <value>77</value>
            <value>1108-4189</value>
            <value>Hippokratia</value>
            <value>Hippokratia</value>
        </row>
        <row>
            <value>78</value>
            <value>1009-3591</value>
            <value>Zhonghua nan ke xue = National journal of andrology</value>
            <value>Zhonghua Nan Ke Xue</value>
        </row>
        <row>
            <value>79</value>
            <value>1518-8345</value>
            <value>Revista latino-americana de enfermagem</value>
            <value>Rev Lat Am Enfermagem</value>
        </row>
        <row>
            <value>80</value>
            <value>1521-0103</value>
            <value>The Journal of pharmacology and experimental therapeutics</value>
            <value>J Pharmacol Exp Ther</value>
        </row>
        <row>
            <value>81</value>
            <value>1468-3288</value>
            <value>Gut</value>
            <value>Gut</value>
        </row>
        <row>
            <value>82</value>
            <value>1875-9777</value>
            <value>Cell stem cell</value>
            <value>Cell Stem Cell</value>
        </row>
        <row>
            <value>83</value>
            <value>1523-6536</value>
            <value>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow
                Transplantation
            </value>
            <value>Biol Blood Marrow Transplant</value>
        </row>
        <row>
            <value>84</value>
            <value>1879-1913</value>
            <value>The American journal of cardiology</value>
            <value>Am J Cardiol</value>
        </row>
        <row>
            <value>85</value>
            <value>1433-6510</value>
            <value>Clinical laboratory</value>
            <value>Clin Lab</value>
        </row>
        <row>
            <value>86</value>
            <value>0971-4502</value>
            <value>Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of
                Hematology and Blood Transfusion
            </value>
            <value>Indian J Hematol Blood Transfus</value>
        </row>
        <row>
            <value>87</value>
            <value>1878-5905</value>
            <value>Biomaterials</value>
            <value>Biomaterials</value>
        </row>
        <row>
            <value>88</value>
            <value>1559-6109</value>
            <value>Journal of the American Association for Laboratory Animal Science : JAALAS</value>
            <value>J Am Assoc Lab Anim Sci</value>
        </row>
        <row>
            <value>89</value>
            <value>1473-4257</value>
            <value>Journal of medical ethics</value>
            <value>J Med Ethics</value>
        </row>
        <row>
            <value>90</value>
            <value>1098-1101</value>
            <value>Journal of clinical apheresis</value>
            <value>J Clin Apher</value>
        </row>
        <row>
            <value>91</value>
            <value>1555-3892</value>
            <value>Cell transplantation</value>
            <value>Cell Transplant</value>
        </row>
        <row>
            <value>92</value>
            <value>1473-0502</value>
            <value>Transfusion and apheresis science : official journal of the World Apheresis Association : official
                journal of the European Society for Haemapheresis
            </value>
            <value>Transfus Apher Sci</value>
        </row>
        <row>
            <value>93</value>
            <value>1873-2518</value>
            <value>Vaccine</value>
            <value>Vaccine</value>
        </row>
        <row>
            <value>94</value>
            <value>1522-1504</value>
            <value>American journal of physiology. Lung cellular and molecular physiology</value>
            <value>Am J Physiol Lung Cell Mol Physiol</value>
        </row>
        <row>
            <value>95</value>
            <value>1098-660X</value>
            <value>Journal of clinical microbiology</value>
            <value>J Clin Microbiol</value>
        </row>
        <row>
            <value>96</value>
            <value>1476-5365</value>
            <value>Bone marrow transplantation</value>
            <value>Bone Marrow Transplant</value>
        </row>
        <row>
            <value>97</value>
            <value>1872-8421</value>
            <value>Journal of neuroimmunology</value>
            <value>J Neuroimmunol</value>
        </row>
        <row>
            <value>98</value>
            <value>1747-4094</value>
            <value>Expert review of hematology</value>
            <value>Expert Rev Hematol</value>
        </row>
        <row>
            <value>99</value>
            <value>2282-8419</value>
            <value>Heart, lung and vessels</value>
            <value>Heart Lung Vessel</value>
        </row>
        <row>
            <value>100</value>
            <value>1098-5522</value>
            <value>Infection and immunity</value>
            <value>Infect Immun</value>
        </row>
        <row>
            <value>101</value>
            <value>1567-2387</value>
            <value>Journal of molecular histology</value>
            <value>J Mol Histol</value>
        </row>
        <row>
            <value>102</value>
            <value>1598-2998</value>
            <value>Cancer research and treatment : official journal of Korean Cancer Association</value>
            <value>Cancer Res Treat</value>
        </row>
        <row>
            <value>103</value>
            <value>1471-2369</value>
            <value>BMC nephrology</value>
            <value>BMC Nephrol</value>
        </row>
        <row>
            <value>104</value>
            <value>1432-0843</value>
            <value>Cancer chemotherapy and pharmacology</value>
            <value>Cancer Chemother Pharmacol</value>
        </row>
        <row>
            <value>105</value>
            <value>1878-3511</value>
            <value>International journal of infectious diseases : IJID : official publication of the International
                Society for Infectious Diseases
            </value>
            <value>Int J Infect Dis</value>
        </row>
        <row>
            <value>106</value>
            <value>1873-6815</value>
            <value>Experimental gerontology</value>
            <value>Exp Gerontol</value>
        </row>
        <row>
            <value>107</value>
            <value>1873-3913</value>
            <value>Cellular signalling</value>
            <value>Cell Signal</value>
        </row>
        <row>
            <value>108</value>
            <value>1550-6606</value>
            <value>Journal of immunology (Baltimore, Md. : 1950)</value>
            <value>J Immunol</value>
        </row>
        <row>
            <value>109</value>
            <value>2157-6564</value>
            <value>Stem cells translational medicine</value>
            <value>Stem Cells Transl Med</value>
        </row>
        <row>
            <value>110</value>
            <value>1539-2864</value>
            <value>Retina (Philadelphia, Pa.)</value>
            <value>Retina (Philadelphia, Pa)</value>
        </row>
        <row>
            <value>111</value>
            <value>1029-2330</value>
            <value>Journal of drug targeting</value>
            <value>J Drug Target</value>
        </row>
        <row>
            <value>112</value>
            <value>1097-0177</value>
            <value>Developmental dynamics : an official publication of the American Association of Anatomists</value>
            <value>Dev Dyn</value>
        </row>
        <row>
            <value>113</value>
            <value>1724-6016</value>
            <value>European journal of ophthalmology</value>
            <value>Eur J Ophthalmol</value>
        </row>
        <row>
            <value>114</value>
            <value>1097-4547</value>
            <value>Journal of neuroscience research</value>
            <value>J Neurosci Res</value>
        </row>
        <row>
            <value>115</value>
            <value>1755-3768</value>
            <value>Acta ophthalmologica</value>
            <value>Acta Ophthalmol</value>
        </row>
        <row>
            <value>116</value>
            <value>1177-5467</value>
            <value>Clinical ophthalmology (Auckland, N.Z.)</value>
            <value>Clin Ophthalmol</value>
        </row>
        <row>
            <value>117</value>
            <value>1552-5783</value>
            <value>Investigative ophthalmology &amp; visual science</value>
            <value>Invest Ophthalmol Vis Sci</value>
        </row>
        <row>
            <value>118</value>
            <value>1463-5224</value>
            <value>Veterinary ophthalmology</value>
            <value>Vet Ophthalmol</value>
        </row>
        <row>
            <value>119</value>
            <value>1468-201X</value>
            <value>Heart (British Cardiac Society)</value>
            <value>Heart</value>
        </row>
        <row>
            <value>120</value>
            <value>2005-6648</value>
            <value>The Korean journal of internal medicine</value>
            <value>Korean J Intern Med</value>
        </row>
        <row>
            <value>121</value>
            <value>0253-3758</value>
            <value>Zhonghua xin xue guan bing za zhi</value>
            <value>Zhonghua Xin Xue Guan Bing Za Zhi</value>
        </row>
        <row>
            <value>122</value>
            <value>1969-6213</value>
            <value>EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional
                Cardiology of the European Society of Cardiology
            </value>
            <value>EuroIntervention</value>
        </row>
        <row>
            <value>123</value>
            <value>1540-8183</value>
            <value>Journal of interventional cardiology</value>
            <value>J Interv Cardiol</value>
        </row>
        <row>
            <value>124</value>
            <value>1542-474X</value>
            <value>Annals of noninvasive electrocardiology : the official journal of the International Society for
                Holter and Noninvasive Electrocardiology, Inc
            </value>
            <value>Ann Noninvasive Electrocardiol</value>
        </row>
        <row>
            <value>125</value>
            <value>1308-0032</value>
            <value>Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology</value>
            <value>Anadolu Kardiyol Derg</value>
        </row>
        <row>
            <value>126</value>
            <value>1365-4632</value>
            <value>International journal of dermatology</value>
            <value>Int J Dermatol</value>
        </row>
        <row>
            <value>127</value>
            <value>1096-0961</value>
            <value>Blood cells, molecules &amp; diseases</value>
            <value>Blood Cells Mol Dis</value>
        </row>
        <row>
            <value>128</value>
            <value>0485-1439</value>
            <value>[Rinsh? ketsueki] The Japanese journal of clinical hematology</value>
            <value>Rinsho Ketsueki</value>
        </row>
        <row>
            <value>129</value>
            <value>1681-7168</value>
            <value>Journal of the College of Physicians and Surgeons--Pakistan : JCPSP</value>
            <value>J Coll Physicians Surg Pak</value>
        </row>
        <row>
            <value>130</value>
            <value>1757-790X</value>
            <value>BMJ case reports</value>
            <value>BMJ Case Rep</value>
        </row>
        <row>
            <value>131</value>
            <value>0005-9366</value>
            <value></value>
            <value>Berl Munch Tierarztl Wochenschr</value>
        </row>
        <row>
            <value>132</value>
            <value>1865-3774</value>
            <value>International journal of hematology</value>
            <value>Int J Hematol</value>
        </row>
        <row>
            <value>133</value>
            <value>1539-6304</value>
            <value>Allergy and asthma proceedings : the official journal of regional and state allergy societies</value>
            <value>Allergy Asthma Proc</value>
        </row>
        <row>
            <value>134</value>
            <value>1399-0012</value>
            <value>Clinical transplantation</value>
            <value>Clin Transplant</value>
        </row>
        <row>
            <value>135</value>
            <value>1735-8604</value>
            <value>Iranian journal of kidney diseases</value>
            <value>Iran J Kidney Dis</value>
        </row>
        <row>
            <value>136</value>
            <value>1521-0669</value>
            <value>Pediatric hematology and oncology</value>
            <value>Pediatr Hematol Oncol</value>
        </row>
        <row>
            <value>137</value>
            <value>1432-1076</value>
            <value>European journal of pediatrics</value>
            <value>Eur J Pediatr</value>
        </row>
        <row>
            <value>138</value>
            <value>1758-1052</value>
            <value>International journal of STD &amp; AIDS</value>
            <value>Int J STD AIDS</value>
        </row>
        <row>
            <value>139</value>
            <value>1531-5037</value>
            <value>Journal of pediatric surgery</value>
            <value>J Pediatr Surg</value>
        </row>
        <row>
            <value>140</value>
            <value>1752-1947</value>
            <value>Journal of medical case reports</value>
            <value>J Med Case Rep</value>
        </row>
        <row>
            <value>141</value>
            <value>0019-5847</value>
            <value>Journal of the Indian Medical Association</value>
            <value>J Indian Med Assoc</value>
        </row>
        <row>
            <value>142</value>
            <value>1728-7731</value>
            <value>Journal of the Chinese Medical Association : JCMA</value>
            <value>J Chin Med Assoc</value>
        </row>
        <row>
            <value>143</value>
            <value>1769-6690</value>
            <value></value>
            <value>Med Mal Infect</value>
        </row>
        <row>
            <value>144</value>
            <value>1976-2437</value>
            <value>Yonsei medical journal</value>
            <value>Yonsei Med J</value>
        </row>
        <row>
            <value>145</value>
            <value>1536-3678</value>
            <value>Journal of pediatric hematology/oncology</value>
            <value>J Pediatr Hematol Oncol</value>
        </row>
        <row>
            <value>146</value>
            <value>1873-2550</value>
            <value>Veterinary parasitology</value>
            <value>Vet Parasitol</value>
        </row>
        <row>
            <value>147</value>
            <value>1473-5865</value>
            <value>Journal of pediatric orthopedics. Part B</value>
            <value>J Pediatr Orthop B</value>
        </row>
        <row>
            <value>148</value>
            <value>1432-1238</value>
            <value>Intensive care medicine</value>
            <value>Intensive Care Med</value>
        </row>
        <row>
            <value>149</value>
            <value>1523-6838</value>
            <value>American journal of kidney diseases : the official journal of the National Kidney Foundation</value>
            <value>Am J Kidney Dis</value>
        </row>
        <row>
            <value>150</value>
            <value>1423-0240</value>
            <value>Onkologie</value>
            <value>Onkologie</value>
        </row>
        <row>
            <value>151</value>
            <value>1525-6049</value>
            <value>Renal failure</value>
            <value>Ren Fail</value>
        </row>
        <row>
            <value>152</value>
            <value>1437-160X</value>
            <value>Rheumatology international</value>
            <value>Rheumatol Int</value>
        </row>
        <row>
            <value>153</value>
            <value>2326-5205</value>
            <value>Arthritis &amp; rheumatology (Hoboken, N.J.)</value>
            <value></value>
        </row>
        <row>
            <value>154</value>
            <value>1439-7803</value>
            <value></value>
            <value>Z Gastroenterol</value>
        </row>
        <row>
            <value>155</value>
            <value>2035-3006</value>
            <value>Mediterranean journal of hematology and infectious diseases</value>
            <value>Mediterr J Hematol Infect Dis</value>
        </row>
        <row>
            <value>156</value>
            <value>1536-5964</value>
            <value>Medicine</value>
            <value>Medicine (Baltimore)</value>
        </row>
        <row>
            <value>157</value>
            <value>0030-6002</value>
            <value>Orvosi hetilap</value>
            <value>Orv Hetil</value>
        </row>
        <row>
            <value>158</value>
            <value>1879-0372</value>
            <value>Current opinion in immunology</value>
            <value>Curr Opin Immunol</value>
        </row>
        <row>
            <value>159</value>
            <value>1600-0609</value>
            <value>European journal of haematology</value>
            <value>Eur J Haematol</value>
        </row>
        <row>
            <value>160</value>
            <value>1435-1250</value>
            <value></value>
            <value>Z Rheumatol</value>
        </row>
        <row>
            <value>161</value>
            <value>1607-8454</value>
            <value>Hematology (Amsterdam, Netherlands)</value>
            <value>Hematology</value>
        </row>
        <row>
            <value>162</value>
            <value>1879-1883</value>
            <value>American journal of surgery</value>
            <value>Am J Surg</value>
        </row>
        <row>
            <value>163</value>
            <value>0717-6163</value>
            <value></value>
            <value>Rev Med Chil</value>
        </row>
        <row>
            <value>164</value>
            <value>1931-3543</value>
            <value>Chest</value>
            <value>Chest</value>
        </row>
        <row>
            <value>165</value>
            <value>1525-1489</value>
            <value>Journal of intensive care medicine</value>
            <value>J Intensive Care Med</value>
        </row>
        <row>
            <value>166</value>
            <value>1573-2568</value>
            <value>Digestive diseases and sciences</value>
            <value>Dig Dis Sci</value>
        </row>
        <row>
            <value>167</value>
            <value>1658-3876</value>
            <value>Hematology/oncology and stem cell therapy</value>
            <value>Hematol Oncol Stem Cell Ther</value>
        </row>
        <row>
            <value>168</value>
            <value>1473-5687</value>
            <value>European journal of gastroenterology &amp; hepatology</value>
            <value>Eur J Gastroenterol Hepatol</value>
        </row>
        <row>
            <value>169</value>
            <value>0033-8338</value>
            <value></value>
            <value>Radiologia</value>
        </row>
        <row>
            <value>170</value>
            <value>1529-7535</value>
            <value>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World
                Federation of Pediatric Intensive and Critical Care Societies
            </value>
            <value>Pediatr Crit Care Med</value>
        </row>
        <row>
            <value>171</value>
            <value>1445-5994</value>
            <value>Internal medicine journal</value>
            <value>Intern Med J</value>
        </row>
        <row>
            <value>172</value>
            <value>0361-8609</value>
            <value>American journal of hematology</value>
            <value>Am J Hematol</value>
        </row>
        <row>
            <value>173</value>
            <value>1540-9740</value>
            <value>Skinmed</value>
            <value>Skinmed</value>
        </row>
        <row>
            <value>174</value>
            <value>0025-7680</value>
            <value>Medicina</value>
            <value>Medicina (B Aires)</value>
        </row>
        <row>
            <value>175</value>
            <value>1428-345X</value>
            <value>Medycyna wieku rozwojowego</value>
            <value>Med Wieku Rozwoj</value>
        </row>
        <row>
            <value>176</value>
            <value>0002-9270</value>
            <value>The American journal of gastroenterology</value>
            <value>Am J Gastroenterol</value>
        </row>
        <row>
            <value>177</value>
            <value>0145-2126</value>
            <value>Leukemia research</value>
            <value>Leuk Res</value>
        </row>
        <row>
            <value>178</value>
            <value>0171-6425</value>
            <value>The Thoracic and cardiovascular surgeon</value>
            <value>Thorac Cardiovasc Surg</value>
        </row>
        <row>
            <value>179</value>
            <value>0041-1337</value>
            <value>Transplantation</value>
            <value>Transplantation</value>
        </row>
        <row>
            <value>180</value>
            <value>0022-4790</value>
            <value>Journal of surgical oncology</value>
            <value>J Surg Oncol</value>
        </row>
        <row>
            <value>181</value>
            <value>0378-1135</value>
            <value>Veterinary microbiology</value>
            <value>Vet Microbiol</value>
        </row>
        <row>
            <value>182</value>
            <value>0028-4793</value>
            <value>The New England journal of medicine</value>
            <value>N Engl J Med</value>
        </row>
        <row>
            <value>183</value>
            <value>0250-8095</value>
            <value>American journal of nephrology</value>
            <value>Am J Nephrol</value>
        </row>
        <row>
            <value>184</value>
            <value>0007-1048</value>
            <value>British journal of haematology</value>
            <value>Br J Haematol</value>
        </row>
        <row>
            <value>185</value>
            <value>1357-0560</value>
            <value>Medical oncology (Northwood, London, England)</value>
            <value>Med Oncol</value>
        </row>
        <row>
            <value>186</value>
            <value>0029-2001</value>
            <value></value>
            <value>Tidsskr Nor Laegeforen</value>
        </row>
        <row>
            <value>187</value>
            <value>0146-6615</value>
            <value>Journal of medical virology</value>
            <value>J Med Virol</value>
        </row>
        <row>
            <value>188</value>
            <value>1058-4838</value>
            <value>Clinical infectious diseases : an official publication of the Infectious Diseases Society of
                America
            </value>
            <value>Clin Infect Dis</value>
        </row>
        <row>
            <value>189</value>
            <value>0042-773X</value>
            <value></value>
            <value>Vnitr Lek</value>
        </row>
        <row>
            <value>190</value>
            <value>0008-543X</value>
            <value>Cancer</value>
            <value>Cancer</value>
        </row>
        <row>
            <value>191</value>
            <value>0929-6646</value>
            <value>Journal of the Formosan Medical Association = Taiwan yi zhi</value>
            <value>J Formos Med Assoc</value>
        </row>
        <row>
            <value>192</value>
            <value>0022-5347</value>
            <value>The Journal of urology</value>
            <value>J Urol</value>
        </row>
        <row>
            <value>193</value>
            <value>0003-1348</value>
            <value>The American surgeon</value>
            <value>Am Surg</value>
        </row>
        <row>
            <value>194</value>
            <value>0142-6338</value>
            <value>Journal of tropical pediatrics</value>
            <value>J Trop Pediatr</value>
        </row>
        <row>
            <value>195</value>
            <value>1682-024X</value>
            <value>Pakistan journal of medical sciences</value>
            <value>Pak J Med Sci</value>
        </row>
        <row>
            <value>196</value>
            <value>1008-8830</value>
            <value>Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</value>
            <value>Zhongguo Dang Dai Er Ke Za Zhi</value>
        </row>
        <row>
            <value>197</value>
            <value>1022-386X</value>
            <value>Journal of the College of Physicians and Surgeons--Pakistan : JCPSP</value>
            <value>J Coll Physicians Surg Pak</value>
        </row>
        <row>
            <value>198</value>
            <value>0025-7753</value>
            <value></value>
            <value>Med Clin (Barc)</value>
        </row>
        <row>
            <value>199</value>
            <value>0019-6061</value>
            <value>Indian pediatrics</value>
            <value>Indian Pediatr</value>
        </row>
        <row>
            <value>200</value>
            <value>1210-7832</value>
            <value>Ceska gynekologie / Ceska lekarska spolecnost J. Ev. Purkyne</value>
            <value>Ceska Gynekol</value>
        </row>
        <row>
            <value>201</value>
            <value>1479-683X</value>
            <value>European journal of endocrinology / European Federation of Endocrine Societies</value>
            <value>Eur J Endocrinol</value>
        </row>
        <row>
            <value>202</value>
            <value>0308-8146</value>
            <value>Food chemistry</value>
            <value>Food Chem</value>
        </row>
        <row>
            <value>203</value>
            <value>1432-0614</value>
            <value>Applied microbiology and biotechnology</value>
            <value>Appl Microbiol Biotechnol</value>
        </row>
        <row>
            <value>204</value>
            <value>2228-7930</value>
            <value>Avicenna journal of phytomedicine</value>
            <value>Avicenna J Phytomed</value>
        </row>
        <row>
            <value>205</value>
            <value>1011-2367</value>
            <value>Asian-Australasian journal of animal sciences</value>
            <value>Asian-australas J Anim Sci</value>
        </row>
        <row>
            <value>206</value>
            <value>1477-0334</value>
            <value>Statistical methods in medical research</value>
            <value>Stat Methods Med Res</value>
        </row>
        <row>
            <value>207</value>
            <value>1469-0705</value>
            <value>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of
                Ultrasound in Obstetrics and Gynecology
            </value>
            <value>Ultrasound Obstet Gynecol</value>
        </row>
        <row>
            <value>208</value>
            <value>1026-3543</value>
            <value>Morfologii?a (Saint Petersburg, Russia)</value>
            <value>Morfologiia</value>
        </row>
        <row>
            <value>209</value>
            <value>1872-6232</value>
            <value>Early human development</value>
            <value>Early Hum Dev</value>
        </row>
    </table>
    <table name="roles">
        <column>id</column>
        <column>name</column>
        <row>
            <value>1</value>
            <value>user</value>
        </row>
        <row>
            <value>2</value>
            <value>moderator</value>
        </row>
        <row>
            <value>3</value>
            <value>admin</value>
        </row>
    </table>
    <table name="socials">
        <column>id</column>
        <column>name</column>
        <row>
            <value>1</value>
            <value>Facebook</value>
        </row>
        <row>
            <value>2</value>
            <value>Google</value>
        </row>
    </table>
    <table name="user_socials">
        <column>user_id</column>
        <column>social_id</column>
        <column>social</column>
        <column>picture</column>
        <row>
            <value>1</value>
            <value>109671001037346774242</value>
            <value>2</value>
            <value>https://lh6.googleusercontent.com/-huEFicSGyKU/AAAAAAAAAAI/AAAAAAAAA4I/m0PFsWD8QFg/photo.jpg</value>
        </row>
        <row>
            <value>1</value>
            <value>702348216485397</value>
            <value>1</value>
            <value>
                https://fbcdn-profile-a.akamaihd.net/hprofile-ak-xpa1/v/t1.0-1/c64.5.114.114/s50x50/1891165_635032089883677_31263367_n.jpg?oh=0be4ee6087d32d4aab412a935b117a3c&amp;oe=544ED228&amp;__gda__=1414885525_c271e46dace41453bd9cc4e08426217d
            </value>
        </row>
        <row>
            <value>2</value>
            <value>10201596577796234</value>
            <value>1</value>
            <value>
                https://fbcdn-profile-a.akamaihd.net/hprofile-ak-xpa1/t1.0-1/c0.0.50.50/p50x50/31568_10200644901964933_969761106_n.jpg
            </value>
        </row>
        <row>
            <value>2</value>
            <value>102623028356905318282</value>
            <value>2</value>
            <value>https://lh5.googleusercontent.com/-Ogbdwbnz9jU/AAAAAAAAAAI/AAAAAAAABJQ/cnloqihJyug/photo.jpg</value>
        </row>
        <row>
            <value>3</value>
            <value>116662090606954236795</value>
            <value>2</value>
            <value>https://lh3.googleusercontent.com/-R-VrIwNVp6E/AAAAAAAAAAI/AAAAAAAAAB0/1nm_k5aGDh4/photo.jpg</value>
        </row>
        <row>
            <value>4</value>
            <value>109057272140035741568</value>
            <value>2</value>
            <value>https://lh6.googleusercontent.com/-NIrXvXmjsPw/AAAAAAAAAAI/AAAAAAAABuo/OeqjBhq_Fhs/photo.jpg</value>
        </row>
        <row>
            <value>5</value>
            <value>109587774615724350162</value>
            <value>2</value>
            <value>https://lh5.googleusercontent.com/-R4FVzcJB74A/AAAAAAAAAAI/AAAAAAAABAc/ZFZtGtRk-6g/photo.jpg</value>
        </row>
        <row>
            <value>6</value>
            <value>106904554194481876715</value>
            <value>2</value>
            <value>https://lh3.googleusercontent.com/-XdUIqdMkCWA/AAAAAAAAAAI/AAAAAAAAAAA/4252rscbv5M/photo.jpg</value>
        </row>
    </table>
    <table name="users">
        <column>id</column>
        <column>email</column>
        <column>first_name</column>
        <column>middle_name</column>
        <column>last_name</column>
        <column>name</column>
        <column>role</column>
        <column>created_on</column>
        <column>last_logged_in</column>
        <row>
            <value>1</value>
            <value>dr.vikramraj87@gmail.com</value>
            <value>Vikram Raj</value>
            <value></value>
            <value>Gopinathan</value>
            <value>Vikram Raj Gopinathan</value>
            <value>3</value>
            <value>2014-07-20 18:28:27</value>
            <value>2014-07-24 19:42:03</value>
        </row>
        <row>
            <value>2</value>
            <value>kirthiviswanath@gmail.com</value>
            <value>Kirthika</value>
            <value></value>
            <value>Viswanathan</value>
            <value>Kirthika Viswanathan</value>
            <value>2</value>
            <value>2014-07-20 18:35:38</value>
            <value>2014-07-24 18:54:32</value>
        </row>
        <row>
            <value>3</value>
            <value>kirthika2203@gmail.com</value>
            <value>kirthika</value>
            <value></value>
            <value>viswanathan</value>
            <value>kirthika viswanathan</value>
            <value>1</value>
            <value>2014-07-20 18:56:10</value>
            <value>2014-07-21 03:21:26</value>
        </row>
        <row>
            <value>4</value>
            <value>ishuips6@gmail.com</value>
            <value>Iyswarya</value>
            <value></value>
            <value>Viswanathan</value>
            <value>Iyswarya Viswanathan</value>
            <value>1</value>
            <value>2014-07-20 19:26:12</value>
            <value>2014-07-20 19:26:12</value>
        </row>
        <row>
            <value>5</value>
            <value>gpkumaran@gmail.com</value>
            <value>Kumaran</value>
            <value></value>
            <value>G P</value>
            <value>Kumaran G P</value>
            <value>1</value>
            <value>2014-07-22 17:18:14</value>
            <value>2014-07-22 17:18:14</value>
        </row>
        <row>
            <value>6</value>
            <value>sumangalagopinathan@gmail.com</value>
            <value>Sumangala</value>
            <value></value>
            <value>Gopinathan</value>
            <value>Sumangala Gopinathan</value>
            <value>1</value>
            <value>2014-07-23 14:46:04</value>
            <value>2014-07-24 18:54:18</value>
        </row>
    </table>
</dataset>
